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Preface
This is a resubmission of a thesis for the degree of Doctor of Philosophy. New work has
been performed in accordance with the examiners' comments, and the text entirely
restructured and revised.
The thesis assesses whether microenvironmental stimuli relevant to atherosclerosis alter
monocyte survival, phenotype and gene transcription. These themes are emphasised through
the text.
Thesis structure
The thesis commences with a general introduction, followed by methodology. Individual
data chapters have further specific introductory, results, and discussion sections. The data
presented is set into context, and follows the structure of the thesis. An overview of the
thesis findings in the context of the current literature and future work is offered in the final
chapter. The presentation of the thesis is in accordance with the University of Edinburgh
postgraduate regulations with regard to character fonts, pagination, and formatting.
The following specific issues raised by the examiners have been directly addressed.
Introduction
The general introduction has been restructured, in the context of the principal research
targets. The work presented is set in the context of the current literature documenting the
general histology, cellular mechanisms and clinical sequelae of atherosclerosis, with a focus
upon the distinction between early atherogenesis and advanced plaque progression. The
thesis focuses upon the role of monocyte involvement in atherosclerosis, and upon the role
that modified lipoproteins may play. However, further consideration is given to the wide
range of other pathogenic factors and processes involved in atherogenesis. General
mechanisms of inflammation are outlined, and the evidence suggesting a role for
inflammation in atherosclerosis is reviewed. Specific mechanisms of arterial remodelling are
described according to original references. The role that monocytes play in inflammation and
vascular injury, and the kinetics of monocyte migration and sequestration at inflammatory
sites are reviewed. The literature pertaining to monocyte apoptosis and survival is reviewed
in the general introduction and in subsequent chapters, in the context of inflammation and
atherosclerosis. Specific note is made of the influences of growth factors and inflammatory
activation upon monocyte survival in the general introduction and in the relevant subsequent
chapters. The balance of cell survival and cell clearance in chronic inflammation is
introduced, and is also reviewed in detail in subsequent chapters. Alternative strategies for
investigating atherosclerosis including the use of animal models are discussed.
Methodology
Details of leukocyte isolation and culture are provided in full. Details of immuno-magnetic
separation monoclonal antibodies are listed, along with specific details regarding suspension
culture and the polytetrafluoroethylene containers used. Descriptions of apoptosis assays are
provided, including details of blinding of observers during apoptosis assessment. Cell
isolation and nucleic acid preparation for gene array studies are described in full. Details of
light, fluorescence, con-focal and electron microscopy techniques, including cell preparation
prior to image acquisition, are provided. Assessment of monocyte calcium flux is
specifically described.
Data presentation
The order of chapters has been altered, with data on cell survival now presented first,
followed by transcriptional profiling work and then monocyte surface phenotyping data.
Micrographic evidence for lipid uptake by monocytes is presented. However, monocytes are
referred to as lipid-laden, rather than using the specific term "foam cell". Details of
monocyte purity are given, to demonstrate quality control during leukocyte isolation. The
rationale for using reagents at the concentrations described is explained with reference to
established literature in the field, and also by presenting data demonstrating concentration
responses to the reagents used. The activity of specific agents used in studies has been
formally assessed. Variation of monocyte responses over time and in differing culture
conditions has been explored. Experiments have thus been repeated and extended for both
apoptosis and phenotyping studies, to allow assessment of varying primary cell responses.
Data regarding the transfection of monocytic cell lines are presented in a separate chapter.
Transcriptional profiling data are presented in full, with data tables in the attached appendix.
Statistical analysis, sampling issues
The candidate has attended a course on medical statistics at the University of Edinburgh, and
has received advice from professional statisticians regarding the use of tests for in vitro small
sample number assays. The additional data for the experiments described have been analysed
accordingly, with data analyses shown in the relevant appendices. The issue of population
xvii
variation in cell surface molecule expression and random sampling has been discussed, as
the in vitro assays presented are not comparable to clinical studies or a clinical trial.
Discussion
The limitations of individual experiments, and potential studies that might extend the work
presented, are discussed in individual relevant chapters. The data presented is critically
assessed, and related to findings from other workers in the field. In particular, issues of flow
cytometric analysis techniques and the use of appropriate controls have been discussed in
detail. The concept of in vitro studies being artefactual and the use of alternative techniques
including in vivo studies have been discussed. The use of transcriptional profiling in contrast
with other assessments of cell function has been reviewed. A further overview of the work is




Atherosclerosis is a disease process that reduces arterial blood vessel calibre, and is a major
cause of morbidity and mortality in the industrialised world. Decreased vascular flow
reduces tissue viability, resulting in cardiac, cerebrovascular, renovascular and peripheral
arterial diseases. Inflammatory leukocyte responses underlie atherosclerosis. Clinical
epidemiological data show that pro-atherogenic factors, including hyperlipidaemia,
uncontrolled hypertension and cigarette smoking increase vascular inflammation, elevating
an individual's risk of developing atherosclerosis. Local inflammation may alter leukocyte
phenotype, function and survival, activating resident atherosclerotic plaque macrophages,
and exacerbating vascular injury.
This thesis aimed to assess whether monocyte survival, phenotype and gene transcription
alters in response to pro-atherogenic and pro-inflammatory micro-environmental stimuli
including oxidised low-density lipoprotein and cyclopentenone prostaglandins, metabolites
of arachidonic acid.
Oxidised low-density lipoproteins and cyclopentenone prostaglandins accelerated monocyte
apoptosis, in serum-free conditions, in a concentration dependent manner. Cyclopentenone
prostaglandin-induced monocyte apoptosis was caspase dependent, but oxidised low-density
lipoprotein-induced monocyte apoptosis only partially caspase-dependent. Monocyte
apoptosis appeared to be independent of the nuclear receptor and transcriptional controller
peroxisome proliferator receptor gamma PPARy. Arachidonate-induced monocyte apoptosis
appeared to be caused by a disruption of NF-kB mediated signalling. Monocyte apoptosis
appeared inversely related to maturation, with nai've undifferentiated monocytes being more
susceptible to programmed cell death than committed macrophages.
Monocyte transcriptional responses to oxidised LDL were assessed using gene mini-arrays.
Genes for CD47 and CD1 la showed significant levels of variation on the array, with CD1 la
changes being confirmed by polymerase chain reaction assessment.
Monocyte surface molecular changes induced by low-density lipoprotein were directly
assessed by indirect immuno-labelling and flow cytometric analysis. Oxidised low-density
lipoprotein elevated monocyte surface CD54 in early suspension culture, but then caused a
down-regulation of CD54 in prolonged adherent culture. Oxidised low-density lipoprotein
diminished monocyte surface expression of CD1 lb and CD1 lc in a manner dependent upon
adhesion and maturation. CD49d expression appeared to be reduced by oxidised low-density
lipoprotein in mature adherent monocytes. Early marginal reductions in CDlla expression
were not seen in more mature monocytes.
xix
Pro-atherogenic and pro-inflammatory micro-environmental influences thus appeared to
regulate monocyte viability and gene transcription, although this is not necessarily reflected
at a protein level. Monocyte surface phenotype appeared to alter following exposure to
modified lipoproteins, in a manner that may cause changes in monocyte mobility. These
findings may contribute to our understanding of cell death in atherosclerotic lesions, and
potential limitations on cell mobility out of atherosclerotic plaque.
XX
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CHAPTER 1 PERSPECTIVES ON THE CELLULAR CONTRIBUTIONS TO
ATHEROSCLEROSIS AND ITS COMPLICATIONS
Section A Introduction
Atherosclerosis is a progressive chronic inflammatory disease of large and medium calibre
arteries. The accumulation of atherosclerotic plaque, a complex aggregate of cellular
infiltration, altered extracellular matrix and lipid components within the arterial wall causes
progressive or acute vascular occlusion (Davies 1996). Atherosclerosis places a large burden
on health care systems, and cardiovascular diseases are currently the largest cause of death
worldwide (Yach et al. 2004). Despite public health and pharmaceutical approaches to
reduce risk factors including serum cholesterol concentrations (Scandinavian Simvastatin
Survival Study investigators 1994), cardiovascular diseases remain the leading causes of
death in the United States, Europe, and much of Asia (Braunwald 1997).
This thesis assesses microenvironmental influences upon peripheral blood monocytes that
may promote atherosclerosis. The causes of cardiovascular disease and the natural history of
atherosclerosis will be presented in this chapter. Basic concepts of inflammation will be
introduced, and specific inflammatory mechanisms relevant to atherosclerosis will be
considered. The role of the monocyte in inflammation will be reviewed in detail, with
respect to survival and phenotype, and the control of gene transcription.
1.1 Cardiovascular risk
A combination of environmental risks including tobacco smoking (Villablanca, McDonald,
& Rutledge 2000), hypertension (Dzau 1990) and genetic factors (Lusis, Mar, & Pajukanta
2004) increase the probability of developing clinical cardiovascular disease. Clinical
manifestations of atherosclerosis increase with advanced age (Bilato & Crow 1996), and
positively correlate to male gender (Schildkraut et al. 1989), increased body mass and central
abdominal fat distribution (Bhatt et al. 2006). An increasing prevalence of obesity is causing
a rise in diabetes and the metabolic syndrome, raising the risks of associated vascular
damage in affected individuals (Dandona & Aljada 2002; Hak et al. 1999; Temelkova-
Kurktschiev et al. 2002). Early clinical evidence demonstrated that elevated plasma
cholesterol concentrations, especially low-density lipoprotein (LDL) cholesterol, constituted
a major risk factor for accelerated atherosclerosis (Slack 1969). LDL reduction has been
subsequently been associated with lower rates of clinical episodes in patients with
documented coronary, cerebrovascular and peripheral arterial disease (Shepherd et al. 1995).
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1.2 Histology of atherosclerosis: normal arterial structure
Atherosclerosis refers to specific histological changes within arterial walls, typified by lipid
and cellular accumulation and arterial wall remodelling (Stary et al. 1995). The wall of
normal arteries consists of an intimal layer lined by endothelium on the inner luminal aspect,
and by elastic lamina on the outer aspect. The media, the muscular wall of the artery, lies
abluminal to the intima, and is in turn surrounded by the densely collagenous adventitial
layer (Figure 1.1).
1.2.1 Endothelium
The luminal contents of blood are separated from the arterial wall by an endothelial
monolayer that acts as a high selectivity permeable barrier. A highly metabolic tissue lining
the entire vascular tree, the endothelium is non-thrombogenic due to local prostacyclin
production inhibiting platelet activation, whilst local plasminogen production promotes
endogenous fibrinolysis (reviewed by Pearson 1994). Endothelial production of the
vasodilator nitric oxide (Furchgott & Zawadzki 1980) balances with vasoconstrictors
including endothelin, angiotensin and platelet-derived growth factor (PDGF), maintaining
arterial tone (reviewed by Drexler & Flornig 1999). Endothelial cells (ECs) bear LDL
receptors, facilitating LDL transport into the artery wall, an event associated with LDL
modification (Kim, Dawes, & Jessup 1994). Endothelial injury is a primary trigger for
atherogenic cellular responses (Rangaswamy et al. 1997) (see section B 1.5).
1.2.2 Intima
The normal intima is a thin basement membrane layer of connective tissue comprising of the
matrix protein collagen IV and mixed proteoglycans, with occasional isolated vascular
smooth muscle cells (VSMCs), (see section C 1.6). Collagen and elastin fibre deposition
occurs during ageing, accompanied by concentric smooth muscle cell hyperplasia (Tracy
2001). The intima is the site of extracellular deposition of amorphous lipids and
atherosclerotic plaque development (Stary 1992), a process accelerated in hyper-Iipidaemic
subjects (Simionescu et al. 1986).
1.2.3 Media
The arterial media consists of smooth muscle cells in a collagen and proteoglycan matrix
(see section C 1.6). Medial smooth muscle cells form lamellar units, increasing in number
proportional to arterial size, each sandwiched between fenestrated sheets of elastic fibres.
Elastic internal and external laminae offer structural strength, whilst still permitting the
transit of cells and molecules. Large calibre vessels with more than 29 concentric laminae
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require their own vascular network, or vasa vasorum, to provide a blood supply to outer
lamellae (Wolinsky & Glagov 1967).
1.2.4 Adventitia
The adventitia is a dense collagenous structure with collagen fibrils, elastic fibres and
multiple fibroblasts. The adventitia is innervated, has lymphatic drainage and a separate
vascular supply from the vasa vasorum. Novel microfibril glycoproteins have been recently
identified that bind to elastin molecules, contributing to arterial strength (Toyoshima et al.
2005).
1.3 Gross histological change in atherosclerosis
Various pathological classifications have been used for atherosclerotic lesion grading. The
American Heart Association (AHA) classification stages atherosclerosis according to
histological composition, and further categorises phases of clinico-pathological progression
(reviewed by Stary et al. 1994; Stary et al. 1995; Stary 2000). The phases, graded 1 to 5
describe the clinical activity of the lesion, from clinically silent, asymptomatic chronic
occlusive and symptomatic angina to acute coronary syndromes. The histological stages
grade lesions from I to VI according to cellular composition and histological structure,
dependent upon the smooth muscle cell, macrophage and lipid composition (see Figure 1.2).
Plaque complications including thin cap fibro-atheromata, and plaque erosions are not
specifically included in this scheme, and have been addressed by other classifications
(Virmani et al. 2000).
1.3.1 Early atherogenesis: Fatty streaks
Pre-atherosclerotic lesions are described as "fatty streaks." Evidence of fatty streaks in post¬
mortem studies of large arteries taken from infants and young children emphasises the early
onset of atherogenesis (Napoli et al. 1997). Fatty streaks correspond to histological types I to
111, part of the clinically silent Phase 1 of atherosclerosis (see Figure 1.2). Fatty streaks
represent lipid-laden macrophages and smooth muscle cells, filled with cholesterol and
cholesteryl ester, that have been transferred to the intima through the endothelial monolayer.
A simplified view of fatty streaks is outlined in Figure 1.3.
1.3.1.1 Type I Lesions
Type I lesions have microscopically visible lipid droplets in the intima, and macrophage
infiltrates. Hypercholesterolemia enhances monocyte adherence to the endothelium in
porcine, (Gerrity 1981a) and non-human primate models of atherosclerosis (Faggiotto, Ross,
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& Harker 1984). In the first 8 months of life, 45% of infants have coronary arterial
macrophage foam cells, and a doubling of lipid-free macrophages (Stary 1987).
1.3.1.2 Type II Lesions
Type II lesions are visible as yellow streaks or spots on gross inspection. Lesional lipid
content is readily labelled with fat-soluble dyes (Uemura 1964), and consists of cholesterol,
phospholipids and cholesteryl oleate and cholesteryl linoleate esters (Katz, Shipley, & Small
1976). Macrophages increase in number further, appearing stratified rather than isolated.
Intimal smooth muscle cells show intra-cytoplasmic lipid droplets, and T cell infiltration is
notable (Munro et al. 1987).
Type Ila lesions preferentially progress to more advanced stages, typified by the increased
presence of smooth muscle cells, intercellular matrix and deep intimal macrophage-derived
foam cells and extracellular lipid droplets. Mechanical forces are associated with intimal
thickening, increased lipid influx and early lipid accumulation in hyperlipidaemic subjects.
Low shear stress prolongs LDL and arterial wall interactions increasing trans-endothelial
LDL diffusion (Glagov et al. 1988). Type lib lesions by contrast appear more resistant to
lesion progression, and are associated with thinner intimal layers, and low levels of smooth
muscle cell infdtrates.
The aorta, bifurcation points and ostia of large vessels, and the coronary arteries are
associated with an increased likelihood of Type II lesion progression. 99% of children aged 2
to 15 years have type 11 lesions in the aortic arch, descending thoracic aorta, and abdominal
aorta with further involvement throughout the length of the aorta from puberty (Strong &
McGill, Jr. 1969) to the age of 20 years (Eggen & Solberg 1968). Type II lesions are seen in
the coronary arteries by the time of puberty (Eggen & Solberg 1968), especially in the
proximal 2cm of the left coronary artery (Montenegro & Eggen 1968). The intima of the
proximal left anterior descending artery is particularly prone to Type Ila lesion formation in
young adults (Stary 1989).
1.3.1.3 Type III Lesions
Also known as intermediate, transitional, or pre-atheromatous lesions, type III lesions have
extracellular lipid droplets and pools distributed among smooth muscle cells in a thickened
intima but no large lipid core is present (Stary et al. 1994). These lesions arise in the same
progression-prone areas as Type Ila lesions and as more advanced lesions, suggesting they
form part of a continuous spectrum of cellular change. Lipid pools lie below layers of
macrophages and macrophage-derived foam cells, replacing intercellular matrix
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proteoglycans, and drive smooth muscle cells apart (reviewed by Fuster, Badimon, &
Badimon 1992).
1.3.2 Atherosclerotic lesion progression
Type IV lesions and lesions of greater complexity constitute the histological definition of
atheroma. Type IV and Va lesions may be clinically silent (Phase 2 lesions), with lesions of
type Vb, Vc and VI commonly producing clinical manifestations (see Figure 1.2).
1.3.2.1 Type IV Lesions
Type IV lesions have dense focal accumulations of extracellular lipid within the intima,
termed lipid cores, a progression of the separate extracellular lipid pools in type III lesions,
contributing to an atheromatous, or gruel-like plaque composition (see Figure 1.4). Type IV
lesions are the first lesions considered advanced due to the marked intimal disruption that the
lipid core causes (Stary 1989). Though non-stenotic, and classed as clinically silent Phase 2
lesions whilst quiescent (see Figure 1.2), these lesions are capable of rupture (Fuster et al.
2005). The intima appears thickened although atheroma may fail to narrow the vascular
lumen, due to increases in the external boundary of the artery (Glagov et al. 1987). Intimal
smooth muscle cells and deep intimal matrix are dispersed or replaced by accumulated
extracellular lipid particles. Smooth muscle cell organelles may be calcified, and calcium
particles are seen within the lipid core. The intima contains macrophages, and smooth
muscle cells (with and without lipid inclusions) as well as lymphocytes and mast cells in the
area between the lipid core and the endothelial surface (Jonasson et al. 1986). Populations of
smooth muscle cells and collagen fibres are lower in this area in type IV lesions, and, along
with high density macrophage and lymphocyte populations, contribute to structural weakness
in the lesion periphery.
Capillary networks border the lipid core, particularly at the lateral margins and facing the
lumen. Neo-vascularisation has been noted in advanced lesions. Vasa vasora infiltrate the
adventitia and outer media but not intima of the aorta, coronary femoral and carotid arteries
(Kwon et al. 1998), contributing to 70% of the capillary supply of a plaque, the rest being
luminally derived. Micro-vascular infiltration in the base of lesions is associated with plaque
degradation (Moreno et al. 2004).
Much of the tissue between the core and the surface endothelium corresponds to the
proteoglycan-rich layer of the intima. A further increase in collagen content increases the
fibrotic nature of type IV plaques. The upper intimal layer of a type IV lesion is
indistinguishable from the fibrotic cap of a type V lesion, and both type IV and type V
lesions are labelled fibrous plaque.
1.3.3 Complex atherosclerotic lesions; atherothrombotic events
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1.3.3.1 Type V lesions
Type V lesions, or fibro-atheromata, have prominent fibrotic tissue. Medial smooth muscle
cells are reduced in number and structurally disorganised. The media and adventitia contain
macrophages, macrophage foam cells mast cells and lymphocytes, the latter in large groups
near adventitial vasa vasorum (Jonasson et al. 1986) (see Figure 1.5). Type V lesions may be
sub-classified.
Type Va lesions have multiple lipid cores, separated by thick fibrous connective tissue
forming a multilayered fibro-atheroma. Fibrotic organisation of haematomas and thrombi is
followed by further lipid-laden macrophage accumulation and extracellular lipid between
fibrotic layers and the endothelial surface. Such lesions may be clinically silent (Phase 2),
but may progress to Phase 3 or 4 with thrombotic complications (see Figure 1.2).
Type Vb lesions have calcified lipid cores and mineralised cell debris (Stary et al. 1992).
Coronary calcification consists of hydroxyapatite crystals, and organic matrix calcification,
including Collagen I and non-collagenous bone proteins, chiefly osteopontin (Fitzpatrick et
al. 1994). Type Vc fibrotic lesions have no lipid core, minimal lipid content overall, and
replacement of normal intima by fibrotic tissue. Often seen in large lower limb vessels (Ross
et al. 1984), fibrosis is due to thrombus organisation, fibrotic extension from adjacent fibro-
atheromata, or lipid core resorption. Type Vb and Vc lesions may cause clinical ischaemia
(Phase 5). However, due to slow disease progression, collateral vessel development may
protect target tissue resulting in clinically silent vessel occlusion, (see Figure 1.2).
Luminal encroachment of all type V lesions is greater than type IV lesions, but, as with type
IV lesions, type V lesions may develop fissures, haematomata, and/or thrombus (progression
to a type VI lesion, clinical Phase 3 or 4, see Figure 1.2).
1.3.3.2 Type VI complex lesions
Disruptions of the atherosclerotic lesion surface, haematoma or haemorrhage, and
thrombotic deposits all classify a lesion as complex, or type VI, with the latter referred to as
atherothrombotic events (see Figure 1.2). Although these lesions may be clinically silent
they generally cause clinical symptoms and signs of ischaemia, and are sub-classified
according to the type of lesional disruption, which varies in extent and severity. A schematic
overview of these events is outlined in Figure 1.6.
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1.3.3.3 Type Via Surface Defects; Type Vlb Haematoma
Microscopic surface ulcerations consist of focal endothelial cell loss; deep macroscopic
ulcerations expose and release lipid from the lesion core. Type IV and Va lesions are prone
to surface disruption, associated with high levels of inflammatory cell infiltration, proteolytic
enzyme release by macrophages, coronary spasm and shear stress, and structural weakness
related to lesion composition, (reviewed by Falk 1989). Fissuring is pronounced in areas of
high density macrophage foam cell populations. In type Vlb lesions, haematomas and
thrombi are incorporated into lesions during fissure repair, accelerating plaque progression
(Kolodgie et al. 2003) (see Figure 1.6).
1.3.3.4 Type Vic, thrombotic lesions
Advanced atherosclerotic lesions containing thrombi or thrombus remnants are common in
humans from the fourth decade of life onwards. Thrombi vary in size from microscopic to
grossly visible deposits, with some showing stratified layers suggesting repeated thrombotic
deposition (see Figure 1.6). Hypercholesterolemia enhances platelet recruitment via adhesive
interactions with endothelial cells, mediated by molecules including von Willebrand factor
(vWF), glycoprotein Iba (GPIba), and P-selectin to lesion-prone sites (Theilmeier et al.
2002). Local release of tissue factor, a powerful pro-coagulant, further accelerates thrombus
formation (Ardissino et al. 2001). Surface thrombi were noted in early studies of human
atherosclerosis and more recently reported in advanced lesions seen in murine models of
atherosclerosis (Rosenfeld et al. 2000). Thrombi may form over lesions with no gross surface
disruption, through shear stress effects upon endothelial function at points of arterial
angulation or flow division (Taeymans et al. 1992). Hyperlidaemia per se may promote
endothelial vWF expression (Theilmeier et al. 2002) and platelet binding (Massberg et al.
2002) even in undisrupted lesions. Fissures and haematomas underlying thrombi may recur,
inducing repeated formation of small thrombi. Lesion surface disruption greatly enhances
thrombus formation, facilitated by local endothelial dysfunction and focal loss of small areas
of endothelial cells (see Figure 1.6). Intra-lesional capillary haemorrhage may disrupt lesions
to precipitate surface thrombosis, an event that may be associated with elevated secretion of
proteolytic metalloproteinase enzymes (de Nooijer et al. 2006). Elevated plasma fibrinogen
levels are seen in subjects suffering acute vascular occlusions, suggesting a systemic
predisposition to thrombus formation (Woodward et al. 2003). Groups at high risk for
atherothrombotic complications including cigarette smokers show exaggerated platelet
aggregation in conjunction with elevated plasma fibrinogen levels (Fusegawa et al. 1999).
Further enhancement of local thrombosis is caused by loss of natural endothelial fibrinolytic
8
mechanisms. Decreased fibrinolytic capacity is caused by increased levels of type 1
plasminogen activator inhibitor (de Bono 1994), and may be directly related to
hyperlipidaemia. Lipoprotein(a), associated with high risk for clinical coronary heart disease,
is structurally similar to plasminogen and may thus inhibit fibrinolysis by binding to fibrin or
disrupting the assembly of fibrinolytic proteins (Loscalzo 1990).
Non-occlusive non-fatal thrombi that are not lysed contribute to increased lesion thickness
(see Figure 1.6). Incorporation of such recurrent thrombi contributes to lesion bulk, with
some thrombi enlarging and occluding lumina ofmedium-sized vessels within hours or days.
Intimal smooth muscle cells invade thrombi and synthesise collagen, whilst the luminal
surface of the thrombus is overgrown by endothelial cells. The presence of platelet-derived
growth factor and platelet factor 4 contribute to smooth muscle cell proliferation, migration,
and collagen synthesis (Pitsilos et al. 2003).
1.3.3.5 High-risk and vulnerable plaques
The progression of atheroma to complex stages is variable. More recent classifications have
been devised to address the fact that advanced plaque progression to Type VI may occur
rapidly and reflecting widespread vascular disease related to inflammation (Asakura et al.
2001). Early plaque, without a lipid or necrotic core but with marked local endothelial
dysfunction may progress to thrombosis. Such plaque erosion occurs despite preserved
smooth muscle cell and proteoglycan integrity, and the absence of matrix exposure (Schaar
et al. 2004). Actual plaque rupture with thrombosis is usually associated with a lipid-rich
core, and expansive compensatory remodelling. A thin fibrous cap covers rich macrophage
and lymphocyte infiltrates but few smooth muscle cells, and is termed an inflamed thin cap
fibroatheroma (Varnava, Mills, & Davies 2002). Plaques with calcified nodules also progress
to thrombosis, and are characterised by heavy local calcification and luminal encroachment
(Virmani et al. 2000). These additions to plaque classification correlate in more detail to
acute clinical events, but complement the previous histological grading system.
1.3.4 Pathological and clinical sequelae of atherothrombosis
Atherothrombosis producing luminal encroachment may cause haemodynamic flow-
limitation, inducing end-organ ischaemia in the myocardium, brain, major abdominal viscera
or peripheral limbs (Virmani et al. 2000). If unresolved, or complicated by vessel occlusion,
infarction and necrosis of susceptible tissue ensues, during ischaemic cerebrovascular
accidents (Spagnoli et al. 2004) and during acute myocardial infarction (Falk, Shah, & Fuster
1995). Loss of end-differentiated neuronal or myocardial cells results in local fibrosis,
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compromising organ function, with severe implications for patient morbidity and mortality
(Collins et al. 2002).
Section B Inflammatory vascular injury
1.4 Overview of inflammation
Inflammation, the innate first response of the immune system to infection or cellular injury,
is characterised by redness {rubor), heat {calor), swelling {tumor), pain {dolor) and
dysfunction of the organs involved (functio laesa). Inflammatory cellular responses enable
organisms to fight pathogens and limit severe infections (Anderson et al. 1985), while
limiting cell damage and optimising cell recovery from mechanical and thermal injury.
Redness and heat are caused by the vasodilatation upstream of tissue injury sites, while local
capillary permeability is increased, resulting in plasma extravasation and retention of water
in hyaluronan-rich extracellular matrix (Mikecz et al. 1995). Downstream vasoconstriction
increases oedema, distending and compressing nerve endings, causing pain. Stretch receptor
mediated mast cell activation induces histamine and prostaglandin release. Activated mast
cells also bind immunoglobulins via a repertoire of Fc receptors (Ra et al. 1989).
1.4.1 Inflammatory responses to primary cell injury
Classical inflammatory responses involve neutrophil recruitment to primary injury sites
(Issekutz & Movat 1980). Excessive, unregulated inflammatory responses may be
detrimental, causing inappropriate tissue destruction by proteolytic enzymes such as
neutrophil elastase (Gadek et al. 1981). Cytokines, molecules that play a central role in local
and systemic inflammatory responses, activate endothelial cells, upregulating adhesion
molecule expression (see section 1.5, and Chapter 6 section 6.1.5), and aiding leukocyte
extravasation from capillaries into tissue (Chuluyan et al. 1995). Cell motility is further
enhanced in response to the CXC and CC chemokines, molecules that promote cell
migration to inflammatory sites (del Pozo et al. 1995). Adhesion to activated endothelium
activates neutrophils (Takahashi et al. 2001), priming them for a respiratory burst, producing
high levels of hydrogen peroxide (Nathan 1987) enabling microbial destruction. Although
tumour necrosis factor alpha (TNF-a) promotes NF-kB activation in endothelial cells, the
co-existence of platelet-derived thromboxane (A)2 may induce endothelial cell apoptosis,
furthering vessel wall injury (Ashton et al. 2003).
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1.4.2 Overview of cell death and phagocytosis in inflammation
Apoptosis or programmed cell death of extravasated leukocytes and their subsequent swift
removal by phagocytes prevents excessive leukocyte accumulation at inflammatory sites
(Haslett et al. 1994). Rapid phagocytic resolution of granulocyte influx is evident in clinical
acute inflammatory diseases (Cox, Crossley, & Xing 1995). Phagocyte engulfment of
apoptotic cells induces transforming growth factor-beta (TGF-P) inhibition of pro¬
inflammatory cytokine responses (Fadok et al. 1998a), although pro-inflammatory effects
may be observed (Kurosaka, Watanabe, & Kobayashi 2001). Uncleared apoptotic cells may' '
—
progress to secondary necrosis (Flebert et al. 1996), with resultant local pro-inflammatory
consequences limiting reparative mechanisms. Necrotic cells may induce adaptive immune
mechanisms by enabling dendritic cell maturation and cross-presentation of antigens to T
lymphocytes thus prolonging inflammatory responses (Sauter et al. 2000). Chronic
inflammatory responses to intracellular pathogens such as mycobacteria may cause
granuloma formation by inhibiting normal phagosome function (Clemens & Horwitz 1995),
or in the case of helminthic infections, by promoting anti-inflammatory cytokines
(Ramaswamy, Kumar, & He 2000). The persistence of T-cells and monocytes are a feature
of non-caseating granuloinata in sarcoidosis, with reduced levels of apoptosis contributing to
chronic inflammation (Xaus et al. 2003).
1.4.3 Inflammatory repair mechanisms
Restoration of function when inflammation subsides is dependent upon the regenerative
capacity of injured cells. TGF-P 1 plays multiple roles in inflammation, not only promoting
monocyte chemotaxis, but also aiding resolution by increasing monocyte interleukin (IL)-l
production that in turn enhances fibroblast growth (Wahl et al. 1987). TGF-P directly
promotes fibroblast production of fibronectin and collagen synthesis and incorporation into
the extracellular matrix (Ignotz & Massague 1986), and regulates adherent leukocyte
fibroblastic responses in an integrin dependent fashion (Munger et al. 1999). Fibrosis of
specialised tissue composed of terminally differentiated cells is associated with functional
loss. TGF-P2 directed responses provoke fibrosis following neuronal injury (Lagord, Berry,
& Logan 2002). Cardiomyocyte replacement by collagen following myocardial infarction,
(Colucci MD 1997) or auto-immune myocardial inflammation (Clancy & Buyon 2003) is
associated with reduced cardiac ventricular function. IL-la and IL-lp co-ordinate
fibroproliferative responses by modulating growth factor production (Tamura et al. 1993).
IL-ip directs fibroblast growth factor-2 mediated switching of collagen types in corneal
injury, causing corneal opacification. In vascular structures, basic fibroblastic growth factor
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(bFGF) and vascular endothelial growth factor (VEGF) contribute to arterial smooth muscle
cell hyperplasia, diminishing vessel calibre (Lazarous et al. 1996).
Excessive fibrotic responses may thus limit recovery from injury by replacing damaged cells
with matrix proteins, with implications in glomerulosclerosis (Stein-Oakley et al. 1997),
pulmonary fibrosis (Huaux et al. 2003) and central nervous system inflammation (Logan et
al. 1999) as well as in cardiovascular disease.
1.5 Specific inflammatory cellular mechanisms direct atherogenesis and
atherosclerotic plaque progression
Atherogenesis was previously considered to be a passive process of lipid accumulation
within the artery wall (Ross & Harker 1976). Subsequent data have suggested that lipid
accumulation is only partially responsible for the development of atherosclerosis. The
specific cellular and molecular responses underpinning the initiation and progression of
atherosclerosis bear the hallmarks of an inflammatory disease (Libby, Ridker, & Maseri
2002). Studies in humans and animals suggest that atherosclerosis is a response to injury
rather than simple lipid accrual, and it is reasonable to view atherosclerosis as a chronic
inflammatory response to lipid retention (Hansson 2005).
Lesions may be initiated, regress or advance throughout an individual's lifetime, due to
changing chronic inflammatory responses in the arterial wall. However, relatively small non-
flow-limiting lesions may display elevated macrophage activation at vulnerable sites
(Jonasson et al. 1986). Uncontrolled pro-inflammatory responses driven by local factors
including CD40L ligation (Lutgens et al. 1999) may promote matrix metalloproteinase
proteolytic enzymatic degradation of vascular wall components. The resulting exposure of
matrix components may cause local thrombus deposition and thus vessel closure at sites of
non-flow limiting, but inflamed plaque(Libby et al. 1996).
1.5.1 Inflammatory initiation of atherogenesis
Endothelial denudation, or endothelial cell layer loss, was previously thought to be the
primary injury in the development of atherosclerosis (Bjorkerud & Bondjers 1973). More
recent revisions of this model suggest that endothelial dysfunction rather than physical
denudation of the endothelial monolayer is the critical initiating factor (see Figure 1.7). Key
factors causing endothelial dysfunction include high concentrations of LDL, particularly
modified LDL, and free radicals produced in response to cigarette smoking, hypertension,
and glycosylation end-products in diabetes mellitus (Busse & Fleming 1996). Elevated
plasma homocysteine concentrations, infectious micro-organisms such as herpes viruses or
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Chlamydia pneumoniae, and combinations of these or other factors may also result in
abnormal endothelial cell responses (Ross 1981).
Endothelial dysfunction promotes endothelial permeability (Hennig & Chow 1988)
leukocyte-endothelial adhesion (Cybulsky & Gimbrone, Jr. 1991) and platelet-endothelial
adhesion, permitting inflammatory responses to endothelial injury. The balance of pro-
fibrinolytic endothelial properties is lost, with increases in vWF and reductions in endothelial
cell production factors such as tissue plasminogen activator inducing a locally anti-
fibrinolytic state (al Azhary, Wojta, & Binder 1994). High levels of angiotensin II further
contribute to inflammatory endothelial cell injury (Weiss, Kools, & Taylor 2001), and
augmented endothelial permeability to lipoproteins is enhanced by platelet-derived growth
factor (Becker et al. 2000) and endothelin-1 (Schiffrin 2001).
The individual factors inducing endothelial injury relevant to atherosclerotic merit specific
consideration.
1.5.2 Causes of endothelial injury: shear stress
Low haemodynamic shear stresses, and turbulent flow predict the anatomical sites of
atheroma formation. Laminar shear forces are atheroprotective (Traub & Berk 1998), and
disordered shear stress at vessel branch points, bifurcations and regions of high curvature are
vulnerable to atherosclerotic plaque formation (Davies 1997). Cellular mechanotransducers
include a complex containing the VEGF receptor-2 (VEGF-R2), the adherens junction
proteins VE-cadherin and P-catenin (Shay-Salit 2002), and a complex composed of platelet
endothelial cell adhesion molecule-1 (PECAM-1) in association with VEGF-R2 and vascular
endothelial cell cadherin (Tzima et al. 2005). Transmitted shear stress from endothelial cell
apices through cytoskeleton to cell-cell and cell-matrix adherens junctions induces the
association of avP3 and pi integrins with the adaptor protein She (Chen et al. 1999).
Conformational activation of avP3 polarises endothelial cells in the direction of vascular
flow, signalled by the small GTPases Rho (Tzima et al. 2001) and Racl. The resultant NF-
kB activation augments intercellular adhesion molecule-1 (1CAM-1/CD54) production
(Tzima 2002) explaining earlier observations of this molecule in damaged endothelium
(Nagel et al. 1994). Rheological influences alter the expression of endothelial cell genes with
promoter regions responsive to shear stress (Topper & Gimbrone 1999). Expression of tissue
factor on damaged endothelial cell surfaces is increased by shear stress (Lin et al. 1997),
whereas endothelial cell-derived platelet-derived growth factor B chain is decreased by
shear-stress, suggesting differential flow-related control of arterial wall remodelling in
different areas of diseased vasculature (Resnick et al. 1993). Alterations in blood flow thus
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critically determine which arterial sites are prone to atherogenesis (McMillan 1985) by
regulating cellular recruitment signals to the endothelium.
1.5.3 Further causes of inflammatory vascular injury: Hypertension
Hypertension has pro-inflammatory effects, increasing the formation of hydrogen peroxide
and free radicals such as superoxide anion and hydroxyl radicals in plasma (Lacy, O'Connor,
& Schmid-Schonbein 1998; Morel, Hessler, & Chisolm 1983), substances that reduce
endothelial cell production of nitric oxide, increase leukocyte adhesion, and increase
peripheral arterial resistance. Concentrations of angiotensin II (Angll), a potent
vasoconstrictor and principal product of the renin-angiotensin system, may be elevated in
patients with hypertension, although this is not always apparent (Williams 2001). Angll may
cause endothelial cell injury, and smooth muscle proliferation (Dzau 1993). Angll receptor-
mediated activation of phospholipase C increases intracellular calcium concentrations,
enhancing smooth-muscle contractility and hypertrophy (Gibbons, Pratt, & Dzau 1992).
Angll also increases smooth-muscle lipoxygenase activity, which may increase LDL
oxidation.
1.5.4 Further causes of endothelial and vascular injury: Homocysteine
Homocysteine, a sulphur containing amino acid, is a product of methionine catabolism and
may alter oxidation-reduction balance within the arterial wall, with potentially toxic effects
upon endothelial cells (Harker et al. 1976). Homocysteine promotes a pro-thrombotic state,
(Hajjar 1993) increases collagen production (Majors, Ehrhart, & Pezacka 1997) and
decreases local nitric oxide availability (Upchurch, Jr. et al. 1997). Homocysteine may
upregulate apoB oxidation and increase monocyte activation and platelet aggregation.
Elevated plasma homocysteine concentrations are linked with advanced atherosclerosis and
severe early-onset atherosclerosis in subjects bearing homozygous defects in homocysteine
metabolism enzymes, such as cystathionine beta-synthase or methylenetetrahydrofolate
reductase (McCully 1993; Nygard et al. 1997). Plasma homocysteine concentrations are also
slightly elevated in many subjects with no enzymatic defects in homocysteine metabolism,
but with an increased risk of coronary, peripheral and cerebral atherosclerosis. Folic acid
supplementation may reduce plasma homocysteine concentrations to normal (Omenn,
Beresford, & Motulsky 1998). However, recent data suggest that despite homocysteine
reduction, folic acid supplementation may not substantially alter vascular disease progression
(Liem et al. 2003), arguing that homocysteine elevation may be a marker rather than a
mediator of continuing vascular injury.
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1.5.5 Further causes of endothelial and vascular injury: infection
Studies have suggested an association between atherosclerosis and at least two infectious
microorganisms: herpesviruses and Chlamydia pneumoniae (Hendrix et al. 1990; Jackson et
al. 1997; Libby, Egan, & Skarlatos 1997). Both organisms have been identified in
atheromatous lesions in coronary arteries at post-mortem (Gupta et al. 1997a), and increased
antibody titres of these organisms have been used to predict the occurrence of further
adverse events in patients who have had a myocardial infarction. However, there is to date
no direct evidence that these organisms are directly causative for atherosclerotic plaques
(Hajjar et al. 1986; Nicholson & Hajjar 1998). Although these organisms are seen in many
tissues and organs, the fact that lesions cannot be induced experimentally in animals by
infection with these organisms leaves their role as aetiologic agents in question. Recent data
suggests that respiratory tract infections are associated with a higher incidence of
cerebrovascular accidents and myocardial infarction (Smeeth et al. 2004). It is possible that a
protracted inflammatory stimulus derived primarily from a single or repeated infection, in
the context of other secondary factors, may be responsible for atherogenesis or
atherosclerotic progression in some subjects (Danesh, Collins, & Peto 1997).
1.5.6 Hyperlipidaemia, modified lipoproteins & inflammatory vascular injury
A key cause of endothelial dysfunction in atherosclerosis is systemic dyslipidaemia. LDL
may be modified by oxidation, glycation in diabetes, direct lipid aggregation, association
with proteoglycans, or incorporation into immune complexes (Khoo et al. 1988; Klioo et al.
1992; Navab et al. 1996; Steinberg 1997). Altered lipoproteins not only cause endothelial
injury but also affect underlying smooth muscle cells (Griendling & Alexander 1997). LDL
particles undergo progressive but variable oxidation in the vessel wall with the initial
production of minimally modified LDL (mmLDL, see Figure 1.7) subsequently followed by
ox-LDL species (Liao et al. 1991). LDL uptake via LDL receptors (LDL-R) results in
homeostatic downregulation of LDL-R surface density (Kita et al. 1982). Modified LDL is
internalised by macrophages via surface scavenger receptors, an alternative route for lipid
intake, leading to further intracellular oxidation (see Figure 1.8), with lipid peroxide
formation facilitating the accumulation of cholesterol esters (Han et al. 1997; Morel, Hessler,
& Chisolm 1983). Removal and sequestration of modified LDL may represent an important
part of the initial protective role of the macrophage in minimising the toxic effects of
modified LDL on endothelial and smooth-muscle cells (Falcone, McCaffrey, & Vergilio
1991; Han et al. 1997). Antioxidants such as vitamin E may reduce the capacity for free-
radical formation by modified LDL (Nunes et al. 1997). Modified LDL has been reported to
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be chemotactic for monocytes and can augment transcription of genes for macrophage
colony-stimulating factor (Quinn et al. 1987) and monocyte chemotactic protein (Leonard &
Yoshimura 1990) derived from endothelial cells. It might be postulated that LDL acts to
expand the inflammatory response by promoting the entry of circulating monocytes into
lesions increasing the number of monocyte-derived macrophages present within
atherosclerotic plaque.
Sub-particles within LDL, in particular apoprotein B100, trigger inflammatory responses.
Binding between atherogenic lipoproteins and proteoglycans is mediated via ionic
interactions between basic amino acids in apoBlOO and negatively charged sulphate groups
on the proteoglycan components of the arterial extracellular matrix. Mice expressing
proteoglycan-binding-defective LDL develop significantly less atherosclerosis than mice
expressing wild-type control LDL, suggesting that sub-endothelial retention of apoBlOO is
critical in atherogenic initiation (Skalen et al. 2002).
Inflammatory mediators including tumor necrosis factor-oc, IL-1 and M-CSF, promote LDL
binding to endothelium and smooth muscle and increase LDL-receptor gene transcription
(Hajjar & Haberland 1997; Stopeck et al. 1993). Scavenger receptor binding to modified
LDL in vitro, initiates a cascade of intracellular events that include the production of
urokinase (Falcone, McCaffrey, & Vergilio 1991) and inflammatory cytokines including IL-
1 (Geng & Libby 1995; Palkama 1991; Palkama, Matikainen, & Hurme 1993). Modified
LDL thus promotes local vascular inflammation at sites of vascular injury.
Ox-LDL has been directly identified in human atherosclerotic lesions (Yla-Herttuala et al.
1989). A role for ox-LDL in the pathogenesis of atherosclerosis has been further
strengthened by evidence from studies of antioxidant therapies. In animals with
hypercholesterolaemia, antioxidants can lower adhesion molecule expression. (Fruebis et al.
1997) and reduce the size of atherosclerotic lesions, (Carew, Schwenke, & Steinberg 1987;
Chang et al. 1995; Griendling & Alexander 1997; Kita et al. 1987) and fatty streaks in non-
human primates (Sasahara et al. 1994). Antioxidants increase the resistance of human LDL
to oxidation ex vivo (Reaven et al. 1993) in proportion to the vitamin E content of the
plasma. Vitamin E intake was found to be inversely correlated with the incidence of
myocardial infarction, and vitamin E supplementation was found to reduce coronary events
in a preliminary clinical trial (Rimm et al. 1993; Stampfer et al. 1993; Stephens et al. 1996).
However, other antioxidants, such as beta carotene, have no benefit, (Hennekens et al. 1996;
Omenn et al. 1996) and recent clinical data have failed to confirm any significant clinical
benefit from Vitamin E supplementation(Collins et al. 2002) questioning the role of systemic
anti-oxidant therapies in vascular disease.
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1.5.7 Cellular lipid trafficking in inflammatory cells
Lipoprotein trafficking within mammalian vasculature is controlled at the level of
absorption, hepatic processing and uptake by target cells, including adipocytes under the
control of orphan nuclear receptors (Schoonjans, Staels, & Auwerx 1996) and leukocytes
within atherosclerotic plaque (Hajjar & Haberland 1997). Ingested fatty acids from dietary
sources cross the gut wall via active transport mechanisms in the form of chylomicrons:
large particles with a high fat to protein ratio (Hussain et al. 1996). After being directed
towards the liver (Kita et al. 1982), chylomicrons undergo specific degradation steps. The
residual remnant lipoproteins are also pro-atherogenic, altering endothelial cell adhesion
molecule expression (Doi et al. 2000) and inducing foam cell phenotypic changes in
monocytes (Saito et al. 1996; Yu & Mamo 2000). Smaller, denser lipid-laden particles are
also produced with higher protein to lipid ratios, and are classified by density. ApoB48-
containing very low density (VLDL) (Luchoomun et al. 1997) bears a high triglyceride
content, whilst apoBlOO-rich LDL has a higher protein to lipid ratio, the specific
composition of which has been correlated to vascular disease (Capell et al. 1996).
Epidemiological observations further demonstrate a relationship between atherosclerosis and
elevated LDL levels (Gordon et al. 1981). High density lipoproteins (HDL) with lower lipid
to protein ratio, are implicated in reverse cholesterol transport and cholesterol efflux (see
Figure 1.8) involving the ATP binding cassette (ABC) transport mechanism a group of
evolutionary highly conserved cellular transmembrane transport proteins that govern trans¬
membrane molecular trafficking (Aiello, Brees, & Francone 2003). HDL levels are inversely
related to adverse cardiovascular clinical events (Mertens & Holvoet 2001). HDL effectively
clears lipid from tissues during normal cholesterol trafficking via ABC-1 transporters,
explaining the clinical observation that elevated HDL:LDL ratios limit atherosclerotic
disease sequelae even if high total lipid levels remain elevated (Navab et al. 1995). Mutation
of an ABC family member, the ATP-binding cassette Al (ABCA1), causes Tangier disease
(Rust et al. 1999), producing hypersplenism, macrophage accumulation and deposition of
cholesteryl esters in the reticuloendothelial system, low plasma HDL and premature
atherosclerosis. ABCA1 mRNA and protein levels are upregulated by uptake of modified
LDL and downregulated by HDL-mediated lipid efflux in macrophages, suggesting that
local lipoprotein species may directly affect inflammatory leukocyte function in
atherosclerosis (Hovingh et al. 2003; Oram & Lawn 2001).
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1.5.8 Inflammatory processes in fatty-streak formation
Macroscopic infiltration of fatty streaks by lipid-laden monocytes and macrophages together
with T lymphocytes (Stary et al. 1994) contributes to the early initiation of inflammatory
responses to lipid retention (Libby, Ridker, & Maseri 2002) (see Figure 1.8). T-cell
association with macrophages in the setting of elevated levels of TNF-a and IL-2 is visible
in early atherosclerotic plaque (Kishikawa, Shimokama, & Watanabe 1993). T-lymphocyte
activation mediated by CD40/CD40 ligand interactions (Buchner et al. 2003) contributes to
altering local cytokine responses within an evolving lesion, affecting local monocyte or
monocyte-derived macrophages (see Figure 1.9). Monocytes within fatty streaks are exposed
to pro-inflammatory input from oxidised LDL (ox-LDL), monocyte chemoattractant protein-
1 (MCP-1) (Takeya et al. 1993) and IL-1P (Kirii et al. 2003). TNF-a, although pro¬
inflammatory, may act to protect against early atheroma by reducing macrophage scavenger
receptor expression, limiting lipid ingestion (Schreyer, Peschon, & LeBoeuf 1996). Early
vascular smooth-muscle cell (VSMC) migration is stimulated by PDGF in a MAP-kinase
dependent manner (Graf et al. 1997).
1.5.9 Cell kinetics of inflammation in atheroma
Inflammatory mechanisms involve the ordered recruitment of leukocytes to facilitate
efficient resolution of cell damage. Following primary cell injury in most tissues neutrophil
infiltration enables the phagocytic engulfment of infectious organisms, and release of
cytotoxic granulocyte contents (Flaslett, Savill, & Meagher 1989). Polymorphonuclear cells
undergoing programmed cell death are cleared by infiltrating macrophages that act to
dispose of granulocyte debris whilst minimising local inflammatory responses (Meagher et
al. 1992). Macrophages then emigrate to draining lymph nodes, where antigen presentation
of pathogens may occur (Bellmgan et al. 1996). Atherosclerotic plaque is dynamic,
continually recruiting new inflammatory cells, and altering structurally in a response to
chronic inflammation. Compensatory outward vascular remodelling counteracts initial
luminal loss by an increase in arterial luminal diameter, involving matrix degradation,
cellular division and hyperplasia and fibroproliferative repair responses, so that the effective
luminal diameter remains unaltered (Glagov et al. 1987; Korshunov & Berk 2003). Although
this process may allow for maintenance of intra-luminal blood flow, further increase in
atheroma plaque bulk may ultimately contribute to reduced blood flow rates. Cell dynamics
in atheroma have been described using in vitro models and also ex vivo histological samples
in an attempt to address the temporal sequence of cell infiltration into atheroma (Kling,
Flolzschuh, & Betz 1993).
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1.5.10 Role of granulocytes in inflammatory vascular injury
Although monocytes and lymphocyte infiltrates are well documented in histological
descriptions of atherosclerosis, the involvement of granulocytes was rarely reported in early
analyses of atherosclerotic plaque (Ross & Glomset 1976). The absence of neutrophils would
be unusual for a classical inflammatory response and neutrophil infiltrates have indeed been
reported in experimental models of atherosclerosis (Trillo 1982). Subsequent evidence has
highlighted neutrophil interactions with endothelial cells (Topham et al. 1998) and responses
to vascular trauma (Welt et al. 2000) relevant to arterial disease. Neutrophil recruitment to
areas of vascular injury may alter local repair mechanisms, particularly acting to promote
neointimal growth at sites of vascular trauma (Bienvenu et al. 2001). Neutrophils may be
recruited to arterial injury sites by at points of endothelial dysfunction (see Figure 1.7), or by
binding locally sequestered platelets (see Figure 1.12). Downstream signalling from platelet
GPIba to neutrophil Mac-1 integrin may then increase neutrophil activation promoting local
tissue injury (Simon et al. 2000a).
Previous studies reporting an absence of intra-plaque granulocytes may not have visualized
lesions at the precise time of granulocyte infdtration. Clinical studies and animal models
suggest the absence of neutrophils, or components of neutrophil mediated inflammation, may
reduce atherosclerotic initiation and progression (Kawaguchi et al. 1996; Provost & Merhi
1996). Neutrophils further regulate atherothrombosis by enhancing monocyte tissue factor
production, indirectly promoting thrombosis at sites of monocyte infiltration within
atherosclerotic plaque (Cadroy et al. 2000).
Granulocytes have not been frequently reported in atherosclerotic lesions beyond an initial
injury phase (Kling et al. 1987), contrasting with the chronic inflammatory infiltrates in
glomerulonephritis (Naish et al. 1975), rheumatoid arthritis (Mohr & Menninger 1980) and
pulmonary fibrosis (Jones et al. 1998). In arthritis, granulocyte infiltration of the joint cavity
is an initial feature. Macrophage and lymphocyte invasion of synovial cavities then
contributes to cartilage and bone erosion (Jensen & Christensen 1990), leaving fibrous
pannus (Chu et al. 1991). In pulmonary fibrosis, granulocytes initially appear in the alveolar
spaces; however, the lung parenchyma, where fibrosis ultimately occurs, is infiltrated by
macrophages and lymphocytes (Krombach et al. 1996). Thus, there are parallels between
atherosclerosis and these other inflammatory diseases, albeit in the more chronic phases of
disease progression.
Section C Complications of atherothrombosis
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1.6 Matrix and smooth muscle cells in vascular inflammation responses
Atherosclerotic lesion complexity is added to by the continued recruitment of VSMCs,
mediated by specific growth factors, (see section 1.18, and Figure 1.9). TGF-B enhances
VSMC fibroproliferative reponses increasing lesion bulk (Ma et al. 2000) and contributing to
fibrous cap formation (Figure 1.9 and 1.10). PDGF regulates VSMC production of fibroblast
growth factor-2 (Midgley & Khachigian 2004), suggesting that platelet-derived stimuli may
contribute to lesion expansion and organisation (Figure 1.11). Smooth-muscle cells in the
media of arteries, and in atherosclerotic lesions, are surrounded by different types of
connective tissue (see Figure 1.10). In arterial media the matrix consists of type I and III
fibrillar collagen, whereas in the lesions of atherosclerosis biglycan and decorin
proteoglycans predominate intermixed with loosely scattered fibrils of collagen types I and
III (Riessen et al. 1994). When cultured human arterial smooth-muscle cells are plated on
collagen in fibrillar form, the collagen inhibits cell proliferation by up-regulating specific
inhibitors of the cell cycle (Koyama et al. 1996). In vivo degradation of the collagen by
collagenase, or migration away from this inhibitory environment, may allow smooth-muscle
cells to respond to mitogenic stimuli and replicate, as they do when they are cultured on non-
fibrillar, monomeric collagen. Other matrix molecules, such as fibronectin and heparan
sulphate, may also be involved, because they have also been shown to inhibit the cell cycle,
and cell-matrix interactions can lead to the induction of chemokines (Assoian &
Marcantonio 1996; Mercurius & Morla 1998; Wesley, II et al. 1998).
The influence of matrix microenvironment on macrophage behaviour within plaque is less
well defined. Matrix interactions have been shown to influence cellular production of
reactive oxygen species, enzymes and cellular survival, with profound implications for
inflammatory and fibroproliferative responses (Smith et al. 1997). Effects of monocyte
activation upon matrix proteins regulate atherosclerotic plaque structure. Monocyte-derived
matrix-metalloproteinase (MMP) activity compromises vessel wall integrity by degrading
extra-cellular matrix (Galis et al. 1994) (see Figure 1.11). Exposure of extra-cellular matrix
components to intra luminal blood promotes additional local MMP-9 production, enhances
local tissue factor production and contributes to in situ thrombus formation (Morishige et al.
2003). Smooth muscle cells produce tissue factor themselves, following CD40 ligation (see
Figure 1.9), accelerating thrombus formation in vascular injury (Schonbeck et al. 2000).
20
1.7 Platelets and vascular injury
Platelet adhesion and activation are important in animal and human atherogenesis. Platelets
can adhere to dysfunctional endothelium, exposed collagen, and macrophages. When
activated, platelets release granule contents containing cytokines and growth factors that,
together with thrombin, may contribute to the migration and proliferation of smooth-muscle
cells and monocytes (Bombeli, Schwartz, & Harlan 1998). Activation of platelets induces
arachidonic acid formation, which can further be transformed into prostaglandins including
the vasoconstrictor and platelet-aggregator thromboxane A2, or into leukotrienes which can
amplify the inflammatory response (Matthias 1997).
Plaque rupture and thrombosis are notable complications of advanced atherosclerotic lesions
that lead to acute vascular occlusion (Ross 1993). Platelets are physiologically important in
maintaining vascular integrity and protecting against spontaneous haemorrhage (Harker &
Ross 1978). Activated platelets can accumulate on the arterial walls and recruit additional
platelets into an expanding thrombus (see Figure 1.11). The integrin GPIIb/IlIa receptor
appears on the surface of platelets during platelet activation and thrombus formation (Coller
1985, see Chapter 6 section 6.1.6.2). However, increased platelet aggregation may be
detrimental in vascular injury, and GPllb/IIIa antagonists aid the prevention of intra-vascular
thrombus formation in patients suffering from acute coronary syndromes (ACS) (Goodman
et al. 2003). Platelet-leukocyte signalling may be important in promoting leukocyte
activation (see Figure 1.12), and is elevated in ACS (Sarma et al. 2002). Platelet derived
components including platelet activating factor (PAF) and CD40 ligand may activate
macrophage protease secretion, resulting in further acute plaque matrix degradation (May et
al. 2002), and platelet leukocyte interactions are associated with neo-intimal proliferation
(Wang et al. 2005).
1.8 Immune responses in plaque progression and instability
The majority of myocardial infarctions occur as a result of erosion or uneven thinning and
rupture of the fibrous cap, at macrophage-rich shoulders of the lesion. An immunoregulatory
molecule, CD40 ligand (Hollenbaugh et al. 1995), can be expressed by macrophages, T cells,
endothelium, and smooth muscle in atherosclerotic lesions in vivo, and its receptor, CD40, is
expressed on the same cells. Activated T cells stimulate macrophages to release IL-ip and
increase MMP production via CD40/CD40L dyad mediated signalling (see Figure 1.9)
enhancing the inflammatory responses within lesions and promoting plaque instability
(Schonbeck et al. 1997). CD40-mediated signalling promotes tissue-factor production
(Bavendiek et al. 2002; Mach et al. 1997) leading to thrombosis. Inhibition of CD40 with
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blocking antibodies reduces lesion formation in apolipoprotein E-deficient mice (Mach et al.
1998) supporting a role for this molecule in atherosclerosis. Although experiments with mice
bearing gene deletions for both apo-E and recombinase activating gene-1 Rag-1
demonstrated that lymphocytes are not required for atherosclerotic plaque formation, it
appears that they contribute to inflammatory injury in established lesions (Dansky et al.
1997). Thl lymphocytes produce interferon gamma, inhibiting smooth muscle cell collagen
production and smooth muscle cell proliferation (Gupta et al. 1997b), limiting
fibroproliferative repair. Together, these findings implicate adaptive immune responses in
the development of unstable atherosclerotic plaque.
Section D The role of monocytes in orchestrating atherosclerosis
1.9 Monocytes in Inflammatory Vascular Injury
Monocytes are crucial in the inflammatory cascade that follows cellular injury. Monocyte
phagocytic function is central to disposal of cellular debris and the ingestion and clearance of
pathogenic material (Elaslett 1992; Savill et al. 1993). In addition, monocytes help direct
reparative changes at the lesion sites. Monocytes contribute to the innate immune response
the resolution of inflammation and the initiation and regulation of acquired immune
responses. Monocytes adopt diverse roles in these fundamental processes with external
influences, including cell-cell interactions during transmigration, regulating the high-level of
monocyte phenotypic and functional plasticity (Gordon, Keshav, & Chung 1988). The
transition of monocytes to tissue-specific differentiated cells is a response to specific
trafficking and migratory stimuli (Randolph et al. 1998) integrated with local inputs from
chemical (Mohty et al. 2003) and autocrine signals (Brewington et al. 2001). Disparate
triggers may thus produce uniquely tailored responses peculiar to individual pathological
insults, correlating with the high diversity of in vitro monocyte differentiation (Golub &
Pagan 1986; Lyakh et al. 2000; Ruppert et al. 1991; Young, Lowe, & Clark 1990). In
atherosclerosis, local tissue injury at the level of the endothelium (although not necessarily
endothelial denudation (Joris et al. 1983)) results in recruitment of circulating intra-vascular
monocytes by promoting monocyte margination to the vascular wall (Cybulsky & Gimbrone,
Jr. 1991). Subsequent differentiation following transendothelial migration is further
modulated by contact with resident cells, matrix components (Rekhter et al. 1993), and
chemokine and cytokine signals (Sugiyama et al. 2001). The role of lipids has been of key
interest in the development of this model. Human post mortem specimens demonstrate
elevated lipid infiltration at heavy plaque burden sites within the arterial tree (Faggiotto &
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Ross 1984), and suggest that monocyte handling of lipid is crucial to atherosclerotic plaque
progression (Adams, Bayliss, & Turner 1975; Smith et al. 1995).
1.10 Monocyte Origin
Monocytes are myeloid-derived leukocytes that act specifically early in innate immune
responses. Early myeloid precursors may differentiate along multiple pathways (see Figure
1.13) including a granulocyte developmental programme, or a monocytic programme
(Nichols & Weinberg 1989) determined by critical transcriptional changes (Orkin 1995;
Shivdasani & Orkin 1996). Basophils and eosinophils also originate from this precursor,
although the latter cell type may undergo a separate differentiation pathway (Lawson &
Berliner 1998). Bone marrow stromal maturation signals drive differentiation programmes
influenced by systemic levels of cytokines including GM-CSF and IL-4 (Keisari et al. 2000),
and colony stimulating factor-1 (CSF-1) (Serreze, Gaedeke, & Leiter 1993), altering the
balance of myeloid cell production. Myeloid progenitor to monocyte progression is
irreversible (Akashi et al. 2000), but monocytes are not entirely terminally differentiated.
Further phenotypic variation denoting differential maturation (Dransfield et al. 1988), and
response to environment (Freedman et al. 1991), with implications for functional specificity
have been shown. The acquisition of specific phagocytic receptor repertoires (Fadok et al.
1992; Fadok et al. 1998a; Savill et al. 1990; Wahl et al. 1992), or differentiation into specific
antigen presenting cells (Pickl et al. 1996) is of particular interest. Sub-specialised or altered
monocyte phenotypes may be found in a number of pathological conditions, and may range
from multi-nucleate giant cells through Kupffer cells in the liver, to foam cells in the
atheromatous plaques of diseased arterial vessels. Recent attention has been drawn to
phenotypically distinct pro-inflammatory monocyte subsets with characteristic low CD 14
expression and high CD16 levels (Fingerle et al. 1993). Although only comprising a small
percentage of total monocyte numbers, such monocyte subsets may disproportionately
contribute to inflammatory responses.
1.11 Monocyte characteristics
Monocytes are typically in the order of 7-10 micron in diameter (Arenson, Jr., Epstein, &
Seeger 1980). Morphologically they have large ovoid nuclei classically bearing a central
indentation, with very densely packed and clumped chromatin (van Furth, Raeburn, & van
Zwet 1979). In contrast to lymphocytes, monocytes have a relatively high cytoplasmic to
nuclear ratio. The cytoplasm often vacuolates during monocyte differentiation, and this
appearance may become marked during the progression towards a functional macrophage
phenotype (Edelson & Cohn 1974; Lotan, Sharon, & Goldman 1977). Monocytes bear
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markers including CD 13 and CDwl23 (Leveque et al. 1998; van Hal et al. 1992) derived
from and denoting their myeloid lineage in marked distinction to lymphocyte precursors
which classically bear markers including CD10, CD34 CD38 CD127 and HLA-DR (Bender
et al. 1994; Plum et al. 2000; Tazzari et al. 1987; Terstappen, Huang, & Picker 1992). By
contrast, HLA-DR becomes more evident in monocytes during maturation (Te Velde et al.
1988). The progression from pre-monocyte to monocyte introduces a significant increase in
cell surface markers (Allavena et al. 1998), with further changes apparent during maturation
to a macrophage phenotype. CD16 (low-affinity Fc receptor) and CD51 (vitronectin receptor
alpha chain) are only expressed after serum-induced macrophage differentiation (Andreesen
et al. 1990).
1.12 Monocyte Kinetics
Monocytes spend a limited time within the bone marrow following production and are
rapidly seen entering the intra-vascular compartment (Lord 1992). Extrinsic stimuli
involving the monocyte during key recruitment events to areas of inflammation include
signals derived from adhesion and subsequent transmigration across endothelial cells (Muller
& Randolph 1999; Rosenfeld 2002), but also involve chemokine inputs including MCP-1,
IL-8 and the CXC chemokine Regulated on Activation Normally T-Expressed presumably
Secreted (RANTES) that are relevant to atherosclerosis (Gerszten et al. 1999; Schober et al.
2002). Circulation times for monocytes at early stages of differentiation are between 20-40
hours (Koeffler, Gale, & Golde 1980). If recruited to sites of inflammation following trans-
endothelial migration, monocytes may perform phagocytic clearance functions (Duvall,
Wyllie, & Morris 1985; Haslett 1992). Alternatively, monocytes may take up tissue specific
roles (MacDonald et al. 2002; Massey & Flanagan 1999; Tomita et al. 1994), a phase of
monocyte life that is governed by specific cytokine stimuli and may be protracted (Fries,
Perneczky, & Kempski 1994).
1.13 Monocyte recruitment and migration
Monocyte behaviour is divided into defined phases from the time of entry into the
circulation. Initial chemotactic influences direct intra-vascular monocytes to localise to
inflammatory sites such as areas of bacterial infection (Doherty et al. 1987). Further
chemotactic stimuli may be provided by complement components thereby increasing cell
numbers (Ember et al. 1994). Local cell death at target sites of injury enhances extracellular
calcium levels released from apoptotic cells, potentially promoting calcium-dependent
monocyte chemotaxis (Olszak et al. 2000) and Fas ligation at macrophage surfaces increases
IL-8 and TNF-a production, as well as potentiating neutrophil chemotaxis (Park et al. 2003).
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Increasing adhesion molecule expression on endothelial cell surfaces in vessels serving sites
of inflammation augments local monocyte recruitment, with increased levels of ICAM-1, E-
selectin, and vascular cell adhesion molecule-1 (VCAM-1/CD106) are particularly apparent
in immunohistochemical studies of human atheroma (Duplaa et al. 1996).
1.14 Monocyte and endothelial cell interactions
Haemodynamic alterations at individual vulnerable arterial sites, such as branch points,
bifurcations, and tortuous curvatures, alter endothelial function. Haemodynamic stimuli in
the vessel wall including decreased shear stress and increased turbulence modulate the
expression of endothelial adhesion molecules e.g. selectins, VCAM-l and ICAM-1
(Chappell et al. 1998), which enable more avid binding of monocytes through surface
counter-receptors. Molecules mediating trans-endothelial leukocyte migration, such as
PECAM-1 (Muller et al. 1993), act in conjunction with chemoattractant molecules, such as
MCP-1, osteopontin (Giachelli et al. 1998), and modified LDL to attract monocytes into the
artery wall (Rajavashisth et al. 1990).
1.15 Monocyte subsets may differentially modify inflammatory responses
Surface molecular phenotyping has demonstrated that monocyte maturation produces
functionally specific phenotypic alterations. Alveolar macrophages express high class II
major histocompatibility (MHC) antigens but low CD14; peritoneal macrophages display an
inverse phenotype (Andreesen et al. 1990). Plasmacytoid monocytes in interfollicular areas
of lymph nodes bear increased levels ofCD36+ CD68+ and CD123+ but low levels of CD3,
CDllc, CD14, CD20 and CD56 (Facchetti & Vermi 2002), and may progress to dendritic
cell morphology and function (Grouard et al. 1997). Kupffer cells in the liver, conversely,
are notable for a high surface expression ofMac-2 and Mac-3 (Hashimoto et al. 1996).
Specific subsets of monocytes may be responsible for varying inflammatory responses in
vivo (Geissmann, Jung, & Littman 2003). The classical phenotype for circulating monocytes
is most commonly CD14++/CD16-/HLA-DR+. In disease states with parallel inflammatory
cellular mechanisms to atherosclerosis such as rheumatoid arthritis, it has been suggested
that CD14+/CD16+ subsets produce significantly different inflammatory effects, as has been
demonstrated in clinical studies on rheumatoid arthritis (Kawanaka et al. 2002), systemic
sepsis (Skrzeczynska et al. 2002), and pulmonary injury (Horelt et al. 2002; Yoshioka et al.
2002). An alteration in monocyte phenotype with respect to relative CD 14 and CD 16
(FcyRIII) levels may critically up-regulate TNF-a production responses, thus altering final
monocyte/macrophage effector outcomes in inflammation (Beige et al. 2002). The uptake of
differentially modified lipids also appears to be heterogenous in monocyte populations:
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CD14+/CD16+ subsets display higher uptake of enzymatically degraded LDL in contrast to
nai've CD14++/CD16- subsets, resulting in rapid ultra-structural transformation of
CD14+/CD16+ monocytes into foam cells (Kapinsky et al. 2001). Acetylated, native or even
copper-oxidised LDL uptake is less avid, with little involvement of classical scavenger
receptor pathways including SR-A and CD36.
Associations have also been made between hyperlipidaemia and rare monocyte subsets, with
HDL levels inversely correlating to the population size of CD64-CD16+ monocytes.
Subjects with high levels of particular lipoproteins, in particular apolipoprotein E3/E4 and
E4/E4 phenotypes, show a tendency towards larger circulating populations of CD64-CD16+-
monocytes (Rothe et al. 1996). Such pre-differentiated monocyte subtypes may specifically
target the vascular wall and at least three different types of macrophages, each regulated by
different T-cell cytokines have been identified (Tormey et al. 1997). Differences in arterial
endothelium and micro-vascular endothelium may exist to preferentially attract different
types of monocytes (Garlanda & Dejana 1997). If individual monocyte inflammatory
responses can specify lipid handling and modification during the transition from monocyte
into foam cell, these studies raise the possibility that individual monocyte subsets and
differentiated monocytes play varying roles in atherogenesis and foam cell formation.
Auto-immune processes may be driven by a change in monocytes towards a dendritic cell
phenotype, potentially involving immune presentation of epitopes within the plaque in a way
that prolongs inflammation. Monocyte sub-differentiation into dendritic cells has been linked
to a number of microenvironmental stimuli including critical adhesion interactions and
movement of monocytes across endothelial monolayers. Interactions mediated by CD31 or
PECAM (Muller & Randolph 1999) may be implicated in the maturation of monocytes
entering lymph nodes, and subsequent transformation into dendritic cells. Influences upon
monocyte differentiation by pro-atherogenic stimuli are thus relevant to innate immune and
adaptive immune responses.
1.16 Monocyte maturation and foam cell differentiation
Previously described by light microscopic appearances, the presence of foam cells has been
documented as a basic ultrastructural feature of atheroma (Buja, Kovanen, & Bilheimer
1979), but it is only in the recent past that attempts have been made to address the origins of
such cells (Gerrity 198la), and explain the cellular dynamics of these lesions (Jerome &
Lewis 1997). Immunophenotyping originally suggested that foam cells were derived from
monocytes, rather than being lipid laden smooth muscle cells (Aqel et al. 1984). Once
resident within plaque these monocyte-derived foam cells still maintain certain phenotypic
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and functional features of monocyte/macrophages (Inaba et al. 1993; Trogan et al. 2002),
suggesting that a dynamic inflammatory role for this cell population might be fundamentally
important in plaque behaviour. Data from experiments involving the in vitro exposure of
monocytes to lipoproteins, and to other pro-inflammatory and pro-atherogenic stimuli have
suggested that the local environment regulates the progression of naive monocytes towards a
foam cell phenotype (Wang et al. 1996). Alteration of this phenotype may determine
monocyte functional responses within an atheromatous lesion, with the production of
extracellular matrix metalloproteinase inducer (EMMPRIN) (Major et al. 2002). Ox-LDL,
TNF-a, or M-CSF all cause concentration and time-dependent increases in macrophage
production of MMP-3 (Uzui et al. 2002) contributing to proteolytic degradation of
extracellular matrix. This model of inflammatory plaque destabilisation offers potential for
future therapies, as an ability to modify plaque inflammation may limit further injury, and
promote vascular repair.
1.17 Monocyte apoptosis
Although the mechanisms of apoptotic cell clearance by monocyte-derived macrophages
have been extensively researched (Henson, Bratton, & Fadok 2001), relatively less attention
has been paid to death programmes in monocytes than in granulocytes. However, apoptosis
in monocyte pre-cursors perform a physiologically important role in haematopoiesis (Ohishi
et al. 2000), and peripheral blood monocytes may undergo programmed cell death in
common with other leukocytes (Mangan & Wahl 1991). Monocyte susceptibility to
apoptosis varies with maturation status (Kiener et al. 1997), the response to extrinsic stimuli
including lipopolysaccharide (LPS) exposure (Um, Orenstein, & Wahl 1996), and the
influence of cytokines including IL-4 (Mangan, Robertson, & Wahl 1992). Active sites of
inflammation may provide an environment that is non-supportive of uncommitted immature
monocyte survival. In atherosclerotic plaque, the absence of non-cytokine protective serum
components such as lysophosphatidic acid (Koh et al. 1998) may expose the naive monocyte
to pro-apoptotic signals, and engagement of apoptotic pathways may be accelerated.
Leukocyte apoptosis may be induced by discrete cellular triggers, including the surface
ligation of CD95 (Fas) (Iwai et al. 1994), and the withdrawal of survival proteins including
key cytokines such as macrophage colony stimulating factor (Munn et al. 1995). Monocyte
apoptotic behaviour contrasts with that seen in granulocytes, which display induction of cell
death via TNF-a ligation of the TNF-R1 receptor (Murray et al. 1997), driving death via
TRADD (TNF receptor associated death domain) (Hsu, Xiong, & Goeddel 1995), FADD
(Fas associating protein with death domain), and RAIDD (receptor interactivity protein
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(RlP)-associated ICH-l/CED-3 homologous protein with a death domain). Monocytes in
distinction appear to be activated by TNF ligation (Langstein et al. 1998), and TRAIL (TNF-
related apoptosis-inducing ligand) which confer protection against cell death via activation
of NF-kB (Secchiero et al. 2003). The pro-apoptotic cytokine TRAIL (TNF-related
apoptosis-inducing ligand) acts to promote both apoptosis and cell activation, performing a
complex dual role analogous to that of TNF receptors (Schneider et al. 1997; Walczak et al.
1997). TWEAK/Apo3L, another TNF family member (Chicheportiche et al. 1997), acts to
initiate the downstream activation of caspases (Nakayama et al. 2002) and can cause
monocyte apoptosis that may be important in auto-immune disease (Kaplan et al. 2002).
Caspases, cysteine proteases that have been highly conserved through evolution, activate
nucleases including caspase-activated DNAse (Thornberry & Lazebnik 1998). The resultant
cleavage ofDNA causes nuclear fragmentation, one of the hallmarks of apoptosis, which has
been demonstrated in spontaneous monocyte apoptosis (Fahy, Doseff, & Wewers 1999).
TWEAK is expressed on human monocytes at low levels, but appears to be upregulated
following interferon gamma exposure, adding a further level of sophistication to monocyte
apoptotic control mechanisms in the context of inflammation (Nakayama et al. 2000).
Phagocyte uptake of apoptotic cells is regulated by integrin mediated signalling, and
dependent upon the number of apoptotic cells already ingested (Erwig et al. 1999).
Phagocytosis of apoptotic cells may alter inflammatory balance, promoting TGFp production
(Huynh, Fadok, & Henson 2002) and cross-presenting ingested antigens (Savill et al. 2002),
events discussed further in Chapters 3 and 6. Unregulated apoptosis in vivo, especially in the
context of overburdened or inefficient clearance mechanisms, may lead to marked cellular
necrosis (Ogasawara et al. 1993) increasing local pro-inflammatory mediators levels and
exacerbating local cell damage. This may be a contributory factor in the protracted pro¬
inflammatory state present within unstable plaque. Balanced apoptotic cell clearance is thus
of central importance in maintaining plaque dynamics in a stable pattern.
1.18 Growth factor influences upon monocytes and atherogenesis
Growth factors regulate vascular repair and neovascularisation processes relevant to arterial
disease. Vascular endothelial growth factor (VEGF) promotes angiogenesis and may also
regulate the rate of atherosclerotic plaque development. Data from both rabbit models and
murine apolipoprotein E/apolipoprotein B100 gene deletion models suggest that VEGF
increases atherosclerotic plaque area, as well as plaque macrophage and endothelial cell
content (Celletti et al. 2001). Ox-LDL increases VEGF mRNA and protein expression in the
monocytic cell line RAW 264. Immunohistochemical analyses of human atherosclerotic
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plaques demonstrate VEGF staining in foam cell-rich regions of plaque adjacent to the lipid
core and neovascularized basal regions, with VEGF localising to macrophage cell surfaces
(Ramos et al. 1998). Monocytes entering atherosclerotic plaque thus potentiate
neovascularisation, with increased visible capillary density and tissue perfusion seen in
murine models (Silvestre et al. 2003). Neovascularisation at a microscopic level may provide
alternative routes for leucocytes recruitment into lesions (Moulton et al. 2003). Microvessel
density in lipid-rich plaques is higher than fibrous plaques, with most vessels located in
shoulder-regions or the base of the plaque, adjacent to intra-plaque inflammatory cellular
infiltrates. Microvessels in lipid-rich plaques show increased levels of ICAM-1, VCAM-1,
E-Selectin and CD40, with VEGF being confined to vessels and mononuclear cells within
lipid-rich plaques alone. Increased cellular influx may augment local inflammation,
potentially increasing plaque vulnerability (de Boer et al. 1999). The sequestration, survival,
and replication of monocytes in atheromatous plaque are partially dependent upon M-CSF
and granulocyte-macrophage colony-stimulating factor (GM-CSF). Prolonged exposure to
M-CSF has been reported to rescue macrophages from cell death in vitro and, within the
lesions, may offer a mechanism for local monocyte/macrophage replication and
proliferation. In contrast, inflammatory cytokines such as interferon-y (IFNy) activate
macrophages and under certain circumstances induce them to undergo apoptosis.
1.19 PPARy: a role in monocyte differentiation, survival and functional
regulation
Nuclear receptors are involved in regulation of leukocyte cellular homeostasis and
inflammatory responses, and have numerous actions in metabolic control and cellular
survival. Nuclear receptors are ligand-activated transcription factors which mediate steroid
hormone, thyroid hormone, and fat-soluble vitamin signaling (Evans 1988). Orphan nuclear
receptors, with initially unknown ligands, target genes and physiological functions, bear
homology to steroid nuclear hormone receptors. The role of the peroxisome proliferator
receptor gamma (PPARy), previously regarded as an orphan nuclear receptor is increasingly
studied with regard to glucose homeostasis, adipocyte metabolism and leukocyte
inflammatory function (Giguere 1999). All nuclear receptors have a DNA binding site and a
ligand binding site, enabling the receptor to bind to specific hormone response elements
within the gene (Chambon 1996). PPARy acts via heterodimerisation with retinoid X
receptor (RXR) ligands, to bind a PPAR response element (PPRE) within the genome thus
regulating transcription of target genes (Tugwood et al. 1992). PPARy appears to alter
cellular phenotype and function dependent on cell type and cell environment which has
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relevance to atherogenic processes (Chinetti, Fruchart, & Staels 2001; Ricote et al. 1999).
Variation in responses may be partially attributable to differential expression of PPAR
subtypes as well as cell specificity, dictating differential transcription for
monocyte/macrophages in distinction to adipocytes (Spiegelman 1998) hepatocytes
(Schoonjans et al. 1996) or endothelial cells (Marx et al. 1999).
1.20 PPARy effects on lipid handling and phenotype
PPARy induction of an altered monocyte surface phenotype increases lipid entry into the cell
via the scavenger receptor B, CD36 (Huang et al. 1999a; Tontonoz et al. 1998) but
downregulates lipid influx via other routes such as scavenger receptor A (SR-A) (Ricote et
al. 1998b). Initially it was suggested that in vitro PPARy ligation by specific ox-LDL
derivatives produced massive lipid accumulation and the production of a foam cell
phenotype (Tontonoz et al. 1998). However, net lipid balance is mitigated by lipid efflux via
the ABC1A transport mechanism and is also under the control of PPARy and the liver X
receptor (LXR) (Chawla et al. 2001b), which may produce a net lipid deficit dependent upon
the predominant lipid type present. Scavenger receptor expression is controlled during
inflammatory responses, via TGF-Pi and TGF~p2 phosphorylation of MAP kinase.
Subsequent MAP kinase phosphorylation of PPARy in turn reduces CD36 gene transcription
(Han et al. 2000). Thus, altered lipid handling due to ligation of PPARy does not result
necessarily result in acquisition of a foam cell phenotype, but may have more subtle effects
upon monocyte/macrophage function.
1.21 PPARy and inflammation
Inflammatory mediators are implicated in PPARy ligation and subsequent transcriptional
regulation of inflammatory cells. The cyclopentenone prostaglandins 15dPGJ2 and Al2PGJ2,
products of arachidonic acid metabolism derived from the hydroxylation of Prostaglandin D2
to Prostaglandin J2, are present in normal inflammatory reactions and have been noted to act
as natural ligands for PPARy (Kliewer et al. 1995). They have been demonstrated to govern
survival in leukocytes (Chinetti et al. 1998) and endothelial cells (Bishop-Bailey & Hla
1999) and act as anti-inflammatory modulators of macrophage function aiding the resolution
of inflammatory injury (Ricote et al. 1998b). Furthermore, given the role of glucose
regulation by PPARy, specific assessment of the role of PPARy in monocyte
microenvironmental responses is important, as diabetic disease correlates strongly to clinical
atherosclerotic progression (Glass 2001). Thus, because cyclopentenones may modulate
30
inflammation and cell survival within atherosclerotic plaque, a potential link to monocyte
apoptosis through PPARy will be explored in this thesis.
1.22 Monocytes and innate immune responses
Peripheral blood-derived monocytes, the precursor of tissue macrophages, are present at all
stages of atherogenesis. Monocyte-derived macrophages act to scavenge cellular debris and
perform as antigen-presentation cells in concert with both B and T lymphocytes. The role of
monocytes in innate immune mechanisms is crucial and inflammatory injury outcomes rest
on the balance of their functions. They are responsible for the local secretion of cytokines,
chemokines, growth-regulating molecules, metalloproteinases and other hydrolytic enzymes,
thus regulating potential extracellular matrix degradation. Altered chemotaxis and increased
accumulation of monocytes in fatty streaks may be mediated by differentially regulated
chemokine expression (Boisvert et al. 1998; Boring et al. 1997). Monocyte activation results
in increased surface expression of chemokine receptors, mucin-like molecules that bind
selectins, integrins that bind adhesion molecules in the immunoglobulin superfamily, and
receptors that bind chemoattractant molecules (Springer TA & Cybulsky MI 1996) (see
Chapter 6 section 6.1.6). These classical inflammatory ligand-receptor interactions further
activate mononuclear cells, induce cell proliferation, promoting and localizing inflammatory
responses at lesion sites. In a number of inflammatory diseases, elevated plasma levels of
cleaved plasma membrane adhesion receptors have been reported, and taken to be markers of
a sustained inflammatory response. Metalloproteinase activity results in the cleavage of L-
selectin (by L-selectin sheddase) and the cleavage of CD18. Some cell-surface molecular
shedding may be undertaken by disintegrins, sometimes called metalloproteinase-like,
disintegrin-like, cysteine-rich proteins (MDCs) or a disintegrin and metalloproteinase
(ADAMs), identifiable in endothelium, smooth muscle, and macrophages. These trans¬
membrane proteins contain a metalloproteinase sequence in their extracellular segment
permitting activation of molecules such as TNF-a (Black et al. 1997; Moss et al. 1997).
Although absent in normal arteries, one particular disintegrin, MDC15/ADAM15, has been
shown to be present in lesions of atherosclerosis (Herren, Raines, & Ross 1997). Increased
plasma concentrations of cleaved cell surface molecules might thus be used to identify
patients at risk for atherosclerosis or other inflammatory diseases.
Although smooth muscle cells were the only cells thought to proliferate during expansion of
atherosclerotic lesions, monocyte-derived macrophage replication is now thought to be
equally important in plaque progression. The ability of macrophages to produce cytokines
including TNF-a, IL-1, and TGF-B, proteolytic enzymes including metalloproteinases, and
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growth factors such as PDGF and insulin-like growth factor (IGF)-I, may be critical for the
cycles of damage and repair that ensue as the lesions progress. Thus resident plaque
monocyte/macrophages may dictate plaque behaviour and hence clinical outcomes more
than other resident cell types including smooth muscle cells (Rosenfeld & Ross 1990).
Since activated macrophages express class II histocompatibility antigens and have the
potential to present antigen to CD4 and CD8 T lymphocytes present within developing
lesions, (Raines EW, Rosenfeld ME, & Ross R 1996) cell-mediated immune responses may
also be involved in atherogenesis (Hansson et al. 1989). T cells are activated when they bind
antigen processed and presented by macrophages in the context of co-stimulatory molecules
such as CD80, CD86 and CD40 Ligand. T-cell activation results in the secretion of
cytokines, including interferon-y and TNF-a and B, amplifying the inflammatory response.
Lesional smooth-muscle cells that express Class II molecules may also present antigens to T
cells. One putative antigen may be ox-LDL, (Stemme et al. 1995) which can be produced by
macrophages (Folcik, Aamir, & Cathcart 1997). Heat-shock protein 60 may also contribute
to autoimmunity. This and other heat-shock proteins perform several functions, including the
assembly, intracellular transport, and breakdown of proteins and the prevention of protein
denaturation. Heat shock proteins may be present at elevated levels on endothelial cells and
provide a stimulus for innate immune responses thus contributing to local arterial wall
inflammation (Xu et al. 1993).
1.23 Animal models of atherosclerosis
The use of targeted gene deletions has increased our understanding of the role played by
individual components of the leukocyte inflammatory response in atherogenesis particularly
animals bearing gene deletions for apolipoprotein E (apo E) (Nakashima et al. 1994; Plump
et al. 1992) and the LDL receptor (LDL-R)(Kowala et al. 2000), that mimic elevated plasma
lipoprotein states seen in human subjects. Recent work using double knockouts of apo E and
LDL-R (Ishibashi et al. 1994), shows aggressive atherosclerosis in these animals more
representative of human atherosclerotic lesions (McGillicuddy, Carrier, & Weinberg 2001).
In the absence of apolipoprotein E, lipoprotein remnants are not carried to the liver, where
they are normally metabolized, and the mice become hypercholesterolaemic and lesions of
atherosclerosis develop that are similar to those in humans. Murine models emphasise the
importance of adhesion molecules in monocyte recruitment to atherosclerotic plaque, and
subsequent monocyte phenotypic change. Mice deficient in apolipoprotein E, show increased
ICAM-1 expression at lesion-prone sites, above baseline levels seen in wild-type animals. In
contrast, VCAM-1 is absent in normal mice but is is also expressed at lesion-prone sites in
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mice with apolipoprotein E deficiency (Nakashima et al. 1998). Thus, adherence of
monocytes may be driven by increased expression of one or more of the different families of
adhesion molecules, induced primarily by increased local lipid levels. Blockade of adhesion
molecules might thus be predicted to be protective. In mice deficient in intercellular
adhesion molecule 1, P-selectin, CD18, or combinations of these molecules, lipid
supplementation was shown to cause smaller atherosclerotic lesions (Hynes & Wagner
1996). The work presented here does not make use of murine models, focusing instead on
responses of primary human cells. However, it was felt to be important to address altered
monocyte transcription of adhesion molecules, following exposure to varying forms of LDL.
This, in conjunction with surface molecular phenotyping, may offer insights into the changes
occurring in the transition from uncommitted circulating monocyte to a mature plaque-based
macrophage with an altered phenotype.
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Section E Hypothesis and specific aims of the work
The overall hypothesis being proposed is that pro-atherogenic and pro-inflammatory
microenvironments affect monocyte survival and monocyte phenotype.
1.24 Specific aims and structure of thesis
The specific aims of this work are outlined.
a) To determine whether modified lipoproteins and inflammatory mediators alter
monocyte survival, the effects of both LDL and cyclopentenone prostaglandins
upon monocyte apoptosis will be assessed in Chapter 3.
b) To evaluate the role of PPARy in monocyte survival the effects of PPARy
ligands upon monocyte apoptosis will be assessed, and intra-cellular levels of
monocyte PPARy will be measured in Chapter 3.
c) The dependence of monocyte apoptosis upon PPARy will be specifically
explored using a dominant co-repressor mutant gene to suppress PPARy gene
function, and will be described in Chapter 4.
d) Changes in monocyte transcription following LDL exposure will be evaluated
using gene miniarrays in Chapter 5.
e) To determine whether modified lipoproteins and inflammatory mediators alter
monocyte phenotype, the effects of LDL upon monocyte structure, and of both
LDL and cyclopentenone prostaglandins upon monocyte surface molecule
expression, will be assessed in Chapter 6.
f) The data presented will be set in the context of current literature, with a view to
potential further work and clinical relevance in Chapter 7.
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VESSEL LUMEN Endothelial cells
Intima
Figure 1-1 Normal artery wall structure
Blood in the vessel lumen is separated from the artery wall and thrombogenic matrix
proteins by the endothelial monolayer.
The intima is bounded by the internal elastic lamina, separating this sub-endothelial
area from the smooth muscle rich media. Further structural strength is offered by the
external elastic lamina.
The adventitia is rich in matrix proteins and bears vasa vasora, lymphatic channels
























Figure 1-2 American Heart Association classification of atherosclerosis
Initial pre-atheromatous lesions (fatty streaks) graded type l-lll are clinically silent
and may not progress to produce symptoms (Phase 1). More advanced
atherosclerotic lesions may also be clinically silent (type IV and Va lesions, clinical
Phase 2).
Increasing lesion complexity results in changes in phase of disease, and eventually
leads to the involvement of thrombus within a Type VI lesion. If this is clinically silent
(Phase 3), it may resolve leaving an organised type V lesion. This again may be
clinically silent or produce symptoms of chronic ischaemia (Phase 5).
Alternatively a Type VI thrombotically complicated lesion may progress rapidly to
cause vessel occlusion and potentially fatal outcomes (phase 4). Resolution of such
a thrombotic episode is possible, resulting in a stable Type V lesion that is often
associated with clinical symptoms (Phase 5).
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VESSEL LUMEN Endothelial dysfunction
Figure 1-3 Gross overview of fatty streak formation
Lipid retention, denoted by small yellow spheres in the sub-endothelial space, alters
the intima, and enhances leukocyte infiltration. Endothelial dysfunction may enhance
lipid penetration of the artery wall. A predominant influx of monocytes is seen in this
early stage of atherogenesis, with preservation of medial and adventitial structure.
This corresponds to the early clinically silent Phase 1 lesions in the Stary/American
Heart Association (AHA) classification, with lesions from stage I to III.
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VESSEL LUMEN
Figure 1-4 Early atheroma
Increasing macrophage infiltration into the intima is accompanied by the formation of
extracellular lipid pools. Smooth muscle cells and T cells are present in the intima
which appears diffusely thickened, with an increase in connective tissue.
These AHA Type IV lesions are termed atheroma, due to their gruel-like
composition.
Although clinically silent (Phase 2), they may progress to plaque erosion, rupture or




Figure 1-5 Advanced atheroma
Smooth muscle infiltration into the intima along with matrix protein synthesis
promotes fibrous cap formation sub-endothelially, adding to lesion bulk.
Further increases in macrophage populations are seen, and neo-vascularisation is
visible in the media as well as adventitia.
These AHA type V lesions are also known as fibro-atheroma, and may be
complicated by thrombus formation at the luminal surface.
Type Va lesions have multiple lipid cores, and are usually clinically silent (Phase 2),
but may progress to plaque rupture.











Figure 1-6 Complex atheroma
Progression of advanced plaque to clinically complex lesions may be driven by
endothelial cell loss and/or plaque fissuring, often at areas of high macrophage
density, causing progression to AHA type VI lesions.
Surface defects have been classed as type Via lesions and may represent rapid
progression form type IV or type Va lesions.
Intra-plaque haemorrhage may contribute to lesion volume, in type Vlb lesions. If
this extends into the more luminal areas of plaque, this may potentially disrupt
plaque architecture.
Exposure of matrix components to intra-luminal blood initiates platelet adherence,
causing local thrombus formation in AHA type Vic lesions. Luminal thrombus may
resolve, and be incorporated into the plaque adding to lesion bulk.
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Lumen
Figure 1-7 Early inflammatory vessel wall injury in atherosclerosis
Vascular injury mediated by factors including LDL, hypertension, shear stress and
glycosylation end products may induce endothelial dysfunction (denoted by green
endothelial cells), accompanied by a reduction in local nitric oxide production.
Systemic inflammation during microbial infection may contribute to vascular
inflammation and endothelial dysfunction, although this remains controversial.
Associated increases in adhesion molecule expression direct leukocyte
transmigration into the vessel wall. The influx of monocytes is most notable,
although a role for granulocytes in early atherogenesis is possible.
Early leukocyte lipid and collagen deposition correspond to fatty streaks, or Stage I




Figure 1-8 Inflammatory contributions to fatty streak formation
Monocytes exit the lumen and differentiate according to local cellular stimuli
including cytokines and inflammatory mediators.
LDL is subject to progressive oxidative changes in the sub-endothelial space. Both
minimally modified LDL (mmLDL) and oxidised LDL (ox-LDL) contribute to
macrophage lipid uptake via macrophage scavenger receptors. Scavenger
receptors are a large family of surface molecules, but key players in macrophage
uptake of altered LDL appear to be scavenger receptor A (SR-A) and scavenger
receptor B-l or CD36.
Cholesterol efflux mechanisms act to limit lipid accumulation, and drive HDL efflux
via the ABCA1 transporter mechanism, a homeostatic process that appears to be
under the regulation of nuclear receptors, including PPARy. However, excessive
local lipid concentrations may overwhelm the capacity of these lipid disposal routes.




Figure 1-9 Immune mechanisms promote atherosclerotic progression
The influx of T-lymphocytes promotes a chronic inflammatory response in the vessel
wall. Cytokines, derived from pro-inflammatory T-helper1 (Th1) and anti¬
inflammatory T-helper2 (Th2) cells, regulates macrophage and vascular smooth
muscle cell (VSMC) responses in atherosclerosis.
Th1 inputs, including the signalling molecule CD40 ligand (CD40L), influence VSMC
migration into the intima from the arterial media. Lesion bulk is further enhanced by
fibroblastic VSMC responses including collagen synthesis.
However, Th1 cells also stimulate both macrophages and VSMCs with interferon
gamma (IFNy), to promote macrophage Class II major histocompatibility (MHC)
expression, decrease collagen synthesis and inhibit VSMC proliferation.
Th1 signalling via the CD40/CD40L dyad to macrophages enhances secretion of
matrix metalloproteinases (MMPs), contributing to extracellular matrix degradation in
the shoulder areas of plaque. Th1 CD40 signalling to VSMCs also enhances tissue
factor production, promoting local thrombus formation.
The Th2 derived cytokines interleukin (IL)-4, IL-10 and IL-13 limit Th1 activity,
antagonise IFNy, and reduce pro-inflammatory macrophage function.
Th1 and Th2 cells self-regulate their responses via IL-4 and IL-10 feedback.
T cells may also present ox-LDL derived antigens, suggesting an adaptive immune
component to atherosclerotic disease.









Figure 1-10 Inflammatory influences increasing plaque complexity
Free intimal lipid pools may reflect overwhelmed macrophage lipid-uptake capacity.
Smooth muscle cells may also ingest lipid, adopting a foam cell phenotype.
An increasingly organised fibrous cap is strengthened by fibrin derived from
circulating fibrinogen, and further VSMC recruitment. The proteoglycans biglycan and
decorin displace normal arterial collagen I and III fibrils.
Collagen and proteoglycans increase locally, increasing lesion bulk.
These changes broadly correspond to the Type V fibrotic plaques in the Stary
classification, although lipid content in these lesions may be variable.
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Figure 1-11 Inflammatory influences upon atherothrombosis
Accumulation of intracellular lipid promotes apoptosis of lipid-laden macrophages,
contributing to free lipid within the necrotic core of the plaque.
VSMCs also ingest lipid, adopting a foam cell phenotype.
Elevated macrophage infiltration of plaque shoulder regions is accompanied by high
levels of MMP activity, predisposing to proteolytic degradation, and potential plaque
erosion, fissuring or rupture.
Exposure of both vascular matrix collagen, and the plaque necrotic core, to intra¬
luminal blood enhances platelet deposition and thrombus formation. Contact with free
lipid components including lysophosphatidic acid is a further pro-thrombotic stimulus.
These events correspond to AHA type VI lesions that may be clinically symptomatic.
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Figure 1-12 Inflammatory sequelae of continued atherothrombotic events
Platelet activation compounds local inflammatory activity via interactions between the
platelet surface adhesion molecule P-selectin and macrophage surface P-selectin
glycoprotein ligand-1 (PSGL-1).
Signalling between platelet GPIba and the leukocyte Mac-1 integrin exacerbates
leukocyte mediated vascular damage, and platelet-neutrophil interactions may be
specifically important in this regard.
Platelet-derived growth factor (PDGF) may enhance VSMC proliferation and lesion
bulk during lesion resolution.
This suggests that platelet-derived signals propagate inflammatory vascular damage
resulting in neo-intimal hyperplasia during inflammatory repair. Thrombotic
incorporation into resolving plaque inflammation may occur, further contributing to
lesion volume.
Unregulated inflammation and plaque rupture correspond to Stage VI of the
























Figure 1-13 Myeloid cell precursor differentiation schematic
Adapted from Immunobiology, 5th edition Janeway et al, 1999.
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Chapter 2 MATERIALS AND METHODS
2.1 General materials
Affinity Research Products, Exeter, UK:
A12PGJ2 & 15-deoxyl2PGJ2 (both dissolved in DMSO at lOOmM, stored at -20°C.)
z-VAD-fmk methyl ester.
Ambion Europe Huntingdon UK:
DNase I, lOx DNase buffer, and DNase inactivation reagent
Diethylpyrocarbonate (DEPC) treated water
Nuclease-free water
Chromogenix AB, Sweden:
Limulus amoebocyte lysate-based COATEST® endotoxin analysis system.
Amersham Pharmacia Biotech, Bucks, UK:
Ficoll-Hypaque
Horse-radish peroxidase-conjugated donkey anti-rabbit immunoglobulin antibody.
Hybond C nitrocellulose membrane.
33Phosphorus labelled dATP.
Baxter Healthcare Ltd., Glasgow, UK:
DiffQuik stain, solution I (Eosin G in phosphate buffer, pH6.0)
Solution II, (Thiazine blue in phosphate buffer; pH6.0).
Sterile normal saline solution (0.9%)
Becton Dickinson, UK.
Tissue culture plasticware/polypropylene tubes.
Bender MedSystems (Vienna Austria):
Fluorescein Isothiocyanate (FITC)-labelled recombinant human Annexin V
Calbiochem USA:
Mowoil
Cell Signalling Technology MA USA.
Polyclonal rabbit anti-IxBa antibody
Clontech Laboratories, BD Biosciences, Palo Alto, CA, USA:
Atlas Nucleospin extraction kit.
Atlas pure total RNA Labelling system.
Atlas Cardiovascular nylon membrane gene array.
Gibco Life Technologies Paisley UK:
30% (w/v) acrylamide/bis solution.
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Culture supplements: penicillin (50 U/ml)/streptomycin (50 U/ml); L-glutamine
(200mM)
10% SDS
Hanks Balanced Salt Solution (HBSS)
Iscove's Dulbecco's modified Eagles medium without supplements with L-glutamine
(Iscove's DMEM)
Superscript II RNase H Reverse Transcriptase.
Taq DNA polymerase, recombinant.
Leo Laboratories, UK
Unfractionated heparin sodium, lOOOU/ml




Miltenyi Biotech Bergisch Gladbach, Germany:
CD61 microbeads
LS+ ferromagnetic cell separation columns.
MACS monocyte isolation system
Molecular Dynamics, Sunnyvale CA, USA:
Image Quant phosphorimager analysis software.
Perimmune/Intracel Corporation, Maryland USA:
Oxidised, native and acetylated low density lipoprotein, (unlabelled and 3,3'-
dioctadecylindocarbocyanin-iodide (Di-I) labelled).
Pharmacia Fine Chemicals, Uppsala, Sweden:
Percoll.
Phoenix Pharmaceuticals Gloucestershire UK:
Sodium citrate solution
Promega Corporation WI USA:
lkb DNA ladder.
dNTP mix (dATP, dCTP, dGTP, dTTP).
0.1MDTT.
MgCl2
Oligo dT 15 Primer
pSP72 vector.
Smal, Xhol, Xbal restriction enzymes.
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Taq DNA polymerase in Storage Buffer A.
T4 DNA ligase;
R&D systems Europe Oxon UK:
TNF alpha (stock solution 10p.g/ml).
Sigma chemicals UK, further reagents:
Acrylamide
0.1% Bovine Serum Albumin.
Bromophenol blue.
100% Chloroform
Dextran-500, (dissolved in sterile 0.9% saline, 6% w/v, stored at 4°C until use.)
Dimethyl sulphoxide (DMSO)
Dithiothreitol (in H20 at lOOpg/ml stored at 4°C)
Dulbecco's phosphate buffered saline (PBS) sterile, endotoxin-free, pH7.4 with and





Hoechst 33248, and 33342.
LPS, dissolved in PBS at 1 mg/ml, sonicated (ultrawave sonic bath, Belmont
Instruments Glasgow).





Prostaglandin J2 (in ethanol at 2.99mM stored at -20°C).
Protease inhibitors:
Aprotinin (in H20 at 1 OOpg/ml stored at -20°C)
Leupeptin and pepstatin A (in methanol at 1 OOpg/ml stored at -20°C).
4-(2-amonoethyl)-benzenesulphonyl fluoride (in H20 at 50 mM at 4 deg C)
Sodium orthovanadate, (in H20 at lOOmM at -20°C).
Benzamadine (in H20 at 50mM stored at -20°C)







PPARy, clone 4.17.2 (gift), GlaxoWellcome, Stevenage UK.
PPARy, clone E8 Santa Cruz Biotechnology Inc., (USA),
Ser-32 phospho I-kB New England Biotechnologies, USA.
Flow cytometry
Epitope Clone Isotype Manufacturer/source
IgG, W3/25 Serotec, Oxon, UK
IgG2a MRC OX-34 Serotec, Oxon, UK
CDlla Wac70 IgG2a Dr J Ross, University of
Edinburgh
CDllb Clone 44 IgG, ICRF, London UK
CDllc 3.9 IgG, ICRF, London UK
CD14 UCHM1 IgG, ICRF, London,UK
MEM 18 IgG, Serotec, Oxon, UK
CD16 3G8 IgG, JC Unkeless, Rockefeller
University, New York
CD29 12G10 IgG, Serotec, Oxon, UK
CD36 siwj) IgG, ICRF, London UK
CD36 IVC-7 IgG, Pelicluster; Amsterdam, NL
CD47 B6H12 IgG, Abeam, UK
CD49d 44H6 IgG, Serotec, Oxon, UK
CD49e JBS5 IgG, Serotec, Oxon, UK
CD54 Clone 15.2 IgG, ICRF, London UK
CD61 PM6/13 IgG, Serotec, Oxon, UK
CD64 10.1 IgG, Serotec, Oxon, UK
CD86 BU63 IgG, Caltag, Burlingame CA, USA
Class II WR18 IgG2a Serotec, Oxon, UK








2.3.1.1 Discontinuous density centrifugation
Human peripheral blood leukocytes were isolated using discontinuous density centrifugation
(Dransfield et al. 1994; Szefler et al. 1987). With local ethical approval, in accordance with
the Declaration of Helsinki, whole blood was obtained by venepuncture using 19 gauge
needles (Sarstedt UK), from healthy volunteers with no history of inflammatory disease, and
on no current drug therapies. 36 ml whole blood was collected into 50ml Falcon
polypropylene tubes containing 4mls of 3.8% sodium citrate pre-warmed to room
temperature to anti-coagulate samples. Samples were gently inverted to mix with minimal
cell activation, and then centrifuged at 350g at room temperature for 20 minutes. Platelet-
rich plasma was separated from the leukocyte and erythrocyte pellet, which was re-
suspended in sterile normal saline at 37°C with the addition of 5m!s of 6% Dextran (T500) to
promote erythrocyte sedimentation. Samples were allowed to sediment for 30 minutes at
room temperature, before removal of the now well-defined upper leukocyte layer. This was
further centrifuged at 350g at room temperature, and the supernatant discarded leaving a
leukocyte pellet, which was resuspended in 2.5mls of 55% isotonic Percoll (9:1 vol/vol
PercolklOxPBS). Discontinuous gradients were formed by overlaying 2.5ml of a 68%
Percoll mixture over 2.5ml of a 79% Percoll mixture, before careful overlaying of the 55%
Percoll/leukocyte mixture on top. Gradients were centrifuged (720g, 20 minutes) resulting in
distinct leukocyte bands forming: an upper mononuclear cell layer and a lower
polymorphonuclear granulocyte layer. Mononuclear cells were carefully harvested by
aspiration, using a sterile disposable Pasteur pipette. Mononuclear cells were resuspended in
PBS and cell yield was assessed with a haemocytometer. Volunteers were screened to ensure
that they did not have elevated eosinophil levels, by flow cytometry and light microscopic
assessment of cytocentrifuge preparations stained with haematoxylin/eosin according to
previous protocols (Ward et al. 1999).
2.3.1.2 Ficoll-Paque centrifugation
An alternative method was used to produce a granulocyte-free mononuclear cell preparation.
Mononuclear cells were isolated using centrifugation through Ficoll-Paque®. Freshly drawn
human venous blood was anti-coagulated with heparin at lOU/ml. Cells were diluted with 2
volumes of cation deplete phosphate buffered saline. 35 mL of diluted cell suspension were
layered over !5mL Ficoll-Paque® in a 50mL conical tube and centrifuged at 400g for 30
minutes at 20°C. The upper layer was aspirated, leaving the mononuclear cell layer
undisturbed at the interphase. The interphase was then aspirated and deposited in a fresh
50mL conical tube. Cells were washed with cation-depleted PBS and centrifuged at 300g for
6 minutes at 20 °C. This step was repeated to enhance removal of platelets.
For both discontinuous gradients and Ficoll-paque separation, cell purity was assessed by
flow cytometric scatter properties. 20pl samples of isolated cell suspensions were used to
quantify individual leukocyte populations, before proceeding to further purification.
2.3.1.3 Further monocyte purification: immunomagnetic separation
Further monocyte purification was performed either by using in vitro adhesion to tissue
culture plastic, and/or by immunomagnetic separation.
For adhesion mediated purification without prior immunomagnetic bead separation, cells
suspended in Iscove's DMEM at a concentration of 4x106 per ml were allowed to adhere to
tissue culture plastic (Falcon or BioWhittaker, UK), for one hour at 37°C/5%C02. Non¬
adherent cells were removed by circumferential washing of cell culture wells three times
with cation replete PBS, using sterile plastic pastettes.
Immunomagnetic purification was performed using a magnetic bead separation technique
(MACS, Miltenyi Biotech GmBH Germany). Mononuclear leukocytes, isolated either by
Ficoll-Hypaque or Percoll density gradient centrifugation, were incubated with 5%
autologous plasma, prepared from platelet rich plasma by centrifugation at 1000g for 5
minutes on ice, to block potential Fc receptor binding. Leukocytes were incubated with
monoclonal antibodies to CD3, CD7, CD16, CD19, CD56 and glycophorin A, in a pre-
prepared cocktail (Miltenyi Biotech GmBFI Germany) for 15mins. Cells were washed in
cation-deplete PBS/5% plasma before repeated plasma incubation for lOmins on ice. Target
leukocytes were incubated with hapten conjugated beads. Leukocytes were filtered through a
30 micron pore-diameter sterile mesh and pipetted onto a ferromagnetic cell separation
column (LS+ column, Miltenyi Biotech GmBH), held in a magnetic field. Eluate was thus
composed purely of monocytes, with lymphocytes, megakaryocytes and natural killer cells
being left attached to the elution column. Purity post-elution consistently approached 90%.
Cell numbers retrieved were consistent with the estimated monocyte sub-population
percentage ascertained by flow cytometric scatter properties prior to purification.
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2.3.2 Primary human monocyte culture
2.3.2.1 Adhesion based experiments
Monocytes were plated onto tissue culture plastic (BioWhittaker, UK) at lxlO6 cells/ml in
Iscove's DMEM for 1 hour, washed with PBS plus cations, and cultured in Iscove's DMEM
plus 10% autologous serum at 37°C/5%C02. Monocytes were cultured for relevant time
periods from 24 hours to 14 days. Prolonged incubation necessitated the replenishment of
culture medium and serum and treatment supplements every 48 hours.
2.3.2.2 Suspension culture experiments
For suspension culture, monocytes were re-suspended at lxlO6 cells/ml, in Iscove's DMEM
plus 10% autologous serum. Cells were then aliquoted into 5, 7 or 15 ml Teflon pots (Tuf
Tainer, Pierce Chemical USA/Perbio UK), and cultured at 37°C/5%CC>2. Cell number was
verified at sampling time-points to assess cell loss, and trypan blue exclusion was used to
assess cell membrane integrity, as a marker of a lack of necrosis during culture.
2.3.2.3 Apoptosis response experiments
Monocytes were cultured adherent to tissue culture plastic in serum free conditions using
Iscove's DMEM, or X-Vivo 10 medium (BioWhittaker, UK). Cells were incubated at
37°C/5%C02.
2.3.3 Culture of THP-1 monocytic cell lines
THP-1 human monocytic leukaemia cells were sourced from the European Collection of Cell
Cultures, Salisbury Wiltshire UK (cell line no. 88081201). Cells were rapidly thawed and
resuspended in 4ml of RPMI medium supplemented with 20% foetal bovine serum and 2mM
glutamine in a 20ml conical tube. The cell suspension was centrifuged at 150g for 5 minutes.
THP-1 cells were resuspended at a density of 5xl05 cells/ml in fresh medium in 200ml tissue
culture flasks, incubated at 37°C/5%C02, until the cells reached the exponential phase of
growth. Once cultures were established the serum concentration was reduced to 10%. Cell
numbers were monitored on a daily basis, and kept at a constant concentration of 5xl05/ml to
maintain exponential growth.
2.4 Electrophoresis
2.4.1 Buffers for protein electrophoresis
Materials were purchased from Sigma (Poole, Dorset) unless specified
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Triton X-100 Lysis buffer
lOmM Tris-HCl, 100 mMNaCl, 1 mM EDTA, 0.1% Triton X-100, pHto7.4 with
cone HC1, one tablet protease inhibitor cocktail per 20ml buffer.
NP-40 lysis buffer
1% NP-40 non-ionic detergent; 0.5% sodium deoxycholate; 0.05M Tris pH 8.0; sodium
chloride 0.15M; protease inhibitor cocktail
Blocking buffer
TBS or PBS with Tween-20 0.1%; 5% non-fat milk-protein (Marvel) freshly
prepared.
Stacking buffer(x4)
0.5M Tris, pH adjusted to 6.8 with conc. HC1.
Separating gel buffer(x4)
1.5M Tris, pH adjusted to 8.8 with conc. HC1.
SDS-Tris glycine electrophoresis buffer (xlO)
0.25M Tris-HCl, 1.92M glycine, 1% SDS stored at room temperature.
Acrylamide stock:
30% Acrylamide/0.8% Bis-acrylamide in 250ml dH20, filtered through Whatman
Nol paper, stored in darkness at 4°C.
9 % gels
2.5ml 4x Separating buffer; 3ml acrylamide stock; 50pl SDS; 20(il TEMED; 40 p.1
10% ammonium persulphate; 4.4ml dH20.
12% gels
2.5ml 4x Separating buffer; 4ml acrylamide stock; 50p.l SDS; 20pl TEMED; 40pl
10% ammonium persulphate; 3.4ml dH20.
Equilibration/Sample buffer
2.5ml 4x stacking gel buffer, 2ml 20% SDS, 5.5ml 50% glycerol, 20pl
Bromophenol blue (1% w/v in ethanol).
Methanol Based Transfer Buffer
0.192M glycine, 0.025M Tris-HCl, 20% Methanol by volume. Freshly prepared
2.4.2 Immunoblotting
Acrylamide gels were cast using a BioRad casting stand and cleaned glass plates fitting a
"Mini-gel" system, (BioRad UK). Running gel layers were cast at room temperature, and
after pouring were layered with 10pl of ethanol to allow clean setting. The alcohol was
removed after setting was complete. A 4.5% stacking gel solution was poured, and a pre-
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formed 1mm gel comb inserted between glass panels. Gels were allowed to finally set at
room temperature, and were used immediately after casting. Gels were run in tandem using a
proprietary BioRad gel tank, and running buffer. Standard protein ladders were used to
gauge protein size (Gibco Life Sciences, Paisley UK). 20pl aliquots of sample in sample
buffer were pipetted into separate wells using a Hutchinson needle. Slow electrophoresis was
used through stacking layers, with more rapid electrophoresis through running gel layers.
Standardised transfers were performed with Hybond nitrocellulose membrane or PVDF
membranes according to proteins being examined, with the latter being pre-wetted in
methanol. Transferred blots were processed using ECL or ECL plus reagents (Amersham,
UK), before wrapping in Saran-Wrap and exposing to photographic film (Kodak, UK).
2.4.3 LDL electrophoresis
LDL samples were analysed by electrophoresis using a semi-automatic Hydrasys system
designed for the use of Hydragel agarose gels (Sebia, Issy-les-Moulineaux, France), under
the supervision of Dr G Beckett, Clinical Chemistry, New Royal Infirmary Edinburgh (Dr
Beckett prepared the hydragel agarose gel with 8g/L agarose in Tris barbital buffer, pH
8.5±0.1).
lOpL aliquots of LDL fractions were applied to the gel and electrophoresis carried out at a
constant 10W for 7 min at 20°C. The plate was dried for lOmin at 65°C. The gel was
developed using a proprietary Sebia Amidoblack staining solution (4g/L), destained with
Sebia's destaining solution and dried. The gel was then photographed.
2.5 Flow cytometric analysis
Isolated monocytes were prepared by re-suspending at 2xl06/ml in flow buffer (PBS with
cations, 0.1% BSA 0.1% sodium azide) and then washing in flow buffer in Immunotech
flexible plates, followed by centrifugation at 200g for 3 minutes at 4°C. Non-specific Fc
receptor binding was avoided by blocking samples with 5% heat-inactivate human AB serum
or 5% normal rabbit serum for 5 minutes on ice. Cells were labelled with un-conjugated
monoclonal antibodies, used at saturating concentrations as determined by flow cytometry,
for 30 minutes on ice. Cells were then washed twice in flow buffer, before being
resuspended and labelled with fluorochrome-conjugated secondary antibodies. Two further
wash cycles in flow buffer were performed before cell pellets were resuspended in lOOpl of
flow buffer. Alternatively, for Annexin V binding assays, cells were resuspended in cation-
replete buffer (PBS with 5mM CaCl2) and incubated with 50pL of a 1:200 dilution of FITC-
annexin V at 4°C for lOmins (Bender Med Systems). Cells were analysed using either a
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Becton Dickinson FACSCalibur flow cytometer running CellQuest software
(BectonDickinson UK) or a Coulter XL flow cytometer running EXPO 32 software
(Beckman Coulter UK). Baseline fluorescence was measured on unlabelled cells and on
isotype controls. Fluorescence was quantified as follows. Net mean fluorescence for each
surface marker was calculated by subtracting the mean fluorescent intensity (MFI) for the
appropriate isotype control (AMFI). The net difference of this figure for each treatment was
then compared to control, with the net change being noted as a positive or negative value
(AAMFI).
2.6 Statistical analysis
The candidate attended the University of Edinburgh Department of Public flealth medical
and biostatistics course. All statistical analyses presented were performed following
consultation with Dr Sarah Wilde, Senior Lecturer in Public Health, University of
Edinburgh, and Dr Ernst Wit, Reader in Statistics, University of Glasgow.
Statistical analysis on fluorescence data for two variables was performed using the student's
t test. Data were assessed for differences between standard deviations to ascertain if pairing
was appropriate. If not, Mann-Whitney U tests were perfomed. For calculations of relative
fluorescence, Wilcoxon signed rank tests are given to calculate deviation from a theoretical
median of zero, and differences in fluorescence between individual treatments are calculated
separately. For multiple treatment experiments, one-way analysis of variance tests (Tukey or
Bonferroni methods) appropriate to sample size were used. If two variables were being
assessed, e.g. in apoptosis data, then 2-way ANOVA was used as appropriate. Statistical
significance is given as p<0.05.
2.7 Measurement of intracellular calcium
Fura-2 loaded monocytes at lxl06/ml were equilibrated in a Perkins Elmer
spectrophotometer at 37°C for 10 minutes, to achieve a stable baseline. The
spectrophotometer was set to excitation wavelengths of 340 and 380nm with an emission
wavelength of 580nm. A baseline recording was performed for 1 minute before the addition
of cyclopentenone prostaglandin ligands, fMLP and digitonin. Calcium flux was recorded for
5 minutes and data analysed on FL Win software (Perkins Elmer USA).
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2.8 Cell labelling and microscopy
2.8.1 DiffQuick labelling
Leukocytes were washed in PBS without cations, and 50pl droplets placed in cytocentrifuge
chambers containing glass microscopy slides, with the addition of 5pl of serum to promote
cell stability. After centrifugation at 300rpm for 3mins (Cyto-tek, Miles Scientific, USA),
slides were immersed in methanol, and then sequentially in the two Diff-QuikTM stainsets
for 1 minute each. Slides were washed in double distilled water and air-dried before
mounting coverslips fixed in distrene plasticiser xylene (DPX) medium.
2.8.2 Oil Red O labelling
Monocytes were cultured at lxl06/ml on glass coverslips in the base of 12 well tissue culture
plate (BioWhittaker, USA), or in 8 well glass slide-chambers (Nunc Biosciences, USA).
Iscove's preparation of Dulbecco's modified Eagle's medium was used with the addition of
L-glutamine, penicillin and streptomycin, as for phenotyping experiments. Medium was
supplemented with 10% autologous serum, with or without the addition of n-LDL or Ox-
LDL at concentrations of 10, 50 and lOOpg/ml. Adherent monocytes were washed with PBS
with cations, and fixed with formaldehyde, before being washed briefly with propan-l,2-diol
(propylene glycol). Powdered Oil Red O was dissolved in 65% propan-l,2-diol by heating at
95°C for 1 hour and passed through a 45 micron filter, and cooled to room temperature. Oil
Red O solution was applied to coverslips or slide chambers for 20 minutes at room
temperature, whilst slowly agitating coverslips or slide chambers on a flat-bed shaker. Slides
were washed with 65% propan-l,2-diol at room temperature before counterstaining with
Harris haematoxylin for 1 minute. Final conversion of haematoxylin was performed using
Scott's tap water solution (magnesium sulphate 29mM; sodium bicarbonate 42mM). Slides
were rinsed in double distilled water processed through a MilliQ filter, before mounting
coverslips. Slides were imaged immediately.
2.8.3 Fluorescent lipoprotein labelling
Monocytes were cultured at lxl06/ml in identical conditions to cells used for Oil Red O
labelling, with the exception of the type of LDL supplementation used. Di-I labelled n-LDL
and ox-LDL was used to supplement culture media, and cells grown in adherent culture for
up to 8 days. Cells were fixed in methanol-free 3%w/v para-formaldehyde/phosphate-
buffered saline. Nuclei were counterstained with Hoechst 33248, and coverslips or slides




Light microscopy was used to image monocytes labelled with DiffQuik or Oil Red O as
described in sections 2.8.1 and 2.8.2. Images were captured using a Zeiss Axiovert
microscope, using xlO, x20, and x32 lenses. A CCD digital camera enabled multiple images
to be taken with different fluorescent labels. Image processing was carried out using
OpenLab 3.15 or 4.01 software, utilising automated time exposure and contrast-balancing.
2.9.2 Fluorescent microscopy: assessment of apoptosis and LDL uptake
A Zeiss Axiovert microscope connected to a fluorescent light source was used with xlO, x20,
x32 and xlOO lenses, the latter in oil immersion conditions.
Hoechst nuclear labelling was imaged using a DAPI filter for assessment of apoptosis. Cell
samples were blinded to the operator, and a key used to decode cell counts. 500 cells per
field were counted, with cell nuclear morphology used to define apoptosis. Apoptotic bodies/
"ghosts" were also counted, defined by visible cytoplasm, but with a total absence of nuclear
fluorescence. Percentage cell death was calculated per treatment.
For assessment of Di-I LDL uptake, monocytes were visualised using phase contrast and
then with a rhodamine filter set, enabling imaging of fluorescence between 550 and 565nm,
the excitation and emission wavelengths of Di-I. Counter-labelling with Hoechst 33248
enabled nuclear imaging for these preparations also.
Post-hoc image processing was carried out using OpenLab 3.15 or 4.01 software.
2.9.3 Confocal microscopy
Monocytes were grown in adherent culture supplemented with Di-I labelled n-LDL or ox-
LDL, as for fluorescent microscopy. Monocytes were fixed in methanol-free 3%w/v para-
formaldehyde/phosphate-buffered saline. Nuclei were counterlabelled with ToPro3,
(Molecular Probes USA). Cells were observed using a x40 oil immersion objective lens with
a numerical aperture of 1.2 on a Zeiss confocal laser scanning microscope system (Carl Zeiss
AG, Jena, GmBH). Single optical sections of the images captured with Zeiss LSM software
were digitally processed using Adobe Photoshop CS8.
2.9.4 Electron microscopy
Monocytes isolated by density gradient centrifugation followed by immunomagnetic
separation were cultured in suspension in 10ml Teflon pots. Culture media were
supplemented with 10% autologous serum, with or without LDL. Cells were matured for 7
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days, before being washed in warm PBS with cations, and resuspended at lxl06/ml. Cells
were fixed in 2% glutaraldehyde in PBS/0.1M sodium cacodylate for 15 minutes, and
centrifuged at 5,000 rpm for 5 mins to form a cohesive pellet. Cell pellets were set in 1%
high strength agar/distilled water to form plugs for section preparation. With the assistance
and supervision of Mr S Mitchell, Royal Dick Veterinary School, University of Edinburgh,
cell plugs were cut into 1mm cubes and placed in 0.1M sodium cacodylate buffer. Sections
were made using a diamond ultra-microtome set to cut at lOOnm using heat advance.
Sections were picked up onto 300-mesh (300 squares), thin-bar, copper grids and examined
using a Philips CM12 transmission electron microscope. Photomicrographs were produced
with a magnification of xl 0,000.
2.10 Microarray methods
2.10.1 Monocyte preparation for mini array analysis
Human peripheral blood mononuclear cells were isolated as described above, from citrate-
anti-coagulated whole blood separated by density gradient centrifugation. Purity was
maximised by magnetic bead separation, monocytes attached to tissue culture plastic at
4x106 cells/ml in Iscove's DMEM for 1 hour and washed with PBS plus cations. Monocytes
were cultured in Iscove's DMEM plus 10% autologous serum supplemented with ox-LDL at
50pg/ml. Monocytes were incubated at 37°C/5%C02 for 24 hours before carefully removing
supernatants, rinsing briefly in cation replete PBS at 37°C, and lysing with Trizol.
2.10.2 Mini-array preparation
RNA was prepared by chloroform separation and centrifugation, followed by precipitation
and washing with isopropanol and ethanol according to standard RNA preparation
procedures (see section 2.13). Purity and sample mass was checked by a combination of
absorbance spectrometry and agarose gel electrophoresis of samples run against standard
molecular weight makers, Hind III digests, (Promega, UK), and low molecular mass DNA
ladders (Life Sciences Paisley, UK). Samples were treated with DNase I to remove
contaminating genomic DNA, which would reduce probe purity and sensitivity. For each
microlitre of RNA isolated and resuspended in nuclease free distilled water, O.lpl of lOx
DNase I buffer was added in a 0.5ml Eppendorf container. 2 units of DNase I enzyme were
added, and the reagents gently mixed, prior to incubation for 30 minutes at 37°C, before
inactivation of the enzyme for 2 minutes at 37°C in 1/10th of the reaction volume of an
EDTA based inactivation buffer (Ambion, UK) to stop enzyme activity. Samples were
subject to centrifugation at 16,11 Og-, and the supernatant containing DNase I treated RNA
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was aspirated. Sample purity was again checked by spectrophotometry and agarose gel
electrophoresis.
2.10.3 Mini-array probe synthesis
Between 2 and 5pg of total RNA was used to synthesise 32P radioactively labelled first-
strand cDNA. A "master mix" was prepared as for reverse transcriptase polymerase chain
reaction (RT-PCR) work (Section 2.10.8.1), using 2pl of 5x reaction buffer (Clontech USA)
per sample. 1 jul of lOx dNTP mix was added to this, plus 3.5pl of a-32P dATP, at 3,000
Ci/mmol (10p.Ci/p,l). 0.5pl of lOOmM dithiothreitol per sample was then added before
addition of lp.1 ofMouse Moloney Leukaemia Virus reverse transcriptase (MMLV-RT). In a
separate tube, l-2pl of RNA sample was added to 1 pi of a 1 Ox solution of array gene-
specific cDNA primer mix, and made up as necessary to a final volume of 3pl with nuclease
free distilled water. The sample/primer mix was heated to 70°C for 2 minutes before cooling
to 50°C for a further 2 minutes. 8pl of the Master Mix previously prepared was then added to
each reaction, and this was allowed to incubate at 50°C for 25 minutes, before the reaction
was stopped using lpl of lOx termination mix (0.1M EDTA, pH 8.0, 1 mg/ml glycogen).
2.10.4 Mini-array probe isolation
Purification of synthesised probe was carried out initially using modified gel filtration
columns. This process used sequential elutions through gel columns, which were prepared at
room temperature by pre-wetting with distilled water. Samples were then applied to the flat
surface of each gel column, and then rinsed with 40pl of distilled water, followed by a
further 250pl of distilled water. These wash fractions were discarded. Columns were then
consecutively placed over 6 separate 1.5ml Eppendorf tubes, and lOOp.1 of distilled water
was applied to the column surface. Each lOOpl fraction was collected by gravity, before the
next aliquot of water was applied. Samples were collected into each of the different
Eppendorf tubes. 2pl aliquots of each sample were then added to 5ml scintillation-counter
vials, and the volume made up to 5ml with scintillation fluid. Each vial was then assayed
using a 32"P channel protocol using a Packard 1900 CA scintillation counter (Packard
Biosciences, Pangbourne, Berks UK). Elution profiles were plotted using data from the
counts, and estimates of activity of each fraction drawn from these figures. In a properly
incorporated probe, an initial peak of activity in fraction 2 and 3 is seen. This is followed by
a low activity eluate and then a high activity peak in fractions 5 and 6 indicating
unincorporated nucleotide. Eluates prepared by this method did not show this profile, and for
this reason, an alternative method of probe isolation was employed. Active probe was
61
bonded onto the surface of a micro-centrifuge tube containing a silica membrane in
conjunction with a chaotropic salt, enabling nucleic acid binding (Clontech USA). After
absorption of nucleic acids to the membrane, cellular debris was centrifuged at 16,1 lOg
through the column and discarded. Purified nucleic acid was eluted from the membrane in a
proprietary elution buffer (Clontech USA), by centrifugation at 16,110g at room temperature
for 1 minute, and collected as a single fraction.
Samples were assayed for activity by a scintillation counter, and relative activity to an
internal poly A+ positive control was assessed. Counts within the recommended range were
deemed acceptable. To minimise differences between individual probe activities, probes
were diluted to the same activity per unit volume before adding to hybridisation buffer.
2.10.5 Mini-array hybridisation
Membranes were handled carefully to avoid tearing or distorting the arrayed surface. For
pre-hybridisation of membranes, 0.5mg of sheared salmon testes DNA (SS-DNA) was
heated to 99-100°C, and then immediately chilled on ice. Proprietary hybridisation buffer
(Clontech USA) was pre-warmed in a water bath to 68°C. 5ml of hybridisation buffer was
mixed with SS-DNA and held at 68°C until use. The nylon membrane arrays were pre-
wetted with distilled water, and surplus water shaken off. Arrays were then rolled carefully
and placed in Hybaid hybridisation bottles (Thermo Electron Inc., USA), and 5mls of pre-
hybridisation buffer containing SS-DNA evenly poured over them. Pre-hybridisation was
carried out for 30 minutes with bottles rotating at 7 rpm at 68°C. To prepare isolated probe
for hybridisation, 200p.l of probe was added to 22pl of lOx denaturation buffer (ImM
NaOH, 10 mM EDTA), and incubated for 2 minutes at 68°C. 5p.l of Cot-1 DNA was added
to 225p.l of neutralisation solution (1M NaH2P04, pH 7.0), and this mixture added to the
incubating denatured probe at 68°C. This mixture was incubated for a further 10 minutes.
Isolated, denatured and neutralised probe was then added directly to the hybridisation buffer
at the base of the hybridisation bottle taking care not to coat the membrane directly with
probe. Once probe had been mixed with hybridisation buffer, an extra 20 ml of pre-warmed
buffer was added to each bottle to ensure adequate coating of the membrane surface. Bottles
were rotated at 6-10 rpm at 68°C in a hybridisation oven for 16 hours. Prior to exposure of
array membranes to probe, blank membrane was exposed to radioactive probe under the
same hybridisation conditions used for actual array analysis. This was performed using blank
membrane fragments, and hybridising for 12 hours. Blank membranes were exposed in the
same manner as actual arrays, using autoradiography or storm analysis. Blank membranes
were used to indicate the possible presence of contaminating genomic DNA within the
62
samples and the level of non-specific background due to binding to the membrane material
directly. Following hybridisation, membranes were drained of hybridisation buffer, which
was discarded according to radiation disposal guidelines. 200ml of a pre-warmed wash
solution-1 (2x SSC, 1% SDS) was added to the hybridisation bottles, and this was used to
wash membranes rotated at 15 rpm at 68°C for 30 minutes. This step was repeated 3 more
times, and then two further 30 minute washes performed with wash solution-2 (0.1 SSC, 0.5
% SDS). A final wash using 200ml of 2xSSC at 15 rpm at room temperature was
undertaken, before the membrane being removed and excess buffer being shaken off. The
membrane was kept damp, and transferred into plastic film-wrap.
2.10.6 Mini-array membrane exposure and image acquisition
Array membranes were wrapped in Clingfilm, and mounted on Whatman 3MM
Chromatography paper. Membranes were then taped onto a pre-drawn grid within a prepared
phosphor imager screen cassette, and a blank phosphor imager screen clamped into the
cassette. Membranes were exposed to the phosphor imager screen for 24 hours at room
temperature, or Kodak BioMax MS film for 48-72 hours at -80°C. Internal control blank
membranes were also exposed to active probe to ensure no significant background signal
was present. These membranes were hybridised and exposed at the same time to ensure
consistency of hybridisation and exposure conditions. Following exposure, membranes were
stripped ready for re-probing. 500ml of a 0.5 % SDS solution was heated to boiling point in a
glass beaker, and the unwrapped array membrane placed in the solution for 10 minutes. The
solution was then cooled at room temperature for 10 minutes, and the membrane washed in a
solution of 2xSSC, and 1% SDS. The stripped damp membrane was wrapped in fresh
Clingfilm, and then re-exposed to a phosphor screen or film to assess stripping efficiency.
After this the membrane was stored in Clingfilm at -20°C.
2.10.7 Mini-array software analysis
Two software analysis methods were used to read signals. ImageQuant software supplied by
Molecular Dynamics was used to examine background radiation signals, by assaying local
area background around each gene spot and and comparing signal to areas of blank
membrane. Housekeeping gene expression was checked with this software package by
assessing signal strength across all housekeeping genes, and averaging these signals.
Use of a Clontech Atlas Navigator software package was also made. This utilises pre¬
programmed grids to fit membrane array arrangements and has the option of eliminating
poor quality signals from the analysis. Both methods were used, and compared.
Raw signal levels were taken and compared to housekeeping gene average signal levels,
after background signals had been subtracted. Finally net signals were tabulated for each
gene in a Microsoft Excel spreadsheet. The ratio of signals from ox-LDL treated samples
was compared to that of control samples. Ratios were stratified into those showing over 2-
fold changes, and those over 3-fold expression changes. Any significant changes were
crosschecked with the actual appearance of membranes to ensure that apparently high ratio
differences were based on good quality signals.
2.10.8 Confirmation of array transcriptional data
2.10.8.1 Reverse-transcriptase polymerase chain reaction
Initial confirmation of transcription changes was performed by RT-PCR, using separate
donors and blood preparations. Monocytes were purified by density gradient centrifugation
and adhesion to tissue culture plastic after magnetic bead separation using the negative
selection protocol described (Section 2.3.1). Using Trizol prepared RNA from 24 hour old
treated monocytes standard 1st strand synthesis was carried out using Superscript II reverse
transcriptase (Gibco Life Sciences Paisley UK). 5pg of target RNA at 2 mg/ml was added to
lpl of oligo dT (Promega, UK), and 8.5 pi of nuclease free distilled water (Ambion Corp.,
USA). This was pre-prepared by heating to 70°C for 5 minutes and then chilling on ice,
followed by a 15 second centrifugation at 16,1 lOg. A Master Mix was made using 4 pi of 5x
1st strand reaction buffer, and 1 pi of dNTP mix at lOmM. 2 pi of Dithiothreitol was added to
this followed by 1 pi of Superscript II (Gibco Life Sciences, Paisley UK). The entire
contents of each volume of master mix were added to the prepared RNA sample, and
incubated at 42°C for 60 minutes. Following incubation, the reaction was stopped by chilling
on ice. 20% of the cDNA from the PCR reaction (4pl) was used as a template for a
polymerase chain reaction, by adding 2.5pl of Mg-free PCR buffer, (Promega), lpl each of
forward and reverse gene specific primers and 16.5pl of nuclease-free distilled water. This
was pre-heated to 94°C for 2 minutes and then cooled and held at 80°C. A polymerase
cocktail was added to this mixture, containing 2.5pl Mg-free PCR buffer, 3 pi MgCf at
25mM, 0.2 pi of Taq polymerase (Promega) and 18.8pl of nuclease free distilled water. PCR
was carried out using a program allowing for primer dissociation at 96°C for 30 seconds,
annealing at 62°C for 30 seconds and primer extension at 74°C for 30 seconds. This was
carried out for 35 cycles. An assessment of product was made at 2 cycle increments across a
range of cycle numbers from 18 to 30 to examine the linear range of transcripts. To stop the
reaction, samples were held at 74°C for 5 minutes and then held at 20°C until analysis. lOpl
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aliquots of each sample were run in 1.5 % w/v agarose gels made up with lx Tris Borate
EDTA (TBE) at pH 8.0, containing 0.1% by volume of Ethidium Bromide. Gels were cast
and electrophoresed in iso-osmotic TBE to allow resolution of product bands. All samples
were run alongside a 4pl of a lkB molecular weight ladder (Life Sciences, Paisley UK). The
internal control for cell housekeeping was G3 PDH (GAPDH).
Primer sequences used for LFA-1 a were as follows:
Primer 1 Forward: 5' CCT CGA GCT ACA ACC TGG AC 3'
Primer 1 Reverse: 5' GTT GGA ACC TCT CAG GGT GA 3'
Primer 2 Forward: 5' ACA GAC CCC ACA GAT GGA AG 3'
Primer 2 Reverse: 5' CAA GCT CAT CGA ACC ATC AA 3'
Primer sequences for CD47 were as follows:
Primer 1 Forward: 5' CTG CCT GTG ACG CGC GGC GTC 3'
Primer 2 Forward: 5' AGC GGC GCT GTT GCT GGG CTC GGC 3'
Common Reverse Primer: 5' GCA CCA TGG CCT TGA TGA TTC ACT 3'
Primer sequences for human GAPDH-S were as follows:
Forward: 5'-TGC CTC CTG CAC CAC CAA CTG C-3' Tm 65.8°C
Reverse: 5'-AAT GCC AGC CCC AGC GTC AAA G-3' Tm 64°C
2.10.8.2 Confirmation of array data at a protein level
Assessment of cell surface protein changes was performed by flow-cytometric analysis of
cultured monocytes. Cells isolated by density gradient centrifugation and magnetic bead
isolation were then cultured in suspension or adherent to plastic in Iscove's DMEM
supplemented with 10% autologous serum. Lipid supplement of 50pg/ml Ox-LDL was
added to experimental samples. Cells in suspension were cultured in Teflon pots, to allow for
flow cytometry preparation. Cells in adherent cultures were removed from tissue culture
wells by trypsin/EDTA treatment at 37°C for 5 minutes followed by washing in cold PBS
without cations. Cells were pelleted, and cell surface expression determined by flow
cytometric analysis (section 2.5).
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2.11 Manipulation of PPARy mutant gene
Wild type PPARy and mutant (AF2) PPARy were sourced in a pcDNA3 vector (Fig 2.1).
Initial restriction digestion was performed using Xhol to release a PPARy containing insert.
2.11.1 Restriction enzyme reactions:




Nuclease free dH20 9 pi
Buffer D 2 pi
PPARy or pSP72 Minimum of lpg per reaction: volume of FLO adjusted
for DNA concentration
2.11.2 Gel purification of cut DNA fragments
Gel purification of ligation and restriction products was performed using common techniques
described in detail in section 2.14. Gel fragments containing product of interest were
resolubilised and used for further ligations, diagnostic restriction digests, or bacterial
transformation. pIRES2-GFP vector was sourced from Clontech USA, (Fig 2.3).
2.11.3 Ligation of pSP72 cut fragments and PPARy fragments
0.5pl T4 DNA ligase
1.0 pi DNA ligase buffer (Promega USA)
1:1 and 3:1 mass ratio of insert to vector, adjusted according to concentration
(ng of vector x kb size of insert x molar ratio of insert = ng of insert)
kb size of vector vector
The reaction volume was made up to lOpl with Nuclease free water. The reaction was
processed in a PCR cycler alternating between 15°C for 30 sees, and 24°C for 30 sees for 12
hours and then held at 4°C, allowing for latitude in ligation efficiency.
2.11.4 pSP72/PPARy restriction digests with Smal
Large volume digests of shuttle vector (pSP72/PPARy insert) were performed with Smal:
30 pi DNA




10 pi nuclease free dH20
Allowed to digest overnight at 25°C.
2.12 Plasmid DNA isolation
2.12.1 Specific reagents for plasmid DNA preparation
Bacterial growth medium: Luria-Bertani lysogeny broth (LB Broth # BP1426, Fisher UK)
10 g tryptone
5 g yeast extract
10 grams ofNaCI
Dissolved in 1 L of distilled water, autoclaved for 30 minutes.
2M Glucose fdter sterilised and stored at 4°C.
RNAse A stock solution
50 mg Bovine Pancreas RNAse (Sigma R-6513)
Made up to 10 mg/ml in lOmM Tris (7.5) 15mM NaCI, stored at-20°C.
Used at 50 pg/ml
Glucose buffer (Buffer 1)
1.25ml 2M glucose 50mM
1.25ml 1M Tris (pH 8.0) 25mM
lml 0.5M EDTA lOmM
250 ml RNAse 50pg/ml
made up to 50 ml dH20, stored at 4°C.
Lysis buffer (Buffer II)
2ml 5N NaOH 200mM
5ml 10% SDS 1%
made up to 50 ml in dH20 freshly as required
High salt buffer (Buffer III)
150ml 5M potassium acetate
28.75ml glacial acetic acid




53g LiCl (MW 42.294)
2.6g MOPS (MW 209.26) 50mM
5M
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made up to 250ml in dH20, pH adjusted to 8.0
Tris buffered phenol/chloroform
Pre-buffered phenol (Sigma P4557) added to equal volumes chloroform with l/25th
volume Iso-amyl alcohol, stored in dark glass at 4°C.
TE Buffer
500 p.1 Tris (pH 8.0) 1M
100 pi EDTA (pH 8.0) 0.5M
made up to 50 ml in dH20
Sodium Acetate solution
150 ml sodium acetate 5M
28.75 ml glacial acetic acid 5M
made up to 250 ml in dH20
2.12.2 Bacterial transformation, plasmid preparation
50pl of transformation competent TOPIO Escherichia coli (Invitrogen) were thawed and
chemically transformed using 5pg of relevant plasmid DNA added on ice and left for 30
minutes. Cells were thermally shocked at 42°C for 30 seconds before replacing on ice.
Bacteria were then transferred to LB broth with ampicillin for initial culture. Preparation of
DNA was done using either small-scale mini-preps or large volume bacterial preparations,
using locally derived protocols (after Maniatis) or commercial plasmid preparation systems
(Qiagen Midi-preps, Qiagen USA). In summary, fresh colonies grown on agar plates with
appropriate antibiotic supplements were picked in an aseptic manner and mini-preps grown
in 2ml volumes of LB broth. Bacterial cultures were grown overnight at 37°C with 200-250
rpm agitation using a 5:1 flaskiculture volume ratio for good aeration. For larger
preparations, 1ml of overnight culture was further grown in larger (250ml) volumes of LB
broth. Optical density of 0.8-1.0 was targeted as optimal for log phase growth. Bacteria were
centrifuged at 8,000g for 2 minutes at room temperature. Pellets were resuspended in glucose
buffer (buffer I section 2.12.1), using 1/10th volume of culture=l volume) by vigorous
vortexing/pipetting. Bacteria were then lysed using 2 volumes of lysis buffer II (section
2.12.1), and rolled until a viscous lysate was formed. 3 volumes of cold high salt buffer
(buffer III, section 2.12.1) were then added and the samples mixed until a genomic
DNA/SDS/protein precipitate formed. Samples were chilled on ice for 10 minutes to
maximise genomic DNA yield, and then centrifuged at 16,110g for 20 minutes to ensure
protein precipitation. The genomic DNA replete supernatant was aspirated and filtered to
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ensure a clean bacterial lysate yield. For small 2ml (mini-) preps, phenol/chloroform
extraction was performed: an equal volume of phenol/chloroform was added to the cleared
bacterial lysate before vortexing and centrifugation at 16,1 lOg. The aqueous supernatant was
transferred to a fresh eppendorf tube and the remaining phenol/chloroform discarded. This
was repeated once, 450ju.l of room temperature propan-2-ol (isopropyl alcohol, 1PA) added
and mixed, and the sample centrifuged at 16,1lOg for 10 minutes. Supernatant was aspirated
and the DNA pellet air-dried for 5 minutes before re-suspension in 50pl TE. To minimise
RNA contamination, RNAse treatment was performed prior to phenol/chloroform extraction.
For larger plasmid preparations, IPA (l/7th volume of bacterial lysate) was added to
precipitate nucleic acid, which was further separated by centrifugation (16,1 lOg for 10
minutes, or until supernatant cleared). Supernatant was then aspirated and the pellet dried,
before re-suspending in 1 /50th volume dH20. RNA was precipitated by adding an equal
volume of LiCl solution chilling on ice for 30 minutes and centrifuging at 16,1 lOg for 10
minutes). Supernatant was transferred to a fresh tube and an equal volume of
phenol/chloroform added, and the mixture centrifuged at 3,000g for 4 minutes. The aqueous
layer was transferred to a fresh tube, and phenol/chloroform discarded. This was repeated
once, and then DNA precipitated in 2.2 volumes of cold ethanol (sample chilled at -20°C for
one hour). DNA was then pelleted by centrifugation at 16,1 lOg for 10 minutes and all
supernatant removed. The pellet was then RNAse treated (resuspended in 200ml (for initial
culture volumes of 200-500ml) or 2ml (initial culture volumes of 500ml and above) of
TE/RNAse (20p.g/ml), and incubated for one hour at 37°C. Phenol/chloroform extraction
was again performed, and DNA precipitated with 1/10th volume sodium acetate, and then 2.2
volumes cold ethanol. Purified plasmid DNA was centrifuged at 16,1 lOg /10 mins, ethanol
removed and the pellet re-suspended in lOOpl (medium preps) or 1ml (large preps) of TE.
2.13 RNA preparation
Cells grown in monolayers were lysed directly by the addition of lml TRIzol per 106 cells,
and repeatedly pipetting to ensure homogenisation. Cells in suspension were pelleted by
centrifugation in 14mL polypropylene Falcon tubes, and liquid supernatant discarded. lmL
of TRIzol (Gibco Life Sciences Paisley) was added per 106 cells. Cells were disrupted by
shaking for 1 minute room temperature (RT), and then allowed to stand for 5 minutes at RT
to allow dissociation of nucleoprotein complexes. 0.2mL chloroform was then added for
each lmL of TRIzol used. The mixture was shaken vigorously by hand for 15 seconds and
allowed to stand at RT for a further 2 minutes. Samples were then centrifuged for 10 minutes
at 10,000g at 4°C, ensuring clear separation into an upper aqueous (RNA) phase, an
69
interphase (DNA) and a lower red phenol/chloroform (organic protein and contaminant)
phase. The top aqueous RNA rich layer was transferred and aliquoted into RNase-free 1.5ml
Eppendorf tubes, and then precipitated with 0.5mL 100% isopropyl alcohol added per lmL
TRIzol used. Samples were allowed to rest for 10 minutes at RT before inverting 3 times to
mix, and centrifuging for 15 minutes at 10,000g at 4°C. The supernatant was carefully
poured off, and the residual "glassy" or gel-like RNA pellet or smear became apparent at the
base or wall of the tube. The pellet was washed lmL 75% ethanol per ml if TRIzol originally
used, vortexed and then centrifuged at 7,500g at 4°C for 5 minutes. The ethanol wash was
repeated to remove salt from the RNA pellet. The pellet was then briefly air-dried at RT for
5 minutes, before re-suspending it in 100ml RNase-free water and assessing purity by
spectrophotometry at 260nm and 280nm. An A260/A280 absorption ratio of >1.8 was deemed
minimum purity, and ribosomal RNA integrity was further checked by gel electrophoresis.
RNA was utilised immediately or stored at -80°C.
2.14 DNA extraction following gel electrophoresis
Gel extractions were performed on gel purified restriction fragments prior to ligations, and
on ligation products prior to transformation of competent bacteria. Qiagen gel extraction kits
were used. In brief, DNA fragments were excised from TAE or TBE/agarose gels using a
sharp scalpel under UV light guidance. Gel slices were transferred to 1.5ml Eppendorf
containers and weighed. Solubilising buffer (Buffer QG, Qiagen UK) was added to gel
slices, using 3 volumes of buffer for each unit gel mass (e.g. 300pl for lOOpg gel), and
incubated for 10 minutes at 50°C. Solubilisation was assisted by intermittent vortexing of gel
fragments. pEl was adjusted to 5.0 using a commercial pH indicator (Qiagen). DNA was then
bound to a proprietary membrane in a centrifugation column (QIAquick spin column,
Qiagen, UK), with the sample being centrifuged at 16,1 10g for 1 minute. To remove agarose,
a further treatment of dissolving buffer was added and the sample centrifuged, before DNA
treatment with wash buffer, and final centrifugation at 16,1 lOg for 1 minute. DNA was then
eluted by adding 50pl of elution buffer (lOmM TrisHCl, pH8.5) or nuclease free water to the
DNA binding membrane and the column re-centrifuged at 16,1 lOg for 1 minute.
2.15 Transfection of THP-1 cells with mutant PPARy DNA
Transfection of THP-1 cells was performed using electroporation techniques. Equibio
electroporators or Amaxa nucelofector electroporators were used, with pulse strength varied
to optimise transfection success. THP-1 cells were split 1:2 in Iscoves medium with serum to
ensure log phase growth at the time of transfection. Electroporation was performed in 4mm
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cuvettes, using 1 Ojitg of DNA per lxlO6 cells. Both single and double pulse protocols were
used. Cell membrane permeability was assessed by trypan blue exclusion immediately after
electroporation, and cell viability of less than 5% was aimed for. As an alternative to Equibio
protocols, transfection was attempted in nocodazole, a cell cycle inhibitor. Cells were held in
Go by pre-treatment with nocodazole to promote DNA entry during electroporation. Cell
viability was assessed by trypan blue exclusion and transfection success by flow cytometry
and fluorescence microscopy at 488nm.
2.16 Measurement of intracellular calcium levels
1.5ml aliquots of monocytes pre-treated with 15dPGJ2 were equilibrated in a Perkins Elmer
spectrometer for lOmins, or until a stable baseline was achieved. The spectrometer was set at
excitation wavelengths of 340 and 380nm, with an emission wavelength of 510nm.
Following equilibration, a baseline was recorded for 1 min prior to the addition of platelet
activating factor, fMLP and leukotriene B4 as positive control stimuli, and digitonin to
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Chapter 3 MONOCYTE APOPTOSIS INDUCED BY MODIFIED LOW DENSITY
LIPOPROTEINS AND CYCLOPENTENONE PROSTAGLANDINS
3.1 Introduction: impact of apoptosis on inflammation
Apoptotic cells have the potential to influence the outcomes of local inflammatory reactions
(Haslett et al. 1994). Infiltrating leukocytes, usually granulocytes, undergo programmed cell
death once their actions at tissue injury or infection sites are complete, and inflammatory
stimuli have been removed (Grigg et al. 1991). Monocyte recruitment to an area of
inflammation follows granulocyte recruitment (Hopper 1986) perhaps reflecting monocyte
roles in the clearance of effete granulocytes and cellular debris, and the regulation of tissue
repair. Mature macrophages specifically recognise apoptotic cells, via mechanisms that
allow non-inflammatory clearance to occur with minimal tissue injury (Fadok et al. 1998b).
By contrast, necrotic cell debris initiates pro-inflammatory macrophage behaviour, resulting
in a more aggravated local cellular response, with the production of pro-inflammatory
cytokines, secretion of proteolytic enzymes and resultant local extracellular matrix
degradation (Savill & Haslett 1995). This has implications for the optimal resolution of
inflammatory insults. A defined time period for non-inflammatory clearance and repair
exists, beyond which pro-inflammatory mechanisms are initiated (Savill et al. 2002).
Macrophage responses to apoptotic cells vary temporally, with initial priming of
inflammatory effector mechanisms being followed by the secretion of the anti-inflammatory
cytokine TGF-P (Lucas et al. 2003).
3.1.1 Apoptotic effector mechanisms
Apoptosis represents a mechanism of cell deletion that has been conserved through
evolution, with caspase group of cysteine proteases intrinsic to this process. Two caspase-
dependent pathways leading to apoptosis, termed extrinsic and intrinsic (Scoltock &
Cidlowski 2004). The extrinsic or death receptor pathway is initiated by TNF-receptor
family members by recruiting adaptor and signalling molecules to assemble the death-
inducing signalling complex (DISC) (Kischkel et al. 1995). This complex leads to activation
of caspases 8 and/or 10, which then activate downstream effector caspases such as caspase 3,
6, and 7 (Medema et al. 1997). An alternate extrinsic pathway operates in so-called Fas-
responsive type II cells. Plasma membrane receptors signal to the mitochondria allowing
caspase 8 to cleave Bid. The truncated form of Bid (tBid) translocates to the mitochondrial
membrane, triggering apoptosis via mitochondrial release of cytochrome c and downstream
caspase 9 activation (Li et al. 1998; Scaffidi et al. 1998).
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An intrinsic pathway for apoptosis is activated by cellular stress stimuli, including serum
deprivation. The mitochondrion undergoes loss of membrane potential (AT™,,,) following the
insertion of pro-apoptotic Bax sub-family proteins into the membrane. Apoptotic proteins,
particularly cytochrome c, are then released, activating formation of the apoptosome
(activated caspase 9 and apoptotic protease activating factor 1, or Apaf-1), a process
regulated by Bcl-2 family members (Kroemer, Zamzami, & Susin 1997). Further regulation
of caspases occurs beyond mitochondrial checkpoints, with inhibitors of apoptosis proteins
(IAP) binding and inhibiting caspase 9 (Devereux 1999) and possibly caspase 3. IAPs are
themselves regulated by Smac/Diablo, (Chai et al. 2000), with this pathway eventually
converging on downstream effectors of cell death including caspase 3 (reviewed by Green
1998). The role of caspases in dissecting apoptosis is thus of major interest, and offers
insights into potential routes of manipulating cell death.
Cell viability is dependent upon a balance between normal cell cycle progression and factors
that induce cell-death. Tumour suppressor genes including p53 and the retinoblastoma (Rb)
gene regulate inappropriate cell cycle progression and are central to this balance. Such anti-
oncogenes promote apoptosis, limiting neoplasia (Evan & Littlewood 1998). Cell cycle
checkpoints have been extensively explored in the context of VSMC apoptosis (Mercer et al.
2005), and in macrophages (van Vlijmen et al. 2001), but were not examined in these
studies. Monocyte apoptosis has been reviewed in Chapter 1, but the implications of
apoptosis for inflammatory vascular injury merit further description.
3.1.2 Imbalances in apoptosis & clearance govern local inflammation
Resolution of inflammatory injury requires efficient recognition ingestion and disposal of
apoptotic debris by professional phagocytes (Savill & Fadok 2000). Physiologically
appropriate clearance of apoptotic cells engenders anti-inflammatory macrophage responses
including suppression of TNF-a(Voll et al. 1997), and promotion of TGF-P secretion in
specific recognition of cell membrane phosphatidylserine (PS) exposure (Huynh, Fadok, &
Henson 2002) aiding local tissue repair. By contrast, inefficient phagocytic clearance impairs
local repair and resolution of tissue injury, a phenomenon definitively proven in targeted
gene deletion models of the Clq complement component which acts as a phagocytic receptor
(Botto et al. 1998). Reduced apoptotic clearance is seen in clinical systemic lupus
erythematosus (SLE) and promotes local inflammation (Flerrmann et al. 1998). Uncleared
apoptotic cells progressing to secondary necrosis produce further adverse sequelae.
Monocyte-derived dendritic cells invoke pro-inflammatory responses from T cells following
the ingestion of necrotic but not apoptotic cells (Sauter et al. 2000). Two alternative
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outcomes follow augmented local inflammation. Fibroblastic responses may predominate,
with loss of functional tissue. Models of inflammation using MRL/Mp mice prone to
systemic lupus erythematosus show alterations in TGF-(3 secretion reflecting the fibrosis
seen in clinical SLE (Kench et al. 1999). Alternatively, continuing inflammation may cause
granuloma formation as seen in mycobacterial infection. This may be driven by over-
expression of osteopontin, mediating elevated macrophage influx, and increasing local IL-8
and TNFa secretion (Nau et al. 1997). Osteopontin may mediate calcification in advanced
atherosclerotic lesions, reflecting generic mechanisms that operate during chronic
inflammation (Abedin, Tintut, & Demer 2004). An additional important consideration is the
effect of ingestion of apoptotic cells upon antigen cross-presentation, a task that is under¬
taken by immature monocyte-derived dendritic cells in a discrete integrin mediated fashion
(Albert et al. 1998). Although apoptotic cells are cleared in a non-inflammatory manner,
dendritic cells are able to process apoptotic cell contents and efficiently present them to CD-
8+ T-lymphocytes in a manner that may promote auto-immunity (Albert, Sauter, &
Bhardwaj 1998). Responses to apoptotic cell membranes as well as cell contents may thus be
a factor in promoting local atherosclerotic inflammation, and provide a further argument for
an auto-immune component to atherogenesis.
3.1.3 Inflammatory imbalances relevant to vascular injury
Vascular inflammation and in particular, the effects of endothelial injury are of particular
importance in the recruitment of platelets and leukocytes to the surface of damaged vessel
lumina, as discussed in Chapter 1 section 1.7. Local apoptosis of endothelial cells promotes
thrombogenesis (Bombeli et al. 1997). Pro-thrombotic factors not only regulate platelet and
haemostatic function, but also direct inflammatory responses in the vessel wall (Major et al.
2003). Platelet sequestration to endothelial surfaces necessitates phagocytic clearance:
macrophages are less susceptible to apoptosis following ingestion of platelets (Lang et al.
2002), prolonging the life of such macrophages at sites of vascular injury. Activated
macrophages may induce Fas-mediated apoptosis in neighbouring VSMCs, with adverse
consequences for atherosclerotic plaque structural stability (Boyle et al. 2001). Apoptotic
VSMCs generate thrombin (Flynn et al. 1997), stabilising local thrombus by cleaving
fibrinogen to fibrin, and activating platelets (Davey 1967). Monocytes may display
paradoxical activation by pro-apoptotic stimuli such as Fas ligand ligation (Park et al. 2003),
demanding careful exploration of any monocyte viability responses to microenvironment.
Efficient apoptotic cell clearance may be compromised in atherosclerosis, resulting in local
phagocytic capacity being exceeded (see section 3.1.2). This phenomenon that may be
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directly linked to apoprotein E levels the absence of which has been associated with
enhanced levels of systemic macrophage apoptosis as well as reduced clearance (Grainger,
Reckless, & McKilligin 2004). Apoptotic control mechanisms, especially in the context of
impaired clearance and progression to necrosis, are thus of direct interest in the study of
atherosclerosis.
3.1.4 Evidence of apoptosis in atheroma
Multiple studies have established the presence of apoptotic cells in atherosclerotic plaque .
Variation in reported levels of apoptosis reflect diverse methodologies used in quantification.
Human fatty streaks contain pro-apoptotic proteins, in contrast to areas of adaptive intimal
thickening. High levels of apoptosis have been shown in advanced atherosclerotic plaques
with dense macrophage infiltration (Kockx 1998). Late apoptotic macrophages are more
highly represented in areas of atherosclerotic lesions surrounding the necrotic core. Human
ruptured plaques show extensive macrophage infiltration of plaque fibrous caps. Active
apoptosis, defined by the presence of the apoptotic precursor caspase-1, is seen in areas of
plaque degradation and macrophage infiltration (Kolodgie et al. 2000). This argues strongly
- ■>
for a role ofmonocyte apoptosis in plaque stability.
3.1.5 Pro-atherogenic factors that promote apoptosis
Multiple pro-apoptotic stimuli exist in atherosclerotic plaques, where VSMCs and ECs as
well as monocyte/macrophages may be exposed to biologically active micro-environmental
factors that modulate cell death. These include mechanical shear forces (Tricot et al. 2000),
reactive oxygen species (Heermeier et al. 1999), and pro-inflammatory T-lymphocyte
derived cytokines (Geng et al. 1996) as well as lipid species (Galle et al. 1999), resulting in a
dynamic turnover of cells within active plaque. In particular, the pro-apoptotic roles of high
levels of nitric oxide (Patel et al. 2000) and local hypoxia (Aoki et al. 2001) present within
atherosclerotic plaque have been highlighted. These factors together with other detrimental
stimuli such as altered local levels of growth factors that would normally promote survival,
all contribute to a milieu that enhances apoptosis of vulnerable cells.
Lipid accumulation is a separate pro-apoptotic stimulus, with free cholesterol (FC) loading
of macrophages being linked to cell death (Tabas 2002), possibly because of defective
cholesterol efflux caused by dysfunctional ABCA-1 transport mechanisms (Feng & Tabas
2002). Excessive intra-cellular FC may contribute to alterations in the physical compliance
of the endoplasmic reticulum ER. This alters integral ER membrane protein mobility,
affecting downstream signalling pathways including sarcoendoplasmic reticulum ATPase
(SERCA). Activation of the ER-based Unfolded Protein Response (UPR) signal transduction
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pathway results in the activation of the C/EBP homologous protein (CHOP) (Zinszner et al.
1998). Downstream death pathways are then activated in cholesterol laden macrophages
(Feng et al. 2003), including c-Jun NH2-terminal kinase (JNK)2, in a manner that is directed
by SR-A ligation by lipids (DeVries-Seimon et al. 2005). The mechanics of cholesterol-
induced apoptosis are complex. Early studies suggest that free cholesterol promotes
mitochondrial stability (Graham & Green 1970), arguing for mitochondrial independent
apoptotic paths. Mitochondrial control of apoptosis is often pivotal in directing leukocyte
cell death, activating signalling cascades including the Smac/Diablo pathway, and the
elaboration of initiator caspases (Maianski et al. 2004). However, further data suggest that
the modification state ofLDL may be more important in dictating apoptotic responses.
3.1.6 Ox-LDL and atheroma: links to apoptosis and leukocyte responses
Oxysterols and ox-LDL have been linked to apoptosis in atherosclerotic lesions (Salvayre et
al. 2002). Discrepancies exist in the literature between the correlation of ox-LDL and
macrophage-rich areas in plaque (Akishima et al. 2005), with some reports that ox-LDL
occupies medial territory deep within the vessel wall beyond sites of active macrophage
infiltration (Fukuchi et al. 2002). However, oxysterol species have been found to be highly
represented within the necrotic core of atherosclerotic plaques (Garcia-Cruset et al. 1999), an
area where the lipid pool and cell debris are products of the programmed cell death of local
plaque cell populations (see Chapter 1, sections 1.3 and 1.17). Ox-LDL appears to
differentially augment Fas ligand expression in endothelial cells that have undergone
hypoxia/re-oxygenation injury, suggesting that local ox-LDL may adversely impact upon
cell survival in atherosclerotic plaque (Li, Yang, & Mehta 1998).
3.1.7 Cyclopentenone induction of apoptosis
Prostaglandins (PGs) are a family of naturally occurring cyclic 20-carbon fatty acids
synthesised mainly from arachidonate and other fatty acids released from cell membrane
phospholipids by phospholipases (Straus & Glass 2001). Arachidonic acid is derived from
the action of phospholipase A2 upon membrane phospholipids, and is thus present at sites of
inflammation, where leukocytes undergo cell death (Zurier 1993). Cyclooxygenase (COX)
transforms arachidonic acid into an unstable endoperoxide intermediate, which is converted
by PG synthases into PGD2, PGE2, and PGF2a. Prostaglandins of the J series originate from
dehydration within the cyclopentane ring of PGD, producing a cyclopentenone structure
characterized by the presence of a reactive a,P-unsaturated carbonyl group.
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Cyclopentenone prostaglandins (cyPGs) are biologically very potent molecules with diverse
actions, and act as natural ligands for the nuclear steroid hormone receptor PPARy,
(reviewed in Chapter 1, section 1.19). Their influence upon the cell cycle is marked, with the
ability to induce cell growth arrest (Santoro et al. 1986). The terminal derivative of
prostaglandin J2 (PGJ2) metabolism, 15-deoxy-A12'14-PGJ2 (15dPGJ2), shows particularly
marked effects upon cell survival. 15dPGJ2 has been reported to induce cell death in vitro and
in vivo in tumour cells. Autophagic cell death is induced by 15dPGJ2 in prostatic tumour
cells (Butler et al. 2000), whereas classical apoptosis is induced by 15dPGJ2 in tumour cells
from mammary (Clay et al. 1999), colonic (Shimada et al. 2002), haematopoietic (Laurora et
al. 2003), and lymphoid malignancies (Padilla, Leung, & Phipps 2002). cyPGs also display
anti-inflammatory activity, an observation that has been directly linked to the induction of
granulocyte and macrophage apoptosis (Gilroy et al. 2003).
3.1.8 Role of NF-kB in cyclopentenone effects upon cell survival
15dPGJ2 was shown to exert some of its effects by binding to the peroxisome proliferator-
activated receptor y (PPARy) (Kliewer et al. 1995). However, although 15dPGJ2 induces
classical changes in mitochondrial potential during lymphocyte apoptosis, this may not occur
in an exclusively PPARy specific manner (Nencioni et al. 2002). Further evidence suggests
that 15dPGJ2 may act independently from PPARy activation, with disparities between cyPGs
and thiazolidinedione PPARy. ligands being evident in assays of cell function (Boyault et al.
2001) as well as survival (Ward et al. 2002). 15dPGJ2 acts as a potent inhibitor of the I-kB
kinase (IKK), preventing the activation of nuclear factor-xB (NF-kB) through PPARy-
independent means, offering an alternative mechanism for apoptotic induction by cyPGs
(Rossi et al. 2000). Given that NF-kB is a critical regulator of early inflammatory responses,
as well as cell proliferation and survival, the latter consideration is important. Normally an
inactive intra-cytoplasmic complex, NF-kB is composed of a heterodimer of p50 and p65
(RelA) subunits bound to inhibitory proteins of the I-kB family (I-kBs). NF-kB is induced in
response to a range of stimuli varying from UV radiation, pro-inflammatory cytokines or
mitogens and microbial infection, including bacterial LPS (Li & Verma 2002). NF-kB
induction by pro-inflammatory cytokines requires activation of the IKK complex, containing
two catalytic subunits, IKKa and IKKp, and the IKKy regulatory subunit. The complex
phosphorylates I-kBs triggering their ubiquitination and proteasome-mediated degradation
(Karin & Ben Neriah 2000). I-kB release permits nuclear translocation of NF-kB and its
binding to DNA at specific kB sites, inducing the transcription of genes encoding cell
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adhesion molecules, inflammatory and chemotactic cytokines, cytokine receptors, and
enzymes that produce inflammatory mediators (Li & Verma 2002). Studies show that NF-kB
activation protects cells from apoptotic pathways that might be invoked during
inflammation, including TNFa mediated cell death (Beg & Baltimore 1996). Inhibition of
NF-kB by 15dPGJ2 in Burkitt lymphoma cell lines induces the down-regulation of the
expression of several NF-KB-dependent anti-apoptotic gene products and the activation of
caspase-8 and caspase-9 (Piva et al. 2005). Evidence suggests that PPARy may be similarly
irrelevant to inflammatory leukocyte apoptosis, the survival of which is more clearly
governed by I-kB degradation (Ward et al. 2002). Exploration of the role of cyPGs was thus
of interest not only in evaluating the survival responses of monocytes entering a pro¬
inflammatory environment but also in order to assess the biochemical mechanism behind any
alterations in survival that might be evident.
3.1.9 Link between ox-LDL and cyclopentenones via PPARy
Potential links between PPARy and ox-LDL were introduced in Chapter 1. PPARy plays a
role in regulating lipid flux in monocytes (Chawla et al. 2001b), the complexity of which
was previously underestimated (Evans 1988). Critical inflammatory functions are induced by
PPARy ligation with modified LDL products. Altered phosphocholines, acting as natural
PPARy ligands to enhance endothelial cell production of MCP-1 and IL-8 (Lee et al. 2000).
Given the data showing that free cholesterol accumulation drives apoptosis (Tabas 2000), the
effects of PPARy upon CD36 expression suggest a potential paradox. The concept of
unlimited lipid influx should lead to monocyte cell death, yet certain macrophages remain
viable in atherosclerotic plaque, despite an adverse local environment.
Monocyte/macrophages have been shown to undergo cyPG-induced apoptosis in a manner
ascribed to both PPARy and PPARa mediated mechanisms (Chinetti et al. 1998). If this
were true, PPARy-mediated apoptosis should modulate monocyte survival in response to
modified LDL. A pro-apoptotic response might further alter cell numbers in an inflamed
atherosclerotic plaque with a high local concentration of cyPGs. Monocyte survival
responses to PPARy ligation are relevant to the use of high-affinity ligands of the
thiazolidinedione family, which act to alter insulin resistance at a cellular level. These agents
have been shown to be anti-inflammatory (Ricote et al. 1998b), and may act to stabilise
atherosclerotic plaque (Li et al. 2000). Elucidating a role, if any, for PPARy in monocyte
survival is thus of central interest in determining monocyte cell population changes in
atherosclerotic plaque.
3.1.10 Aims and objectives in assessing monocyte survival responses
The aims of this chapter are to discern if LDL induces monocyte apoptosis, and whether
LDL oxidation state influences monocyte survival.
Specifically:
• The involvement of PPARy in ox-LDL-mediated effects upon monocyte survival
will be assessed.
• The survival of cells bound to different extracellular matrices will be measured to
assess a regulatory role of adhesion upon monocyte apoptosis.




All data tables and photomicrographs referred to are viewable on the supplementary CD-
ROM, and in print form in the appendix.
3.2.1 Monocyte preparation and purification
Peripheral blood monocytes were isolated using discontinuous Percoll™ gradient
centrifugation, and negative immuno-selection using magnetic bead separation. Purities of
>90% (as assessed by flow cytometry scatter profiles) were achieved with this technique.
Data for this are presented in Chapter 6, (section 6.2.2), as the same methods were used to
isolate cells for monocyte phenotyping experiments. Monocytes were assessed for apoptosis
in suspension culture and adhesion culture. Cells in suspension appeared to reduce in cell
number with prolonged periods of culture with less than 40% recovery after 24hrs (n=5, see
Chapter 3 appendix, Table 3.1). Furthermore, it was apparent that cell fragments and post-
apoptotic cell bodies were not visible in cell suspensions (data not shown). This suggested
that fragile late apoptotic cells and apoptotic bodies were not being assessed. For this reason,
further assessments of apoptosis were performed on cells in adherent culture, using
morphological changes to quantify apoptosis. Although DNA intercalating dyes label nuclear
material, it was also possible to visualise apoptotic bodies using this method.
3.2.2 Oxidised LDL induces monocyte apoptosis
Monocytes were exposed to control serum-free medium, or to ox-LDL at 50pg/ml, a
concentration that is physiologically active and has been used to produce a monocyte-
derived foam-cell phenotype in vitro (Nagy et al. 1998), for 24hrs. Control cells retained
monocyte nuclear architecture with a typical horseshoe appearance, and open granular
nuclear matrices (Figure 3.1). Ox-LDL exposed monocytes displayed nuclear morphological
changes consistent with apoptosis. Apoptotic cells showed punctate nuclei consistent with
chromatin condensation caused by DNA damage in the execution phase of apoptosis (figure
3.2). Further evidence that monocyte were undergoing apoptosis was provided by assessing
Annexin V-FITC binding on ox-LDL exposed monocytes in suspension. This confirmed that
ox-LDL exposure induced monocyte PS exposure (Figure 3.3). Further assessments of
apoptosis were made by morphological criteria alone.
3.2.3 Oxidised LDL induced monocyte apoptosis is concentration dependent
The level of oxidised low-density lipoprotein (ox-LDL) necessary for monocyte apoptosis
was determined by examining concentration responses of adherent cells exposed in serum-
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free conditions for 24 hours to increasing concentrations of ox-LDL. In these experiments a
concentration-dependent relationship between monocyte apoptosis and ox-LDL levels was
observed when compared to control untreated monocytes (Table 3.2, Figure 3.4). Although
untreated monocytes in serum-free culture displayed constitutive apoptosis, in the presence
of ox-LDL the observed percentage of cell death was significantly elevated (2-way ANOVA,
p<0.0001, n=4). This was seen for all concentrations between 25pg/ml and 100p.g/ml. A
significant reduction in apoptosis was seen for all ox-LDL concentrations with the addition
of serum to the culture medium (2-way ANOVA, p<0.0001, n=4). It is speculative to predict
the levels of oxidised LDL components that might be present within active atherosclerotic
lesions, making direct comparisons of these in vitro LDL levels with concentrations found in
vivo difficult. Local levels of such lipid species may be concentrated to a high level within
active lesions. For the purpose of these experiments, it was important to use a concentration
of ox-LDL capable of consistently inducing apoptosis. For this reason the concentration of
50pg/ml was used for subsequent experiments.
3.2.4 LDL induction of apoptosis is dependent on oxidation status
To assess whether specific alterations of LDL were important in the induction of monocyte
apoptosis in serum-free culture, a direct comparison of the effects of a 50pg/ml level of ox-
LDL with the same concentration of native LDL was made. Ox-LDL oxidation status was
assessed by electrophoretic mobility, which was qualitatively shown to be higher than n-
LDL mobility (Appendix Figure 3.1). Monocyte apoptosis was not altered by n-LDL, but
was significantly increased by exposure to 50pg/ml ox-LDL (Friedman one-way ANOVA,
n=4, p=0.0046). (Table 3.3, Figure 3.5)
3.2.5 Effect of caspase inhibition upon ox-LDL induced apoptosis
The dependence of ox-LDL induced apoptosis upon caspases, apoptotic execution enzymes,
was assessed. Purified nai've monocytes in serum-free culture were pre-treated with lOOpM
of the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-(OMe) fluoromethyl ketone
(zVAD-fmk) for 30 mins before exposure to oxidised LDL at 50pg/ml and lOOpg/ml.
Although a decrement in apoptosis was seen in zVAD-fmk treated samples, inhibition of
apoptosis was incomplete (2-way ANOVA, n=4, p=0.7289) (Table 3.4, Figure 3.6).
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3.2.6 Effect of a PPARy antagonist upon ox-LDL-induced monocyte
apoptosis
To ascertain whether PPARy-induced mechanisms mediated ox-LDL-induced monocyte
death, monocytes were pre-incubated with lOpM of GW9662, a specific pharmacological
antagonist to PPARy (see section 3.2.16). No significant inhibition of ox-LDL mediated
death was apparent (2-way ANOVA with Bonferroni post-tests, p=0.3532, n=4, see Table
3.5, Figure 3.7). This observation suggested that ox-LDL induced apoptosis might be
mediated via a PPARy independent mechanism.
3.2.7 Ox-LDL products that are natural ligands for PPARy produce low level
monocyte apoptosis
n-S-hydroxyoctadecadienoic acid (13(5)HODE) is the main product of 15-lipoxygenase-l
(15-LOX-l) metabolism of linoleic acid (Zuo et al. 2005). Previous workers in this field
have used concentrations of lOpM or up to 10p,g/ml in assaying the functional activation of
PPARy and consequent downstream sequelae (Bull et al. 2003). The effects upon monocyte
apoptosis of a range of concentrations of 13(S)HODE were tested and compared against
control media and the vehicle (DMSO) in which the 13(S)EIODE was solubilised. Adherent
and suspension cultured monocytes were treated for 24 hours in serum-free conditions. Low
levels of 13(S)HODE induced no statistically significant increment over constitutive
apoptosis in adherent monocyte culture (2-way ANOVA, n=4, p=0.0217) (see Table 3.6,
Figure 3.8).
3.2.8 High-affinity synthetic PPARy ligands do not induce monocyte
apoptosis
To address the role of PPARy in the induction of monocyte apoptosis adherent monocytes
were treated with ciglitazone, a thiazolidinedione class of PPARy agonists. Published data
suggest that this synthetic PPARy ligand binds and activates the receptor nanomolar
concentrations (Gurnell et al. 2000). A saturating concentration may be achieved with these
ligands at between 1 and 10pM during in vitro culture (Tontonoz, Hu, & Spiegelman 1995).
A range of ciglitazone concentrations was tested upon monocyte survival responses. These
experiments showed evidence of significant elevation of apoptosis rates for ciglitazone at
lpM, (2-way ANOVA, n=4, p=0.0217) but not for other concentrations of ciglitazone (2-
way ANOVA, n=4, p=0.0217) (Table 3.7, Figure 3.9).
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3.2.9 Cyclopentenone prostaglandins induce monocyte apoptosis in serum-
free conditions
The effects of the cyPGs A12PGJ2 and 15dPGJ2 were examined to assess the role of these
inflammatory mediators and naturally occurring PPARy ligands on primary monocyte
survival. Initial studies showed that lpM concentrations of cyPG did not elevate monocyte
apoptosis. lOpM concentrations, reported as physiologically active, and lOOpM
concentrations of A12PGJ2 and 15dPGJ2 induced similar and significant levels of monocyte
apoptosis (n=4, p<0.0001, Table 3.8, Figure 3.10). Further studies confirmed that monocyte
apoptosis was significantly enhanced by lOpM A12PGJ2 and 15dPGJ2, in a manner
dependent upon serum-withdrawal (2-way ANOVA, p<0.0001, n=10) (Table 3.8, Figure
3.11). In parallel experiments, THP-1 monocytic cells were exposed to the 10pM of 15dPGJ2
and cultured in two different types of serum-free media. THP-1 cells demonstrated a
significant apoptotic response to 15dPGJ2 (2-way ANOVA, p<0.0001, n=4, Table 3.9,
Figure 3.12), but with lower absolute levels of cell death in comparison to primary human
monocytes. cyPG-induced apoptosis was significantly reduced by the pan-caspase inhibitor
zVAD-fmk, (2-way ANOVA, p<0.001, n=4), although this did not return apoptosis rates to
control levels (Table 3.10, Figure 3.13).
3.2.10 Cis-retinoic acid fails to induce further augmentation of monocyte
apoptosis in conjunction with cyclopentenones
Ligation of PPARy is the first biochemical step in altering transcription via this nuclear
hormone super-family member. PPARy forms a heterodimer with RXR, resulting in a
complex that binds onto a PPAR response element (PPRE), an upstream binding sequence at
the 5' end of target genes (Tugwood et al. 1992). The activity of RXR thus introduces a
further level of control of gene transcription PPAR-mediated nuclear signalling. However it
is also possible for 9 (cis) retinoic acid and other synthetic RXR ligands to act independently
at this site (Kliewer et al. 1992) owing to the permissive nature of the RXR component of the
heterodimer site (Mangelsdorf & Evans 1995). One prediction would be that RXR ligands
such as cis-retinoic acid would act to augment monocyte apoptosis, if it was driven by a
PPARy/PPRE mediated mechanism. To assess the validity of this suggestion, 9 cis-retinoic
acid was used to co-treat adherent monocytes in serum-free culture. For each individual
treatment, no significant further up-regulation of apoptosis was seen with 9 (cis) retinoic acid
(2-way ANOVA, p=0.2116, n=4) (Table 3.11, Figure 3.14).
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3.2.11 PPARy antagonism does not limit cyclopentenone induced monocyte
apoptosis
The action of cyPGs has been suggested to modulate the transcription of genes central to
inflammatory activation, by acting via PPARy to induce anti-inflammatory phenotypes in a
variety of leukocytes with resultant beneficial effects on resolving tissue injury (Willoughby,
Moore, & Colville-Nash 2000). Evidence from luciferase reporter-sequences indicates that
PPARy activation may block NF-kB activation albeit at high concentrations (Rossi et al.
2000). This suggests that modulation of anti-inflammatory activity is achieved at a
transcriptional level, and might affect leukocyte apoptosis. The effects of pharmacological
PPARy blockade upon cyPG-induced monocyte cell death were tested. Monocytes cultured
in serum-free conditions were pre-treated with 10pM of the specific PPARy antagonist GW
9662 prior to exposure to cyPGs. No significant reduction in cyPG-induced apoptosis was
seen (2-way ANOVA, n=3, p=0.7053) (Table 3.12, Figure 3.15).
3.2.12 Factors modulating cyclopentenone-induced monocyte apoptosis:
maturation
Maturation may offer protection against apoptosis, a phenomenon noted in monocyte-
derived DCs (Lundqvist et al. 2002). To examine if this was relevant to cyPG-induced
monocyte apoptosis, adherent monocytes were matured for increasing periods of time before
exposure to cyPGs. Monocytes in medium supplemented with 10% autologous serum for
24hrs, 48hrs and 6 days were washed in serum-free PBS, prior to a further 24-hour period of
culture in serum-free conditions with or without cyPGs. Monocyte apoptosis was
significantly reduced in all pre-cultured cells (2-way ANOVA, p<0.0001, n=3), in a manner
that appeared to relate to their maturation state (Table 3.13, Figure 3.16).
3.2.13 Factors modulating cyclopentenone-induced monocyte apoptosis:
adhesion
To investigate whether monocyte adhesion to matrices regulated monocyte apoptosis,
monocytes were cultured on tissue culture plastic coated with different extra-cellular matrix
proteins. The effects upon monocyte apoptosis of laminins, collagen I and IV and
fibronectin, were investigated. 15 isoforms of mammalian laminin proteins are documented,
composed of heterotrimers of a, p and y chains, assembled into cross-shaped molecules
(Aumailley et al. 2005). Commercially prepared tissue culture plastic coated with ECM
proteins was used for monocyte adhesion, with a mixed composition of laminin proteins or
fibronectin proteins. Mononuclear cells were allowed to adhere to matrix-component-coated
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tissue culture plastic immediately after isolation, with no previous activation or maturation
having taken place, and then treated in serum-free conditions with the same concentrations
of cyPGs. Collagen I appeared to confer partial protection against apoptosis induced by
A12PGJ2 at 10p.M (2-way ANOVA, p<0.001, n=4). However, no reduction in apoptosis was
noted following adhesion to collagen IV, laminins or fibronectin (Table 3.14, Figure 3.17).
Responses to increasing concentrations of cyPG were assessed separately for monocytes
adherent to laminin and fibronectin. Monocytes adherent to fibronectin showed significantly
increased apoptosis relative to control treatments, and relative to serum-replete culture, but
only at cyPG concentrations above lOpM (2-way ANOVA, p<0.0001, n=4) (Table 3.15,
Figure 3.18). For laminin adhesion, significant increases in apoptosis in serum-free culture
compared to serum-replete culture were noted (2-way ANOVA, p<0.0001, n=4). An
elevated level of monocyte apoptosis was seen in control conditions on laminin compared
with tissue culture plastic (2-way ANOVA, p<0.01, n=4). (Table 3.16, Figure 3.19).
3.2.14 Presence of PPARy increases with monocyte maturation
To examine whether monocyte expression of PPARy was altered by LDL, freshly isolated
un-stimulated purified monocytes were cultured in serum-replete conditions 7 days. Whole
cell lysates sampled at 24hrs and 7 days were examined for the presence of PPARy by
immunoblotting. PPARy was not detectable in monocyte lysates taken from control cells, or
cells treated with ox-LDL at 24 hours (Figure 3.20). An increase in PPARy expression was
noted in both ox-LDL treated and control monocytes matured to a 7-day macrophage
phenotype, a time-point where susceptibility to pro-apoptotic stimuli had diminished (see
section 3.2.12). These data suggest PPARy may have no role in monocyte apoptosis. They
also suggest that PPARy may counter-regulate apoptosis in monocyte/macrophages.
3.2.15 PPARy mediated responses depend on monocyte maturity
If PPARy is only expressed in mature monocytes, PPARy responses should be maturation
dependent. Transcriptional up-regulation of CD36 has been reported to be a reproducible
marker of PPARy ligation (Nagy et al. 1998), conferring increased lipid handling capabilities
as well as augmented phagocytic abilities upon individual monocytes as they progress
towards a macrophage phenotype. Monocytes cultured in suspension for increasing time
periods in the presence or absence of ciglitazone at 10p.M were assessed for CD36
expression. Monocytes exposed for less than 24 hours showed a low level of antibody
binding with or without ciglitazone treatment. Monocytes matured for 5 days in suspension
culture followed by 24hrs of ciglitazone exposure demonstrated enhancement of CD36
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expression (Figure 3.21). Specific antagonism of PPARy with GW9662 completely
abolished the ciglitazone-mediated enhancement of CD36 in these cells (Figure 3.22). Thus
only mature monocytes appear able to functionally respond to PPARy ligation. The effects of
ox-LDL upon monocyte CD36 expression are explored in detail in Chapter 6.
3.2.16 PPARy antagonists do not alter apoptosis in mature monocytes
The possibility that PPARy exerted protection from apoptosis might explain why
undifferentiated monocytes with low levels of PPARy readily underwent apoptosis, whereas
mature cells with high levels of PPARy intra-nuclear protein were less susceptible to cell
death. To test whether PPARy conferred protection from apoptosis, monocyte-macrophages
matured for 6 days were pre-treated with the PPARy antagonist GW 9662 at 1 OpM for 24 hrs
to inhibit PPARy activity. Following this pre-treatment, cells were again exposed to cyPGs at
lOpM for 24 hours before morphological assessment of apoptosis. No statistical difference
in apoptosis was noted with the GW9662 compound (2-way ANOVA, n=4, p=0.4294)
(Table 3.17, Figure 3.23).
3.2.17 Cyclopentenones do not alter calcium flux in naive monocytes
Transient calcium influx may be responsible for the alterations in mitochondrial membrane
potential that are a causative trigger in programmed cell death (Cerella et al. 2003). Other
inflammatory mediators such as leukotriene B4 (LTB4) cause a rapid release of membrane-
bound calcium at physiologically relevant concentrations. The pool of calcium affected by
LTB4 is the same as that released by other chemotactic factors such as formyl-methionyl-
leucyl-phenylalanine (f-Met-Leu-Phe/fMLP) (Naccache et al. 1984). The effect upon
calcium potentials across monocyte plasma membranes was assayed after monocyte
exposure to 15dPGJ2 at lOpM. Freshly isolated un-stimulated monocytes were assayed using
a Perkin-Elmer spectrophotometer. Positive control stimuli including fMLP and LTB-4
induced calcium transient fluxes across monocyte cell membranes. However, immediate
prior treatment of cell with 15dPGJ2 failed to alter calcium potentials, suggesting that cyPG-
induced monocyte apoptosis is not mediated by cation flux. Demonstration that the system
was functional was provided by the positive inward calcium flux seen after cell
permeabilisation with digitonin and the ready reversal of this phenomenon after treatment of
the same monocyte samples with the cation-chelating agent EGTA (Figure 3.24, control data
not shown). These data are presented as qualitative data representative of experiments
performed on two separate monocyte samples.
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3.2.18 Cyclopentenones block I-kB degradation in naive monocytes
Cellular transcriptional activation via NF-kB acts to block default apoptosis in leukocytes, an
observation made in human peripheral blood polymorphonuclear granulocytes (Ward et al.
1999) (see section 3.1.8). To ascertain whether this inhibition ofNF-kB activation accounted
for cyPG mediated apoptosis, monocytes were pre-incubated in cyPGs for 1 hour and then
exposed to TNF-a or LPS. Lysates prepared from untreated cells demonstrated clear I-kB
bands by immuno-blotting (Figure 3.25). Pre-treatment of monocytes with cyPGs A12PGJ2
and 15dPGJ2 at 10p.M for one hour increased the strength of immuno-blotting signal seen for
I-kB. TNF-a and LPS treated positive controls degraded I-kB after 15 minutes and 30
minutes incubation respectively. TNF-a mediated I-kB degradation was partially reduced by
cyPG treatment, whereas LPS induced I-kB degradation was unaffected, raising the
possibility that cyPGs may act at a novel checkpoint of the NF-kB activation pathway in
monocytes, upstream of I-kB.
3.2.19 Summary of findings
Monocytes undergo LDL mediated apoptosis dependent upon LDL oxidation status.
Monocyte apoptotic responses to LDL are concentration dependent, and dependent on serum
withdrawal.
Ox-LDL induced monocyte apoptosis appears to be partially caspase dependent.
Ox-LDL induced monocyte apoptosis is not directly controlled by PPARy.
Monocyte apoptosis is induced by the cyPGs A12PGJ2 and 15dPGJ2, in a serum-dependent
and concentration dependent manner.
cyPG induced apoptosis is not PPARy dependent, but is mediated by an inhibition ofNF-kB
activation.
Monocyte maturation confers resistance to cyPG mediated apoptosis in aged macrophages.




3.3.1 Monocyte isolation techniques
Monocytes were isolated from whole blood by density gradient centrifugation, followed by
immuno-magnetic separation. This additional step increased purity at the expense of adding
complexity to the isolation protocol. However, lymphocyte-derived cytokines may influence
monocyte activation and survival (Lopez et al. 1993). Vitronectin receptor-mediated
engagement and subsequent phagocytosis of apoptotic cells promotes monocyte survival, the
result of simultaneous activation of Akt and inhibition of the mitogen-activated protein
kinases extracellular signal-regulated kinase (ERK)l and ERK2 (ERK1/2) (Reddy et al.
2002). Contaminating granulocyte and lymphocyte may undergo constitutive early apoptosis,
and be ingested by monocytes. Cell purity was thus a critical part of isolating an un¬
stimulated monocyte population for subsequent analyses ofmonocyte apoptosis induction.
Immuno-magnetic separation is now an established means of producing purified populations
of leukocytes by a negative selection process, avoiding cell loss issues that occur in counter-
current elutriation (Lund et al. 2000). Immuno-magnetic separation has been reported to
produce lower levels of lymphocyte contamination and maintain stable monocyte adhesion
molecule expression, in comparison to adhesion mediated purification of monocytes (Nohe
et al. 2002). This makes immuno-magnetic separation an attractive option for isolating
monocytes, with monocyte purities of 90-95% published in studies on monocyte-derived
DCs (Hafsi et al. 2004; Hu et al. 2004). For these reasons, this method of purification was
used in preference to elutriation or adhesion-based techniques.
3.3.2 Methods of apoptosis assessment
Markers of apoptosis include terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labelling, (TUNEL) to demonstrate DNA damage, and assays of caspase activity (Tzima
et al. 2005). However, certain modes of apoptosis may be caspase independent and TUNEL
labelling is often non-specific, necessitating other modalities for quantification (Grasl-
Kraupp et al. 1995). DNA damage may be demonstrated by electrophoresis, an established
tool that has shown LDL mediated apoptosis in monocytes (Hutter et al. 2004). However,
this would involve the use of nucleosomal ELISA assays to provide an indirect means of
quantification (Salgame et al. 1997). Moreover, DNA fragmentation is not exclusive to
apoptosis, being present in necrotic cells (Collins et al. 1992). Phosphatidylserine (PS)
exposure correlates with apoptotic cell death, reflecting loss of asymmetric PS distribution at
the plasma membrane. However, PS exposure may not be truly specific in representing
apoptosis. Cells undergoing oncosis, the early stage of cell swelling during primary necrosis,
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have been shown to display PS by flow cytometry (Lecoeur, Prevost, & Gougeon 2001).
Simpler methodologies, including counting cell nuclei bearing the hallmark condensation
morphology seen in apoptosis, are well established. Evidence of nuclear damage during
apoptosis is often best visualised by microscopy, with data from electron, fluorescent and
light microscopy being robust and consistently corroborated (Kerr, Wyllie, & Currie 1972).
Direct visualisation of cells allows the ability to count cells that have passed into post-
apoptotic stages of fragility and necrosis (Majno & Joris 1995) that might be missed during
processing for flow cytometry to assess Annexin V binding. This type of swollen cell
appearance with extrusion of nuclear contents may be a function consequence of failed
phagocytic clearance of apoptotic cells, resulting in the production of post-apoptotic
("ghost") cell bodies (Fink & Cookson 2005). Preparation of cells for flow cytometry by
washing may alter total numbers of cells seen, causing removal of fragile "ghost" cells and
late-apoptotic cells, and thus underestimate the levels of apoptosis seen. It should also be
noted that the percentage of cells labelled positively with Annexin V in Figure 3.3 is higher
than the percentage apoptosis assessed by microscopy. This may suggest that Annexin V is
more sensitive than microscopy in terms of apoptosis detection. However, variable binding
of Annexin V may be induced by buffer composition, and there is also a possibility of
apoptosis induction during cell sampling and preparation for flow cytometry. Variable
survival was also noted in early counts of recovered cells from suspension culture (section
3.2.1). For these reasons, although Annexin-V binding on suspension cells would have been
a more technically expedient means of assessing apoptosis, it was decided to measure
apoptosis in adherent cells fixed immediately after treatments without washing. These cells
were labelled with fluorescent dyes that intercalate with nucleic acids, highlighting
condensation of nuclear material. This was the criterion forjudging apoptosis. Data for these
experiments were then collected by manual counting using fluorescent microscopy, offering
the highest level of accuracy for apoptosis assessment.
3.3.3 Activity of reagents used
3.3.3.1 Oxidation status of LDL
FDF was initially isolated locally from individual donors. However, routine limulus
amoebocyte lysates testing revealed levels of EPS that were sufficient to cause monocyte
activation (data not shown). This necessitated the use of commercial EDL with LPS
contamination less than 8 femtogram/ml, (both n-LDL and ox-LDL), to minimise alterations
in monocyte viability secondary to activation. Oxidation status was confirmed by gel
electrophoresis (Chapter 3 appendix), a more reliable method than assessment of
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thiobarbituric acid reactive species (TBARS) (Moore & Roberts 1998). More reliable
alternative assays such as gas chromatography, mass spectrometry or immunoassays for
isoprostane lipid peroxidation products were not available. Commercially sourced ox-LDL
showed marked electrophoretic mobility in comparison to n-LDL but also to locally isolated
and oxidised LDL. Commercial LDL is pooled from multiple donors. This avoids issues of
individual variation in apoprotein fatty acid chain composition that might affect monocyte
responses (Kim et al. 2005). Commercial LDL also avoided issues ofmatching LDL samples
to individual donors, which would have severely limited progress with experiments. The use
of copper oxidation of LDL allows production of markedly oxidised LDL species, in an
attempt to reflect divalent metal-ion oxidation in vivo (Heinecke, Rosen, & Chait 1984), and
copper-oxidised LDL has been used to examine monocyte responses in other studies (Burkitt
2001). However, the use of minimally modified LDL and enzymatically-oxidised LDL
would have offered a wider view of the actions of modified LDL effects upon monocytes,
perhaps more accurately reflecting the actions of LDL degradation in the vessel wall.
3.3.3.2 Activity of PPARy ligands: thiazolidinediones, GW9662 antagonist and
cyclopentenones
PPARy activation by thiazolidinedione ligation enhances CD36 expression, a phenomenon
reported in monocyte/macrophages (Tontonoz et al. 1998) and adipocytes (Yu et al. 2003).
Ciglitazone reproducibly induced CD36 expression in cultured monocytes, indicating
functional activity of this agent. The GW9662 antagonist produced specific inhibition of
CD36 up-regulation, and has been reported to inhibit PPARy activity in ECs at lower
concentrations than those described in this chapter (Polikandriotis et al. 2005). GW9662 has
been subsequently shown to be highly specific for PPARy alone, removing concern that this
agent might be acting through other PPAR receptors or that it might be acting as a partial
agonist (Seimandi et al. 2005). Studies in ECs utilised luciferase reporter sequences to verify
agonist or antagonist effects upon PPARy. This relies on the use of cell lines as targets for
experiments and was thus not relevant to work on primary cells.
3.3.3.3 Activity of caspase inhibitor
The pan-caspase inhibitor z-VAD-fmk non-specifically inhibits caspases. Thus the existence
of caspase dependence in apoptotic processes under study may be discerned but no further
distinction is possible. z-VAD-fmk compound has a t!4> of 40mins at a concentration of lpM
(Garcia-Calvo et al. 1998), and it is unlikely that activity was lost during the duration of
these experiments, which used lOOpM concentrations. Care was taken to ensure that
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preparation of z-VAD-fmk occurred immediately prior to each assay, from stocks used
successfully in the inhibition of apoptosis in granulocytes (Ward et al. 2002).
The dependence ofmonocyte apoptosis upon caspases has been explored in detail (Sun et al.
1999) and is discussed further in section 3.4.
3.3.4 Study limitations
3.3.4.1 Time course of apoptosis
Apoptosis was assessed after at least 24hrs in adherent culture. By using shorter time
intervals of 2-4hrs, the induction of apoptosis could have been followed more closely. This
would help gauge appropriate time-points for further experiments, especially biochemical
investigations of apoptotic mechanisms, and alterations in cell phenotype during apoptosis.
3.3.4.2 Adhesion to matrix proteins
Adhesion of monocytes to matrix proteins was followed by immediate exposure to cyPGs.
This may not have allowed sufficient time to elapse to permit integrin ligation, and thus
differential adhesion-mediated effects upon apoptosis may have been missed. It might be
useful to explore the effects of pre-adhesion to specific matrices by examining time-courses
of adhesion, prior to the addition of pro-apoptotic reagents. This might be done in a parallel
fashion to the maturation studies on tissue culture plastic, and would highlight whether a
critical duration of matrix adhesion was necessary to offer protection from apoptosis.
3.3.4.3 Assessment of NF-kB
Assessment ofNF-kB activation was inferred from immuno-blots of I-kB, on the assumption
that I-kB degradation intrinsically reflects release of NF-kB subunits. Although this is a
validated means of assessing NF-kB activation, a more definitive method of clarifying this
would be to use electromobility shift assays to assess nuclear translocation of the p65
subunit. Further insight into this system might be offered by enhancing cytoplasmic levels of
I-kB (Fujihara et al. 2005) or by altering phosphorylase activity that regulates I-kB
degradation (Karin & Ben Neriah 2000).
3.3.4.4 Examination of serum effects
The induction of apoptosis dependent upon serum withdrawal did not address issues of
individual serum components conferring a survival benefit. Alteration of serum composition
or exploration of individual candidate cytokines including in serum-free culture would
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enable a more comprehensive assessment of the factors responsible for protection against
apoptosis.
The issue of LDL in serum from donors was also considered. LDL concentrations were not
available, due to constraints on clinical data collection in the ethics approval. However,
autologous serum was added at 10%, limiting the levels of LDL in culture media.
Furthermore, distinct effects following ox-LDL supplementation were visible. De-lipidated
non-autologous serum was deliberately not used, to minimise monocyte activation.
3.3.5 Further experiments
The studies presented provide a foundation for more detailed mechanistic analysis of ox-
LDL-induced apoptosis. Closer examination of apoptosis induction in monocytes at earlier
time points could be undertaken, with apoptosis counts performed at 4hr intervals initially. A
time course of maturation needs to be performed with ox-LDL treated samples, to parallel
work on maturation performed with cyPGs.
The mechanism underlying adhesion to specific matrices followed by LDL exposure needs
to be assessed. The use of different ox-LDL species should be considered, with alternative
sources of ox-LDL and minimally modified LDL used. In particular, the use of
enzymatically altered LDL e.g. through the actions of 12/15 lipoxygenase, would offer an
insight into potential in vivo LDL species, and would be more physiologically relevant than
copper oxidised LDL alone.
The biochemistry of both cyPG and ox-LDL mediated monocyte apoptosis demands further
exploration. Inhibition of individual caspases and an assessment of individual caspases'
activity are necessary. An attempt was made to assess caspase 3 activity in monocyte Iysates
by immuno-blotting, but was unsuccessful. This merits repetition, in particular to assess the
apparent caspase independence of ox-LDL-mediated apoptosis. Further information as to the
apoptotic paths followed by LDL exposed monocytes would be gained from assessment of
changes in mitochondrial membrane potential, using fluorochrome-linked markers specific
for apoptosis such as JC-1 (Mancini et al. 1997).
The role that regulatory enzymes controlling NF-xB-mediated monocyte activation play in
modulating monocyte apoptosis requires further study. The mechanism by which cyPGs alter
phosphorylation of I-kB requires exploration of the activity of I-kB kinase (IKK) by
immuno-blotting, and by curcumin-mediated inhibition of IKK (Plummer 1999). Ox-LDL
appeared to show gross degradation of I-kB by immuno-blotting (data not shown),
suggesting that apoptotic effects may occur despite NF-kB activation. This observation
would benefit from repetition. As for cyPG mediated apoptosis, the specific blockade of
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individual components of NF-kB activation would illustrate whether ox-LDL mediate
apoptosis is NF-kB independent.
The role of PPARy in monocyte survival has been examined using a specific antagonist.
Further assessment of PPARy activity in the context of monocyte apoptosis could be made
using a number of gene silencing strategies. These are discussed in detail in Chapter 4.
3.4 DISCUSSION
3.4.1 LDL induction of monocyte apoptosis
Several previous studies have been made of monocyte survival following exposure to lipid-
derived compounds. Initial reports showed that U937 and HL60 monocytic cell lines
undergo apoptosis induced by 7 beta-hydroxycholesterol (Aupeix et al. 1995). Further
evidence showed that human primary monocyte exposure to ox-LDL resulted in ultra-
structural changes consistent with apoptosis (Flardwick et al. 1996). Studies have focused on
the susceptibility of free-cholesterol loaded macrophages to succumb to apoptosis (Yao &
Tabas 2000). However, this is in distinction to other data that suggest a direct influence of
ox-LDL upon monocyte survival influence monocyte death via a CD36-mediated binding of
ox-LDL leading to a caspase-3 mediated death pathway (Wintergerst et al. 2000). This is in
keeping with the data presented in this chapter showing LDL differentially induced
monocyte apoptosis dependent upon oxidation status. The lower level of observed apoptosis
with native LDL (section 3.2.4), suggests that receptor specificity may play a part in survival
responses. Validation of the uptake of different lipid species is difficult to perform and to
quantity, other than by radio-labelling strategies. The possibility of individual receptor
ligation being responsible for apoptosis induction is of interest. Studies using anti-CD36
blocking antibodies would be useful in this regard, but were not performed due to time
constraints. A more definitive experiment would be to use CD36-null murine monocytes
(Febbraio et al. 1999). Human CD36 null subjects are documented, but cells from such
subjects are extremely difficult to access, and this option was not practical.
Further contributory factors to plaque degradation and vulnerability relate to the
thrombogenic profile that areas of monocyte apoptosis may represent, including the
production of tissue factor as a direct result of ox-LDL induced caspase-mediated monocyte
death (Hutter et al. 2004). Further evidence that ox-LDL mediated death is relevant to
atherosclerotic progression has been gained from observations on aortic lesions in LDL R-/-
mice. Deletion of the survival protein apoptosis inhibitor expressed by macrophages (AIM)
in LDL R-/- animals resulted in enhanced macrophage susceptibility to ox-LDL induced
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apoptosis, reducing aortic plaque volume (Arai et al. 2005). This latter observation is also of
interest as AIM is under the transcriptional regulation of LXR/RXR heterodimers, nuclear
transcriptional regulators with similar functions to PPARy.
3.4.1.1 Oxidation and monocyte apoptosis
The role of ox-LDL in the general process of atherosclerosis has been debated. Observations
from clinical studies suggest that systemic anti-oxidant therapies show no benefit in vascular
disease, calling into question the role of ox-LDL not only in the context of monocyte
survival, but also in atherosclerosis per se. The issues here are complex, and may relate to
non-specific blockade of oxidation pathways governing LDL modification, and inadequate
inhibition of oxidative enzymes at a micro-environmental level. It is more likely that pro-
atherosclerotic oxidative stress occurs in localised inflammatory sites at the vessel wall,
rather than being a systemic process (reviewed in Stocker & Keaney, Jr. 2004). These data
are made still more difficult to interpret in the face of evidence that low concentrations of
ox-LDL are anti-apoptotic in macrophages, where survival is promoted by ox-LDL mediated
activation of the phosphokinase Akt (Hundal et al. 2001). The absence of caspase dependent
apoptosis does suggest that oxidation state important in ox-LDL mediated death. Evidence
from ECs shows that superoxide dismutase limits ox-LDL induction of apoptosis, suggesting
that surface membrane oxidative stress may be a trigger to apoptosis (Harada-Shiba et al.
1998).
3.4.2 PPARy role in apoptosis
The role of PPARy in ox-LDL mediated effects upon monocytes is complex. Functional
changes have been demonstrated using ox-LDL itself as well as metabolites that have been
identified as natural ligands for PPARy ((Nagy et al. 1998) see also Chapter 1, section 1.20).
The concept that ox-LDL was mediating apoptosis via PPARy seemed less intuitive. If this
were true, it would cause monocyte deletion, precluding the invocation of pro-atherosclerotic
responses that produce plaque progression. Furthermore, the lack of inhibition of apoptosis
using the GW9662 PPARy antagonist suggested a differential mechanism. Further evidence
that ox-LDL monocyte apoptosis was PPARy-independent was provided by studies using
13(S)HODE, demonstrating lower levels of apoptosis in comparison to ox-LDL mediated
effects. 13(S)F!ODE may induce apoptosis in colonic carcinoma cell lines, and the limited
monocyte apoptosis seen in section 3.2.7 may be representative of a similar mechanism.
The role of PPARy in cyPG-mediated apoptosis posed similar problems. This class of ligand
is pharmacologically active in vitro at 10pM, concentrations that are reported as
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physiological and that are sufficient to initiate PPARy-mediated signalling (Straus & Glass
2001). However, there is controversy in the literature regarding the relevance of cyPGs in
vivo, with some studies suggesting that pharmacologically active doses of 15dPGJ2 are not
seen in biological or pathological systems, with particular regard to inflammatory sites (Bell-
Parikh et al. 2003). Without the ability to sample at a cellular level, it is difficult to refute the
suggestion that high concentrations of these cyPGs might be present in vascular wall lesions,
representing a gradient of inflammatory mediators at sites of active injury. Other reports
confirm cyPG mediated apoptosis in inflammatory cells, albeit at higher concentrations than
used in the experiments presented in this chapter, and suggest that thiazolidinediones also
mediate apoptosis, via PPARy (Kawahito et al. 2000). cyPG-mediated apoptosis has been
described in B cells (Piva et al. 2005) and granulocytes (Ward et al. 2002) with the common
finding that cyPGs blocked cell survival via PPARy-independent mechanisms, specifically
limiting NF-kB translocation. Certainly the lack of apoptotic induction with
thiazolidinediones in monocytes (section 3.2.8) fits with this, as does the failure of the
GW9662 PPARy antagonist to protect monocytes from cyPG mediated apoptosis (section
3.2.6). Immuno-blotting data showing negligible levels of intra-cellular PPARy in naive
monocytes capable of undergoing cyPG-mediated apoptosis (section 3.2.14), and the absence
of a functional PPARy-mediated response in monocytes at a similar stage of culture (section
3.2.15) also strengthen the argument that PPARy is not an apoptotic mediator in these cells.
3.4.3 Protection from apoptosis
3.4.3.1 Serum influences upon apoptosis
The serum dependence ofmonocyte survival has been documented in vitro (Mangan & Wahl
1991). Putative mechanisms that mediate this may involve heat-shock protein 70 up-
regulation (Lang et al. 2000). Detailed examination of individual serum components
conferring monocyte survival was not embarked upon. However it is likely that certain key
molecules are important in this regard. GM-CSF has been shown to up-regulate anti-
apoptotic protein expression in granulocytes (Kobayashi et al. 2005), and similar effects
upon ox-LDL mediated monocyte apoptosis would be of interest. Differential T lymphokine
influences also dictate monocyte survival with IL-12 protecting against apoptosis in contrast
to IL-10 promoting apoptosis (Estaquier & Ameisen 1997). This would be of particular
interest in ox-LDL treated cells, in the context of potential signals derived from T cells
within atherosclerotic plaque. Pro-survival signals from serum include the nuclear
translocation of NF-kB (section 3.1.8) in association with p38 mitogen-activated protein
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kinase (MAPK) (Park et al. 2002). NF-kB promotes survival by enhancing levels of anti-
apoptotic bcl proteins in macrophages (Liu et al. 2004). Differential expression of bcl-2
governs the individual susceptibility of lymphocytes monocytes and granulocytes to Fas-
mediated apoptosis (Iwai et al. 1994), and expression of bcl proteins may change during
monocyte maturation.
3.4.3.2 Maturation governs monocyte apoptosis
Ingestion of free cholesterol has been associated with the induction ofmacrophage apoptosis,
(Yao & Tabas 2001). The effects of ox-LDL upon monocyte apoptosis were tested on early
adherent monocytes (sections 3.2.2-3.2.4). Flowever, subsequent experiments presented here
suggest that mature macrophages are less susceptible to apoptosis, albeit that induced by
cyPGs (section 3.2.12). Maturation dependent alteration of monocyte apoptosis is consistent
with data published by other groups, demonstrating critical changes in pro-and anti-apoptotic
protein balance (Perera & Waldmann 1998). Mature cells may display augmented surface
expression of avp3 (Scatena et al. 1998) and CD16 molecules (Wang et al. 2001), and
downstream signalling following ligation of these molecules can confer a survival
advantage. The role of the bcl family of proteins has been highlighted in the inhibition of
constitutive and induced apoptosis (Milner, Johnson, & Gregory 1992). Evidence that ox-
LDL directly mediates bcl-2 suppression in ECs (Li, Yang, & Mehta 1998), and governs
VSMC apoptotic responses (Bennett 1999), suggests a role for bcl proteins in the control of
cell death within atherosclerotic plaque. Although bcl proteins were not measured in these
studies, further assessment of ox-LDL mediated monocyte apoptosis would necessitate
quantification of their expression.
3.4.3.3 NF-kB activation in monocyte apoptosis
The NF-kB signalling cascade directs cell activation and survival, (reviewed in section
3.1.8). Cell survival is augmented by NF-kB directed transcription of anti-apoptotic proteins
such as survivin (Zhu et al. 2001), and the IAP c-IAP2 (Chu et al. 1997) to limit TNFa-
mediated apoptosis. NF-kB nuclear translocation is cyclical, allowing rapid responses to
stimuli, facilitating responses to inflammatory injury and microbial infection. I-kB
participates in an equally rapid regulatory feedback cycle, to limit NF-kB mediated
responses, making I-kB critical to innate immunity and leukocyte survival, (reviewed in
Ghosh, May, & Kopp 1998). I-kB phosphorylation is regulated by the I-kB kinase (IKK)
complex, comprising IKKa, (3 and y enzymes (Ghosh & Karin 2002). IKKp regulates
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thymocyte apoptosis and IKKa has been shown to inhibit B cell apoptosis (Senftleben et al.
2001).
The reduction in monocyte I-kB degradation seen in response to both LPS and TNFa stimuli
following cyPG treatment (section 3.2.18) raises the possibility that these agents may act at
the level of the IKK complex or higher. PPARy ligands act to down regulate IKK-a, limiting
NF-kB activation and explaining their anti-inflammatory effects (Castrillo et al. 2001). The
immuno-blotting evidence presented shows specific blockade of TNF-a mediated NF-kB
activation and suggests an additional higher level of control in this system. An alternative
checkpoint may be NIK kinase (NF-kB inducing kinase) (Malinin et al. 1997) which
normally interacts with the TNF-receptor associated factor (TRAF)-2 to stimulates I-xBa
degradation, and this possibility requires further exploration in monocytes. In summary, in
the context of other literature in the field, the findings presented here relating to cyPG
monocyte apoptosis suggest that it is driven via inhibition ofNF-kB activation paths.
3.4.3.4 Adhesion regulates monocyte apoptosis
Adhesion may confer cell survival despite the presence of pro-apoptotic stimuli. Integrin-
mediated outside-in signalling promotes biochemical paths that inhibit apoptotic
programmes, including the release of mitochondrial cytochrome c in a PI3 kinase/Akt
dependent manner (Aoudjit & Vuori 2001). The matrix to which cells adhere is a solid
network of proteins, secreted by cells themselves, and rendered insoluble by protein cross-
linking. Adhesive proteins such as fibronectins, laminins, and vitronectin are associated with
this solid matrix phase, the rigidity of which may play a role in strengthening the integrin-
cytoskeleton links (Choquet, Felsenfeld, & Sheetz 1997). Collagen IV and laminins, along
with heparin sulphate proteoglycans, form part of the vascular basement membrane, and
mediate leukocyte adhesion via |31 integrins (Nishiuchi et al. 2006). Type IV collagen is a
polyvalent ligand, with sequences that can bind aipi, a2pi, and a3pl integrins, as well as
cell surface proteoglycan receptors, including CD44/chondroitin sulfate proteoglycan
(CSPG) (Baronas-Lowell et al. 2004). VSMC production of collagen I is implicated in
fibrous cap formation, and is important in the repair mechanisms following vessel wall
injury (Bou-Gharios et al. 2004). Immuno-histochemical studies demonstrate high-levels of
collagen I expression in recently degraded or ruptured atherosclerotic plaques (Kolodgie et
al. 2002).
Fibronectins also serve as ligands for integrin adhesion receptors. Fibronectin type III (FN
III) domains possess the Arg-Gly-Asp (RGD) cell attachment site conferring the ability to
bind to P3 integrins (Ruoslahti & Pierschbacher 1986). Proteases capable of fibronectin
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degradation have been associated with augmented leukocyte apoptosis (Michel 2003). The
interaction between leukocytes and ECM proteins is important in directing the survival as
well as the function of leukocytes in inflammatory response. Binding to collagen IV and
laminin, but not collagen I or fibronectin, protects mesangial cells from apoptosis via a (31
integrin-mediated, but arg-gly-asp (RGD)-independent mechanism, (Mooney et al. 1999).
One explanation for this phenomenon would be that loss of cell numbers might result in low
levels of cell-cell interactions. This concept of anoikis or "homelessness" is seen in other cell
systems, where a default program of apoptosis is reached because a cell "senses" that it is
isolated and has no extrinsic feedback (Hamada et al. 1998).
One possible alternative explanation is that matrix binding of naive undifferentiated cells
invokes apoptosis. This is a phenomenon noted in haematopoiesis, with myeloid pre-cursors
still resident in the bone marrow undergoing programmed cell death following VLA5
mediated binding events (Terui et al. 1996). Within the marrow, this represents a
homeostatic mechanism to regulate leukocyte production. However, it may adversely affect
the survival of early circulating but uncommitted leukocytes. The effects of matrix binding
upon monocyte survival demands further investigation. Adhesion to matrices for increasing
time periods would allow assessment of prolonged binding upon cell survival. The anti-
apoptotic effects of maturation (section 3.4.3.2) might be expected to occur earlier with
matrix adhesion, and the data presented do not refute this possibility. Inhibition of individual
monocyte surface adhesion molecules would add further insight as to the involvement of
adhesion events upon monocyte apoptosis. Finally, an exploration of apoptotic proteins, as
suggested in section 3.4.3.2, would be of equal interest following defined adhesion events, in
the setting of ox-LDL mediated or cyPG mediated apoptosis.
3.4.4 Relevance of apoptosis to atherosclerosis
Apoptosis is important in all inflammatory processes including atherosclerosis, potentially
contributing to plaque core formation, plaque volume and stability (see Chapter 1). Cell
responses to apoptosis vary dramatically, with alterations in susceptibility to cell death
governed by activation state, maturity and the context within which pro- or anti-apoptotic
signals are received. Certain cells may survive given the appropriate stimuli, while others are
deleted. It is likely that apoptosis varies in atherosclerotic lesions, with direct relevance to
atherosclerotic plaque progression, and this merits discussion.
3.4.4.1 Differential apoptosis dependent on stages of atherosclerosis
Atherosclerotic plaque may display differential levels of monocyte apoptosis dependent
upon the stage of atheromatous progression. Monocyte survival within a fatty streak is likely
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to be different to an advanced lesion, possibly because susceptibility to apoptosis may alter
as plaque complexity increases (reviewed by Geng & Libby 2002). In early plaque, apoptosis
may be an appropriate response to pro-atherogenic stimuli. Murine models offer insight into
the homeostatic responses to monocyte lipid loading that appear to operate in early
atheromatous lesions, with apoptosis modulating lesion cellularity and size. The pro-
apoptotic bcl-2 protein Bax appears to be involved in atherosclerotic plaque regulation, with
adoptive transfer of Bax-/- myeloid cells into LDL-R-/- mice reducing atherosclerotic plaque
volume (Liu et al. 2005). Bone marrow reconstitution of apoE*3-Leiden mice with myeloid
cells from p53-deficient mice reduces macrophage apoptosis in early aortic atherosclerotic
plaques. Associated increases in plaque volume suggest there is an absolute requirement for
macrophages to limit early atheromatous progression in vivo (van Vlijmen et al. 2001). The
differential susceptibility to apoptosis displayed by monocytes in response to cyPGs suggests
that maturation status is a further variable that may govern lesion cellularity and local
inflammatory balance. Similar changes may apply to macrophages exposed to differentially
modified LDL, suggesting that apoptotic programmes vary according to lesion type, and cell
population. Although such data may be considered with regard to cell turnover alone, a key
further consideration with regard to apoptotic balance is the role of phagocytic clearance.
3.4.4.2 Monocyte apoptosis and clearance: implications for atherosclerosis
The murine studies discussed suggest that phagocytic clearance mechanisms are still
efficient an early stage of atherosclerosis. However, monocyte cell death is a feature of
atherosclerotic plaque that is visible in ex vivo samples of arteries with advanced lesions
(Kockx 1998). This type of plaque also is rich in apoptotic monocytes that surround the
necrotic plaque core (Hegyi et al. 1996). A suggestion that impaired clearance of apoptotic
cells may be to account for this has been based on observations relating absolute cell counts
to failed clearance of apoptotic cells (Schrijvers et al. 2005). Other in vivo studies have
demonstrated defective phagocytic clearance exacerbates chronic inflammation in disease
states with parallels to atherosclerosis, such as systemic lupus erythematosus (Taylor et al.
2000). In vitro studies have shown that macrophages laden with ox-LDL display impaired
phagocytic capacity for both apoptotic vascular smooth muscle cells (VSMC) and
fibroblasts, although phagocytic recognition remains intact. Moreover, ox-LDL loaded
macrophages demonstrate enhanced secretion of both MCP-1 and IL-6, promoting local
inflammation in the vessel wall (Khan et al. 2003).
A mechanistic link between atherosclerosis and phagocytic clearance may be the shared
mechanism for apoptotic cell recognition and ox-LDL binding by scavenger receptors at the
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monocyte surface (Sambrano & Steinberg 1995). Antibodies to ox-LDL directly interfere
with macrophage binding of apoptotic cells, (Chang et al. 1999), with the implication that
phagocytosis may be impaired by specifically modified LDL species. Antibodies to modified
LDL that localise to human atheroma have been shown to impair phagocytosis in
macrophages (Shaw et al. 2001). Furthermore, minimally-modified LDL limits phagocytosis
at a more fundamental level by promoting actin polymerisation and macrophage spreading,
via a CD14-binding event (Miller et al. 2003).
The consequences of un-cleared apoptosis are relevant to atherothrombosis. Ox-LDL
induced monocyte apoptosis is associated with enhanced tissue factor (TF) production
(Hutter et al. 2004). Shed membrane micro-particles derived from apoptotic cells have been
noted to be pro-coagulant in human atherosclerotic plaque (Mallat & Tedgui 1999). Necrotic
core formation from local monocyte/macrophage apoptosis results in lysophosphatidylic acid
accumulation, a further stimulus to platelet aggregation (Siess et al. 1999).
Apoptosis is as important in atherosclerosis as in other inflammatory conditions. The
influences of inflammatory and atherogenic stimuli may alter lesional cell populations, as
well as affecting inflammation and propagation of vascular injury. Further exploration of
clearance mechanisms as well as apoptosis induction is needed.
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Figure 3-1 Fluorescent micrograph, control monocytes 24hrs
Control adherent monocytes were cultured in serum-free conditions for 24 hours
adherent to tissue culture plastic. Cells were fixed with 1% formaldehyde,
permeabilised with 1% Triton and nuclear material labelled with 3pg/ml of Hoechst
33428. A characteristic normal open granular nuclear matrix appearance is evident,
with a typical "horseshoe" morphology seen in these control cells (x32
magnification).
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Figure 3-2 Fluorescent micrograph, apoptotic monocytes, 24 hrs
Ox-LDL treated adherent monocytes were cultured for 24 hours in serum-free
conditions, adherent to tissue culture plastic. A marked reduction in nuclear size and
rounded pattern of nuclear shrinkage is consistent with the DNA damage




Figure 3-3 Flow cytometric assessment of monocyte apoptosis
Control monocytes were cultured in suspension in serum-free conditions for 24
hours, and subsequently labelled with Annexin V-FITC to demonstrate
phosphatidylserine exposure. Control monocytes in serum-free conditions
demonstrate a low level of constitutive apoptosis, evidenced by the sub-population
comprising 10% of total monocyte numbers that has undergone apoptosis by this
measure (Figure 3.3A).
Monocytes cultured in ox-LDL in suspension in serum-free conditions for 24 hours.
The same labelling of phosphatidylserine using Annexin V-FITC has been
employed. A marked increase in signal is seen, with a clear biphasic signal
indicating dual populations of apoptotic and non-apoptotic cells (Figure 3.3B).
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Figure 3-4 Monocyte apoptosis, serum-free culture, 24hrs, ox-LDL
supplements
Ox-LDL significantly increases monocyte apoptosis relative to control in a
concentration and serum-dependent manner, (2-way ANOVA, p<0.0001, n=4).
Differences in apoptosis between concentrations of ox-LDL, and between serum




Figure 3-5 Monocyte apoptosis, serum free culture, n-LDL vs. ox-LDL
supplements
Monocytes supplemented with 50pg/ml of n-LDL or ox-LDL, were cultured in serum-
free adherent conditions for 24hrs. Apoptosis was assessed by nuclear morphology.
No significant increase in apoptosis was induced by the presence of n-LDL. Ox-LDL
significantly increased apoptosis compared to control, but not compared to n-LDL
























































Figure 3-6 Ox-LDL induction of monocyte apoptosis is not fully reversed by
the pan-caspase inhibitor zVAD-fmk
Increasing levels of apoptosis were seen during serum-free incubation of monocytes
with ox-LDL. Pre-incubation with the caspase-inhibitor benzyloxycarbonyl-Val-Ala-
Asp-(OMe) fluoromethyl ketone zVAD-fmk produced a non-significant reduction in
apoptosis (n=4, p=0.7289).
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Figure 3-7 Ox-LDL induction of monocyte apoptosis is not reduced by the
PPARy antagonist GW9662
Adherent naive monocytes were pre-treated with the pharmacological antagonist to
PPARy GW9662. Ox-LDL supplements were added to culture media for 24hrs
before assessment of apoptosis, and induced significant levels of apoptosis relative
to control. GW9662 treatment produced no significant difference in ox-LDL induction
of apoptosis (2-way ANOVA with Bonferroni post-tests, p=0.3532, n=4).
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Figure 3-8 Monocyte apoptosis, 24hrs, 13(S)HODE supplements
Adherent monocytes cultured in serum-free conditions were assessed
morphologically for apoptosis after 24 hours of exposure to 13 (S) HODE, a product
of ox-LDL degradation which has been reported to act as a natural PPARy ligand.
























































Figure 3-9 Monocyte apoptosis, 24hrs culture, ciglitazone supplements
Increasing concentrations of the thiazolidinedione Ciglitazone caused low-levels of
apoptosis. A small significant increment in apoptosis was seen in serum-replete
cells with 1 (iM of ciglitazone, but not with 10pM (2-way ANOVA, n=4, p=0.0217). No
significant difference in apoptosis was seen between serum and serum-free groups
for each concentration.
Figure 3-10 Monocyte apoptosis, 24hrs serum-free culture, cyclopentenone
prostaglandin concentration responses
Preliminary experiments assessed the concentration of the cyclopentenone
prostaglandins A12PGJ2 and 15dPGJ2 necessary to induce monocyte apoptosis.
Low concentrations produced little elevation in percentage apoptosis over control.
The induction of apoptosis by concentrations of both A12PGJ2 and 15dPGJ2 was
significant (2-way ANOVA, p<0.0001, n=4) but similar, at a concentration of 10pM
and lOOpM.
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Figure 3-11 Monocyte apoptosis, 24hrs, serum free culture, cyclopentenone
prostaglandin supplements
Further data confirmed that cyPGs induced monocyte apoptosis at 10pM, a
concentration reported as physiologically active.
Adherent serum-free monocytes were exposed for 24 hours to the cyclopentenone
prostaglandins A12PGJ2 and 15dPGJ2 at 10pM. Apoptosis was assessed by nuclear
morphology. Both A12PGJ2 and 15dPGJ2 induced significant levels of apoptosis (2-
way ANOVA, Bonferroni post-test, p<0.0001, n=10). Cyclopentenone mediated
monocyte apoptosis was dependent upon serum-withdrawal (2-way ANOVA,






























Figure 3-12 THP-1 monocytic leukaemic cell apoptosis, cyclopentenone
prostaglandin supplements
THP-1 cells show low levels of constitutive apoptosis in serum-free conditions.
Cyclopentenone-induced apoptosis was seen in cells treated at 10pM
concentrations for 24 hours. Use of two separate serum-free media, RPMI and X-
Vivo 10, produced significant apoptosis induction in serum-free conditions compared





























Figure 3-13 Monocyte apoptosis induced by cyclopentenone prostaglandins
is partially caspase-dependent
Adherent monocytes cultured in serum-free conditions were pre-treated with the
pan-capsase inhibitor zVAD-fmk, before exposure to cyclopentenone prostaglandins
at 10pM for 24hrs.
zVAD treatment significantly reduced apoptosis for both cyclopentenone treatments
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Figure 3-14 Monocyte apoptosis: effects of RXR ligation in conjunction with
cyclopentenones
Adherent serum-free monocytes cultured for 24 hours in media supplemented either
with cyclopentenone prostaglandins at 10pM alone or cyclopentenones in
conjunction with 10pM 9-cis retinoic acid were assessed morphologically for
apoptosis. For each treatment, 9(cis) retinoic acid made no significant difference to
rates of apoptosis (2-way ANOVA, p=0.2116, n=4). The cyclopentenone
prostaglandins produced significant increases in monocyte apoptosis relative to
control (n=4, p<0.001, except differences between 15dPGJ2/9(cis) retinoic acid and




Figure 3-15 Monocyte apoptosis: response to the Glaxo-Wellcome PPARy
antagonist GW 9662 in combination with cyclopentenones
Adherent serum-free monocytes were exposed to the cyclopentenone
prostaglandins A12PGJ2 and 15dPGJ2 at 10pM for 24 hours with and without the
addition of the pharmacological PPARy antagonist GW9662. Significant levels of
apoptosis were induced by the cyclopentenones alone (p<0.0001), but this was not
































Maturation time prior to treatment
Figure 3-16
apoptosis
Monocyte maturation protects against cyclopentenone-induced
Maturation of monocytes for increasing period of time prior to exposure to
cyclopentenones conferred protection against apoptosis. Significant reductions in
apoptosis were noted after 24hrs, 48hrs and 6 days maturation (2-way repeated








































Figure 3-17 Cyclopentenone-induced apoptosis in monocytes adherent to
extracellular matrix proteins
Adherence to collagen I reduced monocyte apoptosis induced by A12PGJ2 (2-way
ANOVA, p<0.01, n=4). Adhesion to other extracellular matrix proteins did not confer
protection against cyclopentenone-induced monocyte apoptosis.
Monocyte apoptosis induced by 15dPGJ2 at 10pM was increased in cells adherent
to laminin compared to tissue culture plastic (2-way ANOVA, p<0.05, n=4). This was



























































Figure 3-18 Effects of adhesion to fibronectin upon cyciopentenone induced
monocyte apoptosis
Mononuclear cells were allowed to adhere to tissue culture plastic coated with
fibronectin, before exposure to increasing concentrations of the cyciopentenone
prostaglandin ligands A12PGJ2 and 15dPGJ2. Apoptosis was significantly increased
in serum-free culture compared to serum-replete culture at cyciopentenone
concentrations above 5pM (2-way ANOVA, p<0.001, n=4).
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Figure 3-19 Effects of adhesion to laminin upon cyclopentenone induced
monocyte apoptosis
Mononuclear cells were allowed to adhere to tissue culture plastic coated with
laminin, before exposure to increasing concentrations of the cyclopentenone
prostaglandin ligands A12PGJ2 and 15dPGJ2. Levels of apoptosis were elevated in
monocytes cultured in serum-free coniditions with control media on laminin relative
to tissue culture plastic (2-way ANOVA, p<0.01, n=4).
Both prostaglandin ligands A12PGJ2 and 15dPGJ2 induced significant levels of
apoptosis at all concentrations tested (2-way ANOVA, p<0.001, n=4).
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PPARy




Figure 3-20 Differential PPARy protein expression in monocytes and
macrophages
PPARy expression, assessed by immuno-blotting whole cell lysates, appeared
unaltered in naive monocytes even after exposure to both acetylated and oxidised
LDL at 50pg/ml. However, PPARy levels were augmented in mature
monocyte/macrophages, irrespective of lipid supplementation, or control medium
conditions.
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Figure 3-21 Monocyte functional responses to PPARy ligands are maturation
dependent
Primary human monocytes were cultured in suspension, in serum-replete medium.
The thiazolidinedione ciglitazone did not enhance CD36 expression in monocytes
cultured for 24hrs (left panel). Maturation of monocytes over 5 days followed by
ciglitazone stimulation resulted in a visible increase in CD36 immunofluorescence
(right panel). (Figure representative of 4 separate monocyte samples).
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Figure 3-22 Monocyte responses to PPARy ligands are inhibited by the
PPARy antagonist GW9662
Monocytes were cultured in suspension for 4 days before receiving pre-treatment
with the PPARy antagonist GW9662 at 1pM (left panel) or 10pM (right panel) Cells
were then treated with 10pM ciglitazone for a further 24hrs. GW9662 inhibited
ciglitazone-mediated CD36 expression at both low and high concentrations (blue
histogram overlay). Ciglitazone alone produced an upregulation in CD36 expression








































Figure 3-23 Pre-treatment with the PPARy antagonist GW9662 fails to
prevent apoptosis in mature (8 day old) macrophages
Monocytes were isolated and matured by adhesion to tissue culture plastic, in
serum-replete conditions. Following pre-treatment with GW9662 for 24 hours on day
6, monocytes were then put into serum free conditions with the addition of
cyclopentenone prostaglandins at 10pM for a further 24 hours on day 7. No
significant increase in apoptosis was apparent relevant to control (n=4, p=0.1380).
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Figure 3-24 Calcium flux is unchanged in monocytes exposed to 15dPGJ2
Freshly isolated un-stimulated monocytes in suspension culture were assayed for
calcium flux using a Perkin-Elmer spectrophotometer. Normal responses were seen
after exposure to positive stimuli such as fMLP and PAF. Interestingly LTB4
produced a low level but significant calcium influx. Permeabilisation of cell
membranes using digitonin resulted in marked calcium shifts, reversible by specific
chelation using EGTA (figure representative of two separate monocyte samples).
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I-kB
Figure 3-25 Cyclopentenone prostaglandins cause altered NF-kB activation
Immunoblotting for I-kB demonstrated clear bands in control monocytes.
Lysates taken from monocytes stimulated with TNF-a and LPS alone, showed
marked degradation in I-kB signals.
Monocytes treated with cyclopentenone prostaglandins displayed a stronger I-kB
signal compared to control.
In conjunction with cyclopentenone prostaglandins, TNF-a appeared to only partially
induce I-kB degradation, implying a lower level of NF-kB activation in these
samples.
In contrast, the effects of LPS were unchanged, with clear loss of the I-kB signal.
(Immunoblot representative of three separate experiments).
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Chapter 4 USE OF A DOMINANT CO-REPRESSOR PPARy MUTANT IN THE
THP-1 MONOCYTIC CELL LINE
4.1 Introduction
The question as to whether PPARy directly sub-served apoptosis in monocytes appeared
unresolved from the data presented in Chapter 3. The effects that LDL and cyclopentenones
have upon monocyte survival might be due to alternate pathways, including the ligation of
other PPAR receptors subclasses, such as PPARa and PPAR5. At the time this work was
performed, the specificity ofGW9662 had not been clarified (Kojo et al. 2003). Although the
use of the GW9662 antagonist made the likelihood of a PPARy-mediated mechanism for
monocyte apoptosis induction unlikely, it was felt that further exclusion of the role of
PPARy would help confirm the redundancy of this gene in monocyte survival. One strategy
to elucidate the role of PPARy would be to remove the function of this gene altogether. At
the time these experiments were performed, the only practical option to pursue this was the
attempted introduction of a mutant PPARy gene bearing dominant co-repressor activity. This
technique had already been performed using a dominant mutant that successfully transfected
COS-1 cells (Berger et al. 2000), allowing functional gene silencing. Primary monocytes are
notoriously difficult to transfect (Burke et al. 2002). For this reason the THP-1 monocytic
cell line was chosen as a target for transfection. The vulnerability of these cells to
cyclopentenone mediated apoptosis has already been demonstrated in Chapter 3.
4.1.1 Use of a mutant dominant co-repressor PPARy construct
To gauge the effects of cyclopentenones upon monocyte apoptosis, and to assess the role, if
any of PPARy in monocyte apoptosis, the introduction of a dominant repressor PPARy
mutant gene was attempted. A dominant mutant PPARy gene, differing from the one used in
COS-1 cells, had been noted to repress PPARy effects in adipocytes when delivered within
the vector pcDNA3. This PPARy mutant bears two amino acid substitutions that prevent
ligand binding and cause co-repression of the wild type gene product (Gurnell et al.
2000)(see Figure 4.1a). Initial attempts to utilise a ligation and complementary nucleotide
filling strategy to optimise the introduction of the PPARy mutant into a fluorescently labelled
vector were unsuccessful (Figure 4.2, 4.3 and 4.4). In brief, a "cut-and-fill" strategy was
attempted, with the initial use of Hindlll to digest pIRES2-GFP. The site of this digest was
then to be modified using nucleotides to enable the use of Xhol which would provide a
complementary site in pcDNA3. Ligation from this was unsuccessful, and for this reason, a
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lengthier but more standardised cloning strategy was embarked upon. pcDNA3 bears
multiple cloning sites (MCS) common to pSP72 (Figure 4.1b). This in turn bears common
restriction sites to the MCS of plRES2-GFP (Figure 4.1c). The pSP72 vector was thus used
as a shuttle-vector to move the PPARy insert from pcDNA3 to pIRES2.
Sub-cloning of the construct required multiple manipulations. The PPARy dominant co¬
mpressor mutant was successfully sub-cloned into the shuttle vector, pSP72, with
complementary restriction sites to the original pcDNA3 vector. This latter manoeuvre
allowed for subsequent excision and ligation into the GFP intron-containing vector, at the
correct site (Figure 4.1c). The strategy of utilising a vector with a GFP intron was adopted to
facilitate further selection of successfully transfected cells by flow cytometrically-directed
cell sorting.
At each stage of the sub-cloning process, integrity of the ligations was carefully confirmed
by restriction digestion and gel electrophoresis. Confirmation of the construct's position
within the final vector was performed using restriction digests, at multiple positions. The
vector containing the PPARy mutant was then produced in bulk utilising large scale bacterial
plasmid preparations.
4.1.2 Sub-cloning of PPARy into pSP72
To incorporate PPARy wild type and mutant fragments into pSP72, the multiple cloning sites
were digested using Xhol and Xbal (Figure 4.5), both sites present in pcDNA3/PPARy and
pSP72. The resultant complementary ligation sites enabled the use of pSP72 as a shuttle
vector. Difficulties arose with digestion of pSP72, leading at one stage to concern that this
vector had been contaminated, or modified. Further digests confirmed the vector to be
pSP72, after large scale bulk DNA preparations had been performed (Figure 4.5b). Sufficient
quantities of vector and target insert DNA were critical to this process (Figure 4.6), and
"maxi" preparations of bacteria were used for DNA production prior to ligations. The use of
smaller DNA volumes (Figure 4.7) resulted in unsuccessful ligations (Figure 4.8).
4.1.3 Confirmation of PPARy/pSP72 construct
Incorporation of the substantial PPARy fragment into pSP72 produced a high mass DNA
product, immediately discernible from vector and insert by gel electrophoresis (Figure 4.9).
Confirmation that this was the correct orientation of PPARy in the vector was undertaken by
further restriction digestion using Xhol and Xbal enzymes again, revealing the original
vector and insert fragments (Figure 4.10).
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4.1.4 Excision of PPARy from pSP72; insertion into plRES2
Further manipulations of this shuttle-vector were required to enable the final insertion of
PPARy into pIRES-GFP. Initial attempts were made to use the EcoRI site within pIRES-GFP
in conjunction with an Xhol site. This should have produced a simple complementary
combination of both PPARy and pIRES fragments. Complete sequencing details of the
PPARy sequence were not available, and a further undocumented EcoRI site was apparent
when an extra fragment was revealed after EcoRI restriction digestion (Figure 4.11). For this
reason a process of Smal and Xhol digests was undertaken for pIRES-GFP and
PPARy/pSP72, as this produced a means of introducing the insert into the vector.
4.1.5 Methylation of pSP72 sites; successful re-derivation of constructs
Despite the use of double and single digests, it proved impossible to produce the correct
restriction fragments after enzymatic treatment of PPARy wt and mutants in pSP72.
Variation of restriction digest duration, temperature, buffer pH and the addition or
withholding of BSA made little difference. The prospect that a restriction site had been
methylated arose, and for this reason it was decided to re-prepare DNA using different
competent bacteria. A range of fresh bacteria including TOPIO and GM119 competent cells
were utilised, and initially prepared in bulk, before transformation with the pSP72-PPARy
constructs. Interestingly, DNA prepared with these fresh bacterial stocks of both strains now
proved amenable to restriction digestion. Serial digests performed first with Smal and then
Xhol produced two clear bands of 2.4kb and 1.5kb, the latter corresponding to the correct
length of PPARy insert (Figure 4.12a). Serial digestion of pIRES2-eGFP with Smal and
Xhol produced a large single visible fragment, as the gap between these sites within the
pIRES2 MCS is only 40 bp long (Figure 4.12b).
4.1.6 Confirmation of PPARy insertion into plRES2-GFP
Confirmation of correct insertion of the PPARy insert after this final ligation was performed
by cutting the new construct with BamHI. This produced two large visible (5.9kb and lkb)
fragments as well as a small (9bp) fragment that was obviously not seen on these gels. These
digests were confirmed and also cross-checked with digests of the original vectors and the
shuttle vector, to ensure that no hidden sites had been unaccounted for. Initial BamHI digests
were performed to identify successful ligation products: DNA mini-preparations were made
from colonies of bacteria transformed with PPARy/pIRES2 ligation product (Figure 4.13).
Further restriction digests of all the vectors used at each stage of cloning were then
performed, checking fragment lengths against restriction maps. Fragment lengths were
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appropriate for both mutant and wild type PPARy, and the original vectors showed no
evidence of other hidden BamHI sites (Figure 4.14). This meant that PPARy had
successfully been incorporated into pIRES2-GFP, enabling the use of this construct to
transfect cells with plasmid DNA resulting in the expression of a fluorescent protein marker.
4.1.7 Transfection of THP-1 cells with plRES2/PPARy
Transfection of THP-l monocyte cell lines was attempted. Standard lipofection with
Lipofectamine (Invitrogen USA) proved unsuccessful, with no cells showing any GFP
expression (data not shown). Electroporation of the pIRES-GFP/PPARy construct was then
attempted. This proved to be a significant technical challenge, with multiple modalities of
transfection resulting in no evidence of successful transfection. Utilisation of novel
electroporation protocols with varied pulse times, and pulse morphologies, including
biphasic pulse waveforms (Table 4.1) were also unsuccessful (EquiBio double pulse
electroporation and Amaxa Nucleofector protocol, GmBH, Figure 4.15).
THP-1 cells were pre-treated in ATP-supplemented buffers, prior to electroporation using
the EquiBio double and single pulse systems with vector DNA. Cells were allowed to
recover from electroporation for 48hrs in culture before flow cytometric assessment.
Apparently successful transfection was documented by fluorescent microscopy (Figure
4.16). Double-pulse waveforms, although supposedly more efficient in effecting transfection,
produced little scatter shift with sham electroporations or with wild-type/vector constructs.
Furthermore, sub-gating on these sub-populations revealed no noticeable increase in green
fluorescence in the FL1 channel (Figure 4.17). No changes in fluorescence were noted with
double-pulse electroporation using the pIRES/PPARy mutant construct, even when sub-
gating on the higher side-scatter population (Figure 4.18). Single-pulse electroporation
caused a marked increase in THP-1 cell side-scatter (Figure 4.19). No noticeable increase in
fluorescence was seen in the high side-scatter gate when comparing sham electroporation
with wild-type/vector constructs. Similar results were seen with single-pulse transfections
using the pIRES/PPARy mutant construct (Figure 4.20), again with no noticeable difference
in green fluorescence between sham electroporations, and DNA-loaded electroporations.
This suggested that despite the fluorescent microscopy data being encouraging, the
visualised increase in green fluorescence was an artefact of electroporation. A proportion of
the high side-scatter electroporated cells appeared to have condensed nuclear morphology on
cyto-centrifuge preparations, suggesting reduced viability post-transfection (data not shown).
Use of the Amaxa nucelofector (Amaxa GmBH) with nocodazole supplements to hold cells
in G0 phase was also unsuccessful, (data not shown). The pIRES-GFP vector had already
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been used to transfect COS-1 cells using similar protocols, demonstrating competence of
both vector and electroporation (A. Lacy-Hulbert, pers. comm. 2002). The PPARy mutant
had also been successfully been transfected into COS-1 cells (Berger et al. 2000).
Unfortunately it was not possible to produce any successful transfections of THP-1
monocytes using the PPARy construct, and thus the full range of planned viability assays
was unable to be performed.
4.2 Summary
THP-1 cells were used as a target for the introduction of a dominant mutant PPARy gene
construct.
A mutated PPARy sequence, with documented repressive functions in adipocyte models, was
successfully manipulated through a series of plasmid vectors.
Despite problems with restriction enzyme digestion due to methylation of digestion sites, the
mutant gene was inserted into the multiple cloning site of a pIRES bicistronic vector, which
enabled target cell expression ofGFP.
Lipofection with pIRES/PPARy was unsuccessful.
Electroporation of THP-1 monocytic cells was attempted using two electroporators, varying
electrical pulse width and morphology. To optimise transfection, cells were held in cell cycle




4.3.1 Molecular manipulations of plasmid DNA
Introduction of GFP expressing vectors into eukaryotic cell lines is well described (Rees et
al. 1996). The use of vectors with multiple cloning sites is an established means of
introducing genes of interest into such vectors, allowing the tandem expression of a
fluorescent marker indicating successful translation of the protein (Cormack, Valdivia, &
Falkow 1996). The difficulties in introducing a mutant gene sequence into the pIRES vector
were focused at the level of molecular manipulation. Methylation of a critical digest site in
one of the vectors used to sub-clone the PPARy mutant resulted in a lengthy delay in
progress, and necessitated multiple attempts to re-digest the vector involved (Kessler,
Neumaier, & Wolf 1985). This particular hurdle was overcome by re-deriving the shuttle
vector, and involved freshly transforming competent bacteria, and performing a further
plasmid preparation. This restored the shuttle vector cloning site, with restriction enzyme
sites that were amenable to digestion, facilitating the successful introduction of the PPARy
mutant into the pIRES vector.
4.3.2 Gene transfection
Gene transfection into mammalian cells involves the introduction of nucleic acids across the
cell membrane, with subsequent trafficking to the nucleus (reviewed in Burke et al. 2002).
There are significant obstacles to such a process, including the electrostatic repulsion
between negatively charged nucleic acids and the negatively charged outer membrane of
target cells. Plasmid DNA size is limited in terms of entry to 15kb by membrane pore size,
requiring condensation to enable entry into cells. DNA entering into the cytoplasm is
degraded by endosomal nucleases, limiting the ability of exogenous DNA to reach the
nucleus.
4.3.3 Difficulties with electroporation
Electroporation involves passing an electric pulse through a suspension of cells and
exogenous DNA. Exposure of eukaryotic cells to electric fields is thought to alter membrane
structure, facilitating the transient formation of pores that allow the entry of exogenous
nucleic acids. DNA is believed to move directly into the nucleus of electroporated cells,
bypassing endosomal degradation pathways that would otherwise destroy exogenous nucleic
acids. The success of this technique is critically dependent upon individual factors including
the potential difference and capacitance, ionic strength and temperature of the medium, and
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the quantity of DNA used. To ensure robust transfections, these factors have to be optimized
for each cell type (Weir & Meltzer 1993).
The electroporation techniques described in this chapter are an adaptation of a method
successfully used to transfect a GFP expressing vector into J774 macrophage cell lines, to
explore functional phagocytic responses (Smits et al. 1999). Given that this group was able
to produce an efficient transient transfection, with sufficient cell recovery and viability to
then assay macrophage function, it was hoped that a similar outcome would occur for THP-1
cells. The position that individual target cells occupy within the cell cycle is also of critical
importance. Successful transfection is affected by the proportion of cells in S phase, a factor
of particular importance in the transfection of granulocyte-macrophage progenitors by
electroporation (Takahashi et al. 1992). In an attempt to maximise DNA entry to THP-1
cells, alterations in pulse duration, intensity and pulse type were used. The failure of double-
pulse waveforms to successfully transfect THP-1 cells was surprising. Double-pulse
waveforms produce a transient depolarisation at the cell membrane, followed by a longer
duration electric pulse permitting the passage of larger amounts of DNA into the cell across a
gradient of potential difference (Atkins, Wang, & Burke 2000).
Nucleofection, a refinement of electroporation that has been reported to improve DNA
delivery to the nucleus has been reported as successful in monocyte and macrophages
(Martinet, Schrijvers, & Kockx 2003). Nucleofection relies on pulse forms that optimise
DNA trafficking into the nucleus, bypassing cytoplasmic trafficking and degradation of
nucleic acids. Nucleofection is more efficient if cells are quiescent or held in cell cycle arrest
(Trompeter et al. 2003). Nucleofection was thus performed in the presence of nocodazole, a
cell cycle inhibitor. However, a transfection strategy that arrests cell cycle is perhaps not the
optimal means to examine cell survival. Further exploration of this technique was limited by
time constraints.
Electroporation has been reported in monocyte-derived macrophages in vitro (Weir &
Meltzer 1993), but is poor in pro-monocytic/leukaemic cell lines with reported success rates
of less than 3% (Liao et al. 1997). Electroporation produces high levels of cell death, ranging
from 5% to 60% in cell lines within 72 h after electroporation (Kusumawati et al. 1999), to
30 to 75% within 24 h using primary cells (Weir & Meltzer 1993). In practice, it appears that
lower levels of cell death are associated with lower transfection success rates. CD34+
endothelial progenitor cells are mononuclear cells that have been successfully electroporated
by pelleting cells following pulse delivery, and then incubating them in the caspase
inhibitors B-D-fluoromethyl ketone and z-VAD-fmk, a procedure that reduced osmotically
induced swelling, limiting cell death and produced transfection efficiencies of 20% (Li,
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McCarthy, & Hui 2001). However this has not been reported in primary human
macrophages. Electroporation thus still appears to be a technically difficult in vitro mode of
transfecting primary monocytes and macrophages.
4.3.4 Further transfection options
Transfection of primary cells is technically demanding, with monocyte/macrophages being
notoriously resistant to transfection methods (Burke et al. 2002).
Methods of DNA delivery to primary cells other than electroporation include lipofection
methods direct infection with viral vectors, and more rudimentarily the attempted
introduction of naked DNA.
4.3.5 Naked DNA delivery to macrophages
Macrophages can take up exogenous DNA, possibly via specific transport mechanisms.
However, most extrinsic DNA is degraded in endosomes (Bennett, Gabor, & Merritt 1985).
However, high concentrations of exogenous DNA have been successfully used to transfect
the RAW 264.7 macrophage cell line (Stacey, Sweet, & Hume 1996). Studies on human
dendritic cells have shown the successful transfection of naked DNA into cutaneous DCs in
human subjects (Condon et al. 1996), although this latter approach was non-specific in terms
of target cell uptake of DNA. However, a significant drawback of naked DNA transfection is
the presence of unmethylated CpG dinucleotides (cytosine followed by guanine), which are
rare in eukaryotic DNA. These sequences induce macrophage activation similar to that
caused by LPS, because unmethylated CpG DNA is a potent adjuvant (Krieg 1999). This
makes naked DNA transfection highly impractical for macrophage work.
4.3.6 Liposome DNA delivery and cationic compounds
Enhancing DNA transport through the cell membrane and into the nucleus, requires a variety
of complex-forming and condensing agents (reviewed in Zhdanov, Podobed, & Vlassov
2002). Polyvalent cations including calcium and manganase, polycations (such as spermine,
spermidine, histones, polyethylenimines), cationic polypeptides and dendrimers and cationic
liposomes may all be used. These transfection mediators aid condensation of DNA. The
resultant nucleic acid compaction promotes penetration into the cell, and protects DNA
integrated into condensed complexes from nuclease-mediated degradation. Gene delivery
with liposomes (lipofection) is the commonest current mode for DNA delivery to eukaryotic
cells, offering low toxicity, and permitting delivery of variable sizes of DNA fragments
(Feigner et al. 1994).
135
Attempts at using lipid-based reagents to transfect primary macrophages or myeloid cell
lines in vitro have produced poor transfection efficiencies (<5%), with transgene expression
lasting no more than 24hrs (Kusumawati et al. 1999). Lipofection was attempted with THP-1
cells, but was totally unsuccessful, and these data were not presented. The use of DEAE-
dextran to counter-balance negative charge effects is another means of facilitating DNA
transfection in mammalian cells (Danna & Sompayrac 1982) and has been used as a DNA
transfection method for adherent primary human macrophages, with improved transgene
expression of up to 56 h (Mack et al. 1998). Elowever, this can alter residual monocyte
survival and was avoided. A variety of commercial liposomal agents such as
LipofectAMINE (Invitrogen USA), combining liposomes and DNA with the DNA-
condensing agent protamine sulphate, have been shown to successfully transfect the murine
macrophage cell line RAW 264.7 (Dokka et al. 2000), although success was determined by
luciferase activity for whole culture wells, thereby exaggerating transfection success rates.
The use of GFP-reporter sequences is a more accurate method, offering the ability to
distinguish individual cell transfection success, and was a key factor in the choice of vector
used to perform the THP-1 transfections presented in this chapter.
4.3.7 Adenoviral strategies
Adenoviral vectors have been used successfully to transducer monocytes and macrophages,
both in culture lines and in primary cells. Macrophage activation may be down-regulated
following adenoviral delivery of suppressors of inflammation including small protease
inhibitors (Henriksen et al. 2004) and inhibitors of NF-kB degradation including dominant
negative I-kB mutants (Wilson et al. 2005). However, adenoviral vectors not bearing similar
anti-inflammatory genes introduce the possibility of macrophage activation (Lieber et al.
1997). As discussed in chapter 3, this is a potentially anti-apoptotic stimulus and was thus
avoided for these experiments. Adenoviral-mediated introduction of the same PPARy mutant
used in this chapter has been successfully performed in adipocytes (Nugent et al. 2001).
Discussion with this group suggested that attempts at use of an adenoviral vector for
delivering PPARy to macrophages had indeed produced target cell inflammatory responses
(Agostini M., Gurnell M., pers. comm. 2002) precluding the use of this vector for apoptosis
studies.
4.3.8 Microorganisms
Microbial entry into host cells is a feature of successful pathogens, and has been exploited
for DNA delivery into mammalian cells. Human monocyte-derived macrophages have been
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successfully transfected with Listeria monocytogenes (Dietrich et al. 1998) and Salmonella
typhimurium, with transfection efficiencies in the latter system of 85-95% (Paglia et al.
1998). However, as this is likely to invoke pro-inflammatory and pro-survival responses this
was not a useful strategy.
4.3.9 Receptor-mediated gene transfer
Macrophage surface phenotyping has fostered the development of specific targeting routes to
permit DNA transfection. By exploiting endocytosis to facilitate DNA entry, mannose has
been incorporated into complexes with DNA and used to increase transfection efficacy for
primary in vitro macrophages (Ferkol et al. 1996). Integrins may also serve as a target to aid
DNA entry into macrophages. The use of Ligand Integrin DNA vector systems has been
reported to increase transfection efficiency in conjunction with lipofectin (Hart et al. 1998).
However, a major concern in this work was the use of monocytes which had not undergone
prior activation before exposure to pro-apoptotic stimuli. Adhesion-dependent cell survival is
a principal feature of integrin mediated interactions with extracellular matrices (Giancotti &
Ruoslahti 1999). The anti-apoptotic programmes that may be initiated by adhesion events
were discussed in Chapter 3. pi integrin ligation is particularly relevant in this regard.
Integrin-linked kinase associates with pi integrin in the focal adhesion complex, and has
been recently shown to mediate survival via a PKB/Akt mediated signalling pathway (Nho et
al. 2005). This suggests that receptor mediated transfection is a less than ideal strategy for
gauging subsequent cell death responses.
4.3.10 Alternate strategies to silence genes
Introduction of exogenous proteins into cells may effect inhibition of cell function avoiding
the need for gene transfection. A useful tool in this regard is the Tat protein system, fusing
proteins of interest with a 36-amino acid sequence from the human immunodeficiency virus
protein Tat (Becker-Hapak, McAllister, & Dowdy 2001). However, this was not appropriate
for the introduction of the PPARy dominant suppressor gene sequence.
A more realistic strategy to selectively silence PPARy would be the use of small interfering
RNA (siRNA) sequences. Uptake of short sequences of double stranded RNA results in the
degradation of homologous sequences of mRNA in host cells, offering the ability to suppress
(or "knock down") functions of specific genes (Elbashir et al. 2001). Tailored sequences of
siRNA mimic this natural method of gene silencing, and have been successful in inhibiting
PPARy mediated maturation and differentiation in pro-adipocytes (Hosono et al. 2005).
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Use of PPARy null animals has enabled issues of incomplete pharmacological antagonism or
ineffective gene silencing to be avoided. PPARy is essential for placental and cardiac
growth, making PPARy gene deletions embryonic lethal (Barak et al. 1999). However, work
using PPARy-null embryonic stem cells has allowed the use of embryoid bodies which have
been successfully differentiated into macrophages, enabling further study (Chawla et al.
2001b). Further work has been performed using the Cre/LoxP system of conditional gene
deletions to target tissue specific removal of the PPARy gene, and this latter strategy may be
ofmost use in further monocyte and macrophage work (Akiyama et al. 2002).
4.3.11 PPARy specific responses in monocytes
Gene suppression may be necessary in elucidating the dependence of particular monocyte
responses upon PPARy. Understanding of the intra-cellular handling of cholesterol by
macrophages has been aided by the use of PPAR-null cells. The key issue that led to this part
of the project was the prospect that the PPARy antagonist GW9662 might be either non¬
specific, or lose efficacy during experiments. Subsequent data has shown that GW9662 is
highly PPARy specific, and the data in Chapter 3 showed this agent to be functional.
Monocytes and monocytic cell lines are difficult to transfect, without altering cell viability or
activation status. The individual vectors and electroporation techniques had been used
successfully in other cell culture systems, but were not reproducible in THP-l cells. In
retrospect, the attempt to silence PPARy may not have been necessary. However, such gene
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Figure 4-1 Cloning strategies
Strategies used to introduce PPARy dominant mutant into GFP-expressing pIRES
vector are displayed according to the restriction maps of the vectors used.
The multiple cloning sites for individual vectors are shown. For each vector, relevant
restriction digest sites used for sub-cloning are shown and fragment sizes are
indicated.
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Figure 4-2 Attempted construction of bi-cistronic vector
An attempt was made initially to digest the pIRES-GFP vector with Hindlll (a), and
then fill nucleotide sequences enabling subsequent digestion with Xhol. This would
have produced a complementary site for ligation. The PPARy wild type (b) and
mutant (c) were digested with Xbal and then Xhol to produce ligation-ready sites.
Ligation was performed using DNA ligase I with a 3:1 insert:vector molar ratio. (Lane
1 shows a 500bp molecular weight marker ladder, lane 2 shows a low DNA mass
ladder. Vector mass was estimated as 50-1 OOng using the mass ladder.)
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Figure 4-3 Plasmid preparation of ligated products
Ligation products were transfected into competent bacteria and DNA mini-
preparations used to produce DNA samples for confirmation of ligation success. Six
random plasmid preps producing large products were picked (arrows). Samples were
divided into wild-type (lanes 2-13) and mutant (lanes 15-27). Molecular weight
markers intervene.
Figure 4-4 Failure of ligation using initial methods
Plasmid products were digested using BamHI as this would produce two large
products visible on electrophoresis. Unfortunately, only linearised pIRES-GFP vector
appeared, suggesting that ligation had not occurred using a "cut/fill" strategy to
produce complementary sites.
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Figure 4-5 Use of psp72 as shuttle vector
The vector psp72 bears complementary restriction sites to the pcDNA3 vector.
Insertion of the PPARy construct into psp72 leaves a further restriction site
complementary to sites in the pIRES-GFP vector. Figure 4.5a shows wild type
PPARy, and AF2 mutant run against 1 kb and DNA MW ladder; Figure 4.5b shows
fragments after successful restriction digestion with Xhol and Xbal.
psp72 has linearised, but only one cut fragment is large enough to be visualised.
Both PPARy constructs have cut appropriately, with two visible fragments for both.
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Figure 4-6 Gel purification of Xhol/Xbal fragments.
PPARy-containing pcDNA3 and empty pSP72 vectors were simultaneously cut with
Xhol and Xbal to produce fragments for ligation. Sufficient masses of DNA were used
to enable gel purification from these fragments.
Figure 4-7 Digest products, post-purification
(Lane 1, 1 kb molecular weight ladder; Lane 2, low DNA mass ladder). Gel purification
gave low yields, prejudicing the success of subsequent ligations.
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Figure 4-8 Initially unsuccessful ligation products.
Gel electrophoresis of ligation products from both mutant and wild-type constructs
showed that these fragments had failed to be incorporated into psp72. A single large
fragment should be seen in each lane, instead of which, a separate band of whole









Figure 4-9 Successful ligation of PPARy into pSP72 vector
Successful ligation of PPARy into pSP72 enabled bacterial transformation to produce
large masses of this intermediate construct. Suitable colonies were picked and DNA
from plasmid mini-preparations electrophoresed on agarose gels to assess whether
the PPARy sequences had inserted correctly. A fragment size of approx 4 kb
corresponded to the correct insertion. Smaller fragments seen correspond to vector
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Figure 4-10 Restriction digests of pSP72/PPARy constructs showing correct
insertion of wild type and mutant PPARy sequences.
Digestion of the PPARy/pSP72 construct with Xhol/Xbal shows two fragments of
1.5kb and 2.4 kb respectively, demonstrating that the PPARy fragment had correctly




Figure 4-11 Restriction digests of pSP72-PPARy with EcoRI/Xhol.
An attempt to excise PPARy from pSP72 and subsequent insertion into pIRES-GFP
was made using Xhol and EcoRI. This resulted in extra fragments being produced
(marked in lane 3 and also seen in lane 5) as the full details of restriction digest sites
within the PPARy sequence itself were not known. Unfortunately this meant we could
not use this strategy, and had to resort to the use of Xhol and Smal. (1kb ladder in
lanel; uncut mutant and wildtype pSP72/PPARy lanes 2 and 4).
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Figure 4-12 Restriction digests of pSP72/PPARy construct and plRES2
pSP72/PPARy (AF2 and wild type) were cut with Xhol and Smal (Figure 4.12a),
revealing a 2.4kb vector fragment and a 1.5kb PPARy insert bearing complementary
ends for ligation into plRES2-GFP.
plRES2 -GFP was also cut with Smal and Xhol (Figure 4.12b). This digest produced
a small 40bp fragment between restriction sites, which was not visible on the gel
shown. The large residual vector fragment (just under 5.3kb), bearing complementary
ends for ligation was clearly visualised and further purified by gel extraction prior to
ligation with the PPARy fragment.
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Figure 4-13 Restriction digests of plRES2/PPARy ligation products.
DNA mini-preparations from organisms transformed with plRES2/PPARy ligation
products were digested with BamHI, to assess whether PPARy had been inserted
into the pi RES vector correctly.
Lane 1 is a 1 kb ladder.
Lanes 2-4 show uncut pIRES, pSP72/PPARy mutant, and pSP72/PPARy wildtype
after digestion with BamHI. The small 500bp fragment for the latter two digests is not
clear here.
Lanes 5-8 show plRES2-GFP/PPARy wildtype digested by BamHI. A large 6kb and
small 1 kb fragment are seen as predicted in lanes 6-9.
Lanes 9-14 are plRES2-GFP/PPARy mutant, digested with BamHI. Lanes 11-13
have correct digestion products, confirming correct orientation of the insert.
To finally cross-check this data, further BamHI digests were performed on all vectors
used in this cloning strategy.
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Figure 4-14 Confirmatory BamHI restriction digests on all vectors
Lanes 1,8, 18 are 1 kb ladders.
Lanes 2-7 are: empty plRES2 (partial linearization); pcDNA3/PPARy mutant
(6.5kb+0.5kb fragments); pcDNA3/PPARy wild-type (6.5kb+0.5kb fragments); pSP72
(linearised vector); pSP72/PPARy mutant (3kb+1kb fragment); pSP72/PPARy wild-
type (3kb+1kb fragment).
Lanes 9-13 are plRES2-GFP/PPARy mutant ligation products. All but lane 10 show a
6kb+1kb fragment displaying correct ligation of PPARy into plRES2.
Lanes 14-17 are plRES2-GFP/PPARy wild-type ligation products. All except lane 14














Figure 4-15 THP-1 scatter shift after electroporation
Using both EquiBio and Amaxa electroporation pulse field generators, THP-1 cells
were exposed to electric pulses of varying strength and duration. Electroporation
altered forward and side scatter (see also Figures 4-17-4-20). Trypan blue staining
showed a 95% total death rate in electroporated cells, deemed acceptable for these
protocols. Trypan blue exclusion was maintained at 48 hours for all the profiled THP-
1 cells.
Figure 4-16 THP-1 cell microscopy following transfection
















Figure 4-17 Double pulse wild-type PPARy transfection
THP-1 cells were electroporated with a double waveform electric pulse, with (right
hand panels) and without (left hand panels) the pIRES/PPARy wild-type construct.
All electroporated cell scatter profiles, with or without vector/construct DNA, showed
a higher side-scatter sub-population as in Figure 4.1.5. Gating on individual
populations permitted FL-1 fluorescence to be quantified. Cells were allowed to
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Figure 4-18 Double pulse mutant PPARy transfection
THP-1 cells were electroporated with a double waveform electric pulse, with (right
hand panels) and without (left hand panels) the pIRES/PPARy mutant construct
(termed af2 in figures).
Little change in cell scatter profile in comparison to wild-type transfection was seen.
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Figure 4-19 Single pulse wild-type PPARy transfection
THP-1 cells were electroporated with a single waveform electric pulse, with (right
hand panels) and without (left hand panels) the wild-type PPARy construct.
A noticeable increase in cell scatter profile in cells electroporated with
vector/construct DNA is seen in comparison to sham transfections with buffer alone.
However, although the higher side scatter populations show higher FL-1
fluorescence, this is the same for both sham and vector/construct electroporations.
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Figure 4-20 Single pulse mutant PPARy transfection
THP-1 cells were electroporated with a single waveform electric pulse, with (right
hand panels) and without (left hand panels) the pIRES/PPARy mutant construct
(termed af2 in figures).
A similar increase in cell scatter profile in cells electroporated with vector/construct
DNA is seen in comparison wild-type transfections. However, no noticeable
difference in FL-1 fluorescence is seen between sham and vector/construct
electroporations.
155
Chapter 5 TRANSCRIPTIONAL PROFILING OF MONOCYTE RESPONSES
TO MICROENVIRONMENTAL CHANGE
5.1 Introduction: assessing gene function
Definitions of lipid-laden cells within atherosclerotic plaque have been problematic. The
monocytic origin of lipid-laden foam cells seen in most areas of atherosclerotic plaque has
only been established in the last two decades. Cellular changes at a protein level are
governed in part by transcriptional responses (Brenner, Jacob, & Meselson 1961; Crick et al.
1961). A high throughput screening strategy was therefore sought to efficiently examine
early gene responses to modified lipoproteins.
5.1.1 Expression profiling: assessing cell responses at a gene level
An alternative route to examine the roles of an individual gene in cellular processes is to
determine expression patterns. Gene expression profiling allows analysis of gene activity in
different tissues, similar tissues at different stages of development, or contemporaneously
comparing cell responses following stimulation with different stimuli. High throughput
screening technologies such as micro and macro arrays, allow the multiple analysis of
several hundred or several thousand genes at one time, with obvious applicability for studies
relating to drug development, embryology, cellular and molecular pathology and
microbiology.
Many traditional assays of transcription may be pursued based on the principle of
hybridization between nucleic acid pairs, one of which is immobilized on a matrix. This is a
core technique in molecular biology (Southern, Mir, & Shchepinov 1999) offering highly
sensitive and specific detection at a gene level by exploiting the natural, mandatory and
exclusive complementary binding between nucleic acids strands (Gillespie & Spiegelman
1965). Early applications used purified single labelled oligonucleotide or polynucleotide
species in liquid phase with complex polynucleotide mixtures attached to a solid phase.
Quantitative information about particular transcripts in pooled RNA could be derived using
multiple RNA samples immobilized on the same matrix. mRNA or total RNA was
immobilised on membranes, and then incubated with a radiolabeled, gene-specific target.
The observation that single-stranded DNA binds strongly to nitrocellulose membranes in a
manner that blocked DNA strand re-association but permitted hybridization to
complementary RNA formed the original basis of the original DNA 'blotting' methods,
combining filter hybridization with gel separation of restriction digests (Southern 1975) and
nucleic acid dot-blotting (Kafatos, Jones, & Efstratiadis 1979). Further key techniques,
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including the including northern blot analyses (Alwine, Kemp, & Stark 1977), SI nuclease
protection (Berk & Sharp 1977), and differential display (Liang & Pardee 1992), have
offered the ability to quantify gene expression. Automation and miniaturisation of the dot-
blot proved that hybridisation could be used on a large scale to interrogate cDNA libraries
(Adams 1991; Lennon & Lehrach 1991; Okubo 1992). Serial analysis of gene expression
(SAGE) has applied expression analysis to small cell sub-populations and micro-anatomic
structures, enabling the investigation of small cell or tissue samples (Velculescu et al. 1995).
Qualitative and semi-quantitative comparisons of gene transcription may be made using
standard reverse transcriptase polymerase chain reaction (RT-PCR) assays (Scharf, Horn, &
Erlich 1986), with more robust quantitation available using real-time RT-PCR (Gibson,
Heid, & Williams 1996), and RNase protection assays. These labour-intensive methods,
although well accepted, can only address the transcriptional profiles of a few genes per
assay. Newer techniques now provide the ability to analyse and quantify thousands of
messenger RNA (mRNA) transcripts, using gene expression profiling methods (Duggan et
al. 1999). Both complementary DNA (cDNA) (Schena et al. 1995) and oligonucleotide
arrays (Lockhart 1996) may be used to enable the parallel studies of expression levels in
multiple genes. Gene arrays provide information about tissue specificity of gene expression
and dynamic information that compares relative expression patterns of genes. Both cDNA
and oligonucleotide arrays are capable of analysing patterns of gene expression, but
fundamental technical differences exist between the methods. Oligonucleotide arrays involve
the bonding of short lengths of nucleic acid, using sequencing information, without the need
for PCR reactions or cDNA products. High densities of target genes, in multiples of 104
genes may be spotted onto matrices, usually glass, with high resolution confocal laser
scanning used to read bound signals (Lipshutz et al. 1999). A cDNA microarray by contrast
involves the use of a non-porous solid supports such as a plastic or nylon membrane, or may
also use a glass slide. Up to 10,000 cDNAs can be robotically spotted onto a microscope
slide at high-density, facilitating miniaturization and enabling radioisotope or fluorescence-
based detection. cDNA sequences are hybridized with a double-labelled probe made from
RNA samples, usually by a modification of RT-PCR reactions and the probe labelled either
by a radioisotope, or with a fluorescent marker. At the time of commencement of this
project, few commercially available arrays were available. Profiling experiments were
restricted to facilities with sufficient core expertise in robotics and fluorescence detection to
design and manufacture their own arrays, using oligonucleotide-based techniques. In
contrast, I sought a commercial array using techniques immediately available to me. A
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cDNA array with a relevant selection of genes including those specific to adhesion was a
pragmatic compromise between cost and availability.
The first commercially available small-scale gene arrays were based on nylon membrane
technology, with gene specific spots of cDNA varying between 200 base pairs and 600 base
pairs. A nylon membrane array (Clontech "Atlas" USA) was used, with a range of 588
cDNA sequences specific to known cardiovascular disease processes, enabling a comparison
of gene changes to be made in lipid-treated monocytes.
5.1.2 Overview of nylon membrane procedure
Two identical positively charged nylon membranes were used with cDNA from 588 genes of
interest bonded to their surface enabling the simultaneous transcriptional comparison of two
cellular treatments. Bonded cDNA fragments on the array were originally amplified from
mRNA regions lacking repeat elements, high homology sequences or a poly-A tail. Using
these cDNA specific primers, and incorporating 32P dATP, it is theoretically possible to
detect as few as 20 transcripts per cell. Probe mixtures are synthesised by reverse
transcription of lpg of RNA using a specific cDNA primer mix, tailored to the genes on the
membrane: random primer mixtures are not used. The cDNA primer mix contains specific
primers for each cDNA sequence on the array. Radioactive labelling is executed by
incorporating a-32P dATP into the reverse transcriptase reaction. The labelled probe is then
hybridised to the array surface using a hybridisation buffer, similar in composition to that
used for northern blots. High stringency washes are performed, following which analysis of
signals is carried out after image capture using either autoradiography or phosphor imaging.
Probes manufactured in a cDNA-specific way are less complex than those made with
random or oligo (dT) primers, resulting in higher sensitivities and lower background signals.
Because of this it is possible to use probes manufactured from total cell RNA, without the
need for poly A+ RNA isolation. This reduces sample preparation time, and the level of
RNA degradation per sample. Although poly A+ RNA derived probes are more sensitive
than total RNA derived probes, attempts to use this technique, either by classical preparation
of poly A+ RNA, or by using poly A+ extraction kits, proved detrimental to RNA quality.
Early RNA degradation was seen, and probes produced had poor radioactivity profiles.
Quantification of transcripts is achieved by comparing expression levels of housekeeping
genes to target genes (Yang et al. 2002). Alternative strategies for balancing housekeeping
gene signals involve either examining signals from individual genes that do not vary in
intensity between control and experimental samples, or by taking averages of all
housekeeping genes on a membrane, and comparing individual gene signals to a mean for
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the housekeeping genes, a technique known as global normalisation (Yang et al. 2002). Use
of normalisation techniques offers the ability to quantitatively compare probes manufactured
from different cell treatments, possibly with different RNA yields, without concern for
artefactually induced quantitative differences. Thus within any one membrane array, actual
signals from each individual gene spot are compared to a normalised background signal.
Individual gene spots are then compared to signals derived from a comparable second array
(Smyth & Speed 2003).
5.2 Specific array methodology and technical data
5.2.1 Preparation of RNA derived cDNA probes for array analysis
Although the responses of mononuclear cells to lipid and PPARy ligands have been
explored, a rigorous definition of early gene changes in a human primary cell in vitro system
has not been made to date. Monocytes from whole human venous blood were purified by
adhesion to tissue culture plastic. Monocytes were exposed to control medium or 50pg/ml
ox-LDL for 24 hrs. Cells were then washed and lysed, and RNA extracted from lysates. The
stringency for RNA preparation is higher than that necessary for RT-PCR, and this coupled
with the limited amount of RNA available from human primary monocytes delayed the
isolation procedure.
Preparation of RNA samples used monocytes from MACS preparations with a mean purity
of 90% assessed by flow-cytometric scatter plots (see Chapter 6, section 6.2.2). It is
appreciated that this means of assessment may underestimate actual purity, because of
random scatter events and inclusion of debris, although this is minimised during acquisition.
Cation-deplete washes, immunomagnetic depletion using CD61+ve magnetic beads, and
monocyte adhesion to tissue culture plastic with further subsequent washes prior to cell
treatments all reduced platelet contamination. Initial yields from RNA preparations were
low, despite attempts to isolate cells from 240mls of whole blood. Initial attempts to re-
precipitate RNA to increase RNA concentrations for probe synthesis were also unsuccessful.
Thus for further RNA preparations, at least 240-320 ml were used. Probe synthesis was
performed using a modified Reverse Transcriptase (RT) reaction, utilising a commercially
supplied mouse moloney leukaemia virus (MMLV) RT enzyme. Radiolabelling was
performed with 32P dATP, prepared in a master-mix and added proportionate to the mass of
purified RNA used. Specific primers complementary to the cDNA sequences spotted on the
array membrane surface were used. An internal control to ensure function of the MMLV RT
was performed using a purified Poly A+ RNA sample provided by Clontech. Probe activity
was then assessed on a scintillation counter. However after MMLV-RT reactions were
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performed, low levels of incorporated radioactivity were seen on elution profiles. Agarose
gel electrophoresis from eluted probe showed little cDNA suggesting inefficiency either in
probe synthesis or in probe isolation.
Probes were eluted by high-speed centrifugation (15,000g, lmin) through Chromaspin™
columns designed to separate unlabelled dATP from incorporated nucleotide within a
functional probe. However, only the control Poly A+ RNA succeeded in making a probe
with a defined peak of radioactivity, corresponding to specific isotype-labelled nucleotide
incorporation (see Figure 5.1). Experimental samples showed suboptimal resolution, without
clear peaks of radioactivity, and thus by definition no selective incorporation of 32P dATP
had occurred, indicating unsuccessful probe synthesis. In particular, the expected differential
activity from unincorporated free 32P dATP isotope was not separate from the anticipated
active probe. To address this, an alternative mode of probe separation was sought.
Alternative micro-centrifugation columns were sourced, similar in composition to Sephadex
G50 columns used for nucleic acid or protein separation. Active probe was initially bound to
these "Nucleospin" columns. After serially washing the column an elution buffer was added
and the whole fraction of probe eluate collected. This method removes unincorporated
nucleotide, by serial washes, and allows recovery of whole incorporated probe. Activity of
this single fraction of probe was quantified using scintillation counts running on a specific
32P programme. Initial attempts to manufacture probe were thus severely limited by probe
isolation techniques. Initial sample sizes were of the order of 50ng per pi, and purity by gel
electrophoresis was high. Despite this low levels of incorporated probe were found. A repeat
monocyte RNA preparation from 320 mis whole blood showed clean RNA separation, with
no gel electrophoresis evidence of RNA degradation. Control RNA had a total mass of
32.5pg and ox-LDL treated samples a mass of 34pg following DNase treatment. A260/280
absorbance ratios were 1.97 and 1.92 respectively, confirming high RNA purity.
Probe synthesis was performed according to the commercial recommendations, and probe
separation carried out by elution using nucleospin columns, from Clontech (see Chapter 2).
Internal control blank membranes were also exposed to active probe to ensure no significant
background signal was present. These membranes were hybridised and exposed at the same
time to ensure consistency of hybridisation and exposure conditions. Once elution of clean
probe was achieved, hybridisation was performed with excellent radiographic results using
both autoradiography, and storm phosphor imager analysis. After processing had been




For data analysis of gel images, two strategies were used. Firstly, using Molecular Dynamics
ImageQuant software, background signals were assessed both across the whole membrane
and also locally around each signal spot. This was subtracted from high-level signals giving
an assessment of net signal strength. Secondly, housekeeping genes were assessed for their
expression, and averages of these were taken, either by manual point measurements or by
linear averages through a line of gene spots. This was then used to calculate a ratio for each
membrane, giving a figure in proportion to housekeeping gene expression. Finally the net
signal ratio to control for each gene was then calculated to compare control with
experimental samples. Gene expression changes using this method are catalogued in the
Chapter 5 data tables in the attached Appendix.
The second strategy was to use commercially available software (Atlas software, Clontech,
USA), which automatically adjusts for discrepancies within individual membranes. This
technique allows for the discarding of poor quality signals that may confound analysis e.g.
by preventing a "bleeding" spot to confound neighbouring signals. Corroboration of data
between the two methods was sought. Results were expressed as a ratio to normal. Genes
were stratified according to the change they showed either below or above baseline
expression. Genes with transcription changes at a 2-fold or higher level are immediately
obvious using a colour-coded readout, (Fig 5.3).
5.3 Results
5.3.1 Trends in gene expression changes
Assessment of data from the gene array confirms certain documented transcriptional changes
occurring following macrophage exposure to lipoproteins, and particularly to ox-LDL. These
include the up-regulation of orphan nuclear receptors (Nagy et al. 1998), LDL receptor
(Fogelman et al. 1988), and LDL-related protein (Watanabe et al. 1994).
It was useful to examine expression changes in clusters of functionally related genes, and full
data tables of phosphor-imaging signal strength are presented as supplementary data tables,
(Chapter 5 Appendix). Raw data processing suggested that multiple genes governing lipid
metabolism, matrix adhesion and platelet adhesion were up-regulated by at least 2-fold
following ox-LDL exposure, including genes encoding integrin av, a3, (32, P3, P5, and p7
subunits. Lecithin-cholesterol transferase expression was increased, and up-regulation of
genes for multiple collagen types and collagen precursors were apparent, as well as changes
in integrin signals for ICAM-2, PECAM and P-selectin. Increases in gene expression for
angiopoietin-1 and plasminogen activator inhibitor-3, with a reduction in tissue plasminogen
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activator, suggested altered vascular growth influences and effects upon local fibrinolysis.
Other changes with potential local pro-thrombotic effects incuded increased expression of
thrombin receptor, anti-thrombin III, and platelet-activating factor. A large number of
cytochrome P450 genes were upregulated, suggesting the possibility of alterations in cyclic
GMP flux, and increased oxidative capacity of ox-LDL exposed macrophages. However, use
of the Atlas software package did not confirm all of these gene changes. For this reason, only
genes showing high levels of altered transcription using both software analysis methods were
focused upon.
To examine marked gene expression changes, only genes demonstrating 3-fold changes
using both software techniques were looked at. Target genes deemed of interest and seen to
change by this amount were CD47 and LFA-la subunit. A 2-fold decrement in tissue
plasminogen activator (tPA) was noted. Although this was a less pronounced change, tPA
was deemed to be a relevant target in the context of atherothrombosis, and was further
investigated.
5.3.2 Confirmation of gene array results by RT-PCR
Mini-arrays offer a discrete amount of profiling data in a more tailored format than larger-
scale array technologies. Nylon membrane arrays thus offer a reasonable first screen to
assess transcriptional changes. However, resources limited repetition of each array, and
individual gene responses were thus further investigated by RT-PCR. Primers were designed
for CD47 and LFA-la subunit and tPA. A panel of primers was used with varying melting
temperatures, positions and product lengths, (Chapter 2 section 2.10.8). Samples of RNA
from MACS-purified monocytes cultured for 24 hours in ox-LDL or control media were
used for RT-PCR. Despite the use of a large number of computer-designed primers, no
satisfactory PCR product was obtained for tPA analysis. Each polymerase chain reaction was
optimised by titration of temperature and magnesium ion concentration. Annealing
temperatures were calibrated to primer length and base-pair composition. Samples of RNA
used in these reactions were run contemporaneously with other templates successfully,
proving high quality control. Despite these troubleshooting strategies no successful PCR
reactions occurred with tPA, precluding confirmation of altered levels of expression. No
problems were encountered for the other two target genes. PCR over 35 cycles showed a
down regulation in LFA-la (Figure 5.4). In monocytes matured to 5 days in ox-LDL the
levels of LFA-la transcription appeared to recover, suggesting a transient down-regulation
only on initial exposure to ox-LDL (Figure 5.4). Down-regulation in CD47 was less clear
(Figure 5.5). Although the GAPDH control suggests the ratio of GAPDH to CD47 has
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increased, it was not as unequivocal as with LFA-la. Although the relative ratio of CD47 to
GAPDH appeared slightly lower in ox-LDL treated cells, this was not as clear as on the
array. Moreover, any differences between control and ox-LDL treated samples were no
longer evident in RNA prepared from 5-day old macrophages. This transient change in
transcription suggests that, as with the changes seen in LFA-la transcription, there may be
compensatory changes made with increasing maturation.
5.3.3 Protein level corroboration of array data
The phenomenon of a transient reduction in gene transcription that subsequently returns to
baseline may be due to cells in culture recovering from the effects of lipid exposure.
Furthermore, transient changes in transcription may not be ultimately reflected in functional
cellular changes as protein expression may remain stable. For this reason, despite repeating
the PCR data on 3 different donors, CD47 and LFA-1 cell surface protein expression was
assessed by flow cytometry. Monocytes isolated by MACS were cultured in suspension or
on plastic, with supplements of ox-LDL or control medium. Cells were phenotyped with un¬
conjugated primary anti-CD47 (clone B6H12) or anti-LFA-la (clone Wac70) monoclonal
antibodies and a secondary goat-anti mouse antibody conjugated to FITC. No alteration in
LFA-la levels in suspension-cultured monocytes was observed following Ox-LDL exposure
(Figure 5.6). There was an increase in mean auto-fluorescence as noted for other
phenotyping data in lipid-cultured cells. Cell viability was maintained throughout. Cell
population purity was maintained as denoted by scatter plots and also gating over CD 14
positive samples.
Flow-cytometric data on CD47 showed parity at all stages of cell maturation in LDL
supplementation between ox-LDL, native LDL and control media (Figure 5.6). Cells
matured up to 5 days in suspension showed no reduction in CD47 signal. To reproduce
adhesion conditions used during RNA preparation for array analysis, monocytes were
matured on plastic in lipid-supplemented media for 5 days. After being harvested by
trypsin/EDTA treatment, they were labelled with B6H12 and flow cytometrically assessed.
No reduction in signal was noted.
5.3.4 Further corroboration of LFA-1a data
A time-course of LFA-la expression was performed to see if a lag phase existed during
which protein was lost from the cell surface. Samples cultured in suspension showed clear
expression of LFA-la at 3 and 5 days. Monocytes matured in ox-LDL adherent to tissue
culture plastic, (reproducing the purification procedure used for RNA preparation from
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monocytes), showed a discernible reduction in LFA-la signal (Figure 5.7). A fuller
phenotype of monocyte lipid responses was subsequently performed to validate these
findings, and is described in detail in Chapter 6.
5.4 Discussion
5.4.1 Gene arrays in the investigation of cardiovascular disease
The use of gene arrays in biomedical investigation has rapidly increased since the period that
the work presented in this chapter was performed (Southern 2005). Despite the techniques
used in this thesis being now relatively dated, they do offer an overview of the problems
inherent in using array-based approaches to explore changes in cellular function and
phenotype. Gene profiling in cardiovascular disease is now well established in the fields of
atherosclerosis, hypertension and cardiomyocyte research, with many groups adapting gene
profiling studies for use in existing animal models of cardiovascular disease (Flenriksen &
Kotelevtsev 2002).
Cell-culture systems have advantages over animal models in gene micro-array experiments.
Using single cell types limits signal dilution or noise due to compared to cell heterogeneity
in animal model derived samples (see section 5.5). Tissue culture experiments are
comparatively inexpensive offering larger retrievable masses of RNA, allowing flexibility in
choosing profiling technologies and platforms. Nevertheless, as tissue-culture systems are by
definition remote from human pathology, in vitro findings require further validation. After
such ratification, often few genes are found to be physiologically relevant to the disease
process under study. An example of this was the investigation of hypertension-induced
mechanical strain effects on arterial tissue in early atherosclerosis (Feng et al. 1999). Use of
a cyclic deformation device on smooth muscle cells in culture allows examination of the
cells of interest alone, rather than retrieved arterial sections, and ensures that all cells are
exposed to the same stimuli. Despite using a 5,000 gene microarray, only 17 gene changes
were noted. Few of these were corroborated by Northern blotting at a transcriptional level, or
Western blotting at a protein level.
Similarly small numbers of responding genes were identified in a study designed to identify
vascularisation signalling pathways triggered by interactions between factor Vila and tissue
factor in human fibroblasts. Only five up-regulated genes and one downregulated gene were
found. Nevertheless, two of the up-regulated genes (Cyr61 and connective tissue growth
factor) affect cell adhesion, mitogenesis and migration, relevant to fibroblast proliferative
behaviour in the context of intravascular coagulation and vascular injury (Pendurthi et al.
2000).
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Time-course expression profiling of "foam-cells" has been attempted using RNA from ox-
LDL treated THP-1 cells (Mikita et al. 2001). A previous 10,000-gene cDNA micro-array
using THP-1 cells exposed to Ox-LDL showed differential regulation of 268 genes at one
time point at least. Integrin encoding genes were noted to be up-regulated including those for
a2, a5, aX, (33, (35, and (37 chains (Shiffman et al. 2000). This is of interest, as initial
analysis of the nylon membrane array data presented in this chapter suggested up-regulation
of av, a3, (32, p3, P5, and P7 integrins, although these changes were not corroborated by
subsequent software analysis. Further phenotypic assessment of monocyte surface integrin
expression was thus undertaken using indirect immunolabelling, and is documented in
Chapter 6.
Shiffman and Makita also described suppression of cell-cycle genes and changes in both pro-
and anti-inflammatory gene transcription, suggesting potentially altered inflammatory
function. These observations support previously published work on the anti-inflammatory
effects of Ox-LDL blocking I-kB degradation (Hamilton et al. 1998; Page et al. 1999), but
no protein level assessment of NF-kB activation was performed. Certainly this would be
important given the established pro-inflammatory effects of ox-LDL upon macrophages
(Wang et al. 1996). Although findings from these groups are of interest, they focused on the
responses of a cell-line with no functional assays performed to explore the impact of
transcriptional changes.
5.4.2 Array experimental design and technical issues
The use of RNA from monocytes treated by altered low-density lipoprotein supplements was
felt to be crucial to enable an insight into early gene responses to micro-environmental
stimuli. Such strategies have been used in other similar explorations of monocyte gene
responses, and early work by other groups using large scale gene profiling demonstrated the
variable results that individual experiments may produce. In the work shown in this chapter,
practical and financial constraints dictated that gene arrays could only be used to "screen"
putative candidate genes that might be altered in expression during monocyte exposure to
altered lipid environments. Such genes would be explored thereafter using more standardised
quantification methods, including RT-PCR, and quantification at a protein level using cell
surface immuno-phenotyping. RNA preparation was stringently controlled to prevent RNase
contamination, in order to maintain optimal purity for probe synthesis. The methods for this
vary according to the assays being performed. It was increasingly apparent while performing
this work that higher levels of purity than were acceptable for routine RT-PCR were needed
to ensure adequate probe synthesis. Indeed, probe synthesis was critically dependent on
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higher levels of RNA purity than those recommended by the manufacturers of the gene
arrays (Atlas cDNA Expression Arrays User Manual, Clontech Biotech Corporation USA
1999). Further technical problems were encountered during the probe purification stages.
The initial probe elution methods that were suggested by the manufacturer resulted in loss of
probe, and indeed there was a continuous washout of probe in the sequential eluates that
were produced as part of this method of probe purification. For this reason, an alternative
method was used, involving the use of micro-porous membrane centrifugation columns, and
an elution buffer, that minimised washing the probe, and maximised probe yield. Whilst this
delayed the use of the arrays, it ensured that the probe was of sufficient quality to produce an
interpretable high quality signal. Analysis of nylon membrane gene arrays provided another
technical hurdle, in the context of quantifying what were essentially radiographs, produced
by probe activity. Several control factors were considered. Firstly, background signal levels
from control and sample probes and membranes differed visually. Software supplied with
both the phosphor imager and subsequent analysis with the gene array manufacturers own
software package needed to be used to normalise background levels of signal to avoid
misinterpretation. Furthermore, there were issues with excessively high signal levels,
producing "bleeds" around particular "hotspots" thus distorting signal interpretation in the
area immediately around the gene of interest. Such high-noise areas lead to loss of
interpretable signals from adjacent gene spots, with an inability to then compare subtle
changes in transcription levels in less highly labelled gene spots. Glass or chip base arrays
avoid these issues due to the lower noise levels and more discrete spotting patterns. To
assess the contribution that individual hotspots made to background it was suggested that
spots should be compared to local area background signal to assess the difference in local
signal bias. This was not noticeably different for the majority of spots and thus a general
background subtraction was used.
5.4.3 Further assessment of CD47 and LFA-1 changes
A fuller exploration of CD47 and LFA-1 could have been attempted if sub-cellular fractions
had been separated, thus offering an opportunity to measure expression within monocyte cell
membranes, lipid rafts, and also potentially to look at protein trafficking through organelles.
An active stimulus to remove surface LFA-1 a may be necessary to discern a change at the
monocyte cell surface. LFA-la, along with a3(31, and a4(31 integrins, appears not to
participate in endocytotic cycling, unlike a5(31, a6p4 and Mac-1 integrins. LFA-1 thus
presents a stable profile at the cell surface which may remain constant during monocyte
maturation, although low-level cycling of LFA-1 has been reported (Bretscher 1992).
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Integrin subunits are integrated within cell membranes, and have strong interactions with
structural proteins including talin (Burn, Kupfer, & Singer 1988) and the actin binding
protein actinin, the latter shown to specifically associate with |32 integrin chains (Pavalko &
LaRoche 1993). Furthermore, discrepancies between transcription and translation are
documented for other P2 integrins, notably CD1 lc/CD18 (Noti & Reinemann 1995), and [32
integrin transcription may be directly regulated during inflammation by hypoxia-inducible
factor-1 (HIF-1) (Kong et al. 2004).
Dynamic migration assays might reveal whether changes in integrin transcription correlate
with altered leukocyte function in this setting. The use of murine models with gene deletion
of LFA-la (Ding et al. 1999) would be a key strategy to demonstrate an in vivo role for
LFA-la in the initiation and progression of atherosclerosis. Biotinylation of monocyte
surface LFA-la would allow integrin trafficking following lipid exposure to be explored in
cell lysate sub-fractions, a technique used successfully in assessing a6 integrin mobility (He
et al. 2005). This would be of use in assessing any LFA-1 loss during movement through cell
matrix components or migration across endothelial monolayers.
5.4.4 Transcriptional redundancy: mismatches between gene signals and
protein production and function
Macrophage gene products are under multiple layers of control, with examples including
transcriptional and post-transcriptional regulation of M-CSF-1 (Weber et al. 1989). The
regulation of IFNy mediated induction of IL-1 TNFa and uPA is controlled by short lived
protein repressors, that act to modulate transcription of these target genes (Collart et al.
1986). Increases in P2 integrin surface expression have been noted to correspond to
increased steady state levels of CD18 mRNA in HL60 cells (Hickstein, Back, & Collins
1989). However, it appears that other integrin subunits may undergo post-transcriptional
changes, including LFA-1 (Back, Gollahon, & Hickstein 1992). Further control over LFA-1
gene expression operates at a DNA as well as an RNA level, with Methylation of the LFA-1
intron being responsible for altered mRNA levels, a finding that has been matched to higher
levels of protein expression (Kaplan et al. 2000). Leukocyte surface molecule expression
also depends on intracellular trafficking, and the ability of relevant chaperone proteins to
facilitate transport to the cell membrane. Chaperones such as calnexin (Ihara et al. 1999) and
calreticulin (Saito et al. 1999) are critical for the delivery of functionally competent proteins
to the cell membrane, offering protection from thermal and oxidative stress, and are
dependent upon the conformation of protein products. The failure for transcriptional changes
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to be reflected at the cell surface reinforces the need to substantiate expression profiling data
with further investigation of the relevant proteins themselves.
5.5 Further development of gene profiling
Gene profiling studies demonstrate the potential for new insights into cardiovascular disease
processes. Examples include metabolic shift to glucose metabolism during recovery from
myocardial infarction (Stanton et al. 2000). Validation of microarray technology to
demonstrate biological relevance is currently crucial. Experimental design was deliberately
simplistic, using single measurements at single timepoints. It would clearly be better to opt
for multiple time points to enable the use of statistical methods for analysis of expression
patterns over time or during different cell culture conditions. Moving from in vitro work
using arrays to sampling from animal models or tissue samples is potentially complicated.
Signal dilution of changes in gene expression is a feature of samples containing multiple cell
or tissue types. Although laser microdissection techniques are improving the cell-specific
isolation of nucleic acids, small sample size, especially in the context of patient biopsies,
limits RNA yields. Despite this, studies have been successfully perfomed on aortic arch
tissue samples, showing varied EC gene expression due to shear stress (DePaola et al. 1999).
Alterations in EC pro-inflammatory and anti-oxidative gene expression have also been
highlighted (Passerini et al. 2004). Single-cell or oligocellular PCR-based amplification is
thus feasible and allows this technology's use in examining effects at a tissue or organ level.
RNA profiling has aided identification of genetic defects relevant to cardiovascular and
metabolic disease (Aitman et al. 1999; Lawn et al. 1999). Nevertheless, RNA expression
remains a key focus for most array based experiments, with mammalian genome arrays
containing 5,000-10,000 genes now in common use. Current protocols allow reliable
detection of messages present at several copies per mammalian cell. Advances in robotics
and analysis techniques have meant an improvement in both fabrication and sensitivity. It is
now feasible to produce or commercially purchase standardized oligonucleotide and cDNA
arrays containing the large sets of human and mouse genes in multiples of 10,000 genes.
Careful experimental design is critical to successful utilisation of this technology.
Experimental manipulations need to be rigorously controlled. Responses to
microenvironment are especially prone to producing misleading expression data. When
several thousand genes are being sifted to find variation in small subsets, scrupulous
experimental technique is paramount to limit variation. Simple variables including the
position of a culture dish in an incubator or the time of day at which an assay is performed,
may also be crucial. Comparison of the 'same' experiment performed at different time points
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is thus likely to reveal considerably wider variation than seen when the same sample is tested
by repeated hybridization.
A significant increase in development and availability of technology has altered the way
most laboratories treat the use of gene arrays. From being a specialised tool designed for the
wholesale screening of known and unknown genes, arrays have become widely available for
repeated transcriptional profiling of multiple cell types under varying conditions
(Lobenhofer et al. 2001). The data presented in this chapter is of interest, not merely in terms
of the view of cellular transcriptional changes that occur within monocytes in response to
altered lipid and inflammatory signals, but also because it provides insight into the design of
expression-profiling experiments, highlights the difficulties inherent in such an approach,
and offers some lessons in how to refine such experimental strategies. Certainly, with an
increase in access to higher throughput profiling tools, any attempt to re-visit this work
would involve glass chip arrays. The ability to interrogate multiple sets of gene arrays would
clarify those gene targets with greatest transcriptional variation at an earlier stage, possibly
allowing for a wider cohort of genes and gene products to be examined by PCR and protein
level analyses. Glass arrays benefit from automated signal readout removing operator
variability present when using nylon membrane technology. Nevertheless, it is still
mandatory to persist with a full investigation of target proteins using appropriate assays.
Information processing will become the greatest challenge for expression profiling
experiments (Weinstein et al. 2002). Early studies were deliberately simple, comparing just
two samples, with the aim of identifying those genes whose expression levels differed.
Increased biological insight is only possible from examining datasets with scores of samples.
This requires multiple time points from multiple cell lines treated independently with
multiple treatments. Each gene then defines a point in k-dimensional space, where k is the
number of samples studied (D'Alimonte et al. 2005). Functional similarities are read as gene
clusters in this space. Computational scientists working in array analysis are developing
techniques for clustering and anticipating patterns based on established patterns. However,
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Figure 5-1 Initial probe elution profiles
Initial probe synthesis involved multiple washing steps, resulting in the loss of functional
probe. Elution profiles for each probe should display radioactivity peaks. Instead, all
samples showed a gradual increase in radioactivity, showing failure of 32P dATP specific.
Subsequent probe isolation was performed using micro-porous centrifugation tubes, and
subsequent elution with a pH-adjusted buffer. This technique did not require the
collection of individual elution fractions. Similar scintillation data is thus unavailable for
this technique.
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Figure 5-2 Nylon membrane gene arrays derived from RNA of monocytes
treated with control (upper panel) and oxidised-LDL (lower panel)
cDNA for individual genes are spotted in 6 grids per array, with house keeping genes in
three strips at the base of each array. Differential background signals are compensated
for during post-hoc processing.
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Figure 5-3 Atlas array software analysis of gene expression in control versus
ox-LDL labelled probes
Green colour indicates increased expression, red indicates decreased expression. Blue
indicates a neutral outcome, i.e. no modulation in gene transcription. Fully filled blocks
indicate acceptable signal quality whereas half-filled blocks indicate sub-optimal signal
quality. Blank blocks show that no interpretable signal was produced.
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Figure 5-4 Reduced LFA-1 a transcription in ox-LDL treated monocytes
RNA from monocytes cultured 24 hours in control media, native LDL or ox-LDL was
used in RT-PCR to assay LFA-1 a transcription. ox-LDL reduced gene transcription of
LFA-1 a at 24 hours, with recovery of LFA-1 a transcription apparent at 5 days.
CD47
GAPDH
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Monocytes Macrophages
Figure 5-5 RT-PCR of CD47 in naive monocytes and mature macrophage
treated with control media, Acetylated LDL or Oxidised LDL
RNA samples from 24hr old monocytes exposed to control media, acetylated LDL or ox-
LDL were used to perform RT-PCR with CD47 primers. Results were compared to
GAPDH production for the same RNA samples. 5-day old macrophages were also used
to investigate whether the suggested reduction in CD47 transcription was reproduced at





Figure 5-6 CD47 and LFA-1 a surface expression is unchanged by ox-LDL
Monocytes cultured for 24hrs in Teflon wells using control media or 50|.ig/ml ox-LDL
supplementation were labelled with monoclonal antibodies against CD47 and LFA-1a.





Figure 5-7 Five-day old macrophages display reduced surface expression of
LFA-1 a after treatment with oxidised LDL
Monocytes matured for five days in vitro on tissue culture plastic either in control media
or in media supplemented with oxidised LDL were detached by treatment with
trypsin/EDTA 5mM, then washed, immediately labelled and analysed by flow-cytometry.
A decrease in LFA-1a surface expression was noted.
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Chapter 6 MONOCYTE PHENOTYPIC CHANGES INDUCED BY
MICROENVIRONMENTAL STIMULI
6.1 Introduction
Extracellular stimuli alter the structure and function of naive monocytes, and influence the
responses of phenotypically mature resident macrophages at injury sites. Inflammatory
cellular responses govern local tissue damage progression, a process highly relevant to
vascular injury (Simon et al. 2000b). Naive monocytes entering active atherosclerotic lesions
are exposed to inflammatory stimuli (Plutzky 2001) including altered or modified
lipoproteins, locally produced chemokines and cytokines and arachidonic acid metabolites.
Pro-atherogenic LDL species may directly modulate vascular adhesion in an oxidation status
dependent manner, with vessel wall damage resulting from superoxide mediated injury (Lelir
et al. 1992). Ox-LDL contributes directly to endothelial glycocalyx degradation, enhancing
leukocyte adhesion and promoting inflammatory vascular wall injury (Constantinescu, Vink,
& Spaan 2003). Pro-inflammatory cytokines such as IL-8 reduce production of natural tissue
inhibitors of metalloproteinases (TIMPs), (Moreau et al. 1999) promoting local vascular
tissue injury. Intra-luminal blood flow may be reduced by subsequent fibroblastic responses
during the reparative stages of vessel injury (Lazarous et al. 1996; Schwartz, Majesky, &
Murry 1995). Micro-environmental influences upon monocyte phenotype thus govern
leukocyte function, and are of direct interest in the study of vascular inflammatory injury.
Monocyte surface molecules relevant to atherosclerosis and inflammation were introduced in
Chapter 1, but detailed consideration of specific receptors and ligands is warranted.
Molecules will be principally referred to by Clusters of Differentiation (CD) nomenclature to
keep text succinct, although complex receptors such as integrin heterodimers and Fc receptor
subtypes will be referred to by name.
6.1.1 Monocyte pattern recognition receptors in inflammation
In contrast with the large repertoire of rearranged receptors in the acquired immune system,
the innate immune system recognises micro-organisms via a discrete number of germline-
encoded pattern-recognition receptors (PRRs), (reviewed by Akira, Uematsu, & Takeuchi
2006). PRRs are highly conserved through evolution, and have common characteristics,
recognising conserved microbial components, known as pathogen-associated molecular
patterns (PAMPs). PRRs are expressed constitutively, independent of immunologic memory.
Different PRRs react with specific PAMPs, with distinct expression patterns, signalling
pathways, and anti-pathogen responses. PRRs include toll-like receptors (TLRs) that detect
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bacterial PAMP, scavenger receptors including SR-A and CD36 that may mediate apoptotic
cell recognition (Savill et al. 2002) and ingestion ofmodified LDL (Boullier et al. 2001), and
specific receptors for bacterial LPS including CD 14 (Landmann et al. 1995). PRR
recognition of endogenous ligands, may contribute to chronic inflammatory responses, and
are thus of particular interest in conditions such as rheumatoid arthritis and atherosclerosis
(reviewed by Karin, Lawrence, & Nizet 2006).
6.1.2 CD14 roles in monocyte differentiation and innate immunity
CD 14, a 55kD myeloid membrane glycoprotein linked to the plasma membrane by a
phosphatidylinositol phospholipid is present during early and late stages of monocyte
differentiation (Simmons et al. 1989). CD 14 is important in directing macrophage responses
in infection and inflammation. CD14 binds complexes of lipopolysaccharide (LPS) and LPS
binding protein (LBP), and is involved in LPS induced TNF-a production and IL-6 and IL-8
release by monocytes and alveolar macrophages (Dentener et al. 1993). CD 14 expression is
upregulated by LPS and downregulated by IFN-y and IL-4 (Landmann et al. 1991).
Apoptotic cells interact with a region ofCD14 closely associated with a known LPS binding
region, triggering apoptotic cell phagocytosis but, unlike LPS, without provoking pro¬
inflammatory cytokine release (Devitt et al. 1998). CD14 ligation enhances LFA-l/ICAM-1
interactions via protein kinase mediated coupling, involving CD14, Rho, and PI 3-kinase
(Lauener, Geha, & Vercelli 1990). This converts low avidity LFA-1 into an active form
capable of increased binding to ICAM-1 (Hmama et al. 1999), enhancing monocyte
adhesion.
CD 14 expression is an indicator of monocyte viability, purity and normal maturation in
culture (Ziegler-Heitbrock & Ulevitch 1993). Monocyte surface CD 14 is shed during
apoptosis, a mechanism that may be driven by the action of a cell surface phospholipase
(Fleidenreich et al. 1997). Reduced monocyte CD14 expression may thus suggest in situ cell
death (Heidenreich 1999), but may also be a function of extrinsic IL-4 stimulation (Lauener
et al. 1990), or further differentiation away from a monocyte phenotype, e.g. following
vitamin D3 exposure (Zhang et al. 1994). Cholesterol may be critical in maintaining
expression of GPI anchored membrane proteins, and it has been shown that lipid depletion in
vitro reduces monocyte CD14 (Esfahani et al. 1993). To date, no assessments of surface
CD 14 during exposure to native or modified low-density lipoproteins have been published.
CD 14 binding to LPS primes granulocytes for leukotriene B4 (LTB4) synthesis, in a plasma-
dependent manner (Surette et al. 1993; Surette et al. 1998). LPS also primes monocytes to
release and metabolise arachidonic acid in response to fMLP. LPS priming of monocytes at
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very low concentrations (as low as 10"6mg/ml) is dependent on plasma and CD 14 (Surette et
al. 1996). Although direct LPS stimulation was not the focus of interest in these experiments,
the possibility that CD 14 might be modulated by cyclopentenone arachidonic acid
metabolites was intriguing. This hypothesis, if true, might reveal a potential regulatory
mechanism for CD 14 expression.
6.1.3 Role of the scavenger receptor CD36 in monocyte
The leukocyte differentiation antigen CD36, also known as platelet glycoprotein IV (GP
IHb), is a receptor for thrombospondins a group of widely distributed multimodular secreted
proteins associated with the extracellular matrix (Bornstein 2001) and possessing potent
angiogenic activity (de Fraipont et al. 2000). CD36 is multi-functional. Present on
erythrocytes, (Van Schravendijk et al. 1992) it governs the cytoadherence of erythrocytes
parasitised by Plasmodium falciparum (Oquendo et al. 1989). Platelet surface CD36 is the
primary receptor for platelet-collagen adhesion (Tandon, Kralisz, & Jamieson 1989) and
partially mediates platelet-monocyte binding (Silverstein, Asch, & Nachman 1989). In
monocyte/macrophages, CD36 mediates binding to type I collagen (Janabi et al. 2001) and is
implicated in phagocytic macrophage binding to apoptotic granulocytes, utilising
thrombospondin as a molecular bridge with the av integrin chain/vitronectin receptor CD51
(Savill et al. 1992). Recent data show that CD36 plays an anti-microbial role in the
recognition of Staphylococcal aureus via toll-like receptors 2 and 6 (TLR-2/6) (Hoebe et al.
2005).
Carotid atheroma from hyperglycaemic patients shows elevated expression ofCD36. Human
macrophages differentiated in the presence of high glucose concentrations show increased
cell surface CD36 expression, as glucose enhances CD36 mRNA translational efficiency
(Griffin et al. 2001). CD36 underpins insulin resistance, defective fatty acid metabolism, and
hypertriglyceridemia in spontaneously hypertensive rats (Aitman et al. 1999), facilitates fatty
acid uptake by cardiac and skeletal myocytes, and adipose tissues (Coburn et al. 2000), and
governs triacylglycerol secretion from dietary fats (Drover et al. 2005).
CD36 also belongs to a family of scavenger receptors, instrumental in lipid flux. HDL
selectively delivers cholesterol, not protein, to cells via the class B scavenger receptor SR-
BI, a CD36 family member (Acton et al. 1996). The CD36 and lysosomal integral membrane
protein II analogous-1 (CLA-1) (Calvo & Vega 1993) is homologous to SR-BI (Calvo et al.
1997) and differentially mediates LDL uptake including Ox-LDL on leukocytes, but traffics
HDL in the liver (Murao et al. 1997). Targeted gene deletions of SR-A (Suzuki et al. 1997)
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or CD36 scavenger receptors reduce atherosclerotic plaque size, with gene deletion of CD36
limiting plaque size more than SR-A gene deletion (Febbraio et al. 2000).
In view of the reported transcriptional regulation of CD36 by PPARy in THP-1 monocytic
cells (Tontonoz et al. 1998), it was important to assess whether LDL supplementation,
particularly with ox-LDL, was capable of modulating CD36 in primary human macrophages.
Cyclopentenone ligands were also used to assess the effects of PPARy ligands on this
system, and to assess whether natural arachidonates could potentially influence macrophage
scavenger receptor expression.
6.1.4 Monocyte phenotypic changes relevant to vessel wall adhesion
Adhesion dictates leukocyte margination and transmigration (Springer 1994), regulating
inflammatory cell recruitment to tissue injury sites (Issekutz & Issekutz 1993). Initial
transient interactions underlying leukocyte capture and rolling are mediated by L-, P- and E-
selectins (Puri, Finger, & Springer 1997) at respectively decreasing cell motion velocities.
Integrin mediated binding underpins higher affinity binding interactions, with p2 integrins
governing leukocyte firm adhesion, and a4 integrins regulating both rolling and adhesion,
dependent on integrin activation status. Monocyte adhesion is further influenced by extra¬
cellular inputs including cytokines such as MCP-1 which modulate both pi50-95 and p2
integrin expression (Jiang et al. 1992), and a critical role for p2 integrins in monocyte
transmigration has been described (Weerasinghe et al. 1998).
6.1.5 Physiologic functions of Cell Adhesion Molecules
Endothelial cells throughout the vasculature can express cell adhesion molecules (CAM).
The primary focus for most inflammatory responses is in postcapillary venules, due to the
high density of endothelial CAM expression, and the need to deliver effector leukocytes to
sites of parenchymal injury (Butcher 1991). In vivo observations of leukocyte behaviour in
venules have led to a model of leukocyte-endothelial cell interactions with three sequential
steps for leukocyte recruitment: rolling, firm adhesion, and emigration (Springer 1990).
Intra-vascular leukocytes initially move from the central stream of flowing blood toward the
vessel wall, bound by weak low-affinity adhesive interactions (Figure 6.1a). Although VLA-
4, VCAM-1, MadCAM-1, and a7 integrins have been implicated in early leukocyte rolling
and tethering adhesion, the predominant interactions at this stage are between selectins and
their ligands, an appearance manifest as leukocyte rolling and tethering (Lawrence &
Springer 1991). Tethered leukocytes exposed to low concentrations of chemoattractants and
inflammatory mediators undergo activation accompanied by L-selectin shedding. At sites of
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infection or inflammatory injury, chemokines, bacterial peptides, platelet activating factor
(PAF), and leukotriene B4 act to increase integrin avidity and thus integrin-dependent
leukocyte adherence (Figure 6.1b). The trans-endothelial migration of leukocytes then
proceeds, with movement of adherent monocytes and neutrophils through intercellular
junctions of vascular endothelial cells, a mechanism dependent upon platelet/endothelial cell
adhesion molecule 1 (PECAM-1; CD31; Figure 6.1b) (Muller et al. 1993). Leukocytes
continually establish new adhesive contacts at the migration front, while reducing adhesive
interactions at the tail. Studies showing E- and P-selectin-dependent leukocyte rolling in
mouse aorta confirm that these generic adhesion and motility mechanisms pertain to large
vessel injury also, and are thus of particular relevance to atherosclerosis (Eriksson et al.
2000).
6.1.6 Leukocyte cell adhesion molecules relevant to atherosclerosis
6.1.6.1 Selectins
Selectins are a family of three differing glycoproteins. They share a common structure of an
N-terminal C-type lectin domain, followed by an epidermal growth factor (EGF)-like
domain, varying numbers of short consensus repeat domains, a short transmembrane portion
and a cytoplasmic domain. The three selectins are categorized according to cellular
distribution. L-selectin is constitutively expressed upon almost all leukocytes including T
and B lymphocytes and NK cells, dependent upon activation state, and interacts with the
integrin heterodimer CDllb/CD18 (Mac-1) (Simon et al. 1995). L-selectin is involved in
leukocyte traffic and homing, a mechanism that involves platelet interactions (Diacovo et al.
1996). E-selectin is transcriptionally induced by NF-kB in endothelial cells under the
influence of cytokine stimuli, augmenting leukocyte adhesion via ICAM-1 (Luscinskas et al.
1991) (see section 6.1.6.3). P-selectin is stored in resting cells in a-granules of platelets and
Weibel-Palade bodies of endothelial cells and rapidly recruited within minutes to the surface
of activated platelets.
Following cell activation, selectin molecules are rapidly lost from the cell surface, P- and E-
selectin by internalisation and lysosomal targeting, and L-, and E-selectin by proteolytic
cleavage or shedding. Circulating soluble isoforms of E-selectin and L-selectin are thus
detectable in peripheral blood, soluble L-selectin acting as a further means of leukocyte
recruitment (Hafezi-Moghadam et al. 2001). Soluble P-selectin results from an alternative
splice lacking the transmembrane domain (Ishiwata et al. 1994), and shedding may
contribute to a shorter soluble isoform of P-selectin (Berger, Hartwell, & Wagner 1998).
Shed selectins may act as functional proteins, competing at their normal counter-receptors.
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Selectins interact with fucosylated and sialylated carbohydrates including sialyl Lewis X,
and with higher affinity mucin-like glycoprotein ligands (Kansas 1996). The major ligand for
P-selectin is leukocyte P-selectin glycoprotein ligand (PSGL-l)(Larsen et al. 1989). P-
selectin and PSGL-1 are a pair of extended molecules, functioning as a disulphide-bound
homodimer of fucosylated and sulphated glycoproteins (Li et al. 1996). PSGL-1 is also a
ligand for L-and E-selectins but with lower affinities than P-selectin (Norman et al. 2000).
PSGL-l/P-selectin binding facilitates close interactions between cells, enabling other
adhesion molecules like integrins to take up higher affinity interactions. P-selectin/PSGL-1
binding triggers leukocyte activation, integrin mobilization and induces inflammation and
thrombosis (Evangelista et al. 1999), with antibody inhibition of PSGL-1 function reducing
adhesion and recruitment on P-selectin expressing cells (Moore & Thompson 1992).
Although not directly examined in the studies presented here, it is important to appreciate the
role of selectins in the initiation of leukocyte adhesion, occurring prior to higher affinity
interactions mediated by integrins.
6.1.6.2 Integrins
The integrin family of cell adhesion molecules encompasses heterodimeric proteins
composed of non-covalently bound a and P subunits. 15 a- and 8 p-chains are currently
documented. Monocyte adhesive interactions with extra-cellular matrices are mediated by
integrin ligation, an event that dictates monocyte migration and extrinsic cellular signal
transduction. Early investigations elucidating the nature of integrins suggested that the
existence of three subfamilies within a greater family of human adhesion protein receptor
heterodimers based upon the number of different beta subunits (Hynes 1987). Two key
subfamilies were subsequently defined as the platelet and the endothelial cell heterodimers,
which use GP Ilia, and the leukocyte heterodimers, which contain a 95,000 Da beta subunit,
a protein that is distinct from, but homologous to, GP Ilia.
Conformation dictates integrin function, and is cation dependent. Conformational
rearrangements of integrin extracellular domains increase ligand affinity, an effect mediated
by intracellular binding of cytoskeletal talin to beta-subunit cytoplasmic tails (Tadokoro et
al. 2003). Alterations in signalling competence further determine integrin function, a feature
noted in Glanzmann thrombasthaenia and leukocyte adhesion deficiency-1. Despite normal
levels of p-1 -2 and -3 chain surface expression, a failure of inside-out signalling in these
subjects produces leukocyte dysfunction (McDowall et al. 2003). Individual integrin classes
and subunits with relevance to atherosclerosis and inflammation merit closer consideration in
the context of the work presented.
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(31 integrins
Pi-integrins are comprised of the common P-subunit CD29, linked to a distinct very late
antigen (VLA) a-subunit. The VLA family of heterodimeric cell-surface glycoproteins were
originally identified on activated human T lymphocytes and named because the first such
glycoproteins identified (VLA-l and VLA-2) were expressed at a late stage of T-cell
activation. Six VLA isoforms exist, each consisting of a distinct alpha chain, numbered l to
6. The VLA proteins belong to a superfamily of structurally and functionally related
adhesion-mediating cell surface proteins that include the fibroblast fibronectin receptor
(VLA5), the LFAl/MACl group, and the platelet glycoprotein Ilb/IIIa -fibronectin receptor
group. The a4pi-integrin (CD49d/CD29, VLA-4) aids leukocyte recruitment to the vessel
wall, mediating the adhesion of eosinophils (Schleimer et al. 1992), lymphocytes and natural
killer cells (Allavena et al. 1991), as well as monocytes, to the surface of cytokine-activated
endothelial cells. Binding to relevant ligands is of importance in atherosclerosis, and direct
interactions between VLA-4 and VCAM-1 have been described (Alon et al. 1995).
As with other integrin heterodimers, pi integrin can be multi-functional, pi integrin is
involved at a structural level in multiple developmental paths. a3/pi is required to associate
with reelin in embryonic neurogenesis, (Dulabon et al. 2000), and pi chain deletions cause
fatal neuroglial malformations (Graus-Porta et al. 2001) and alter chondrocyte function
obstructing normal endochondral ossification (Aszodi et al. 2003). In the immune system, pi
integrins are required for marginal B-cell localisation and compartmentalisation of peripheral
lymphoid tissue (Lu & Cyster 2002).
Examples of pi integrin function relevant to vascular biology include manganese-dependent
binding of endothelial junctional adhesion molecules to lymphocyte-surface oc4/|31 integrin
(Cunningham et al. 2002). In the arterial media, a3pi (a multi-functional pi integrin) and
a5pi integrins are expressed upon VSMCs in the media of normal coronary arteries (Hillis
et al. 1998). Galectin-1, a beta-galactoside-binding dimeric lectin involved in smooth muscle
cell migration and proliferation, binds directly to pi integrin in smooth muscle cells,
increasing the cell surface pi integrin copy number and inducing outside-in signalling
(Moiseeva et al. 2003). Integrin pi (ITGB1/CD29) constitutes the beta-chain of the
fibronectin receptor a5pi, mediating cellular interactions with extracellular matrix. Further
matrix interactions are subserved by a2pi, which binds collagen and laminin. Alterations in
pi integrin are thus critical in regulating leukocyte adhesion, but need to be investigated in




The integrin alpha chain CD49d in conjunction with CD29 forms the VLA-4 adhesion
complex present on leukocytes. CD49d is involved in initial vascular wall adhesion of
inflammatory leukocytes, governing transendothelial migration via interactions with vascular
cell adhesion molecule-1 (CD106/VCAM-1), a phenomenon that is pronounced in
endothelial cells that have been activated by IL-la (Chuluyan et al. 1995). VLA-4 is a key
integrin in mononuclear cell recruitment to atherosclerotic plaque in rabbit models of
atherosclerosis (Kling et al. 1995). Macrophage homing to atherosclerotic plaque in murine
models of atherosclerosis has been noted to be VLA-4 as well as ICAM-1 dependent (Patel
et al. 1998). Intra-vital microscopic observations of leukocyte adhesion in atherosclerotic
murine vessels show that a4 integrin interactions contribute more to firm adhesion than to
initial tethering (Eriksson et al. 2001). Monocyte adhesion to endothelial cells that have been
exposed to 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE], a product of 12-lipoxygenase
metabolism of arachidonic acid metabolism, is reduced by mAb to VLA-4. The same VLA-4
dependence of monocyte-endothelial binding is also demonstrated when endothelial cells are
exposed to high glucose concentrations in vitro. These findings suggest VLA-4 expression is
important in diabetic and inflammatory vascular injury (Patricia et al. 1999), although
alteration of other atherogenic stimuli including angiotensin I appears not to modulate VLA-
4 expression in clinical studies (Prasad et al. 2001). Further modification of VLA-4
expression has been noted on monocytes subject to reactive oxygen species and to
inflammatory mediators including arachidonic acid products, and proteases. Alteration of
trafficking in this context means that areas of endothelial injury specifically recruit
monocytes displaying this adhesion molecule,
a5 integrin sub-unit
The a5 integrin chain CD49e associates with pi integrin to form VLA-5, a fibronectin
receptor, expressed across leukocyte populations, including T lymphocytes (Somersalo,
Carpen, & Saksela 1994) and natural killer (NK) cells (Gismondi et al. 1991). In myeloid
cells, VLA-5 is involved in neutrophil adhesion, altering both Mac-1 and FcR expression
following fibronectin ligation (Simms & D'Amico 1995), and assists mononuclear cell
migration across fibroblast barriers, in distinction to VLA-4 assisted transendothelial
migration (Shang, Lang, & Issekutz 1998). This latter phenomenon may be of relevance in
the context of reparative responses to vessel wall injury in advanced stages of
atherosclerosis. LDL may promote the expression of leukocyte surface VLA-5, with
evidence that adsorption of LDL reduces surface monocyte VLA-5 expression in patients
with occlusive arterial disease (Lino et al. 1995). Intriguingly, CD49e transcription has been
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noted to be at lower levels in aortic aneurysmal tissue and occluded arterial vessels than in
normal vessels in humans (Armstrong et al. 2002). Human aortic endothelial cells (HAECs)
cultured with minimally-modified low-density lipoprotein differentially induces the binding
of monocytes but not neutrophils, with concomitant deposition of fibronectin on the
endothelial cell apical surfaces by the activation of pi integrins associated with a5 integrins
(Shih et al. 1999). The response of CD49e to ox-LDL was thus of interest in gauging
potential alterations in monocyte adhesion, and would offer further insight into the relevance
of (31 integrin expression profiles.
P2 integrins
The p2-integrins consist of a common P-subunit CD 18, linked to one of four a-subunits
designated as CD 11a, CD lib, CD 11c, or CD lid, with the alpha-chain encoding genes of
this integrin sub-family tightly clustered on chromosome 16 (Corbi et al. 1988). p2-integrins
are exclusively leukocytes expressed, but p2-integrin subclass distribution varies among
leukocyte subpopulations. All p2-integrins are expressed by neutrophils, monocytes, and
natural killer cells, whereas CD 11 a/CD 18 (the lymphocyte function antigen/LFA-1) is
primarily expressed on peripheral blood lymphocytes. CD1 ld/CD 18 is moderately expressed
on myelomonocytic cell lines and more strongly on tissue-compartmentalized cells such as
foam cells (Van der Vieren et al. 1995). Most of CDllb/CD18 is stored in leukocyte
granules (Lacal et al. 1988), where they can be rapidly (within minutes) mobilized to the cell
surface after stimulation with inflammatory mediators (Freyer, Morganroth, & Todd 1989).
Although CD 18 was not examined in these studies, the effects of LDL and cyPGs upon
relevant alpha subunits were assessed, and these subunits merit introducing individually,
aL integrin, (CD11a/LFA-1a)
Lymphocyte Functional Antigen 1 (LFA-1, CDlla/CD18) mediates leukocyte adhesion and
signalling interactions, and is required for efficient T lymphocyte clonal expansion in T
memory-cell driven adaptive immunity. CD1 la is the unique alpha integrin subunit of LFA-
1 designated aL (Sanchez-Madrid et al., 1983). Lymphocyte function-associated antigen-1
(LFA-1) shares the common p2 integrin chain CD18, with CDllb/CD18 (Mac-1) and
CDllc/CD18 (pi50,95). LFA-1 is expressed on lymphocytes and phagocytic cells and is
involved in cytotoxic T cell adhesion to target cells. Patients with LFA-1 immunodeficiency
disease (LAD) suffer recurrent life-threatening infections, with deficiency of the beta chain
of all 3 molecules, LFA-1, Mac-1 (macrophage antigen-1), and pi50,95, and defects in
adhesion-dependent granulocyte, monocyte, and B- and T-lymphocyte functions (Marlin et
al. 1986). LFA-1 is also implicated in the compartmentalisation of peripheral B cell
responses, in conjunction with pi subunits.
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The relationship between alpha and beta subunits is highly important for LFA-1 function.
Intracellular spatial relations between aL and (32 cytoplasmic domains are grossly altered
during both intracellular activation of integrin adhesion (inside-out signalling) and extrinsic
ligand binding (outside-in signalling). The dependence of bi-directional integrin signalling
upon spatial interactions between cytoplasmic domains as well as extracellular
conformational change, suggests cytoplasmic alpha chain levels may disproportionately
dictate adhesion in the face of modest changes in cell surface LFA-1 alpha chain density
(Kim, Carman, & Springer 2003).
Intravascular mononuclear cell surface CDlla levels are elevated in familial
hyperlipidaemia and reduced by therapeutic lipoprotein apheresis (Rovers et al. 1998).
Increases in counter-receptors for CDlla have been demonstrated in endothelial cells from
atherosclerotic plaque (van der Wal et al. 1992). LFA-1 has been implicated in accelerated
transplant atherosclerosis, in a manner that suggests co-dependence on ICAM-1 (Russell,
Chase, & Colvin 1995). These findings all suggest that an increase in LFA-1 a expression
might be a response to LDL exposure in leukocytes,
aM integrin, (CD11b/Mo1)
CDllb, the aM integrin component of the (32 integrin Mac-l (CDllb/CDl8) complex,
promotes the adhesion of granulocytes to each other (Ding et al. 1999) and to endothelial cell
monolayers (Wetzel et al. 2004). Mac-l contributes to firm leukocyte adhesion, (Kanse et al.
2004) and is implicated in atherosclerotic plaque progression. Recent data shows that
leukocyte-platelet interactions are mediated by the inserted domain of aM, which binds
platelet surface glycoprotein Iba (Wang et al. 2005). Monocyte Mac-l expression increases
following in vitro exposure to ox-LDL at I00p.g/ml (Terasawa et al. 2000), although this
study did not utilise mAb specific to CDl lb epitopes. Treatment of leukocyte donors with
600mg o.d. of alpha-tocopherol, prior to monocyte isolation and culture in ox-LDL blunted
this effect, implying a critical role for LDL oxidation status in this phenotypic switch.
Leukocyte phenotyping of peripheral blood samples from patients with ischaemic heart
disease shows increased levels of CDllb in circulating leukocytes (Kassirer et al. 1999),
although murine LDL-R-/- atherosclerotic models with further CDllb gene deletions show
no obligate role for CDl lb in the initiation of atherosclerosis (Kubo et al. 2000). The crucial
role that CDl lb plays in sequestering leukocytes to inflamed vasculature, and the specific
issues raised by previous studies of CDllb expression in pro-atherogenic environments
made study of this molecule an essential part of phenotyping monocyte responses to LDL.
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aX integrin (CD11c/p150,95)
The alpha integrin chain CDllc (pi50,95/ ITGAX), is a receptor for ICAM-l, iC3b
(Myones et al. 1988) and fibrinogen. The unique CDllc alpha chain shows homology to the
alpha subunits of platelet glycoprotein Ilb/IIIa, the vitronectin and fibronectin receptors
(Corbi et al 1987). In keeping with other integrin alpha chains that heterodimerise with P2
integrin, CDl lc plays a critical role in granulocyte adhesion to fibrinogen (Loike et al. 1991)
and monocyte adhesion to collagen I (Garnotel et al. 2000). Specific CDllc/CDl8 binding
to endothelial cell surfaces has been previously demonstrated (Stacker & Springer 1991),
with implications for vascular injury. CDl lc appears to be implicated in inflammatory injury
during atherogenesis and plaque progression at many levels. Monocyte/macrophage
production of IL-lot and IL-ip in response to LPS is dependent upon CDllc in LDL-R-/-
murine models of atherosclerosis (Netea et al. 1998). CDllc positive macrophages are
present in high numbers in the media of human abdominal aortic aneurysms (Koch et al.
1990), as well as being apparent in human atherosclerotic tissue (van der Wal et al. 1992).
CDl lc, along with CDl la, is elevated in familial hyperlipidaemia, in association with LDL-
dependent upregulation of IL-1 and TNF production (Rovers et al. 1998).
One important monocyte differentiation pathway is that leading to dendritic cell morphology
(Kabel et al. 1989), with the dedicated and specialised antigen presentation functions that
this confers (Sallusto & Lanzavecchia 1994). Dendritic cells are highly efficient at antigen
binding processing and presentation, producing immunogenic or tolerogenic responses
(Finkelman et al. 1996). Dendritic cells are thus relevant to inflammatory responses in the
vessel wall, especially in the context of defined auto-immune mechanisms that may involve
LDL-derived epitopes. CDl lc appears to be a marker of phenotypic change from monocyte
to dendritic cell (Ito et al. 1999). The alteration of monocytes towards a DC phenotype has
been explored in this regard, with special reference to endothelial adhesion and
transmigration. DC adhesion and transmigration appear to be markedly increased after
exposing ECs to hypoxia, ox-LDL or TNF-a, and by specifically inhibiting endothelial NO
synthase (Weis et al. 2002). Modulation of monocyte CDllc expression by LDL or
inflammatory mediators may thus offer an insight into immunoregulatory as well as adhesion
and mobility changes during atherosclerosis.
P3 integrins
The P3 integrin subunit (CD61/GPIIIa) is a multi-functional adhesion molecule, and, in
common with other P integrin heterodimers, recognises ligands bearing Arg-Gly-Asp-
(RGD) sequences in a cation-dependent fashion (D'Souza et al. 1994). P3 integrins serve
structural and developmental roles ranging from osteoclastogenesis (McHugh et al. 2000) to
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placentation (Hodivala-Dilke et al. 1999) and tumour angiogenesis (Reynolds et al. 2002). (3-
3 integrins contribute to adhesion-dependent cell survival, with unligated P-integrin tails
recruiting caspase 8 to the cell surface to act as a death receptor (Stupack et al. 2001). P-3
integrins are also central to inflammatory resolution, with the vitronectin receptor (avp3)
enabling macrophage recognition of apoptotic neutrophils and lymphocytes (Savill et al.
1990). a2p3 integrin (glycoprotein Ilb/IIIa) mediates platelet-platelet aggregation in an
activation-dependent manner (Frojmovic et al. 1991). p3 integrin binds von Willebrand
factor (Lefkovits, Plow, & Topol 1995), linking platelet interactions with endothelial cells
(Bombeli, Schwartz, & Harlan 1998) with direct relevance to atherothrombosis and
leukocytes. CD40L binds to GPIIb/IIIa in a p-3 integrin dependent manner, with binding of
platelets to endothelial cells and leukocytes acting to stabilise thrombus (Andre et al. 2002).
In addition to constituting the beta-chain of the platelet glycoprotein receptor allp3 and the
widely expressed non-platelet integrin avp3, the P3 integrin subunit is important in
governing cellular adhesion interactions that regulate inflammatory leukocyte responses in
the vessel wall. Regulation of P3 expression is important in atherosclerotic plaque
progression and is under sophisticated control mechanisms. p3-endonexin, a protein that
regulates urokinase protease activator receptor (uPAR) expression through direct interaction
with subunits of the NF-KB-complex also modulates p3 integrins. In contrast to uPAR or
NF-kB, the expression of p3-endonexin is reduced in advanced atherosclerotic aortic tissue.
P3 integrin-mediated stimulation of endothelial cells leads to enhanced NF-kB dependent
secretion of monocyte chemoattractant protein-1 (MCP-1), an effect that is down-regulated
by p3-endonexin (Besta et al. 2004). P3 integrins have been demonstrated in ex vivo samples
of human atherosclerosis, with elevation of avP3 being particularly apparent (Hoshiga et al.
1995). Paradoxically, (33 integrins may act to limit inflammation, reducing atherosclerotic
plaque: murine apo E null models of atherosclerosis show accelerated atherosclerosis in mice
with gene deletion of (33 integrin (Weng et al. 2003).
Integrin ligand specificity
Integrin ligand specificity is determined by a-subunits. Two broad groups of ligands exist,
the first consisting of a range of large extracellular matrix proteins including fibronectin
(Sanchez-Aparicio, Dominguez-Jimenez, & Garcia-Pardo 1994), thrombospondin
(Yabkowitz & Dixit 1991), vitronectin, fibrinogen, and complement component iC3b
(Ramos et al. 1989). The second ligand group consists of cell surface adhesion molecules
belonging to the immunoglobulin supergene family.
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6.1.6.3 Immunoglobulin superfamily members
The immunoglobulin (Ig) superfamily includes a broad range of molecules with multiple Ig-
like domains. Members of this family include the intercellular cell adhesion molecules-1 and
-2 (ICAM-1/CD54 (Dustin et al. 1986), ICAM-2/CD102 (Staunton, Dustin, & Springer
1989)), vascular cell adhesion molecule-1 (VCAM-1/CD106) (Strauch et al. 1994), platelet-
endothelial cell adhesion molecule (PECAM)-1/CD31, and the mucosal addressin cell
adhesion molecule-1 (MAdCAM-1) (Berlin et al. 1993).
The mucosal addressin MAdCAM-1 is an alternative counter-ligand to CD49d/p7 integrin
and to L-selectin, expressed in the gastrointestinal tract, on high endothelial venules of
Peyer's patches and embryonic lymph nodes, on small intestinal lamina propri venules and
on the marginal sinus of the spleen (Streeter et al. 1988). CD31 is constitutively expressed on
platelets, most leukocytes, and endothelial cells (Albelda et al. 1991).
CD 106 is minimally expressed on quiescent endothelial cells, but highly upregulated by
cytokine-mediated endothelial cell activation. CD106 mediates lymphocyte and monocyte
adhesion in inflamed vascular beds, binding to the CD49d/CD29 heterodimer.
Endothelial CD54 is central to monocyte trafficking, binding to CD11 a/CD 18 and
CD1 lb/CD18 integrins during transmigration. Basal levels of CD54 are seen on a variety of
cell types, but expression is regulated on endothelial cells, (Dustin et al. 1986). CD54
expression varies between specific organs' vascular beds. Organs with relatively high
constitutive expression of CD54 such as the lung exhibit smaller increments in CD54
expression after cytokine stimulation than organs with low constitutive expression such as
the myocardium (Panes et al. 1995). A soluble isoform of CD54 is detectable in normal
serum (Rothlein et al. 1991), with significantly elevated levels noted in disease states
including viral infections (Furukawa et al. 1993) and lymphoid malignancy (Horst et al.
1991). CDlla/CD18 may also bind to CD102, a truncated form of CD54, is basally
expressed on endothelial cells (de Fougerolles et al. 1991), but not upregulated on activated
endothelial cells (Nortamo et al. 1991).
CD54 is involved in binding CD1 la and CD1 lc during leukocyte margination and migration
events, dictating leukocyte recruitment to inflammatory injury sites (discussed in Section
6.1.6.2). In apoE-null murine models of atherosclerosis, CD54 is highly expressed in aortic
atherosclerotic lesions, in contrast to CD 106 which is more weakly expressed (Nakashima et
al. 1998). CD54 may be upregulated later than CD 106 during atherosclerotic plaque
progression, with CD 106 serving early recruitment interactions to the vessel wall (Cybulsky
et al. 2001). Human coronary arteries, taken from explanted hearts within 5 minutes of
transplantation, show CD54 expression in focal segments of normal arterial endothelium, but
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with high levels of endothelial CD54 expression apparent over atherosclerotic plaques and in
macrophages, (Davies et al. 1993). In vitro incubation of endothelial cells with conditioned
medium from mononuclear cells grown in the presence of ox-LDL enhances CD54
expression on endothelial cells, and the CD54-mediated binding of monocytoid U937 cells,
suggesting a role for monocytes dictating adhesion mechanisms themselves, dependent upon
specific microenvironmental influences (Frostegard et al. 1993).
6.1.7 Leukocyte migration
Leukocyte emigration through the vessel wall is determined by adhesive interactions in
balance with chemoattractant stimuli that promote cell motility. Leukocytes are able to
polarise (MacFarlane, Herzberg, & Nelson 1987) and move along chemoattractant gradients,
in a receptor dependent manner (Nourshargh & Williams 1990). Cell motility is importantly
dependent upon multiple integrin interactions including those between P2 integrin and
urokinase-type plasminogen activator receptor (uPAR) (Wei et al. 1996), a system that is of
specific importance to monocyte migration (Simon et al. 1996). The non-integrin receptor
uPAR may bind promiscuously to multiple integrins (Simon et al. 2000c), although P2
interactions are the most comprehensively described. Loose and firm adhesion interactions
with extracellular matrix components further determine the rate of progression of leukocyte
motion, pi integrin-fibronectin interactions, regulated by Rho family GTPases Rac and
Cdc42, act to limit cell motility (Cox, Sastry, & Huttenlocher 2001).
6.1.7.1 Leukocyte differentiation: links to migration events
Leukocyte differentiation affects mobility and migration, due to alterations in surface
adhesion molecule repertoire. Altered trafficking patterns are necessary to sub-serve
particular functions including lymphocyte recirculation, antigen delivery to lymph nodes,
and disposal of apoptotic and necrotic debris by macrophages. Ligation of CD31 alters
leukocyte phenotype, promoting a6/pl mediated cell migration across the vessel wall
(Dangerfield et al. 2002). Defined trans-endothelial migration events direct myelomonocytic
cells towards a dendritic cell phenotype (Randolph et al. 1998). Models of dendritic cell
further illustrate links between motility and phenotype, with matrix metalloproteinase
activity linked to Langerhans cell egress from the skin, (Ratzinger et al. 2002). The ability of
monocytes to exit atherosclerotic plaque and directly re-enter the vessel lumen has been
documented (Gerrity 1981b). Factors that favour atherosclerotic plaque regression including
reduction of dysplidaemia promote monocyte efflux, with distinct phenotype profiles for
cells that exit lesions (Llodra et al. 2004).
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6.1.8 Leukocyte inflammatory function
The role of inflammatory mediators as well as lipoproteins in the initiation and progression
of atherosclerotic plaque is of current interest. Oxidised LDL has been identified as a natural
ligand of PPARy (Nagy et al. 1998) contributing to plaque progression by increasing
monocyte lipid uptake. Varying concentrations of LDL have been used to explore in vitro
monocyte responses. Published data show that supplementation of medium with 50pg/ml of
LDL induces a transition from a monocyte to a foam-cell phenotype (Nagy et al. 1998). The
role of the nuclear receptor PPARy in atherosclerosis has been explored with regard to foam
cell phenotypic changes (Ricote et al. 1998a). The cyclopentenone-structure arachidonic acid
metabolites A12PGD2 and 15dPGJ2 have been shown to ligate PPARy, and are produced at
sites of acute inflammation. These natural PPARy ligands reduce monocyte inflammatory
responses including matrix metalloproteinase-9 production (Marx et al. 1998), relevant to
extracellular matrix degradation in atherosclerosis. 15dPGJ2 was used to explore the effect of
naturally occurring PPARy ligands as chronic inflammatory stimuli upon
monocyte/macrophages within an atherosclerotic plaque.
6.1.9 Leukocyte immunomodulatory function
6.1.9.1 Role of antigen presentation
Class II major histocompatibility complex (MHC) molecule expression on monocytes is
crucial to the efficient macrophage-mediated presentation of processed antigens to T
lymphocytes during adaptive cell mediated immune responses (Ziegler & Unanue 1981).
The MHC coding region for the D region of human leukocyte antigen on chromosome 6 is
further divided into HLA-DR, DP and DQ regions, producing the variety necessary to
present multiple epitopes (Rudensky et al. 1991) to engage in specific immunological
synapses (Grakoui et al. 1999). MHC Class II a and P chains are present at antigen
presenting cell (APC) surfaces as heterodimers, holding peptides in facilitating peptide
presentation to relevant T cell receptors (Stern et al. 1994), with the distinction from Class I
MHC that antigen does not have to be endogenously processed by the APC (Morrison et al.
1986). T lymphocytes bearing a memory phenotype have been demonstrated in human
atherosclerotic lesions (Hansson, Holm, & Jonasson 1989). T lymphocytes may exert
regulatory as well as pro-atherogenic influences upon monocytes, with data from co-culture
experiments showing that T lymphocyte derived IFN-y reduces macrophage scavenger
receptor expression, limiting lipid uptake (Geng & Hansson 1992). The possibility that
chronic inflammation in atherosclerosis may be driven by an autoimmune mechanism has
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been raised, with clinical data suggesting augmentation of mononuclear cell Class II
expression in atherosclerotic vessels in young adults (Millonig, Malcom, & Wick 2002).
Circulating autoantibodies to putative epitopes including ox-LDL-derived malondialdehyde
(MDA)-lysine are found in serum, and are able to recognise material in atheromatous tissue
(Salonen et al. 1992). Any alterations in Class II MHC expression in response to
differentially modified LDL are thus of interest. Enhanced Class II expression might explain
a process of augmented antigen presentation promoting a chronic inflammatory process in
the vessel wall, due to the invocation of specific immune responses. The influence of
adaptive immunity in atherosclerosis has been further explored using murine models. The
initiation of atherogenesis appeared to proceed despite the absence of lymphocytes in apo E-
null mice bearing a defect in recombination-activating gene 2 (RAG2), a gene that
rearranges V(D)J coding regions underpinning the production of the normally varied
repertoire of immunoglobulins or T cell antigen receptors. Parallel experiments showed no
diminution of onset of atherosclerosis in apo E null mice with targeted gene deletions of both
Class 1 and Class II molecules (Fyfe, Qiao, & Lusis 1994), suggesting that specific immune
mechanisms may not be of importance in very early atherosclerosis.
A reduction in atherosclerotic lesional macrophage Class II expression was subsequently
noted in RAG2 null animals (Daugherty et al. 1997). Class II expression is modulated during
innate as well as adaptive immune responses, and is markedly enhanced by LPS stimulation
(Wentworth & Ziegler 1987). Class II MHC expression is increased during monocyte
activation and maturation under the influence of cytokines including GM-CSF (Hornell et al.
2003) and regulated during differentiation to specialist phenotypes including dendritic cells
(Santin et al. 1999). Atherosclerotic tissue has been immunohistochemically phenotyped for
Class II expression in lesions bearing high numbers of monocytes, T lymphocytes and
dendritic cells (Jonasson et al. 1985), with elevated Class II molecule expression being
evident in vulnerable plaques from human carotid arteries (Yilmaz et al. 2004).
Examination of monocyte Class II expression in the context of LDL and cyclopentenone
exposure was thus considered an important part of monocyte phenotype analysis.
Monocyte/macrophage Class II MHC expression is heterogeneous with marked variability in
basal expression between individuals (Bos et al. 1990). For this reason it was essential to
compare individual basal levels for each donor to calculate net expression.
6.1.9.2 Role of immune co-stimulatory molecules
Primed effector T cells are activated when complementary antigen-specific receptors and
either CD4 or CD8 co-receptors bind to a relevant peptide epitope (van der Merwe & Davis
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2003). However, nai've T cells require co-stimulation to initiate a proliferative response,
crucial in engendering cytotoxic and memory T cell function (Chai et al. 1999). Simple
ligation of the T-cell receptor and co-receptors is insufficient. To enable clonal expansion,
further signals, including the ligation of CD28 and CD40, must be delivered to the surface of
the recipient T lymphocyte (Somoza & Lanier 1995). The B7 molecules, structurally related
homodimeric glycoproteins and members of the immunoglobulin superfamily, are present on
antigen-presenting cell surfaces, with the two most extensively characterised B7 molecules
being B7.1 (CD80) and B7.2 (CD86) (Bajorath, Peach, & Linsley 1994). Their natural ligand
is surface-bound CD28 on T lymphocytes; contemporaneous CD28/B7 binding, along with
ligation of the TCR/CD3 complex by Class II MHC in conjunction with CD4, results in T
helper activation (Linsley et al. 1994).
The presence of the B7 co-stimulatory molecules has been noted in immunohistochemical
analyses of murine atheroma (Lee et al. 1999) with further data suggesting that ox-LDL
differentially up-regulates CD86 along with Class II MHC, in distinction from CD80 on
monocytes (Fortun et al. 2001). Enhanced CD86 expression may also contribute to vascular
inflammation driven by environmental factors including tobacco smoking, with evidence to
suggest that nicotine augments CD86 expression in human and murine monocyte derived
dendritic cells (Aicher et al. 2003). Data from murine models of atherosclerosis bearing gene
deletions for LDL-R and CD80 or CD86 molecules suggests that co-stimulatory molecules
are essential for early atherosclerotic progression, assisting T lymphocyte responses to HSP-
60 and to ox-LDL epitopes in the first stages of plaque formation (Buono et al. 2004). Pro-
atherogenic stimuli including advanced glycosylation end-products (AGE) elevated in
hyperglycaemic states are associated with increased co-stimulatory molecule expression in
cultured dendritic cells with concomitant stimulation of T lymphocytes, suggesting that other
multiple microenvironmental stimuli may affect monocyte, or monocyte-derived cell
function (Ge et al. 2005). It is likely that lymphocytes play a role in propagating
atherosclerotic plaque inflammation, with lipid species acting as a potential specific epitope
(Melian et al. 1999). For these reasons changes in monocyte co-stimulatory molecule
expression following lipid exposure may represent an important switch in functional
phenotype, enhancing chronic inflammatory responses, and merited exploration.
6.1.9.3 Monocyte receptors for immunoglobulin Fc fragments: role in
inflammatory disease
Antibody mediated signalling is mediated by cell surface receptors for the Fc portion of
immunoglobulin G (FcyR). The Fc ("fragment crystallisable") fragment of antibodies is the
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area where complement and anti-human globulin serum (anti-IgG) bind. The Fc portion is a
fundamental means of enabling the recognition and phagocytosis of microbial pathogens
(Leijh et al. 1979). Monocytes express three FcyR, FcyRI, II and III, (CD64, CD32 and
CD 16 respectively). CD64/FcyRI exhibits myeloid lineage specific expression and acts as a
high affinity receptor for IgG, reflecting monocytes' capacity for immune-complex
recognition. CD64 expression is inducible by gamma-interferon, an effect mediated by a
defined nucleotide sequence, the IFN-y response region (GRR) (Pearse et al. 1993), within
the gene encoding human CD64 (Pearse, Feinman, & Ravetch 1991). The removal of
immune complexes, found in many inflammatory diseases, and of particular importance in
type III hypersensitivity reactions (Arthus 1903) is facilitated by monocyte/macrophage Fc
binding (van de Winkel et al. 1988; Van Es & Daha 1984). Recognition and ingestion of
apoptotic cells during clearance and repair phases of inflammatory injury is also enhanced by
Fc receptor mediated interactions with macrophages (Hogg 1987; Jungi & Hafner 1986). The
binding of antibodies to leukocyte surfaces acts as a potential route for promoting auto¬
immune mechanisms, as macrophage recognition of Fc antibody fragments may result in
localised inflammatory responses including glomerulonephritis and vasculitis in the context
of inappropriate recognition of self epitopes (Matsumoto et al. 2003). Fc receptors have
already been linked to C-reactive protein mediated trafficking of LDL via FcRyll (CD32)
(Zwaka, Hombach, & Torzewski 2001). The possibility that CD64 and CD 16 might be
altered in monocyte exposed to LDL species, and to inflammatory mediators that may mimic
the effects of modified LDL, was thus of direct interest to defining the behaviour of
monocytes in pro-atherogenic environments.
CD64/FcRyl involvement in atherosclerosis
Altered lipoproteins may influence cytokine and reactive oxygen species production
subsequent to CD64 ligation: hypotheses that have been postulated previously and fit with
the concept of an immune-mediated pro-inflammatory stimulus for atherogenesis. Whether
aggregated or altered lipoprotein might act in the same way as immune complexes is thus of
particular interest. Cholesterol is necessary for normal expression of CD64 at the monocyte
cell surface (Bigler et al. 1989). However immune complexes of native LDL and acetylated
LDL may increase both CD64 expression and Fc receptor mediated responses in monocyte
cell lines, an effect attributed to apoprotein mediated effects, as free cholesterol fails to
initiate the same responses (Huang et al. 1999b).
CD16/FcRylll involvement in atherosclerosis
The type III Fey receptor (CDl6/FcyRIII) is the predominant FcR on cultured monocytes.
CD 16 exists in two isoforms encoded by separate genes, and is a glycosyl-
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phosphatidyl inositol (GPI) linked receptor on human neutrophil surfaces, but a type I
transmembrane glycoprotein on monocytes, with less carbohydrate than its neutrophil
counterpart (Edberg & Kimberly 1997). Monocyte CD16 mediates both ligand attachment
and phagocytosis, with receptor expression increasing with duration of culture independent
of IFN-y stimulation (Clarkson & Ory 1988). Activation of inflammatory leukocytes rapidly
mobilises CD16, with neutrophils shedding cell surface CD16 during activation, apoptosis,
and chemotaxis (Tosi & Zakem 1992). Actin polymerisation enhances CD 16 shedding,
suggesting that the actin cytoskeleton potentially mediates the association of CD 16 with
integrins including leukocyte-membrane complement receptor-3 (CR3, Mac-1,
CDllb/CD18) (Middelhoven et al. 1999). Soluble CD16 (sCD16) regulates monocyte
inflammatory processes, binding to CR3 and inducing monocyte production of IL-6 and IL-8
(Galon et al. 1996). Elutriated monocytes stimulated by the anti-CD16 mAb 3G8 display
monocyte-specific chemi-luminescent activation responses suggesting that CD16+ monocyte
sub-populations mediate effector functions, including reactive oxygen species (ROS)
generation, via CD16 ligation (Trezzini et al. 1990). Monocyte CD16 expression is altered
by stimuli including LPS and IL-1 (Arend, Ammons, & Kotzin 1987), TNF-a and IL-6, IL-2
and IL-4, suggesting a role in acute inflammatory responses. Binding of LDL complexed to
anti-LDL antibodies via CD64 and CD32 has been shown using THP monocytic cell lines
and augments monocyte production of reactive oxygen species (Kiener et al. 1995). The
ability of monocytes to alter CD 16 expression during lipoprotein supplemented culture and
maturation has not previously been explored.
6.1.10 Specific aims
The effects of in vitro exposure to cyclopentenones and LDL upon monocytes will be
assessed.
• Alterations in monocyte ultra-structure and lipid uptake will be gauged using
microscopy.
• Markers of differentiation, pattern recognition receptors, adhesion molecules and
immuno-regulatory molecules will be specifically assessed.
• Differences in monocyte surface molecule expression will be examined following
suspension and adhesion culture.
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6.2 Results
For brevity, only statistically significant results are described in the text. Sample numbers
and p values are annotated in figure legends. Full statistical analyses, and all data tables,
micrographs and supplementary figures are viewable in the supplementary data CD-ROM,
and in the Chapter 6 Data Appendix.
6.2.1 Blood donor characteristics
Blood was collected from donors under the auspices of local ethical approval. Donor
characteristics were available for experiments to examine adherent monocyte culture and a
limited number of experiments to examine responses to suspension culture. All donors were
non-smokers, with no history of inflammatory or malignant disease. Further exclusion
criteria were the use of anti-inflammatory agents, including inhaled corticosteroids or anti¬
histamines, to serve as a surrogate marker of underlying infection, inflammation or atopy.
Donors who had previously been noted to be eosinophilic were excluded. Predominantly
male donors were used to limit the possibility of menstruation-related platelet activation.
Menstrual cycle was not ascertained during donor screening, as this was not sanctioned by
the ethics committee. Due to local restrictions on use of volunteer samples serum was not
permitted to be biochemically analysed in retrospect. Donor characteristics for adherent
phenotyping experiments and of age, gender, and cardiovascular risk factors are presented as
supplementary data in the Chapter 6 Appendix, Table 6.1.
6.2.2 Monocyte preparation and purification levels
Human peripheral blood monocytes, isolated using discontinuous Percoll gradient
centrifugation, were assessed for cell purity and yield immediately after leukocyte recovery
from gradients. Monocyte percentages varied between 10 and 30% of total mononuclear
cells dependant on individual donors. Further specific monocyte purification was performed
by a negative selection technique using immuno-magnetic bead separation, achieving
purities approaching 90% (mean 89.83% +/- 0.426% s.e.m, n=60). Scatter profiles were used
to determine leukocyte subpopulations by flow cytometry for the purposes of quantification
of purity (Figure 6.2).
6.2.3 Ultra-structural changes in monocytes exposed to LDL
It has been shown that monocytes isolated from ex vivo atherosclerotic plaque demonstrate a
lipid-laden appearance, with marked vacuolation representing lipid ingestion. To delineate
whether differentially modified lipoproteins acted to mature monocytes in a differential
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manner, micrographs were made of cyto-centrifuge preparations using monocytes matured in
serum-replete media (Figure 6.3). Light microscopy suggested that ox-LDL induced
increases in monocyte intracellular vacuoles (Figure 6.4), after 7 days in culture, with
appearances similar to the "foam-cell" phenotype reported by other groups (Aqel et al.
1984). Vacuolation is a feature of normal macrophage maturation (Silverstein, Steinman, &
Colin 1977), and is critical to phagocytic function. Formation of phagolysosomes was
apparent by transmission electron microscopy in monocytes cultured under control
conditions (Figure 6.5). Flowever, more pronounced vacuolation was visible by electron
microscopy following ox-LDL exposure for 7 days (Figure 6.6).
6.2.4 Direct evidence of lipid uptake in cultured monocytes
Cultured monocytes are capable of lipid uptake via multiple routes, including the LDL
receptor, as seen in pathological hyperlipidaemic states (Nguyen et al. 1988), as well as via
scavenger receptors (SR) A and B (Geng, Kodama, & Hansson 1994). Total lipid uptake
may be assessed visually by oil red O (ORO) labelling, non-specifically demarcating
intracellular triglycerides and fatty acid chains. ORO uptake was visible in adherent
monocytes cultured in both n-LDL and ox-LDL at increasing concentrations after only 24hr.
Micrographs taken at low (xlO) magnification indicated that ORO positive-labelling
appeared similar in both n-LDL and ox-LDL supplements (Figure 6.7). Culture of adherent
monocytes in control medium showed low but visible levels of ORO, which was present
following prolonged monocyte culture towards a macrophage phenotype at 8 days, and
confirmed by high-magnification photomicrography (Figure 6.8). Clear ORO labelling was
visible in macrophages cultured contemporaneously in increasing concentrations of n-LDL
at lOpg/ml, 50pg/ml, and lOOpg/ml (Figure 6.9). ORO labelling of in ox-LDL supplemented
macrophages at 8 days was suggestive of higher levels of ORO uptake at 10p.g/ml, 50pg/ml,
and 100p.g/ml (Figure 6.10).
6.2.5 Evidence of specific LDL uptake by cultured adherent monocytes
Direct fluorescence labelling of LDL offers a means of monitoring the uptake of specific
LDL sub-fractions, and modified LDL species (Gorog & Kakkar 1987). In vitro exposure of
monocytes to Di-I-Iabelled ox-LDL resulted in intracellular fluorescence, apparent after only
24 hrs of LDL exposure, and proportional to the concentration of LDL supplementation
(Figure 6.11). Nuclear counter-labelling demonstrated that these monocytes were viable,
with a normal horseshoe nuclear appearance (Figure 6.12). Further exposure to Di-I labelled
ox-LDL for 48hrs increased intracellular fluorescence in proportion to LDL concentration
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(Figure 6.13). Monocyte culture in increasing concentrations of Di-I labelled n-LDL or ox-
LDL for 8 days caused increases in fluorescence proportionate to LDL concentrations, with
ox-LDL taken up more avidly than n-LDL at corresponding concentrations, as assessed by
con-focal microscopy (Figures 6.14 and 6.15). Although it is possible to quantify raw
fluorescence in these micrographs using post hoc software analysis, it was not possible to
adjust fluorescence for cell numbers and more importantly for cytoplasmic volume per cell.
For this reason, fluorescence microscopy and con-focal data are presented as qualitative
representations of intra-cytoplasmic LDL uptake.
6.2.6 Alteration of monocyte flow cytometric properties
Flow cytometric properties of monocytes in suspension did not appear to differ when
comparing cells cultured in control media to those cultured in the presence of n-LDL.
Flowever, alterations in side and forward scatter appeared within 24hrs of suspension culture
in the presence of ox-LDL at high concentrations (Figure 6.16). The differential effects of
ox-LDL did not appear to be present following prolonged culture (Figure 6.17). Prolonged
suspension culture with the cyPG 15dPGJ2 did not appear to alter scatter profiles (data not
shown). For acquisition of data for adherent cultures altered scatter properties necessitated a
switch to logarithmic scale (Figure 6.18). Gating for monocytes was undertaken in this
manner, with further gating using the FL-4 channel for ToPro3 fluorescence to exclude dead
cells (Figure 6.19). The fluorescence for the gated population was represented as a histogram
with median fluorescence being used for quantification. Alteration of monocyte auto-
fluorescence was noted following exposure to ox-LDL in suspension culture for prolonged
periods, with evidence that basal fluorescence of unlabelled cells rose differentially, but
varied between donors (Figure 6.20). This necessitated the subtraction of basal fluorescence
signals during of flow cytometric quantification analysis.
6.2.7 Molecular surface phenotyping of monocytes: pattern recognition
receptors
6.2.7.1 Monocyte CD14 expression following LDL and cyclopentenone
exposure
For these experiments, serum-replete monocytes were cultured in suspension with native or
oxidised LDL, or with cyclopentenone prostaglandins across a 3-log concentration range.
Monocyte surface CD14 expression appeared unchanged in response to supplementation
with both n-LDL and ox-LDL at increasing concentrations during suspension culture at
24hrs, 72hrs and 5 days (Figures 6.21-6.23). CD14 expression remained unchanged during
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suspension culture with at 24hrs, 72hrs and 5 days in medium supplemented with 15dPGJ2
(Figure 6.24). No alteration of monocyte CD14 was noted during adherent culture in the
presence of 50pg/ml of n-LDL and ox-LDL at 48hrs (Figure 6.25). However, at 8 days
50pg/ml n-LDL significantly reduced CD14 expression (n=8, p=0.0303, net median
fluorescence, n=8, p=0.4727, net fluorescence relative to control). Ox-LDL at the same
concentration had no effect upon CD14 expression (Figure 6.26).
For CD 14 data tables, see supplementary data (Chapter 6 Appendix, Tables 6.2-6.9).
6.2.7.2 Monocyte CD36 expression following LDL and cyclopentenone
exposure
Monocyte CD36 was not significantly altered by culture in LDL supplements, during
suspension culture at 24hrs, 72hrs or at 5 days, (Figures 6.27 to 6.29). Furthermore, no
significant alteration of CD36 expression was noted during suspension culture with
increasing concentrations of cyclopentenone 15dPGJ2 after 24hrs, 72hrs or 5days (Figure
6.30), although the later time points suggested lower levels of expression. This could not be
explained by cell death, in view of live-gating to exclude ToPro3 positive cells.
Molecular phenotyping of CD36 in adherent monocytes culture with 50pg/ml of n-LDL and
ox-LDL showed no significant alterations at 48hrs or 8 days (Figures 6.31 and 6.32), again
suggesting stable monocyte CD36 expression, despite LDL supplementation. A non¬
significant trend towards decreased CD36 expression in adherent macrophage cultures was
noted after 8 days of ox-LDL exposure.
For CD36 data tables, see supplementary data (Chapter 6 Appendix, Tables 6.10-6.17).
6.2.8 Molecular phenotyping of monocytes: adhesion molecules
6.2.8.1 Monocyte surface CD29 (pi integrin) expression is unaltered by lipid
exposure
Flow cytometric analysis showed stable monocyte pi integrin expression following exposure
to increasing concentrations of n-LDL and ox-LDL at 24hrs, 72hrs and 5 days in suspension
culture. 24hrs of culture with 15dPGJ2 caused no alteration in CD29 expression. Prolonged
culture with higher concentrations of 15dPGJ2 showed a linear trend to decreased total CD29
expression at 72 hrs, (one-way ANOVA, n=3 p=0.0099), and a significant down-regulation
ofCD29 relative to control at 72hrs (one-way ANOVA, n=3, p=0.0259) but not at 5 days.
Limited samples were available for assessment of monocyte phenotype in response to LDL
supplements at 48hrs in adherent culture, but representative flow cytometry data suggested
that pi integrin expression was not markedly altered, with no further change seen on
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representative plots after 8 days of adherent culture. However, the latter are qualitative data
given the insufficient sample numbers that preclude formal statistical analysis. CD29 data
plots histograms and tables are presented as supplementary data, (Chapter 6 Appendix,
Figures A6.1-A6.6, Tables 6.18-6.24).
6.2.8.2 Adherent monocyte CD49d expression is reduced by ox-LDL
Adherent culture of monocytes on tissue culture plastic in serum-replete conditions with
LDL supplementation did not statistically alter net median fluorescence. However, ox-LDL
appeared to produce a statistically significant decrement in CD49d expression relative to
control at 48hrs (Wilcoxon signed rank test, n=7 p=0.0391, see Figure 6.33), although this
was not obvious from histogram overlays. One-way ANOVA did not show changes of total
net median fluorescence following LDL treatments (n=7 p=0.0515), but 50pg/ml ox-LDL
appeared to reduce net median CD49d fluorescence relative to control at 8 days (Wilcoxon
signed rank test, p=0.0156, n=7, Figure 6.34). CD49d expression was not assessed on
suspension culture monocytes. The histograms suggest that this alteration in fluorescence is
small in absolute terms. Overall, when raw fluorescence data were viewed, CD49d signals
were at the lower range of the fluorescence scale, and changes were not gross despite
statistical analysis suggesting significance. For full data analysis, see supplementary data,
Chapter 6 Appendix, Tables 6.25 and 6.26.
6.2.8.3 Monocyte surface CD49e expression following lipoprotein exposure
Adherent but not suspension cultured monocytes were available for CD49e expression
quantification, but no statistically significant changes were noted following 48hrs or 8 days
in culture supplemented by 50p.g/ml of n-LDL or ox-LDL. Responses to cyclopentenones
were not measured for CD49d or CD49e. (See supplementary data, Chapter 6 appendix
Figure A6.7 and A6.8, and Tables 6.27 and 6.28).
6.2.8.4 Monocyte surface CD11a expression following LDL and
cyclopentenone exposure
Investigation of CDlla expression was initially explored in the context of transcriptional
responses to LDL in Chapter 5. The discrepancies between transcriptional changes and
alterations at a protein level were discussed in Chapter 5, section 5.4.4.
Monocyte surface CD1 la expression was unchanged by LDL supplementation in suspension
culture at 24hrs, 72hrs and 5 days. No statistically significant alteration of CD1 la expression
was noted at the same time points following exposure of suspension cultured monocytes to
increasing concentrations of the cyclopentenone 15dPGJ2. The issue of differential adhesion-
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dependent LFA-1 expression was addressed by assessing mature monocyte/macrophage
CDlla surface expression after culture on tissue culture plastic, followed by detachment.
Although a statistically significant reduction in monocyte CD1 la surface expression relative
to control was noted at 48hrs, histograms showed little reduction in actual fluorescence. No
changes were noted at 8 days in adherent culture. For CD1 la data plots, histograms and data
tables, see supplementary data, Chapter 6 Appendix, Figures A6.9-A6.14, and Tables 6.29-
6.35.
6.2.8.5 Monocyte surface CD11b expression following LDL exposure
CDllb expression on monocytes in suspension culture was assessed at 24hrs only, with no
significant changes noted (Figure 6.35). Early assessment of surface CD1 lb expression on
adherent monocytes after 48hrs revealed a non-significant enhancement of expression in
monocytes exposed to n-LDL at 50p.g/ml, but no significant changes in monocytes exposed
to ox-LDL at 50p.g/ml (Figure 6.36). However, 8 days of exposure of adherent monocytes to
ox-LDL at 50pg/ml significantly reduced net median CD1 lb monocyte surface fluorescence
(n=9, p=0.0029) and net median CD1 lb fluorescence relative to control (n=9, p=0.002), an
effect not reproduced by n-LDL, (Figure 6.37). Ox-LDL also produced a significant
decrement in CDllb compared to n-LDL (n=9, p=0.0003). A divergent change was
apparent, with certain donors showing marked reduction in CD1 lb expression. Overall, this
may suggest differential control of monocyte CDllb expression dependent upon maturation
and adhesion status. For full data analysis, see supplementary Tables 6.37 and 6.39.
6.2.8.6 Monocyte surface CD11c expression following LDL and
cyclopentenone exposure
Suspension culture showed no statistically significant changes in monocyte surface
expression of CDllc in response to LDL supplementation at increasing concentrations at
24hrs (Figure 6.38). A significant reduction in total net median CDllc appeared to be
induced by ox-LDL at 100pg/ml following 72hrs of LDL-supplemented suspension culture,
but this was not apparent when relative fluorescence was compared to control (Figure 6.39).
No alterations in CDllc were seen at 5 days in LDL-supplemented suspension culture
(Figure 6.40). Furthermore, no alteration in CDllc expression was noted in response to
cyclopentenone 15dPGJ2 exposure at the same time points (Figure 6.41). Adherent culture of
monocytes in n-LDL or ox-LDL at 50pg/ml showed no statistically significant alterations in
CD1 lc expression at 48hrs (Figure 6.42), but a marked and statistically significant reduction
in ox-LDL in comparison to control treatments and n-LDL was noted at 8 days (n=9,
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p=0.002 and p=0.0024 respectively, see Figure 6.43). This suggests that a further alpha
integrin subunit alters expression in response to LDL exposure, dependent upon maturation
and adhesion status. (For full data analysis, see supplementary data, Tables 6.40-6.47).
6.2.8.7 Monocyte CD61 ((33 integrin) expression in response to LDL
Monocytes surface P3 integrin expression was assayed by indirect immunofluorescence
using anti-CD61 mAb. 50pg/ml n-LDL, but not ox-LDL, significantly reduced CD61
expression relative to control at 48hrs (Wilcoxon signed rank test, p=0.0391, n=7) but not at
8 days. However, the actual reduction in fluorescence was small. CD61 expression relative
to control appeared significantly reduced by 50pg/ml ox-LDL but not by n-LDL at 8 days
(Wilcoxon signed rank test, n=7, p=0.0078). Absolute changes of fluorescence were low,
with signals being at the lower end of the cytometer range, making interpretation of these
data difficult. Suspension culture phenotyping was not performed using this mAb. CD61
data plots, histograms and data tables, are presented as supplementary data, Chapter 6
Appendix, Figures A6.15 and A6.16, and Tables 6.48-6.49.
6.2.8.8 Monocyte CD54 (ICAM-1) expression in response to LDL
Monocyte CD54 was assessed in suspension culture at 24hrs in 50pg/ml of n-LDL or ox-
LDL supplemented media, and a statistically significant increase in expression noted in
response to ox-LDL, relative to both control and to n-LDL (n=6, p=0.0156, and p=0.0022
respectively, see Figure 6.44). Insufficient samples were available for statistical analysis at
later time points in suspension culture, but representative flow cytometric histograms suggest
that CD54 expression may be unaltered relative to control once suspension culture
monocytes have matured at 5 days (Figure 6.45).
Assessment of adherent monocytes in n-LDL or ox-LDL at 50|o,g/ml showed no alteration in
CD54 immunofluorescence at 48hrs (Figure 6.46). However, protracted adherent culture for
8 days in 50pg/ml of ox-LDL significantly reduced both net median CD54 expression and
net CD54 expression relative to control (n=7, p=0.0272 and p=0.0379 respectively, see
Figure 6.47). These data suggest that differential expression of this immunoglobulin
superfamily member following LDL exposure is dependent upon adhesion status. (For full
data analyses, see supplementary data, Chapter 6 Appendix, Tables 6.50 to 6.52)
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6.2.9 Molecular phenotyping of monocytes: immunoregulatory molecules
6.2.9.1 Monocyte CD64 (FcyRI) expression following LDL and cyclopentenone
exposure
Although assessment of suspension culture monocytes at 24hrs suggested a significant
reduction in CD64 in Ox-LDL treated monocytes compared to n-LDL treated cells at
lOOpg/ml (n=4 to 9, p=0.0117), this was not corroborated when comparing net changes in
fluorescence relative to control at 24hrs. Exposure of suspension-cultured monocytes to n-
LDL or ox-LDL caused no statistically significant changes in CD64 expression at 72hrs, or 5
days. Stable CD64 expression was seen following exposure of suspension cultured
monocytes to increasing concentrations of 15dPGJ2, although a trend towards reduced
expression was noted with lOpM 15dPGJ2 after 5 days culture. However, the data are non¬
significant, suggesting that PPARy is uninvolved in this phenotypic change. Monocytes in
adherent culture exposed to 50pg/ml of n-LDL or ox-LDL showed no alteration of CD64
expression after 48hrs or 8 days. These data suggest that CD64 expression is unaltered by
ox-LDL exposure.
For CD64 data plots, histograms and data tables, see supplementary data, Chapter 6
Appendix, Figures A6.17-A6.22, and Tables 6.53 to 6.60).
6.2.9.2 Monocyte CD16 (FcyRIII) expression following LDL exposure
Phenotypic assessment of CD 16 expression was performed on cells in adherent culture
alone. Exposure of adherent monocytes to 50pg/ml n-LDL or ox-LDL caused no statistically
significant changes in surface CD16 expression at 48hrs or 8 days. The stability of CD16
expression suggests that LDL immune complex binding may not be greatly enhanced in
mature lipid laden macrophages, a hypothesis that would need formal testing using
aggregated LDL and anti-LDL monoclonal antibodies. For CD64 data plots, histograms and
data tables, see supplementary data, Chapter 6 Appendix, Figures A6.23 and A6.24, Tables
6.61 and 6.62.
6.2.9.3 Monocyte Class II MHC expression following LDL and cyclopentenone
exposure
Monocyte Class II expression was not significantly altered by culture in LDL supplements,
during suspension culture at 24hrs, 72hrs, or 5 days. No significant alteration of Class II
expression was noted during suspension culture with increasing concentrations of
cyclopentenone 15dPGJ2 for up to 5 days. Adherent monocytes cultured with 50pg/ml of n-
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LDL showed no significant alterations of Class II expression at 48hrs or 8 days. Ox-LDL did
not alter net median Class II fluorescence but appeared to reduce Class II expression relative
to control after 48hrs of adherent culture (Wilcoxon signed rank test, n=7, p=0.0156). This
was not seen following 8 days of culture. Absolute fluorescence did not appear grossly
reduced on histograms, although elevated isotype control fluorescence was seen as a function
of ox-LDL auto-fluorescence (see Figure 6.20). (For Class II MHC data plots, histograms
and data tables, see supplementary data, Chapter 6 Appendix, Figures A6.25-A6.30, Tables
6.63- 6.70.
6.2.9.4 Monocyte CD86 (B7.2) responses to LDL supplements
Initial lipid exposure caused no statistically significant change ofmonocyte CD86 expression
in either n-LDL or ox-LDL treated monocytes at 24hrs: although the Kruskal-Wallis
ANOVA test suggested a significant variation in CD86 expression (n=4 to 12, p=0.0201),
Dunn's multiple comparison test revealed no significant difference in expression from
control. Furthermore, no changes were noted relative to control monocyte CD86 expression
(n=4-12, p=0.1708), suggesting no real variation in signal. No changes were noted with LDL
exposure at 72hrs, or 5 days in suspension culture. Further phenotyping of monocytes in
adherent culture showed no significant alterations in CD86 expression following exposure to
n-LDL or ox-LDL at 50pg/ml for 48hrs or 8 days.
For CD86 data plots, histograms and data tables, see supplementary data, Chapter 6
Appendix, Figures A6.31-A6.35, Tables 6.71- 6.75.
6.3 Summary: monocyte phenotype changes
LDL alters monocyte surface molecular phenotype in a manner that is dependent upon both
LDL oxidation status, and also upon monocyte adhesion status.
Monocyte CD14 expression was maintained during exposure to n-LDL, ox-LDL and
cyclopentenones in suspension culture, but appeared reduced following prolonged exposure
to n-LDL in adherent culture.
Monocyte scavenger receptor BI expression as assessed by CD36 phenotyping was
statistically unchanged by culture with LDL and cyclopentenone supplements.
Ox-LDL supplementation significantly reduced levels of monocyte surface CDllb, CDllc
and ICAM-1 during prolonged adherent but not suspension culture. Statistical analyses
suggested that CD49d expression was reduced following prolonged adherent culture with ox-
LDL. Changes in CD 11a and P3 expression were noted on statistical analysis, but did not
appear marked when assessing fluorescence histograms.
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No significant alteration of FcyRl or FcyRIII receptor expression was noted.
A transient reduction in Class II MHC molecule expression was noted during early adherent
culture, but this was not reflected by histogram appearances. B7.2 co-stimulatory molecule
appeared stably expressed during culture with LDL and cyclopentenones.
Exposure to pro-atherogenic stimuli thus promotes a monocyte phenotype that potentially
confers altered adhesion properties. Atherosclerosis plaque progression may be affected by
this, due to limited monocyte mobility within the vessel wall. Detailed discussion of the
biological implications of these findings is entered into in section 6.5.
6.4 Technical and experimental issues and study limitations
6.4.1 Use of in vitro models in atherosclerosis research
The ability of individual leukocyte populations to differentially traffic and vary in direct
response to defined stimuli governs the plasticity of the inflammatory responses, tailoring
such cellular reactions to benefit the host. Inappropriate invocation of cell surface changes
may cause disruption of such cell movements, and cause the unwanted retention or
conversely egress of cells from an inflammatory site.
Monocyte culture was undertaken in two different manners: suspension cell culture in Teflon
containers, and adherent cell culture on tissue culture plastic. Both methods utilised highly
purified cells, isolated either by immunomagnetic separation, or by attachment to tissue
culture plastic and washing to remove contaminant lymphocytes and granulocytes. Clearly
no in vitro system will represent a parallel to in vivo physiological conditions, but defined
observations of cell behaviour may be made in this way.
Alternative animal models are widely used in atherosclerosis research. Induction of marked
hyperlipidaemia has been possible with targeted gene disruption of lipid trafficking
molecules. LDL-R null animals have high circulating levels of LDL, but use of the Apo E-/-
murine model currently predominates, with the morphology of the atherosclerotic plaque
thus produced being widespread through the vascular tree and bearing similar cellular
composition to human atheroma (Nakashima et al. 1994). However, murine atheroma shows
distinct differences from human atheroma (Meir & Leitersdorf 2004). Murine gene deletion
models show rapid time courses of plaque progression in comparison to humans (Hockings
et al. 2002), but with a predominance of plaque only in larger arterial vessels. Indeed, even
very early studies demonstrated differences in plaque distribution from human disease
(Wissler & Vesselinovitch 1968). Murine genetic strain differences dictate differential
leukocyte responses contributing to atherosclerotic plaque formation, with C3H backgrounds
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conferring protection, and C57/BL6 backgrounds promoting susceptibility to atheroma
formation (Liao et al. 1994).
By contrast, the use of human ex vivo samples for immediate phenotyping presents problems
of tissue sampling, adequate sample yield and in the case of monocytes the limited ability to
examine end-differentiated cells.
6.4.2 Normal distribution of cell molecules across populations
The variability seen during molecular phenotyping is not surprising, given the donor
heterogeneity that will be present in any study of human primary leukocytes, perhaps
reflecting differential maturation status in circulating cells (Dransfield et al. 1988). Studies
examining surface molecule expression on granulocytes have highlighted phenotypic
variation in association with age, gender pregnancy stress and race (Elghetany & Lacombe
2004). Given this inherent variation of surface molecule expression in circulating primary
leukocytes, the use of such cells in any phenotyping assay might be questioned. However,
the advantages of primary human cells outweigh such issues, because of the limitations of
using cell lines or animal models. Certainly in other models of inflammation, including
airways (Galli 1997) and renal injury, murine models do not offer a full reflection of human
disease processes. Although many homologous genes governing leukocyte function are
present in the murine genome, fundamental differences in inflammatory responses, such as
the variability in IL-8 receptor homologues in mice (Bozic et al. 1994), mean that the use of
animal models must always be carefully considered. The use of selected donors for the data
presented is thus an attempt to ensure a relatively homogeneous cohort to limit confounding
variables that might alter surface molecule expression. Characteristics were only available
for a limited number of donors, but are reflective of all donors used in these studies. Non-
smokers with no recent history of inter-current infection or inflammatory symptoms were
targeted, and the lack of prescribed medication was taken as a surrogate marker of good
health. This donor profile is in keeping with other published work in the field of innate
immunity and inflammation research.
6.4.3 Cell culture: suspension vs. adherent culture
Assessment of suspension cells offers insight into non-adherent monocyte behaviour,
modelling leukocyte behaviour prior to vascular wall tethering events. The use of prolonged
periods in suspension culture may be criticised. It is debatable whether uncommitted
monocytes circulate for more than 72 hours in vivo. Data from murine models shows that
circulating monocyte have a half-life of 17.4hrs (Van Furth, Diesselhoff-den Dulk, & Mattie
1973), with a half-life of three times this value in humans (van Furth 1989). This calls into
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question the relevance of in vitro assays that examine monocyte behaviour beyond this time
point. Suspension cultured cell numbers fall due to constitutive apoptosis, autophagy
(Klionsky & Emr 2000), and presumed phagocytosis of effete cells, producing a potentially
biased phenotype. Use of Teflon culture introduces the possibility of anoikis, with cell death
due to a lack of adhesion-mediated leukocyte activation (Frisch & Francis 1994). High
monocyte purity greatly reduced populations of lymphocytes and granulocytes that would
undergo early apoptosis, suggesting that the monocyte phenotypic data presented here is
realistic. Despite this, no clear pattern of phenotypic change appeared in the cells sampled,
when data were subject to statistical analyses.
Adherent monocyte responses partially govern the progressive changes in monocyte surface
molecule during the transition from intra-luminal to resident inflammatory cells. Suspension
culture fails to mimic these inputs directly. To explore the specific effects of adhesion upon
monocytes exposed to LDL, further phenotypic analysis was performed upon monocytes
adherent to tissue culture plastic. Although this is by definition an artificial environment, it
avoids the limitations inherent in suspension culture. Nevertheless, harvesting of monocytes
from tissue culture plastic introduces further experimental issues. The use of trypsin to
detach cells was avoided to minimise disruption of molecules that might be enzymatically
cleaved from monocyte surfaces. Cells were detached in EDTA on ice followed by agitation
of tissue culture flasks. Viability of cells labelled for immunophenotyping was maintained by
the addition of autologous plasma to detachment buffers, and demonstrated utilising
membrane permeability dyes and Annexin V to assess phosphatidylserine exposure during
flow cytometry. Despite the effects these methods might have upon integrin conformation it
appeared not to alter cell survival, or mAb binding of monocyte surface integrins. Also, in
contrast to mechanical means of cell harvesting including detaching cells with a rubber
spatula, EDTA mediated detachment minimised cell death but at the expense of lower cell
yields.
It must be noted that "two-dimensional" tissue culture in only one horizontal plane fails to
reproduce the three-dimensional structure that governs monocyte differentiation in vivo
(Hakkert et al. 1990). Integrin mediated adhesion stimuli alter cytoskeletal filament tension,
changing cell functions (Maniotis, Chen, & Ingber 1997). Gene transcription is critically
altered by distinct adhesion steps in 3-D models, with differential effects introduced by
culture on individual matrix components in gel form (Li et al. 1987). Further exploration of
LDL induced phenotypic changes would thus necessitate the use of matrix components in
simple three-dimensional structures such as collagen gels.
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6.4.3.1 Cell culture: use of serum-replete media
Cell surface changes are an early manifestation of physiological responses to external stimuli
in circulating and marginating leukocytes. In the absence of serum monocytes may survive
in vitro when cultured adherent to plastic but die rapidly in suspension culture, following a
pattern of cell survival dictated partially by integrin ligation (Frisch & Ruoslahti 1997).
Furthermore, serum-replete culture facilitates the maturation ofmonocytes in a concentration
dependent manner, permitting the in vitro expression of CD 16 and CD51 (the alpha chain of
the vitronectin receptor), in distinction from serum-free matured monocytes, which
demonstrate limited expression of markers such as CD 14 (Andreesen et al. 1990).
Cells cultured in a serum-replete system, although not entirely representative of the intra
vascular milieu, do serve as a model for the observation of such events in vitro. The presence
of serum allows for cellular survival, with specific factors including CSF-1 (Becker, Warren,
& Haskill 1987) and upregulation of heat shock proteins (Lang et al. 2000) preventing
monocyte apoptosis at critical times during monocyte differentiation. This offers the
opportunity to study early cell surface responses by naive undifferentiated monocytes in
order to discern the characteristic changes that dictate transition into a foam cell. The fact
that normal serum contains lipoproteins at varying concentrations has not been discounted.
However, autologous serum was used at 10% by volume, and clear differences were noted
following modified LDL exposure relative to control. It is thus reasonable to view these
studies as representing an augmented effect of modified LDL upon serum-replete
monocytes. Alternative strategies would have entailed the use of heat-inactivated delipidated
human serum. This is costly to produce in large quantities, and was not available for these
studies.
6.4.4 Microscopy: problems assessing monocyte lipid uptake
Cultured monocytes were unequivocally demonstrated to take up intra-cellular lipid, as
demonstrated by both ORO labelling and fluorescent labelling using 3,3'-
dioctadecylindocarbocyanin-iodide (Di-I) LDL species. Although studies have previously
shown that monocyte adoption of a lipid-laden phenotype in vitro requires protracted periods
of culture of up to 14 days (Lesnik et al. 1992), it is clear from the data presented in this
chapter that lipid uptake is initiated much earlier. However, quantification of such lipid
uptake introduces further technical challenges. Micrographic analysis proved too
inconsistent to be of value. Attempts were made to assess hue, saturation and intensity for
each cell using both commercial OpenLab software and ImageJ open-source software
(Abramoff, Magelhaes, & Ram 2004). Correlation of LDL labelling with each cell was not
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possible, as cell numbers were underestimated. Indirect assays including the use of radio
labelled LDL species have been previously used to assess leukocyte lipid uptake (Jones,
Reagan, & Willingham 2000). Replicating this method would have necessitated further
sourcing of different LDL samples, introducing potential inconsistencies with the original
data produced. Also this method would have correlated radioisotope activity to cell protein
content, but would not specifically address the issue of lipid uptake per cell. Thus alterations
in cell size, changing protein concentration in lysed samples, would only confound
assessment of cell numbers per sample.
Other options for quantifying lipid uptake are the use of ORO labelling, followed by
spectrophotometric analysis for colour content, producing a surrogate marker of lipid uptake
(Wilsie et al. 2005). Such analysis would not produce a specific measure of LDL uptake,
neither would it accurately define lipid uptake per cell, offering only an average reading
based on the assumption that cell numbers were constant in each treatment.
The data presented regarding monocyte for lipid uptake are thus qualitative, but demonstrate
a number of factors. Firstly, all monocytes cultured in serum-replete conditions were
exposed to low-levels of lipids in multiple forms, including triglycerides and cholesterol
esters, a factor made apparent by ORO labelling seen in control cells. Secondly, LDL uptake
increases with duration of culture, and maturation of monocytes, an observation that is
reflected by increased ORO labelling indicating total lipid uptake and the increased specific
LDL uptake observed during prolonged culture with Di-I LDL. Thirdly, the type of LDL
supplementation dictates the extent of total lipid uptake, with enhanced ORO labelling seen
in cells treated with ox-LDL in contrast to controls and n-LDL treated cells.
6.4.5 Quantification of indirect immuno-fluorescence
Quantification of indirect immuno-fluorescence requires careful consideration. The use of
controls in particular is a potential source of error. Isotype matched non-specific monoclonal
antibodies are often used to distinguish background antibody labelling, an issue relevant to
work with myeloid cells bearing surface Fc receptors at a biologically important molecular
copy number. However, the use of isotype controls as a definitive mode of quantification
raises further issues (Keeney et al. 1998). The saturation of individual isotype controls needs
to be assessed in relation to individual antibodies. Protein concentrations from manufacturers
may vary from batch to batch, necessitating the titration of isotype non-specific binding on
each occasion. Isotype controls from each experiment would thus have to be titrated to the
same fluorescence level as previous batches. In the case of isotype controls, this single
variable is supposedly the specificity of the isotype for the epitope. Each monoclonal needs
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to be matched to an isotype control at the same protein concentration, to ensure a rational
baseline non-specific binding. In experiments with multiple samples being analysed for the
expression of multiple molecules with multiple antibodies, this may necessitate the use of
considerable numbers of isotype control dilutions. Issues regarding variability of the
fluorochrome to protein ratio are also problematic when using isotype controls as a
quantification tool, although this is clearly more relevant to pre-conjugated antibodies. The
work presented in this chapter utilised un-conjugated monoclonal antibody labelling,
detected with saturating concentrations of anti-mouse immunoglobulin F(ab)2 fragments
conjugated to FITC. Variable primary antibody:fluorochrome ratios were thus avoided.
However, batch variability of secondary antibody remains a theoretical source of
inconsistent labelling between experiments. Any isotype control will by definition represent
a different peptide sequence to the test antibody, and the variation in amino acid sequence
raises the theoretical possibility of selective and differential binding to Fc receptors. Isotype
labelling is important to indicate whether an issue with background non-specific antibody
labelling exists or not (O'Gorman & Thomas 1999). In the absence of an alternative control,
it has been used in the experimental data presented. However, examination of elevated
signals from most of the experimental samples analysed suggests that different isotype
binding characteristics were not consistently seen when IgG| and IgG2a binding were
compared, and then further compared to unlabelled cells. A more robust approach might be
the use of a cell population bearing all but the molecule of interest, the "fluorescence minus
one" method (Roederer 2001), of use in multi-fluorochrome analyses where controls display
all but the molecules under examination on the cell surface. Quantification still remains
unresolved even with this technique, and this might best be dealt with by utilising control
fluorescent microspheres with defined fluorescence profiles, although these quantification
controls must be carefully prepared (Gratama et al. 1998). Microspheres could be used to
calibrate individual cell populations, enabling quantification data to be compared across
multiple experiments.
Isotype control labelling draws attention to overtly high levels of non-specific mAb binding,
a phenomenon that is useful when examining myeloid cells with high levels of FcR,
especially in murine systems. Should non-specific binding then appear unacceptably high
experiments may be redesigned, altering blocking steps used before mAb labelling, or
subsituting different mAb altogether. However, the use of isotype controls as absolute
quantification tools must be regarded as limited in any large scale flow cytometric
assessment that involves multiple samples over a protracted period of time.
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6.4.5.1 Relative fluorescence assessment
In view of the discrepancies in baseline fluorescence signals between different cell
preparations, it was necessary to devise a practical solution to address variable controls.
Whilst a variation in control fluorescence may not appear to be numerically important, the
alterations of high signals on a log scale are critical. Thus removal of control values is
necessary for precise quantification. The adopted method of removing isotype control signals
was used for each sample. The control treatment signal was then further subtracted to give a
net change in fluorescence. Analogous "delta-delta" methods are used in gene array
assessments of variable background control signals, and have been recommended for flow
cytometric quantification in the absence of calibrated signals (Mario Roederer, pers. comm.
2005). The definitive use of fluorescent beads would avoid the need for such a strategy (e.g.
Rainbow beads, Spherotec Inc., IL, USA). Utilising calibrated beads for each assay would
establish a relative fluorescence control level, enabling calibration of each cell for each
individual donor. Relative fluorescence could then be calculated in the same manner, with
the advantage of gaining an absolute control. Calculation of absolute numbers of molecules
per cell becomes possible with this technique, enabling true quantification of cell surface
copy number. It is unusual in experimental immunology to routinely use calibration beads
for such purposes, although their use in clinical phenotyping is important, especially for
monitoring progress of CD4 cell counts in acquired immune deficiency and the responses to
chemotherapy in myeloid neoplasia (Gratama et al. 1998). In the absence of such calibration
beads the data presented still represents relative variation in molecular expression, but a
move to absolute quantification offers an additional level of strength to such experiments,
and would be used in future work.
6.4.5.2 Auto-fluorescence
Monocytes exposed to LDL in both suspension and adherent culture demonstrate auto-
fluorescence in a manner that appears to increase according to the type of LDL species used
to supplement culture media, and the duration of culture. Parallels may be drawn here with
other macrophage flow cytometric analyses, including the phenotypic evaluation of alveolar
macrophages (Lehnert et al. 1986). LDL mediated alteration of auto-fluorescence in
leukocytes has been previously noted (Schmitz et al. 1993), and relates to macrophage
ingestion of ox-LDL aggregates bearing conformational changes caused by creation of
Schiff-base structures (Maeba, Shimasaki, & Ueta 1994). Quantification of relative
fluorescence changes in cell culture systems with high-levels of auto-fluorescence is difficult
when comparing changes with similar cell treatments that do not show the same alteration in
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intrinsic fluorescence. LDL uptake is also problematic in that auto-fluorescence may be
diminished paradoxically, thus producing apparent decrements in cell fluorescence for all
markers in specific cell culture conditions.
6.4.5.3 Statistical analyses of in vitro phenotyping data
Appropriate statistical tests have been carefully chosen to interrogate the flow cytometric
data produced in this chapter, after discussions with an epidemiologist and a statistician.
Although normality tests may be utilised to explore the distribution of data sets, sample
groups with numbers less than 12 cannot be deemed large enough to reliably use such tests
(Dallal & Wilkinson 1986). For this reason, non-parametric assays have been used
throughout. This may have reduced the likelihood of significant difference being highlighted
during analysis.
Changes in fluorescence were assessed using non-parametric analogues of ANOVA tests for
data sets with more than two groups. Data pairing was checked prior to calculations using
Spearman coefficient calculations. For data sets that showed poor data pairing, or where p
values were not calculable with paired data, the Kruskal-Wallis test was utilised. The
Friedman test was utilised for data sets showing effective pairing. Dunn's multiple
comparisons were performed on all data where significant differences were demonstrable
and individual p values for comparisons are shown in data tables. Comparisons of net
fluorescence with a theoretical value of zero were not performed as this would have
necessitated multiple t testing, with the chance of introducing a type II error.
Two-tailed t tests were used for assessment of data sets with two groups. Variation of these
groups from a theoretical value of zero was necessary when assessing fluorescence relative
to control and was performed using Wilcoxon signed-rank testing. Where data matching was
ineffective, the Mann-Whitney U test was utilised. These steps ensured rigorous data
assessment.
6.4.6 Further experiments necessary
The data presented suggest further experiments are necessary to definitively prove some of
the biological findings.
Variation of cell phenotype with prolonged culture suggests temporal change in monocytes.
The use of maturation markers in this context would have been useful, and the quantification
of CD68 expression in permeabilised cells, would give an indication of maturation to a more
functionally phagocytic cell (Holness & Simmons 1993). The introduction of a further
fluorochrome would enable multi-colour analysis in this regard, although with the caveat that
membrane as well as surface expression would be notable for all molecules studied in this
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manner. Such data would not necessarily correlate with the data already produced in this
chapter.
Functional assays were not embarked upon but would be necessary to further corroborate
surface molecule expression with leukocyte activation status. Particular focus upon
migration, response to cytokine and chemokine influences and protease expression, would
allow the relevance of the molecular changes described to be related to potential pathogenic
mechanisms. In particular the alteration of monocyte migratory capacity through artificial
matrices would be of interest. Gels made of extracellular matrix components would be used
to assess alteration of monocyte migration with specific reference to matrix proteins that
bind P2 integrins. Specific assays to explore the movement of lipid-laden macrophages
through collagen and fibrinogen gels would illustrate whether |32 integrin mediated mobility
changes are altered. Use of micro-porous culture wells would enable simple assessments of
monocyte migratory capacity mimicking egress form the vascular wall. Such experiments
could be further developed with the use of endothelial cell monolayers to model trans-
endothelial migration. Phenotyping of molecules, in particular CD49d, needs to be
performed in suspension culture as well as adhesion culture, before embarking on more
functional assays.
Further related experiments that would be useful in extending this work are discussed in
section 6.5.
6.5 Discussion
Macrophages adopt surface molecular repertoires specific to the inflammatory sites they
enter (reviewed in Chapter 1 and section 6.1). Surface expression of Fc receptors, markers of
differentiation and adhesion molecules vary between alveolar macrophages, (Taylor et al.
2000), intestinal macrophages (Smythies et al. 2005) and monocyte-derived Kupffer cells in
the liver (Yamamoto et al. 1995). Although monocyte/macrophage phenotype has been
explored immunohistochemically (van der Wal 1992), monocyte surface molecule
expression in response to defined lipoproteins has not been fully catalogued in vitro.
Monocyte culture with 15dPGJ2 did not appear to cause marked alterations in surface
phenotype and the limited sample number for these experiments makes alterations in cyPG
mediated phenotypic switch difficult to assess. Clear changes were observed following
monocyte exposure to differentially modified LDL, and are discussed in detail.
6.5.1 Pattern recognition receptor responses to LDL: CD14
CD14 links monocyte differentiation to function. CD14+/CD34 mononuclear subsets are a
source of endothelial progenitor cells (Romagnani et al. 2005), and CD14+ peripheral blood
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monocytes are capable of differentiating into monocyte-derived mesenchymal progenitors
(Kuwana et al. 2003) highlighting the remarkable plasticity of CD14+ populations.
Monocyte activation by LPS augments CD14 expression (section 6.1.2), inhibiting
phenotypic switching from monocyte to DC (Palucka et al. 1999), a differentiation step
usually associated with CD 14 loss (Santin et al. 1999). CD 14 ligation promotes subsequent
macrophage activation in a NF-kB dependent fashion (Guha & Mackman 2001) increasing
superoxide release (Landmann et al. 1995). CD 14 is altered by microenvironment, being
down-regulated in response to extrinsic cytokine stimuli including 1L-4 (Lue et al. 1991) and
IL-13 (Cosentino et al. 1995) (section 6.1.2). Conversely IL-6 promotes monocyte CD14
expression (Ikewaki & Inoko 1991).
There appeared to be a reduction in CD14 expression following n-LDL exposure over 8 days
in adherent culture (section 6.2.7.1). All cells demonstrated ToPro3 exclusion, making
reduced cell viability an unlikely explanation for n-LDL mediated CD 14 reduction, which
may instead reflect the heterogeneity of CD14 expression across individual cells and
individual donors, visible on the data scatter plots presented. Cholesterol and lipoproteins
have been previously shown to stabilise monocyte CD 14 expression, (Esfahani et al. 1993)
in contradistinction to the n-LDL-induced effect reported here. CD 14 expression was
preserved in ox-LDL supplemented adherent monocytes, suggesting that
monocyte/macrophage phenotype is maintained despite an atherogenic environment. In
models of leukocyte transmigration, cells remaining in the sub-endothelial space displayed
intact CD14 expression (Randolph et al. 1998), in keeping with the maintenance of CD14
expression in the adherent LDL-exposed monocytes (section 6.2.7.1). Further phenotyping to
assess maturation of monocytes to macrophages might have been performed using anti-
CD68 (macrosialin) mAb (Carlsen et al. 2004). Immuno-histochemical studies have used
CD68 to localise macrophage infiltration in ex vivo atherosclerotic lesions (Geng et al. 1995)
making this a useful tool in further studies.
6.5.1.1 Pattern recognition receptor responses to LDL: CD36
No alteration in the monocyte surface expression of the scavenger receptor CD36 was noted
(section 6.2.7.2). Enhanced CD36 expression in response to ox-LDL and PPARy ligation has
been demonstrated in TPIP-1 monocytic cells (Tontonoz et al. 1998), which do not display
the same surface molecular profiles as primary human monocytes, and may not accurately
reflect primary cell responses to environment (Fleit & Kobasiuk 1991). However, in earlier
experiments primary peripheral blood monocytes did increase CD36 expression in response
to ciglitazone, (chapter 3, section 3.2.15), suggesting that high affinity PPARy ligation is
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capable of promoting CD36 up-regulation. Ox-LDL was obtained from the same source as
used by Tontonoz et al., making variability in oxidation status unlikely, and electrophoretic
mobility data (Chapter 3 Appendix) confirmed consistent lipid oxidation across samples. The
concentration of fatty acid-derived ligands including HODE may be too low in ox-LDL to
reproduce CD36 upregulation in primary cells. Small changes in CD36 copy number may
not be apparent in a small sample size from a heterogenous donor population, demanding a
further expansion of sample numbers to demonstrate changes in molecular expression.
CD36 is an important route for lipid entry to macrophages (Febbraio et al. 2000). PPARy-
RXR regulation of liver X receptor (LXR) transcription in turn modulates scavenger receptor
SR-BI and ABC-1 transporter levels, promoting HDL binding and cholesterol efflux,
(Chawla et al. 2001b) homeostatically limiting monocyte lipid accumulation. A further
feature of transcriptional regulation of cholesterol trafficking in monocytes is the LXR and
RXR mediated down-regulation of CD36 which may explain limited changes seen during
these phenotyping studies.
CD36 has been reported to play a role in macrophage recognition of apoptotic cells via
thrombospondin ligation (Fadok et al. 1992). Common molecular profiles may explain the
avid uptake of ox-LDL by macrophages (Chang et al. 1999). Ox-LDL derived phospholipid
epitopes, including 1-palmitoyl 2-(5-oxovaleroyl) phosphatidylcholine (POVPC), and
antibodies malondialdehyde-LDL may share moieties with apoptotic cells, potentially
affecting the phagocytosis of effete cells (Chang et al. 1999). In view of the fact that
monocyte-derived DCs may present phagocytosed debris to the immune system, (Albert et
al. 1998) this prompted the examination ofmonocyte surface molecules involved in adaptive
as well as immunity.
6.5.2 Adhesion molecules
6.5.2.1 pi integrin stability
Monocyte pi integrin expression appeared unchanged following exposure to LDL in both
suspension and adherent culture, although a significant decrement in pi integrin signal was
noted following exposure to higher concentrations of 15dPGJ2 (section 6.2.8.1). Cells
sampled for the latter assay displayed ToPro3 exclusion and thus reduced pi expression
could not be ascribed to low monocyte viability. However, the small number of samples
makes these data difficult to interpret. Further studies would be needed to confirm these
findings, and to provide a fuller phenotype for early LDL exposure in adherent monocytes.
213
Although functional studies were not performed the stable expression of (31 integrin is still
suggestive that signalling via this integrin may be intact in ox-LDL exposed monocytes.
Ligand-binding regions of integrin beta subunits contain a type A-domain similar to that
found in the binding region of von Willebrand factor. This alpha/beta "Rossmann" fold
contains a metal ion-dependent adhesion site (MIDAS) located on the upper surface. During
receptor activation, the beta subunit A-domain undergoes tertiary structural changes. The
mAb 12G10 recognizes a unique cation-regulated epitope on the beta-1 A-domain. Induction
of this epitope reflects integrin activation status and thus competence for ligand recognition.
The ability of Mn(2+) and Mg(2+) to stimulate 12G10 binding is removed by mutation of the
MIDAS motif, proving that MIDAS is a Mn(2+)/Mg(2+) binding site and that site occupancy
induces A-domain conformational changes. The mechanism of beta subunit A-domain
activation appears to be distinct from that of the A-domains found in some integrin alpha
subunits. In summary, because the epitope recognised by 12G10 equates to an "activation"
epitope in (31 integrins (Mould et al. 2002), the data presented suggest that pi integrin
adhesion and subsequent downstream signalling is unlikely to be altered early after
monocyte exposure to Ox-LDL. LDL-exposed monocytes may still be capable of trans-
endothelial migration via pi integrin mediated interactions (Weber et al. 1996), a process as
crucial in the monocyte efflux from sites of inflammation as it is in leukocyte recruitment
(Bellingan et al. 2002).
6.5.2.2 Reduced CD49d expression
Reductions in CD49d were noted in response to ox-LDL in monocytes (section 6.2.8.2),
although only adherent cells were assessed. Fluorescence signals were at the low end of the
scale, and the decrement seen, although statistically significant, was small in absolute terms.
Free iron supplements, a source of oxidative damage, increase expression ofmonocyte VLA-
4 and VCAM-1 in ECs, promoting in vitro monocyte/EC binding (Kartikasari et al. 2004).
The small reduction of CD49d induced by ox-LDL observed here contradicts this study,
perhaps suggesting that oxidation-related effects are much less marked using ox-LDL than
with free metal ions. Reduced CD49d expression, even if marginal, may have functional
implications for lipid-laden macrophages. MMP-1 expression is regulated by a4pi and a5pi
ligation of fibronectin, as well as of VCAM-1 and CD54/ICAM-1 (Matias-Roman et al.
2005). MMP-1 proteolysis of matrix proteins facilitates leukocyte movement, as well as
activating other pro-MMPs, notably MMP-2 and MMP-13 (Seiki et al. 2003). Ox-LDL
mediated down-regulation of CD49d may thus limit macrophage mobility, but may also limit
matrix degradation, a possibility that is of direct relevance to vascular injury and repair.
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Elevated macrophage secretion of MMP has been directly linked to atherosclerotic plaque
rupture in apoE null mice (Gough et al. 2006), and in cultured macrophages exposed to ox-
LDL (Xu et al. 1999). The influence of a4 integrin signalling in controlling MMP secretion
in lipid-enriched micro-environments is of interest, and may offer insights into matrix
influences upon plaque stability. The exploration of CD49d in protease secretion as well as
migration assays is thus a further area of study.
The down-regulation in CD49d was not matched by CD49e (section 6.2.8.3). CD49d is more
important in mediating weak interactions than CD49e, aiding focal adhesion complex
formation influencing cell adhesion and migration through matrices. Conversely, CD49e
may be able to salvage adhesion in the absence of CD49d (Kassner et al. 1995). In contrast
to a5 integrins, a4 mediated binding to fibronectin can be influenced by pi ligation, with
exposure to the 12G10 mAb causing reduced a4pi mediated actin polymerisation, cell
spreading and motility (Humphries et al. 2005). These studies suggest that reduced a4
expression in adherent cells may reduce mobility, but the influence of CD49e expression
needs to be considered, and monocyte migration studies through defined matrices following
blockade ofCD49e would answer this.
The signalling cascades that follow a4 ligation present a further focus for study. a4 integrin-
mediated cell migration is regulated by protein kinase A phosphorylation of the a4
cytoplasmic tail (Chan et al. 1992). Paxillin binding to the a4 integrin tail is essential for cell
movement, but is inhibited by phosphorylation. The effects of modified LDL upon a4
integrin tails and the downstream signalling changes that this might invoke have not been
explored, but might provide additional information relating to altered macrophage mobility
within atherosclerotic plaques.
6.5.2.3 Monocyte CD11a expression
Despite suggestions from gene array data, (Chapter 5), no statistically significant changes in
CDlla expression were apparent during suspension culture following LDL exposure
(section 6.2.8.4). The early reduction in CDlla expression relative to control in adherent
culture, although statistically significant, did not appear marked; it is questionable whether
this would result in reduced CD1 la-mediated responses. Surface CDl la thus appears to be
stable (Bretscher 1992), when using the same adherence culture conditions for gene array
preparation, and does not reflect the reduction in transcription noted in array and PCR work
(Chapter 5). This is of interest as recent data has suggested that CDl la expression may be
downregulated by linoleic acid (Rinker et al. 2004), in keeping with the transcriptional data
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presented. Other modes of assessing CD1 la during dynamic migration or mobility assays
were considered in Chapter 5.
6.5.2.4 Reduced CD11 b expression
CDllb appeared stable in early suspension culture with ox-LDL, but was reduced in
prolonged adherent culture. Thus, although the phenotype analysis performed on monocytes
in suspension culture was incomplete, with only 24hr data available, the reduction in CD1 lb
expression appeared related to monocyte maturation and adhesion status, as well as oxidation
status of LDL supplements (section 6.2.8.5). No initial up-regulation in suspension culture
was obvious following ox-LDL exposure, in contrast to clinical data (Weber et al. 1997) and
histological studies in primates (Strawn et al. 2000) showing elevated leukocyte CDllb
expression in hyperlipidaemia. However, in vitro data using THP-1 cells suggests that
CDllb remains stable following ox-LDL exposure, and is only up-regulated in response to
CC chemokines (Han et al. 2003). Other studies have suggested that circulating leukocytes
do not display basal increases in CDllb expression in hyperlipidaemic states alone
(Couffinhal et al. 1993), but CDllb may be rapidly up-regulated during clinical vascular
events including peripheral arterial disease (Mazzone et al. 1997). Evidence to support the
observed down-regulation of CDllb in adherent monocytes comes from studies in rabbit
models of atherosclerosis. Animals on a high cholesterol diet were subject to aortic
barotrauma, and monocytes were then sampled from lesions. Lower levels of CDllb were
noted in monocytes derived from lesions in hyperlipidaemic animals, with the suggestion
that this compromised macrophage emigration from plaques (Gray & Shankar 1995).
However, this study attempted to compare lesional macrophages with circulating monocytes,
and did not clearly distinguish the role of responses to mechanical injury from those of
responses to dyslipidaemia. Electron microscopy work has shown that macrophages are
capable of leaving atherosclerotic plaque and re-entering the vessel lumen (Gerrity 1981b).
Mac-1 deficient mice confirm the role of P2 integrins in aiding the exit of macrophages from
inflammatory sites (Cao et al. 2005). The differential responses to ox-LDL may suggest that
mature adherent monocytes selectively down-regulate CD1 lb expression producing a poorly
motile or sessile resident macrophage within atherosclerotic plaque.
6.5.2.5 Reduced CD11c expression
CDllc expression was also reduced following ox-LDL exposure in adherent culture alone
(section 6.2.8.6). In conjunction with preserved CD14 expression this supports a mature
monocyte phenotype following LDL exposure, in distinction from CDllc+ dendritic cells.
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Immuno-histochemical studies of atherosclerotic plaque have shown that some CD68+
monocyte derived cells express high levels of the DC marker CDla, (Spanbroek et al. 2003),
and CDl+ve cells harvested from atherosclerotic plaque are capable of presenting lipid
antigens to T cells in vitro (Melian et al. 1999). Adoption of a DC surface phenotype has
been observed in monocytes leaving atherosclerotic plaques (Llodra et al. 2004),
complementing phenotypic data from in vitro models of transmigration (Randolph et al.
1998). Monocytic cells that successfully re-traverse the endothelium have marked increases
in both CD1 lc and CD1 lb, along with a decrease in CD14 expression (Muller & Randolph
1999). A co-ordinated down-regulation of both CD1 lc and CD11 b expression may thus limit
macrophage mobility within the vessel wall, as well as reducing reverse transmigration.
Further study of lipid effects upon DC antigen presentation and mobility would be useful.
More attention should perhaps be paid to lipid-laden immotile CDllc-low monocytes, in
assessing their immune competence and migratory capacity.
6.5.2.6 CD61 (P3) integrin expression
Changes in monocyte surface CD61 (P3/GPIIIa) expression were noted to be statistically
significant following early n-LDL and late ox-LDL exposure, although this was only
assessed in adherent culture. The alterations were all small in terms of total fluorescence,
with signals at the lower end of the cytometer dynamic range. The biological significance of
such changes in debatable, as the actual alteration in surface copy number is unlikely to
produce a functional change in adhesion. A fuller phenotype to assess expression during
other culture conditions might help ascertain whether these alterations are relevant to
monocyte function and the use of alternative mAb and fluorochromes might assist
qunatification. CD61 plays an established but distinct role in platelet aggregation, clearly
relevant to complex atherothrombotic events. CD61-null murine studies (section 6.1.6.2)
have suggested that CD61 tonically inhibits atherogenesis by limiting CD36 and
CD40/CD40L mediated signalling (Weng et al. 2003). However, it is also likely that ocvP3
integrin mediated signalling contributes to VSMC migration and growth (Hoshiga et al.
1995), potentially promoting arterial wall remodelling and reducing vessel calibre. It is likely
that CD61 mediates differing effects particular to leukocyte, VSMC or platelet, a hypothesis
strengthened by studies of polymorphisms of the P1A gene. Increased thrombotic events
appear associated with platelet P1A/A1 polymorphisms, whereas progressive fibrotic
atheroma is associated with VSMC-expressed P1A/A2 (Mikkelsson et al. 2001). Even if
monocyte surface CD61 expression is unaltered by modified LDL, avP3 plays an important
role in phagocytic clearance (Savill et al. 1990) relevant to atherosclerosis, and CD61 is
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important in vascular injury during atherothrombotic complications and vascular
remodelling. The exploration of CD61 responses to modified LDL and resultant effects upon
phagocytosis would be an obvious target for further work.
6.5.2.7 Changes in CD54 (1CAM-1) expression
Monocyte CD54 expression appeared dependent upon lipid oxidation, adhesion status and
maturation. Although monocytes in suspension culture were only assessed at 24hrs, the up-
regulation of CD54 following ox-LDL exposure contrasted with the stable expression noted
following early adherent culture, and the marked down-regulation that followed protracted
adherent culture with ox-LDL (section 6.2.8.8). Suspension culture data may reflect the
responses of uncommitted monocytes, although it is unclear as to whether they would be
exposed to this level of ox-LDL in vivo, and studies ofmonocytes in suspension exposed to a
range of ox-LDL concentrations would be useful in this regard. Ox-LDL mediated up-
regulation of CD54 in non-adherent human primary monocytes suggests an additional pro-
adherent effect of ox-LDL upon monocytes, and has not been previously reported. However,
changes in CD54 responses to ox-LDL have been noted in U937 monocytic cells with a peak
in CD54 transcription after 12hrs exposure (Yang & Rui 2003). CD54 mRNA levels
returned to baseline after 48hrs, suggesting a dynamic response to ox-LDL. Although
resident macrophages in coronary atheroma have been shown to express CD54, (Davies et al.
1993) these data were neither quantified, nor correlated to the stage of the individual plaque.
CD54 is essential for T cell priming, enhancing responses to B7 molecules (Damle et al.
1992), and supports Class II MHC-mediated antigen presentation to T cells, (Altmann et al.
1989). Studies of monocyte responses to ox-LDL by atheroma biologists have focused upon
adhesion to ECs or VSMCs (Thorne et al. 1996), without exploring monocyte surface
adhesion molecule expression. The data presented are of interest in highlighting CD54
changes in response to ox-LDL, and demand further investigation from both adhesion and
adaptive immune perspectives.
6.5.3 Monocyte surface molecules mediating adaptive immune function
6.5.3.1 Immunoglobulin receptors
The reported uptake of ox-LDL incorporated into immune complexes via a CD64(FcyRI)
mediated route (Huang et al. 1999b), suggests that CD64 expression may be an important
route for monocytes to accumulation lipid. However, no significant changes in CD64
expression were seen during adherent cell exposure to ox-LDL. Although an early reduction
in ox-LDL treated cells compared with n-LDL treated cells was noted during total
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fluorescence quantification, this was not significant when adjusted for control fluorescence,
(section 6.2.9.1). Immunoglobulin binding studies would clarify whether the stable
expression of CD64 in vitro in lipid-rich monocytes reflects functional competence. An
alternate mechanism may link atherosclerosis with CD64 mediated inflammatory
mechanisms. Pentraxin proteins including serum amyloid protein and C-reactive protein
(CRP) promote opsonisation and ingestion of apoptotic cells by phagocytes via CD64 (Mold,
Baca, & Du Clos 2002), and evidence demonstrates that raised CRP levels are associated
with adverse clinical outcomes in arterial disease (Ridker, Stampfer, & Rifai 2001). Stable
CD64 expression in lipid-laden monocytes may thus be augmented in vivo by circulating
CRP, promoting phagocytosis in an attempt to clear cell debris at sites of vascular
inflammation. The presence of CD64 in human atheroma has been demonstrated immuno-
histochemically (Ratcliffe, Kennedy, & Morganelli 2001). Determination of relative levels of
CD64 expression within plaque would allow the CD64 levels diminished as plaque
progression occurred. Additional insight might be gained from animal models of
atherosclerosis, to ascertain if CD64 levels were associated with reparative monocyte
responses that parallel those seen in arthritis and bacterial infection (Ioan-Facsinay et al.
2002).
It is perhaps surprising that CD16/FcyRIIla expression was unchanged in LDL-exposed
monocytes (section 6.2.9.2). CD16/FcyRIIIb shedding is well documented during
granulocyte activation (Huizinga et al. 1988). Shedding of CD16/FcyRIIIa has been reported
in inflammatory disease with elevated plasma levels of soluble CD16/FcyRIIIa found in
active rheumatoid arthritis (Masuda et al. 2003). It is possible that concomitant cytokine
input might unmask changes in CD16/FcyRIIIa expression. TGF-pi can reduce y-chain
expression, lowering monocyte surface CD64 and CD 16, and reducing FcyR mediated
production of MCP-1 (Tridandapani et al. 2003). Examination of parallel LDL-mediated
changes in monocyte FcR expression and function would thus require in vitro culture with
individual cytokines and co-culture with lymphocytes, or lymphocyte-conditioned media.
This needs further exploration using blocking antibodies in combination with aggregated
LDL particles. Finally, individual FcR influences upon macrophage behaviour in
hyperlipidaemic states could be elucidated by the use of gene deletion studies against an
apoE background, demonstrating whether defective binding to immune complexes
containing LDL altered atherosclerotic plaque load or morphology in vivo.
CD32/FcyRII is important in binding immune complexes. Neutrophil binding to immune
complexes is mediated by CD32, augmenting phagocytosis of opsonised apoptotic cells
(Hart, Alexander, & Dransfield 2004). Although CD32 plays a role in the binding of LDL to
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leukocytes, it was not explored because of time constraints. However, further assessment of
Fc receptor binding of aggregated LDL particles would require the assessment of CD32
expression and function.
6.5.3.2 Class II MHC molecule expression
An early alteration of monocyte Class II expression relative to control was seen in adherent
but not suspension culture in the presence of ox-LDL (section 6.2.9.3). Total fluorescence
was not statistically altered, and a reduction in Class II expression was not apparent after
prolonged adherent culture. Such data are difficult to interpret in the context of their
biological significance, as changes in absolute fluorescence on histograms appeared minor.
Moreover, although it is possible that molecular copy number, and indeed functional
competence of Class II proteins, might be reduced, this would require confirmation using
formal assays of antigen presentation. In the Rag 2/apoE null model of atherosclerosis,
atherogenesis progressed despite the absence of T cells but with reduced lesional
macrophage Class II expression (Daugherty et al. 1997), suggesting that T cell input is
important in modifying plaque macrophage phenotype in vivo. Class II MHC null mice fed a
pro-atherogenic diet, also show normal progression of atherosclerosis, (Fyfe, Qiao, & Lusis
1994), but no formal studies of macrophage function were performed with these animals.
Additional information about lipid effects upon Class II function and monocyte antigen
processing capability might be gained by examining antigen presentation in mixed leukocyte
reactions (Krieger et al. 1988). Further studies using defined apoprotein-derived peptide
epitopes would help assess whether antigen presentation is altered in lipid laden monocytes,
and whether exposure to ox-LDL alters these responses. The expression of Class II
molecules at the macrophage surface is promoted by T lymphocyte cytokine input,
particularly IFN-y (Steeg et al. 1982) and IL-4 (Stuart, Zlotnik, & Woodward 1988). The
influence of T lymphocyte cross-talk upon lipid-laden macrophages thus merits further
exploration, and the behaviour of macrophages in co-culture would be of particular interest.
6.5.3.3 Co-stimulatory molecules and other immune adaptors
No alteration of CD86 (B7.2) expression by LDL was noted during monocyte phenotyping
in suspension or adherent culture (section 6.2.9.4). The ability of lipid laden VSMCs ECs
and macrophages to initiate B7 up-regulation signal in B cells via CD40 has been
demonstrated (Buono et al. 2004), although no functional data on macrophage B7 responses
to lipid loading have been published to date.
Both CD80 (B7.1) and CD86 (B7.2) molecules bind to CTLA-4 and CD28 on T helper (Th)
cell surfaces promoting T cell activation (Linsley et al. 1994) (see section 6.1.9.2), driving T
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cells along a Thl or Th2 phenotypic path. Thl cells promote a classical path of macrophage
activation enhancing the production of pro-inflammatory cytokines including IFNy aiding
cellular immune responses to mycobacterium and HIV. Th2 lymphocytes assists humoral
immune responses and are associated with some anti-inflammatory cytokine influences upon
macrophages, with the production of IL-4, IL-10 and IL-13 (reviewed by Gordon 2003). T
cell ligation of CD86 molecules favours a switch to a Th2 phenotype, enhancing IL-4
production (Ranger et al. 1996). CD80 ligation promotes Thl production of IL-2 and IFNy
activating macrophages (Kuchroo et al. 1995). The resulting pro-inflammatory state may be
relevant to atherosclerosis, as isolated monocytes from patients suffering acute coronary
syndromes exhibit elevated CD80 expression following ex vivo LPS stimulation (Methe et al.
2005).
Although gene deletion studies show that individual B7 molecule changes may be
insufficient to alter T cell responses (Borriello et al. 1997), it would be useful to assess CD80
expression before commenting on LDL-mediated effects upon macrophage co-stimulatory
molecules. IfCD80 molecular expression is also maintained functional assays would need to
be undertaken to confirm that lipid-laden monocytes are capable of B7 mediated signalling.
This would be possible using mixed leukocyte reactions (MLR) and mAb blocking strategies
to assess cytokine responses to B7 ligation. The possibility that in vivo B7 molecular
signalling might be altered in hyperlipidaemic and pro-inflammatory states thus deserves
further investigation.
6.6 Overview
Monocyte phenotype is altered by modified LDL in an adhesion and maturation dependent
fashion. No effects upon pattern recognition receptors or monocyte immuno-regulatory
molecules were noted, but significant changes in expression of specific adhesion molecules
were seen following exposure to ox-LDL. The implications these findings may have for
monocyte migration and mobility within atherosclerotic plaque, along with a general
consideration of monocyte phenotype and immune function in atherosclerosis will be





















c) Key to figure 6.1
Figure 6-1 Multi-step paradigm of cell recruitment
Unactivated intravascular leukocytes and endothelial cells (Figure 6.1a) do not
interact. Selectin-binding ligands are constitutively expressed on leukocytes.
Quiescent endothelial cells do not express corresponding selectins. Endothelial
injury and cell activation upregulates selectin expression, initiating leukocyte-rolling.
Leukocyte activation enhances leukocyte integrin binding to Ig-supergene family
glycoproteins including ICAM-1 and VCAM-1, permitting firm adhesion.
Transendothelial migration (Figure 6.1b) is then facilitated by other Ig-supergene
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Monocyte purification
Figure 6-2 Monocyte isolation
Density gradient centrifugation produces mononuclear fractions (upper left panel).
Use of immunomagnetic separation techniques enables removal of contaminating
lymphocytes, NK cells, megakaryocytes, platelets and residual granulocytes upper
right panel. Percentage monocytes are shown for 60 leukocyte preparations in the
lower panel.
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Figure 6-3 Light microscopy of control monocytes
Monocytes cultured in adherent serum-replete conditions with control medium
(shown above) maintain normal macrophage ultra-structure, with preserved
cytoplasmic appearances.
Figure 6-4 Light microscopy of ox-LDL supplemented monocytes
Monocytes exposed to oxidised LDL in adherent serum-replete culture increase lipid
ingestion and adopt a lipid-laden vacuolated phenotype (arrows).
Fixation of cytocentrifuge preparations with alcohol dissolves and removes lipids, a
technique used in differential staining. Lipid inclusions in mature macrophages thus
appear as marked vacuoles.
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Figure 6-5 Transmission electron micrograph: control monocyte 7 days
Monocytes in serum-replete suspension culture maintain a cytoplasmic appearance
consistent with maturation towards a macrophage phenotype (x10,000).
Figure 6-6 Transmission electron micrograph: monocyte cultured in ox-
LDL 7 days
Monocytes cultured in serum-replete suspension conditions supplemented with
50(ig/ml ox-LDL show marked increases in intra-cytoplasmic lipid inclusions (arrow).
Although intra-cytoplasmic vacuolation is a mark of macrophage maturation, this







Figure 6-7 Oil Red O uptake: adherent monocytes, 24 hrs, LDL
supplements
Adherent macrophages cultured in medium supplemented with increasing
concentrations of n-LDL and ox-LDL were labelled with Oil Red O. Uptake of ORO is
evident at early time points (arrows) consistent with the presence of intracellular
cholesterol ester and triglycerides (x10 magnification).
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Figure 6-8 Control monocytes, adherent culture, 8 days, Oil Red O labelling
Low levels of uptake of oil red O (arrows) visible in panels a) and b) are seen
following prolonged culture in serum-replete media (x100, oil immersion).
Figure 6-9 Monocyte oil red O uptake, adherent culture, n-LDL supplements
Monocytes supplemented with n-LDL at 10pg/ml (panel a), 50pg/ml (panel b) and
100pg/ml (panels c and d) show increased levels of oil red O labelling (arrows) at 8
days in adherent culture (x100, oil immersion).
Figure 6-10 Monocyte oil red O uptake, adherent culture, 8 days, ox-LDL
supplements
Monocytes cultured in ox-LDL at 10pg/ml (panel a), 50pg/ml (panel b) and 100|ag/ml
(panels c and d) show increased levels of intracellular oil red O at 8 days in





Figure 6-11 Monocyte ox-LDL uptake, 24hrs
Monocytes cultured with 10jag/ml (a) 50pg/ml (b) or 100pg/ml (c) Di-I labelled ox-
LDL showed increasing levels of LDL uptake (arrows) after 24hrs in adherent













Figure 6-12 Monocyte Di-I labelled ox-LDL uptake, 24hrs, adherent culture.
Nuclei are labelled blue with Hoechst 33428 (blue arrow) demonstrating monocyte
viability in adherent culture, with concomitant Di-I labelled ox-LDL uptake (orange
arrow), at 10pg/ml and 50fig/ml
Control
%



























Figure 6-13 Monocyte Di-I labelled ox-LDL uptake, 48hrs adherent culture.
Monocytes cultured in ox-LDL for 48 hrs show marked uptake of Di-I labelled ox-




Figure 6-14 Monocyte LDL uptake, 8 days adherent culture, low
concentration LDL
Contemporaneously cultured human monocytes were exposed to control media or
Di-I labelled n-LDL (left-hand panels) or ox-LDL (right-hand panels) at increasing
concentrations. Cells were fixed after 8 days adherent culture, and nuclei labelled
with ToPro3.
Cells were imaged with a Zeiss confocal microscope using a x40 objective under oil
immersion. Nuclei appear blue, and Di-I LDL appears red (arrows).
Nuclear labelling alone is seen in control samples.
Evidence of intracellular lipid uptake is apparent in both n-LDL and ox-LDL exposed
monocytes at low concentrations, but n-LDL uptake appears much less avid than
ox-LDL uptake.



























Figure 6-15 Monocyte LDL uptake, 8 days adherent culture, medium and
high concentration LDL
Monocytes were prepared contemporaneously, as for Figure 6.14.
Monocytes were exposed to Di-I labelled n-LDL (left-hand panels), or ox-LDL (right-
hand panels) at 50(xg/ml and 100pg/ml.
Evidence of intracellular lipid uptake is visible in all LDL exposed monocytes.
An increase in red fluorescence proportional to the concentration of LDL exposure is
apparent.
n-LDL appears less avidly taken up than ox-LDL at all concentrations used, although
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Figure 6-16 Scatter characteristics of LDL supplemented monocytes, early
suspension culture
Monocytes cultured in suspension for 24 hours in serum-replete control media or
media supplemented with increasing concentrations of native or oxidised LDL. Side
scatter and forward scatter properties are altered at early time points after exposure
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Figure 6-17 Scatter characteristics of LDL supplemented monocytes,
prolonged suspension culture
Monocytes cultured in suspension for 5 days in serum-replete control media or
media supplemented with increasing concentrations of native or oxidised LDL.
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Figure 6-18 Monocyte scatter properties, adherent culture, LDL supplements
Monocyte scatter properties were assessed using linear scale scatter for early
adherent culture at 48hrs (upper left panel). Prolonged adherent culture for 8 days
altered scatter characteristics, reducing visible cell populations on a linear scale
(upper right panel).
Log-scale scatter analysis at 48hrs (lower left panel) and 8 days (lower right panel)
allows visualisation of all cell populations, whilst still enabling the exclusion of low
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Figure 6-19 Derivation of flow data, suspension culture monocytes
Monocytes cultured in suspension were gated by side scatter (upper left panel) and
the uptake of ToPro3 assessed using the FL-4 channel (upper right panel). Cells








Figure 6-20 Monocyte autofluorescence induced by modified LDL
Both n-LDL and ox-LDL exposure enhance monocyte basal fluorescence levels (left
panel). Prolonged culture with ox-LDL differentially increases autofluorescence in
contrast to n-LDL (right panel).
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Figure 6-21 Monocyte CD14 expression after 24hrs in suspension culture
with lipid supplementation
No changes in net median CD14 fluorescence (upper left panel, one-way ANOVA,
n=4 to 9, p=0.1517) or net fluorescence relative to control (upper left panel, one-way
ANOVA, n=4 to 9, p=0.3555) were noted following LDL-supplemented suspension
culture for 24 hours. Representative histograms are shown for the 50pg/ml
treatment, with no alteration in CD14 fluorescence seen. Histograms are offset to
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Figure 6-22 Monocyte CD14 expression, suspension culture 72hrs, LDL
supplements
CD14 expression is unchanged in monocytes cultured with n-LDL or Ox-LDL at 72
hours (net median fluorescence, one-way ANOVA, n=4 to 5, p=0.9999; fluorescence
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Figure 6-23 Monocyte CD14 expression, suspension culture, 5 days, LDL
supplements
No significant changes in net median CD 14 fluorescence (upper left panel, one-way
ANOVA, n=4 to 6, p=0.2131) or in net fluorescence relative to control (upper right
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Figure 6-24 Monocyte CD14 expression, suspension culture, 15dPGJ2
supplements
No significant alterations in net median CD14 expression (left hand panels) or CD14
expression relative to control (right hand panels) were noted during prolonged
culture with 15dPGJ2 at increasing concentrations over a 3-log concentration range,
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Figure 6-25 Monocyte CD14, adherent culture, 48hrs, LDL supplements
Early of adherent monocytes phenotyping in 50pg/ml n-LDL or ox-LDL showed no
significant alteration in net median CD14 fluorescence (upper left panel, one-way
ANOVA, n=7, p=0.7682) or net fluorescence relative to control (upper right panel,
Wilcoxon signed rank test, n=7, p=0.3438). Representative histogram overlays for n-
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Figure 6-26 Monocyte CD14 expression adherent culture 8 days, LDL
supplements
n-LDL reduced total CD14 expression (n=8, p=0.0303, upper left panel), and CD14
expression relative to control (n=8, p=0.0078, upper right panel) after prolonged
culture. Ox-LDL produced no change in relative fluorescence (n=8, p=0.4727).
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Figure 6-27 Monocyte CD36 expression, 24hrs, suspension culture, LDL
supplements
No changes in net median CD36 expression were noted (one-way ANOVA, n=4 to
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Figure 6-28 Monocyte CD36 expression, 72hrs suspension culture, LDL
supplements
No changes in monocyte net median CD36 fluorescence (one-way ANOVA, n=4,
p=0.3343) or net fluorescence relative to control (n=4, p=0.2926) were noted.
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Figure 6-29 Monocyte CD36 expression, 5 days, suspension culture, LDL
supplements
No changes in net median fluorescence (upper left panel, n=4 to 6, p=0.6815) or net
median fluorescence relative to control (right left panel, n=4 to 6, p=0.6126) were




























































































































Figure 6-30 Monocyte CD36 expression, suspension culture, 15dPGJ2
supplements
No alterations in net median CD36 fluorescence or fluorescence relative to control
were apparent following 15dPGJ2 exposure, at 24hrs, 72hrs and 5 days (n=3, all













































Figure 6-31 Monocyte CD36 expression, adherent culture, 48 hours, LDL
supplements
Adherent monocytes were treated with native or oxidised LDL at 50|ag/ml for 48
hours. No significant change was noted in net median CD36 fluorescence (upper left
panel, one-way ANOVA, n=7, p=0.6197), or fluorescence relative to control (upper
right panel, Wilcoxon signed rank test, n=7, p=0.3438). Representative histograms
display stable CD36 expression for both native LDL (lower left panel) and Ox-LDL
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Figure 6-32 Monocyte CD36 expression, day 8, adherent culture, LDL
supplements
No statistically significant difference was seen in net median CD36 expression
(upper left panel, one-way ANOVA, n=8, p=0.0789), or relative fluorescence to
control (upper right panel, Wilcoxon signed rank test n=8, p=0.1914) after prolonged








































Figure 6-33 Monocyte CD49d expression, adherent culture, 48hrs, LDL
supplements
No significant change in total net median expression of CD49d occurred after 48
hours of adherent culture with either n-LDL or ox-LDL supplementation (one-way
ANOVA, n=7, p=0.3046, upper left panel). A decrement in net median fluorescence
relative to control was suggested by statistical analysis (Wilcoxon signed rank test,
n=7, p=0.0391, upper right panel), but was not obvious in histogram overlays, with
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Figure 6-34 Monocyte CD49d expression, day 8, adherent culture, LDL
supplements
Prolonged adherent culture with Ox-LDL at 50^g/ml did not significantly reduce net
median monocyte CD49d expression, (upper left panel, one-way ANOVA n=7,
p=0.0515), although no alteration was noted with respect to n-LDL. Net changes in
fluorescence relative to control were significant for ox-LDL alone (upper right panel
Wilcoxon signed rank test, n=7, p=0.0156). The histogram overlays suggest that




































































Figure 6-35 Monocyte CD11b, 24hrs suspension culture, LDL supplements
No statistically significant alteration in monocyte CD11b expression was seen
following LDL exposure (net median fluorescence, n=3, p=0.5278, net median



















































Figure 6-36 Monocyte CD11b expression, adherent culture, 48hrs, LDL
supplements
No significant changes were noted in net median CD11b expression (n=7,
p=0.4861) following LDL exposure. Net median CD11b fluorescence relative to
control appeared increased by CD11b (n=7, p=0.0156) although this was a small
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Figure 6-37 Monocyte CD11b expression adherent culture, 8 days, LDL
supplementation
Significant reductions of CD11b net total fluorescence (n=9, p=0.0029, panel A), and
net fluorescence relative to control (n=9, p=0.002, panel B) occurred following
monocyte exposure to ox-LDL but not to n-LDL. Representative histograms illustrate
monocyte CD11b expression after n-LDL exposure (panel C) contrasting with
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Figure 6-38 Monocyte CD11c expression, 24hrs suspension culture, LDL
supplements
No significant alterations in CD11c expression were noted during prolonged
suspension culture, for net median fluorescence (one-way ANOVA, n=4 to 9,
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Figure 6-39 Monocyte CD11c, suspension culture, 72 hours, LDL
supplements
A reduction in total monocyte surface expression of CD11c was noted after 72 hours
in 100pg/ml ox-LDL (one-way ANOVA, n=4, p=0.0281), but did not change relative
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Figure 6-40 Monocyte CD11c expression, suspension culture, 5 days, LDL
supplements
No changes in net median CD11c expression (n=4 to 6, p=0.1676) or net
fluorescence relative to control (n=4 to 6, p=0.2926) were noted following prolonged












































































































Figure 6-41 Monocyte CD11c expression, suspension culture, 15dPGJ2
supplementation.
No significant alterations in net median CD11c expression (left hand panels) or
CD11c expression relative to control (right hand panels) were noted during
prolonged culture with 15dPGJ2 at increasing concentrations over a 3-log
































































Figure 6-42 Monocyte CD11c expression, 48hrs, adherent culture, LDL
supplements.
Net median fluorescence was unchanged by LDL treatments (n=7, p=0.1916 upper
left panel), but fluorescence relative to control was reduced following ox-LDL
treatments (n=7, p=0.0391, upper right panel). However, representative histogram
overlays for CD11c following exposure to n-LDL (lower left panel) and ox-LDL (lower






















































































Figure 6-43 Monocytes CD11c surface expression, day 8, adherent culture,
LDL supplements
Ox-LDL mediated statistically significant reductions in net median CD11c
fluorescence (one-way ANOVA, n=9, p<0.0001, upper left panel) and CD11c
fluorescence relative to control (n=9, p=0.002, upper right panel) in mature
monocytes. A significant difference in relative fluorescence between n-LDL and ox-
LDL was noted (n=9, p=0.0244, upper right panel). Representative histograms
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Figure 6-44 Monocyte CD54 surface expression, 24hrs, suspension culture,
LDL supplements
Monocyte CD54 expression is significantly elevated by Ox-LDL at 24hrs (total net
fluorescence). No corresponding changes following n-LDL exposure were seen.
This increase was reflected in total fluorescence levels (one-way ANOVA, p=0.0081,
n=6), as well as net changes in fluorescence relative to control (Wilcoxon signed
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Figure 6-45 Monocyte CD54 expression, suspension culture, 5 days, LDL
supplements
Insufficient samples were available to statistically assess CD54 expression on
suspension culture cells at late time points. It appeared on limited phenotyping that


























































Figure 6-46 Monocyte CD54 expression, 48hrs, adherent culture, LDL
supplements
No significant changes in net median CD54 expression (one-way ANOVA, n=7,
p=0.7682, upper right panel) or net median fluorescence relative to control
(Wilcoxon signed rank test, n=7, p=0.3438, upper right panel) were seen during
early adherent culture following LDL exposure. No differences in relative expression
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Figure 6-47 Monocyte CD54 expression, adherent culture, 8 days, LDL
supplements
Monocyte surface CD54 expression was significantly reduced by exposure to Ox-
LDL at 50mg/ml in adherent culture, but not by n-LDL. Reductions for both net
median fluorescence (one-way ANOVA, n=7, p=0.0272) and net fluorescence
relative to control (Wilcoxon ranked sign test, n=7, p=0.0379) followed ox-LDL
exposure.
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Chapter 7 CONCLUDING REMARKS
7.1 Overview
Atherosclerosis is a process of chronic inflammation and repair in which monocytes play a
central co-ordinating role, directing injurious and reparative response in the vessel wall. The
work presented in this thesis assesses the role that micro-environmental influences, relevant
to both inflammation and atherosclerosis, play in monocyte survival, gene transcription, and
phenotypic change. This concluding chapter will address how these data relate to our current
and future understanding of inflammation and atherosclerosis, in the context of both
biological mechanisms and potential therapies.
7.2 Monocyte apoptosis overview
The survival responses of monocytes to ox-LDL and cyPGs noted in Chapter 3 are relevant
to leukocyte turnover in the inflamed vessel wall. The in vitro induction of monocyte
apoptosis serves not as a model for in vivo vascular events, but as a means of assessing
whether individual pro-inflammatory and pro-atherogenic stimuli may alter leukocyte
lifespan.
7.2.1 Lipoprotein oxidation status: relation to cell death & potential therapies
Clinical trials of anti-oxidant therapies including Vitamin E, beta-carotene and alpha-
tocopherol, aimed at reducing LDL oxidation and free-radical mediated cell death, have had
at best neutral outcomes. Data showing that anti-oxidant therapies reduced the efficacy of
cholesterol lowering therapies caused some critics to call into question the role of ox-LDL in
the pathogenesis of atherosclerosis (Brown et al. 2001). The role of oxidised LDL as a
pathogenic factor in atherosclerosis derives from multiple observations in human disease and
animal models of atheroma (Boullier et al. 2001; Navab et al. 1995; Sasahara et al. 1994).
Macrophage lipid accumulation is facilitated by LDL modification (Brown & Goldstein
1983), demonstrating the role of macrophage scavenger receptors (Endemann et al. 1993).
Further early data highlighted the cytotoxicity of ox-LDL (Hessler et al.). Changes in
monocyte mitochondrial potential during free cholesterol loading of macrophages (Yao &
Tabas 2001), and direct CD36 ligation by ox-LDL particles (Wintergerst et al. 2000) have
both been postulated to act as pro-apoptotic stimuli (see Chapter 3). The rate constant of
Vitamin E with superoxides is 6 log orders lower than that for interactions between vascular
nitric oxide and superoxide, suggesting that Vitamin E is an inappropriate means of reducing
oxidative stress (Landmesser & Harrison 2001). However, this does not detract from the role
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that oxidative stress may play in vascular damage; the complex effects that oxygen species
have upon leukocytes and vascular wall components suggest that clinical trials of anti¬
oxidants have been based on an over-simplistic understanding of the biological processes
involved (Steinberg & Witztum 2002). Data from murine models of atherosclerosis with
12/15 lipoxygenase gene deletions prove these enzymes are critical in inducing lipoprotein
oxidation within the vessel wall (Cyrus et al. 2001). 12/15 eicosanoid products of
lipoxygenases are further elevated in murine models of diabetic atherosclerosis, contributing
to enhanced monocyte/endothelial adhesion (Hatley et al. 2003). Targeting lipoxygenases
within the vessel wall may thus be a more relevant goal for therapies, as a reduction of pro¬
inflammatory lipoprotein oxidation products might reduce local vascular injury. The recent
discovery that terpenoids and chromanes isolated from marine sponge organisms act as
potent recyclable inhibitors of human 15 lipoxygenase may provide novel routes for future
atherosclerosis treatments (Cichewicz et al. 2004).
7.2.2 PPARy and monocyte apoptosis
PPARy is an important nuclear receptor in atherosclerosis, with documented effects upon
atherogenesis and inflammation as well as controlling cellular insulin sensitivity. However,
no direct link between PPARy and monocyte apoptosis appears likely (Chapter 3)
contradicting data from other laboratories that have reported PPARy-mediated programmed
cell death in monocytes or monocytic cells (Chinetti et al. 1998; Kawahito et al. 2000).
The use of high-affinity thiazolidinedione PPARy ligands in current clinical practice is
widespread within diabetes and cardiovascular medicine (Sidhu & Kaski 2001). Despite
concerns regarding PPARy ligation promoting unregulated lipid uptake in leukocytes (Nagy
et al. 1998; Tontonoz et al. 1998), synthetic PPARy agonists in animal models of
atherosclerosis have shown a beneficial modulation of atherosclerotic plaque load (Duval et
al. 2002; Hsueh & Law 2001; Li et al. 2000). Furthermore, increased levels of
atherosclerotic complications or innate immune compromise have not been reported in
clinical studies of patients receiving PPARy agonists, suggesting that neither lipid-uptake nor
dramatic leukocyte cell death follow from the systemic administration of these agents (Wang
& Tafuri 2003).
The indications that NF-kB was involved in cyPG mediated apoptosis fits with known pro-
survival effects of cellular activation, and have already been discussed in Chapter 3. More
intriguingly, the mechanisms of ox-LDL induction of apoptosis are less clear. In separate
experiments, monocyte exposure to LDL appeared to induce 1-kB degradation for both
native and oxidised LDL (data not shown). It is highly likely that distinct mechanisms of cell
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death induction operate for ox-LDL and cyPGs, but neither agent induces apoptosis via
PPARy.
Increasing evidence suggests that ligands for PPARy limit inflammatory responses via
PPARy independent mechanisms (Chawla et al. 2001a). PPARy modulation of inflammatory
responses is mediated by inhibiting NF-kB target genes, but not NF-kB mediated cell
activation per se. The complex mechanics of this involve covalent attachment of the small
ubiquitin-related modifier (SUMO) to the PPARy ligand-binding domain, which targets
PPARy to nuclear receptor co-repressor (NCoR)-histone deacetylase-3 (HDAC3) complexes
on inflammatory gene promoters. SUMOylation prevents recruitment of the ubiquitin/19S
proteosome that mediates the removal of co-repressor complexes required for gene activation
(Pascual et al. 2005), inhibiting PPARy transcriptional activity. Contrary to previous models
of PPARy driving foam cell generation, evidence suggests that PPARy acts to moderate lipid
uptake, controlling foam cell formation (Li et al. 2004). More recent data using conditional
PPARy macrophage gene deletion in murine models have demonstrated increased
atherosclerosis (Babaev et al. 2005). This suggests that PPARy ligation by thiazolidinediones
is not detrimental in atherosclerosis therapies. PPARa may be more important in driving
macrophage lipid loading and this may explain the therapeutic benefit of fibrates in clinical
practice (Vosper et al. 2002).
7.2.3 Monocyte apoptosis: implications for atherogenesis and plaque
progression
Apoptosis is present at all stages of atherosclerosis (DeVries-Seimon et al. 2005), with
distinct outcomes ensuing from cell death at different stages of the disease process (see
Chapter 3 section 3.4.4.). Even within individual plaques, cell surface markers demonstrate
heterogeneity (van der Wal et al. 1992), with macrophages close to the endothelium
displaying altered features of maturation and differentiation, affecting susceptibility to
apoptosis as well as phagocytic capability. The role of apoptosis in early vs. advanced
plaques has already been discussed (Chapter 3), with special reference to plaque progression
and stability (Kolodgie et al. 2000) and thrombosis (Hutter et al. 2004). Alterations in cell
death contribute to the gross histological changes reviewed in Chapter 1, including both
necrotic core formation in advanced lipid rich atheromata (Geng & Libby 1995), and the
hypocellularity noted in advanced fibrotic lesions (Kockx 1998).
Plaque volume is not static, and clinical evidence shows that it may be reduced following
aggressive lipid-lowering treatment with HMG CoA reductase inhibitors (Nissen et al.
2005). In vitro data has suggested that blocking cholesterol transport using an acyl-
268
coenzyme-a:cholesterol acyltransferase (ACAT) inhibitor might induce monocyte-derived
foam cell apoptosis and contribute to lesion regression (Rodriguez, Bachorik, & Wee 1999).
More recent data using ACAT gene deletions, suggest that this strategy so disrupts
cholesterol efflux, that atherogenesis is promoted, despite increased intra-lesional apoptosis
(Dove et al. 2005). Although established lipid lowering therapies offer significant benefits, it
is worth considering further options that might beneficially target cell survival in
atherosclerosis.
The data presented in this thesis cannot be directly extrapolated in order to speculate upon
monocyte behaviour in human atherosclerotic plaque. However, the susceptibility of
monocytes to both cyclopentenones and ox-LDL suggest that local effects that may pertain
to atherosclerotic lesions are able to affect monocyte survival, with potential consequences
for lesion volume and local inflammation.
7.2.4 Potential therapies to manipulate apoptosis in atherosclerosis
The demonstration that ox-LDL alters apoptosis raises the possibility that monocyte
apoptosis may be manipulated pharmacologically, with relevance to vascular injury mediated
by LDL, mechanical trauma, and systemic inflammation. It is arguable that pro-apoptotic
agents might aid lesion resolution at the fatty streak stage. Parallels might be drawn with the
development of anti-neoplastic therapies which have used inhibitors of Bcl-2, Bcl-xl and
Bcl-w proteins to facilitate tumour regression (Oltersdorf et al. 2005). However, the diffuse
nature and heterogeneity of atherosclerosis limits the general applicability of pro-apoptotic
treatments, which could potentially induce multiple adverse events. Systemic pro-apoptotic
therapies may cause unacceptable levels of cell death that may not be obviated by targeting
specific cell types. For example, promotion of leukocyte apoptosis would have the potential
to breach innate immune defences. Promoting VSMC apoptosis might reduce fibro-
reparative responses and arterial wall strength, mimicking inflammatory events following
pathological plaque erosion or Assuring (Boyle et al. 2001), and might be detrimental in
advanced atherosclerotic plaque. Local intra-vascular delivery of pro-apoptotic drugs
introduces the prospect of inducing targeted cell death in VSMCs and ECs, initiating
inflammatory responses and enhancing vascular damage. Cell cycle inhibitors, originally
assessed as immunosuppressant therapies in vascular disease (Gregory et al. 1995), are
successfully used as a focal intervention in coronary disease by limiting cellular hyperplasia
and neo-proliferation, rather than invoking indiscriminate cell death (Serruys, Kutryk, &
Ong 2006). An example of more novel therapeutic approaches to inducing focal apoptosis is
the use of targeted photodynamic therapies that introduce photo-excitable molecules such as
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fullerenes into cells. Illumination induces reactive oxygen species production, and photo-
sensitisers taken up via scavenger receptors may allow the selective induction of cell death in
macrophages (Demidova & Hamblin 2004), with potential for catheter based interventions
when treating focal atherosclerosis.
Prevention of monocyte/macrophage apoptosis might be beneficial in stabilising advanced
atherosclerotic lesions, but would not address the issues of cell accumulation increasing
plaque bulk, nor reduce the possibility that macrophages permitted to survive would still be
capable of pro-inflammatory responses, proteolytic degradation and the induction of VSMC
apoptosis.
7.2.5 Potential therapies to manipulate phagocytosis in atherosclerosis
Altered phagocytic clearance of apoptotic cells has been noted in murine models of
atherosclerosis bearing apoE gene deletions (Grainger, Reckless, & McKilligin 2004).
Furthermore, murine models bearing gene deletions for both FasL and apoE have high levels
of circulating un-cleared apoptotic bodies, suggesting that phagocytic clearance capacity has
been exceeded in this model of accelerated atherosclerosis (Aprahamian et al. 2004).
Phagocytosis is further reduced in this model by the infusion of ox-LDL or lysophosphatidic
acid, and is associated with a low level of uptake of apoptotic cell debris by phagocytes.
Thus, in the setting of already elevated levels of apoptosis, optimising phagocytic clearance
may be a safer strategy for developing new anti-atherosclerotic therapies.
Paradoxically anti-oxidant therapies may limit effective phagocytosis and therefore targeted
inhibition of oxidation may alter clearance of apoptotic cells. Etoposide, a lipid anti-oxidant
and anti-tumour agent that is capable of inducing apoptosis, has been shown to limit
phosphatidylserine (PS) oxidation, thus reducing PS exposure and apoptotic cell recognition
(Tyurina et al. 2004). Promotion of phagocytosis would enable rapid resolution of chronic
inflammatory vascular injury, ensuring that response to retained lipid were not injurious. The
use of gluocorticoids in promoting clearance have been closely investigated (Liu et al. 1999),
and are of clinical benefit in many inflammatory situations (Flaslett 1992). Flowever,
gluocorticoids induce vascular pathology, and are pro-diabetic and atherogenic (del Rincon
et al. 2004), precluding their use in atherosclerosis treatments. Glucocorticoid products such
as Annexin I may be of use as an alternative, to promote phagocytosis. Lipoxins and
epilipoxins form during inflammatory responses and are present in atherosclerotic lesions,
and may alter granulocyte activation (Qiu et al. 2001). Macrophage phagocytosis has been
reported to be enhanced using lipoxins (Godson et al. 2000; Reville et al. 2006) and
epilipoxins (Mitchell et al. 2002).
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The phagocytic defect in apoE null mice was noted to be restored by the infusion of
apoproteins (Grainger, Reckless, & McKilligin 2004), suggesting a potential mode of novel
pro-phagocytic therapy using a small peptide molecule or amino-acid peptide mimetic agents
bearing similar structures to apoproteins. However, it is unclear what effect this may have
upon atherosclerotic plaque bulk and stability.
7.3 Use of gene arrays in examining monocyte transcriptional profiling
Transcriptional profiling is increasingly used to measure biological responses and can offer
initially very rapid screening assays to examine cellular changes after defined stimuli, as
discussed in Chapter 5. Their use is limited by experimental design, in particular the need to
minimise the number of experimental variables. Transcriptional profiling does have a place
in the clinical assessment of complex chronic inflammatory processes such as
atherosclerosis. RNA sampling from clinical subjects for gene array analysis has been
successfully undertaken using explanted human coronary tissue (Satterthwaite et al. 2005).
More novel profiling techniques such as the use of single nucleotide polymorphism profiling
arrays (Syvanen 2005) may help identify risk factors associated with clinical disease
enabling further information to complement in vitro work to elucidate candidate genes
involved in atherosclerotic plaque progression.
7.4 Monocyte phenotypic changes
Monocyte/macrophages within atherosclerotic plaque differ phenotypically from circulating
monocytes (van der Wal et al. 1992). Alteration of monocyte phenotype affects function,
(see Chapter 6), with impact upon the uptake of lipoproteins and apoptotic cells via
scavenger receptors, as well as innate and adaptive immune capacity and macrophage
motility.
7.4.1 Immune mechanisms in vascular disease
The involvement of innate immune mechanisms in atherosclerosis has received increasing
attention (Binder et al. 2002). Pattern-recognition receptors such as scavenger receptors and
toll-like receptors (TLR) are able to recognise pathogen-associated molecular patterns that
may be shared by modified lipoproteins pathogens as well as apoptotic cells. Furthermore,
the acute phase reactant pentraxin-structured C-reactive protein has been shown to bind ox-
LDL and oxidised phosphatidylcholine, with specific binding of CRP to apoptotic Jurkat T
cells (Chang et al. 2002). The lack of change in both scavenger receptor expression and in
surface molecules related to immune function was thus surprising (Chapter 6). Multiple
reports have suggested that the chronic inflammatory stimuli that propagate vascular injury
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may in part be mediated by specific immune pathways (reviewed by Hansson et al. 2002).
Class II MHC is critical to antigen presentation, and is highly expressed in human
atherosclerosis, with further increases noted in post-mortem studies of diabetes-associated
atherosclerosis (Burke et al. 2004). As discussed in Chapter 6, it is likely that the model of
monocyte LDL exposure is too simplistic to allow discernment of changes in adaptive
immunity without embarking upon co-culture work, a criticism that applies equally to the
phenotypic analysis of B7 co-stimulatory molecules.
Monocytes from patients suffering acute coronary syndromes show elevated transcription of
TLRs as well as B7 co-stimulatory molecules (Methe et al. 2005). Early innate immune
responses to microbial pathogens are mediated by TLRs, which initiate NF-kB activation via
the adapter protein MyD88 (Schnare et al. 2001). Macrophage TLR-4 expression is elevated
in aortic atheromatous plaques in apoE-/- mice, and from ex vivo human atherosclerotic
samples, localising to plaque shoulder regions and the periphery of the necrotic core (Xu et
al. 2001), suggesting that monocyte TLRs merit attention in further studies of monocyte
behaviour in plaque. Ischaemia reperfusion injury models highlight a further role of B7
molecules with relevance to atherosclerosis. Blockade of B7 molecules in ischaemia
reperfusion injury during organ transplantation has been associated with lower levels of
lymphocytic infiltration and enhanced tissue viability (Takada et al. 1997). B7 blockade
using a fusion protein made of the competitive CD28 homologue CTLA4 and the IgGj heavy
chain limits chronic cardiac allograft rejection and limits the progression of transplant
accelerated arteriosclerosis (Russell et al. 1996).
The finding that antibodies specifically recognise ox-LDL (Horkko et al. 1999) and cross-
react with apoptotic cell membrane-derived phosphorylcholines (Shaw et al. 2000) remains a
focus of interest. The fact that antibody cross-reactivity also extends to bacterially derived
phosphorylcholines (Binder et al. 2003) suggests that responses to lipid oxidation may
represent conserved mechanisms of pathogen recognition that have been subverted in
atherosclerosis (see Chapter 1 and Chapter 3). Although experiments presented here and by
other investigators have used copper-oxidised LDL is a heterogeneous source of ox-LDL
epitopes, the immuno-dominant epitope in ox-LDL is oxidised phosphorylcholine (Friedman
et al. 2002), suggesting that this particular lipoprotein stimulus is a valid means of assessing
monocyte responses.
A detailed discussion of the role that immune therapies might play in atherosclerosis is
beyond the scope of this thesis. Nonetheless the possibility of using vaccination strategies to
limit atherosclerosis is intriguing. Data from murine models suggests that atheroprotective
effects may follow the generation of predominantly B-cell driven anti-ox-LDL IgM
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antibodies (Palinski, Miller, & Witztum 1995), with derivatives of ox-LDL, particularly
malondialdehyde (MDA), acting as the epitope (Freigang, Witztum, & Palinski 1998).
Parallel experiments have suggested that immunisation against MDA-apoprotein B-100
adducts may also confer atheroprotection, via T cell-dependent IgG production (Schiopu et
al. 2004). Further insights into immune mechanisms governing atherosclerosis may thus
offer novel non-pharmacological therapies.
7.4.2 Changes in macrophage mobility
Responses to ox-LDL may alter macrophage mobility (Terasawa et al. 2000), with effects
upon movement across the vessel wall (Weerasinghe et al. 1998). Ox-LDL has been shown
to affect leukocyte motility at a molecular level by reducing F-Actin polymerisation, a key
step in cytoskeletal rearrangement (Miller et al. 2003), potentially affecting trans-endothelial
migration (TEM).
Alteration in leukocyte TEM is relevant to monocyte recruitment and emigration throughout
atherosclerotic plaque development, and is tightly regulated by phosphorylation cascades
including ephrin tyrosine kinases (Aasheim, Delabie, & Finne 2005), and Wiskott-Aldrich
syndrome protein (Cory et al. 2002). In early lesions, intimal fatty streak formation is not
matched by the development of lymphatic channels or vasa vasorum (Chapter 1), limiting
the exit routes available for infiltrating leukocytes. Advanced plaques have developed these
vascular channels in atherosclerotic vessel walls, although they do not directly communicate
with the resident intimal leukocyte population. Adventitial angiogenesis does not initiate
intimal thickening but may help accelerate intimal changes (Khurana et al. 2004). Inhibition
of angiogenesis can alter neo-intimal hyperplasia and limit intimal plaque formation in
murine atherosclerosis (Moulton et al. 1999) with more recent data suggesting that leukocyte
influx to arterial walls may be dependent upon new adventitial vessels (Moulton et al. 2003).
Electron microscopy data showing monocytes re-entering the arterial lumen from the vessel
wall has been revisited in the context of reverse transmigration patterns (Randolph et al.
1998). The phenotype that lipid laden macrophages display (comprising of reduced CDllb
and CDllc but stable CD14, see Chapter 6) may contribute to limited cell motility. An
inverse phenotype of high CDllb and CD1 lc expression is seen in the dendritic cell (DC)-
like cells that reverse transmigrate across endothelial monolayers (Muller & Randolph
1999), and in similar cells that have been shown to exit atheroma in vivo (Llodra et al. 2004).
The reductions in adhesion molecule expression reported in Chapter 6 are unlikely to
represent a homeostatic mechanisms limitation of lipid-laden macrophage binding to the
vascular wall. Indeed downregulation of CD49d, CD54 and P2 integrins appears to be linked
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to maturation and adhesion. Although the gene array data (Chapter 5) suggested early
increases in a number of integrins including CD1 lb and P3 chains, flow cytometric analysis
showed that surface expression of these molecules was either unchanged, or downregulated.
High levels of integrin subunit stability at the cell membrane may explain this, or the fact
that monocyte transcription alters through prolonged exposure to lipids, a possibility that
could be answered by more extensive profding over multiple time points.
If the phenotype induced by ox-LDL is also seen in non-reverse transmigrating cells, and
more importantly in cells remaining in plaque, this may be an indication of why monocytes
cannot leave atherosclerotic lesions. Furthermore, a rescue of the original phenotype might
be worth pursuing, using lipid withdrawal, or examining anti-oxidant strategies.
Monocyte-derived DCs in apoE null mice display reduced mobility induced specifically by
PAF and ox-LDL. DC emigration can be restored in this model by the intravenous
administration of exogenous HDL, due to the presence of PAF acetylhydrolase (Angeli et al.
2004). Current systemic lipid lowering therapies including HMG CoA reductase inhibitors
("statins") are widely used to reduce cardiovascular risk. Recent data suggest that statins
may act to reduce monocyte CD54 and CD40 expression, decreasing adhesion and
inflammatory signalling (Takahashi et al. 2005). Furthermore, statins and derivative agents
may directly alter adhesion molecule expression and behaviour. CDlla/CD18 integrin
binding to CD54 is limited by allosteric inhibition of a novel binding site in the insertional
domain (Weitz-Schmidt et al. 2001), and expression of CD54 and CDlla was down-
regulated on circulating monocytes in a study of hypercholesterolaemic patients receiving
simvastatin (Rezaie-Majd et al. 2003). Altered adhesion molecule expression may thus be
clinically relevant, and the development of drugs targeting monocyte adhesion molecules
may provide future therapies for atherosclerosis.
Therapies targeting adhesion molecules are now available for other inflammatory diseases.
Efaluzimab, a humanised IgGi monoclonal antibody that blocks CDlla, has been used to
treat psoriasis, by blocking T cell recruitment to skin lesions (Lebwohl et al. 2003). The
prospect that such an agent might inhibit lymphocyte or monocyte recruitment to
atherosclerotic plaque, reducing local vascular inflammation, is intriguing and merits
investigation. Recent studies have suggested that a novel anti-oxidant agent with inhibitory
effects upon VCAM-1 transcription may beneficially decrease post-barotrauma restenosis
following percutaneous coronary intervention (Kunsch et al. 2004). Anti-sense
oligonucleotides are able to inhibit adhesion molecule function (Bennett et al. 1994), and
ulcerative colitis has been successfully treated in humans by inhibiting CD54-mediated
leukocyte adhesion using the anti-sense agent Alicaforsen (van Deventer et al. 2004). This
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latter strategy may be of future use in limiting initial monocyte adhesion and thus monocyte-
mediated inflammatory damage during acute vascular injury, with relevance to plaque
degradation.
7.5 Conclusions
Evidence that pro-atherogenic and pro-inflammatory stimuli alter monocyte survival in vitro
is presented in this thesis.
Monocytes undergo apoptosis in response to modified lipoproteins and arachidonic acid
metabolites. These findings may partially explain locally elevated levels of apoptosis and
inflammation in atherosclerotic plaques.
Oxidised low-density lipoproteins reduce the expression of specific monocyte adhesion
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